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Functional neurological disorders (FND) present as neurological disease for which no organic 
cause can be found. These disorders are common, debilitating, and patients can present to a 
range of medical services. Little is known of the prevalence of patients with functional 
symptoms presenting to stroke settings, their experience once admitted to stroke wards, the 
demographic and clinical features of functional motor disorder (FMD) patients treated in 
psychiatric settings, or their response to psychological treatment. This thesis addresses this 
paucity of evidence. 
A systematic review and meta-analysis found functional stroke patients consistently present to 
stroke settings, constituting 1.7% (95% CI: 1.3% - 2.2%) of all patients with suspected stroke, 
with weakness the most commonly presenting functional symptom. 
A qualitative study using in-depth interviews with 14 hyper acute stroke clinicians, found 
participants named a range of potential causes of functional stroke presentations, but many 
felt unsure in how to discuss a functional diagnosis with patients. In a survey of 120 staff in 
hyper acute stroke wards in England, 90% of clinicians stated they do not believe there are 
clear guidelines on how to manage functional patients and 95.8% believed further research is 
necessary. 
A qualitative study involving interviews with 30 patients with functional stroke symptoms at 
one hyper acute stroke ward found many reported strong negative emotions in response to 
their admission and while on the ward, many believed they had had a stroke. Two months 
after discharge, many patients were uncertain about the cause of their admission and 40% 
experienced residual physical symptoms. Many expressed a desire for a more detailed 
explanation about the potential cause of their symptoms.  
A case-control study of 322 FMD patients found the disorder more commonly affects women, 
patients more frequently work in social or health care settings, patients often have carers or 
are themselves carers, and more frequently have comorbid physical and functional disorders 
when compared to a random sample of psychiatric patients from South London and the 
Maudsley NHS Trust. We found no association between experience of childhood sexual or 
physical abuse and an FMD diagnosis; however tentative evidence suggests patients 





Finally, our case-control cognitive behavioural therapy (CBT) study indicates that both FMD 
patients and patients with organic disease respond to outpatient CBT. Half of the FMD group 
saw improvements in their physical symptoms, and measures of psychological distress and 
depression showed significant clinical improvement between first and last treatment sessions. 
Dropout rates from treatment were comparable between FMD and control patients.  
We conclude that functional disorder symptoms occur in multiple medical settings and present 
to newly established hyper acute stroke wards. A lack of understanding amongst clinicians 
about the nature of FND coupled with increasing financial pressure on the health service may 
serve to entrench patients’ symptoms, and worsen experiences in medical settings. Within 
mental health services, FMD appears to have distinct epidemiological characteristics but the 
fragmentation of neurological and mental health services mean patients are often under-
served and lack continuity of care. 
List of Abbreviations 
5 
 
List of Abbreviations 
ADHD  Attention Deficit Hyperactivity disorder 
A&E  Accident and Emergency Department 
ANOVA  Analysis of variance 
APA  American Psychiatric Association 
APSA  Adult physical or sexual abuse 
BMI  Body Mass Index 
BRC  Biomedical Research Centre 
CBT  Cognitive Behavioural Therapy 
CFS  Chronic Fatigue Syndrome 
CI  Confidence interval 
CORE-OM Clinical Outcomes in Routine Evaluation – Outcome Measure 
CMA  Comprehensive Meta-Analysis 
CPA  Childhood physical abuse 
CRIS  Clinical Records Interactive Search 
CSA  Childhood sexual abuse 
CT  Computed tomography 
CTA  Computed tomography angiography 
DLA  Disability Living Allowance 
DSM  Diagnostic and Statistical Manual 
ECG  Electrocardiogram 
EMS                     Emergency Medical Services 
ePJS  Electronic Patient Journey System 
FMD  Functional motor disorder 
FND  Functional neurological disorder 
GP  General Practitioner 
HASU  Hyper Acute Stroke Unit 
HIV  Human Immunodeficiency Virus 
HoNOS  Health of the Nation Outcome Scales 
HoNOS-ABI Health of the Nation Outcome Scales – Acquired Brain Injury 
IAPT  Improving Access to Psychological Therapies 
IBS  Irritable Bowel Syndrome 
ICD-10  International Statistical Classification of Diseases and Related Health Problems 
ID   Participant identifier  
ISCO – 08 International Standard Classification of Occupations 
List of Abbreviations 
6 
 
IQR  Interquartile range 
MRI  Magnetic resonance imaging 
MS  Multiple Sclerosis  
NA  Not applicable 
NES  Non-epileptic seizures 
NHS  National Health Service 
NICE  National Institute for Health and Care Excellence 
NK  Not known 
OR  Odds ratio 
OT  Occupational therapist 
PACE Pacing, graded Activity, and Cognitive behaviour therapy, a randomised 
Evaluation trial 
PCT  Primary Care Trust 
PHQ-9  Patient Health Questionnaire 
PROSPERO International prospective register of systematic reviews 
RAG  Research and Advisory Group 
RCT  Randomised Controlled Trial 
R&D  Research & Development 
REC  Research Ethics Committee 
ROSIER  Recognition of Stroke in the Emergency Room  
Rt-PA  Tissue plasminogen activator 
TIA  Transient Ischaemic Attack 
SD  Standard deviation 
SE  Standard error 
SES  Socio-economic status 
SLaM  South London and the Maudsley 
SMR  Standardised mortality ratio 
SSNAP  Sentinel Stroke National Audit Programme 
SPSS  Statistical Package for the Social Sciences 




Table of Contents 
7 
 
Table of Contents 
Abstract .......................................................................................................................................... 3 
List of Abbreviations ...................................................................................................................... 5 
Table of Tables ............................................................................................................................. 14 
Table of Figures ............................................................................................................................ 19 
Acknowledgements ...................................................................................................................... 22 
Authorship Statement .................................................................................................................. 23 
Thesis Outline............................................................................................................................... 24 
Chapter One: Introduction ........................................................................................................... 25 
1.1 Definition .......................................................................................................................... 26 
1.2 Historical overview ............................................................................................................ 27 
1.3 Epidemiology ..................................................................................................................... 35 
1.4 Aims of thesis .................................................................................................................... 37 
Chapter Two: A systematic review and meta-analysis of the prevalence of stroke mimics and 
functional stroke mimics across differing medical settings ......................................................... 40 
2.1 Introduction ........................................................................................................................... 41 
2.1.1 Stroke pathway .............................................................................................................. 41 
2.1.2 Stroke mimics ................................................................................................................. 45 
2.1.3 Study aim ....................................................................................................................... 47 
2.2 Methods ................................................................................................................................. 48 
2.2.1 First literature search ..................................................................................................... 48 
2.2.2 Second literature search ................................................................................................ 49 
2.2.3 Inclusion and exclusion criteria ...................................................................................... 50 
2.2.4 Data extracted................................................................................................................ 51 
2.2.5 Statistical analysis .......................................................................................................... 51 
2.3 Results .................................................................................................................................... 52 
Table of Contents 
8 
 
2.3.1 Systematic review .......................................................................................................... 52 
2.3.2 Meta-analysis ................................................................................................................. 58 
2.4 Discussion ............................................................................................................................... 72 
2.4.1 Main findings ................................................................................................................. 72 
2.4.2 Stratified analysis ........................................................................................................... 74 
2.4.3 Limitations...................................................................................................................... 77 
2.4.4 Conclusions .................................................................................................................... 78 
Chapter Three: A qualitative study of stroke clinicians’ experiences treating stroke mimic 
patients in a hyper acute stroke setting ...................................................................................... 79 
3.1 Introduction ........................................................................................................................... 80 
3.1.1 Clinicians’ attitudes to unexplained syndromes ............................................................ 80 
3.1.2 Improving the doctor-patient relationship .................................................................... 83 
3.1.3 Aim of research .............................................................................................................. 84 
3.2 Methods ................................................................................................................................. 85 
3.2.1 Survey procedure ........................................................................................................... 85 
3.2.2 Questionnaire ................................................................................................................ 86 
3.2.3 Survey analysis ............................................................................................................... 86 
3.2.4 Qualitative study ............................................................................................................ 87 
3.3 Results .................................................................................................................................... 90 
3.3.1 Survey results ................................................................................................................. 90 
3.3.2 Qualitative results .......................................................................................................... 96 
3.4 Discussion ............................................................................................................................. 113 
3.4.1 Main findings ............................................................................................................... 113 
3.4.2 Strengths and limitations ............................................................................................. 116 
3.4.3 Conclusions .................................................................................................................. 118 
Chapter Four: Qualitative interviews with patients with unexplained stroke symptoms in a 
hyper acute stroke setting with two-month follow-up interviews. ........................................... 119 
4.1 Introduction ......................................................................................................................... 120 
Table of Contents 
9 
 
4.1.1 Previous qualitative findings ........................................................................................ 121 
4.1.2 Aim of research ............................................................................................................ 125 
4.2 Methods ............................................................................................................................... 126 
4.2.1 Brief Illness Perception questionnaire ......................................................................... 126 
4.2.2 Qualitative interviews .................................................................................................. 127 
4.3 Results .................................................................................................................................. 130 
4.3.1 Participants .................................................................................................................. 130 
4.3.2 Brief Illness Perception questionnaire results ............................................................. 133 
4.3.3 Baseline qualitative interview results .......................................................................... 135 
4.3.4 Two-month follow-up interview results ...................................................................... 151 
4.4 Discussion ............................................................................................................................. 156 
4.4.1 Main findings ............................................................................................................... 156 
4.4.2 Strengths and limitations ............................................................................................. 161 
4.4.3 Conclusions .................................................................................................................. 163 
Chapter Five: A case-control study of 322 functional motor disorder patients in SLaM........... 164 
5.1 Introduction ......................................................................................................................... 165 
5.1.1 Prevalence .................................................................................................................... 165 
5.1.2 Socio-demographics ..................................................................................................... 166 
5.1.3 Clinical features ............................................................................................................ 166 
5.1.4 Life events .................................................................................................................... 171 
5.1.5 Diagnosis ...................................................................................................................... 172 
5.1.6 Prognosis ...................................................................................................................... 173 
5.1.7 Aim of study ................................................................................................................. 174 
5.2 Methods ............................................................................................................................... 174 
5.2.1 Study setting ................................................................................................................ 174 
5.2.2 Data collection ............................................................................................................. 175 
5.2.3 Measures ...................................................................................................................... 177 
5.2.4 Statistical analysis ........................................................................................................ 179 
Table of Contents 
10 
 
5.2.5 Ethical considerations .................................................................................................. 180 
5.3 Results .................................................................................................................................. 180 
5.3.1 Diagnoses ..................................................................................................................... 180 
5.3.2 Socio-demographics ..................................................................................................... 183 
5.3.3 Health ........................................................................................................................... 192 
5.3.4 Life events .................................................................................................................... 204 
5.3.5 Outcome scores ........................................................................................................... 209 
5.3.6 Logistic regression ........................................................................................................ 212 
5.3.7 Sensitivity analysis ....................................................................................................... 213 
5.4 Discussion ............................................................................................................................. 215 
5.4.1 Main findings ............................................................................................................... 215 
5.4.2 Strengths and limitations ............................................................................................. 222 
5.4.3 Conclusions .................................................................................................................. 224 
Chapter Six: A case-control study assessing outcomes of functional motor disorder patients 
receiving outpatient cognitive behavioural therapy in South London and the Maudsley ........ 225 
6.1 Introduction ......................................................................................................................... 226 
6.1.1 The cognitive-behavioural model ................................................................................ 226 
6.1.2 Existing evidence for CBT ............................................................................................. 229 
6.1.3 Aim of study ................................................................................................................. 232 
6.2 Methods ............................................................................................................................... 233 
6.2.1 Study setting ................................................................................................................ 233 
6.2.2 The CBT intervention ................................................................................................... 233 
6.2.3 Data collection ............................................................................................................. 234 
6.2.4 Measures ...................................................................................................................... 237 
6.2.5 Statistical analysis ........................................................................................................ 240 
6.3 Results .................................................................................................................................. 240 
6.3.1 Participants .................................................................................................................. 240 
6.3.2 Diagnoses ..................................................................................................................... 244 
Table of Contents 
11 
 
6.3.3 Health ........................................................................................................................... 249 
6.3.4 Psychiatric inpatient stays ........................................................................................... 250 
6.3.5 Life events .................................................................................................................... 251 
6.3.6 Psychological comorbidity and acceptance of psychological explanations ................. 252 
6.3.7 CBT dropout ................................................................................................................. 254 
6.3.8 CBT treatment length ................................................................................................... 259 
6.3.9 Therapy outcomes ....................................................................................................... 260 
6.4 Discussion ............................................................................................................................. 272 
6.4.1 Main findings ............................................................................................................... 272 
6.4.2 Strengths and limitations ............................................................................................. 278 
6.4.3 Conclusions .................................................................................................................. 281 
Chapter Seven: General discussion and conclusions ................................................................. 282 
7.1 Between- and within-group difference ................................................................................ 284 
7.2 Gender ................................................................................................................................. 289 
7.3 Data collection and the use of medical records .................................................................. 291 
7.4 Future research .................................................................................................................... 293 
7.4.1 Services ........................................................................................................................ 293 
7.4.2 Treatment .................................................................................................................... 296 
7.5 Concluding remarks ............................................................................................................. 297 
References ................................................................................................................................. 299 
Appendices ................................................................................................................................. 334 
Appendix 2.1: Checklist for the assessment of quality of quantitative studies .................... 335 
Appendix 2.2: Exclusion criteria applied across all studies ................................................... 336 
Appendix 2.3 Definitions of stroke across papers ................................................................ 341 
Appendix 2.4: Most common stroke mimic diagnoses across studies ................................. 342 
Appendix 2.5: Functional disorder synonyms across studies ............................................... 343 
Appendix 2.6: Studies reporting no FND patients in their stroke mimic breakdown ........... 344 
Table of Contents 
12 
 
Appendix 2.7: Age and gender of medical mimic and functional mimic patients from studies 
reporting demographic details ............................................................................................. 345 
Appendix 2.8: Stroke mimic forest plot ................................................................................ 346 
Appendix 2.9: Functional stroke mimic forest plot............................................................... 347 
Appendix 3.1: Qualitative survey responses ......................................................................... 348 
Appendix 3.2: Stroke staff questionnaire ............................................................................. 351 
Appendix 3.3: Information sheet for NHS staff .................................................................... 353 
Appendix 3.4: Consent form for NHS staff ............................................................................ 355 
Appendix 3.5: Interview schedule for NHS stroke staff ........................................................ 357 
Appendix 4.1: Brief Illness Perception Questionnaire .......................................................... 359 
Appendix 4.2 Information sheet for patients ....................................................................... 360 
Appendix 4.3: Consent sheet for patients ............................................................................ 363 
Appendix 4.4: Interview schedule for patients ..................................................................... 365 
Appendix 5.1: CRIS search criteria ........................................................................................ 367 
Appendix 5.2: Main diagnoses given in CRIS for FMD and control group patients .............. 368 
Appendix 5.3: List of teams giving first SLaM diagnoses ...................................................... 369 
Appendix 5.4: Employment rates categorised according to ISCO-08 criteria ....................... 370 
Appendix 5.5: Rate of diseases in functional motor and control groups ............................. 371 
Appendix 5.6: History of familial mental health issues......................................................... 374 
Appendix 5.7: Socio-demographic differences between groups with and without complete 
HoNOS scores ........................................................................................................................ 375 
Appendix 5.8: Logistic regression results .............................................................................. 376 
Appendix 6.1: Reasons for early therapy cessation for F44.4 and control groups ............... 378 
Appendix 6.2: Missed treatment sessions and mean days between appointments ............ 379 
Appendix 6.3: Socio-demographic differences between F44.4 and control group patients 
according to their improvement ........................................................................................... 380 
Appendix 6.4: Socio-demographic differences between patients with clinical outcome scores 
and those with one or none .................................................................................................. 381 
Appendix 6.5: CORE-OM mean clinical score sub-analysis: repeated measures  ANOVA .... 384 
Appendix 6.6: Mean adjusted HoNOS-ABI sub-analysis: repeated measures ANOVA ......... 387 
Table of Contents 
13 
 
Appendix 6.7: Mean PHQ-9 scores sub-analyses: repeated measures ANOVA ................... 389 
Table of Tables 
14 
 
Table of Tables 
Table 1 The age and gender characteristics of stroke and stroke mimic patients ..................... 55 
Table 2 Age, gender, and symptom differences between medical and functional mimic patients
 ............................................................................................................................................ 57 
Table 3 Difference in average rates of ‘other’ categories between papers listing an ‘other’ 
category but no ‘functional disorder’ rate with papers listing both categories ................. 57 
Table 4 NHS stroke services participating in the survey ............................................................. 85 
Table 5 Survey participants according to profession, age and gender ....................................... 90 
Table 6 Table displaying agreement to statements on patients with functional stroke 
symptoms ............................................................................................................................ 91 
Table 7 Table displaying frequency of ‘agree’ or ‘strongly agree’ responses to statements by 
profession, age and gender ................................................................................................ 92 
Table 8 Breakdown of responses on where functional stroke patients should be managed and 
which setting provides the most effective treatment ........................................................ 93 
Table 9 The rate of agreement to statements regarding the doctor or health care team’s role in 
managing functional stroke symptoms. Participants could choose up to three. ............... 94 
Table 10 The frequency of responses to survey statements on research and treatments for 
functional stroke patients ................................................................................................... 94 
Table 11 Table displaying percentage of ‘strongly agree’ or ‘agree’ responses to statements 
regarding treatment and research by profession, age and gender .................................... 95 
Table 12 List of qualitative interviewees .................................................................................... 96 
Table 13 Table outlining the themes from qualitative staff interviews and their constituent 
thematic families................................................................................................................. 97 
Table 14 Sex, age, ethnicity, occupation and admission symptoms of qualitative participants
 .......................................................................................................................................... 132 
Table 15 Age and gender profile of Brief-IPQ survey completers versus those that completed 
one or no survey ............................................................................................................... 133 
Table 16 Changes in Brief-IPQ results between baseline and follow-up .................................. 134 
Table 17 Thematic framework derived from baseline qualitative interviews .......................... 135 
Table 18 Main SLaM diagnosis for functional motor and control groups ................................ 181 
Table 19 Secondary diagnoses for functional motor disorder and control group participants 182 
Table 20 Age, ethnicity and marital status for functional motor and control groups .............. 184 
Table 21 Age at analysis, age at psychological symptom onset and mortality rates for functional 
motor and control groups ................................................................................................. 185 
Table 22 Table showing housing type for functional motor and control group participants ... 187 
Table of Tables 
15 
 
Table 23 Table showing employment and benefits status of functional motor control group 
patients ............................................................................................................................. 188 
Table 24 Type of benefits received by functional motor and control groups .......................... 189 
Table 25 Employment rates of functional motor and control group patients according to 
occupational sector ........................................................................................................... 190 
Table 26 Proportion of functional motor and control group patients working in social or health 
care, as carers to family or friends and patients with carers ............................................ 191 
Table 27 Type and frequency of FMD symptoms according to psychosocial variables ........... 193 
Table 28 The rate of mentions of fatigue, anxiety and low mood as a comorbid symptom in the 
functional motor and control groups ................................................................................ 194 
Table 29 Table showing rate of depression, anxiety and fatigue within each symptom type . 195 
Table 30 Lifetime mobility aid use in functional motor disorder patients ............................... 195 
Table 31 Smoking rates and mean BMI scores for functional motor disorder and control group 
patients ............................................................................................................................. 196 
Table 32 Comorbid physical disease rates and mean number of comorbid physical conditions 
for the functional motor and control groups .................................................................... 198 
Table 33 Type of physical health conditions in the functional motor disorder group and control 
group ................................................................................................................................. 199 
Table 34 Diseases of the nervous system for the functional motor and control groups ......... 200 
Table 35 The rate and type of comorbid disorders in the functional motor and control groups
 .......................................................................................................................................... 201 
Table 36 Psychiatric inpatient rates, days in hospital and spells in hospital for functional motor 
and control groups ............................................................................................................ 203 
Table 37 History of childhood sexual and physical abuse and physical or sexual abuse in 
adulthood in the functional motor and control group participants ................................. 205 
Table 38  Reported early life events in functional motor and control group patients ............. 206 
Table 39 Reported adult life events in functional motor and control group patients ............. 208 
Table 40 First and last available adjusted HoNOS scores for the functional motor and control 
groups ............................................................................................................................... 210 
Table 41 First and last available HoNOS-ABI scores in functional motor disorder group ........ 211 
Table 42 First and last available PHQ-9 scores for functional motor disorder patients ........... 212 
Table 43 Logistic regression analysis of factors affecting membership of the functional motor 
disorder group .................................................................................................................. 213 
Table 44 Socio-demographic comparisons with removal of all cases of schizophrenia, 
schizotypal, delusional, and other non-mood psychotic disorders .................................. 214 
Table of Tables 
16 
 
Table 45 Total service users returned in number of CRIS search linked to each clinical 
psychologist ...................................................................................................................... 235 
Table 46 Stage of treatment pathway at which patients were excluded from treatment ....... 236 
Table 47 Breakdown of reasons for pre-CBT treatment dropout ............................................. 237 
Table 48 Gender, ethnicity and marital status of F44.4 and control group patients ............... 241 
Table 49 Age at analysis, symptom onset and assessment for F44.4 and control groups ....... 242 
Table 50 Employment and benefit status of functional motor and control group patients. ... 243 
Table 51 History of employment in social care and health settings and carer status for 
functional motor and control group patients ................................................................... 244 
Table 52 First, second and third psychiatric diagnoses received by F44.4 and control groups in 
SLaM Trust ........................................................................................................................ 246 
Table 53 Breakdown of first, second and third control group diagnoses ................................. 247 
Table 54 Heat map displaying the frequency of functional motor symptom type and the body 
region affected .................................................................................................................. 248 
Table 55 Table showing differences in smoking frequency and BMI mean scores between F44.4 
and control groups ............................................................................................................ 249 
Table 56 Inpatient rates and days for F44.4 and control groups .............................................. 251 
Table 57 Child and adult physical and sexual abuse rates for F44.4 and control groups ......... 252 
Table 58 Life-time prevalence of anxiety, depression and fatigue ........................................... 253 
Table 59 Proportion of F44.4 patients who accept the role of psychological factors in their 
symptom presentation before and after therapy ............................................................. 254 
Table 60 Proportion of F44.4 patients who accepted the role of psychology in their symptoms 
before and after therapy .................................................................................................. 254 
Table 61 Distribution of clinicians treating F44.4 and control groups ...................................... 255 
Table 62 Attendance rates of functional motor and control group participants ..................... 255 
Table 63 Socio-demographic differences between F44.4 patients who attended all CBT sessions 
offered versus those who dropped out early ................................................................... 256 
Table 64 Socio-demographic differences between F44.4 and control patients grouped by their 
attendance at CBT ............................................................................................................. 258 
Table 65 Differences in socio-demographics between F44.4 patients who improved after CBT 
and F44.4 patients who got worse or stayed the same .................................................... 262 
Table 66 Pre- and post-treatment clinical mean CORE-OM score for F44.4 and control group
 .......................................................................................................................................... 264 
Table 67 HoNOS scores for F44.4 and control group participants ........................................... 266 
Table 68 HoNOS-ABI scores and potential confounding variables for F44.4 and control groups
 .......................................................................................................................................... 267 
Table of Tables 
17 
 
Table 69 Mean total PHQ-9 scores before and after CBT treatment for F44.4 and control groups 
by socio-demographic factors ........................................................................................... 270 
Table 70 Checklist for assessment of quality of quantitative studies from Kmet et al.’s (2004) 
paper ................................................................................................................................. 335 
Table 71 List of exclusion criteria applied to study samples and their frequency across studies 
one to nineteen ................................................................................................................. 336 
Table 72 List of exclusion criteria applied to study samples and their frequency across studies 
twenty to forty .................................................................................................................. 337 
Table 73 List of exclusion criteria in studies forty-one to sixty ................................................. 338 
Table 74 List of exclusion criteria applied to studies sixty-one to eighty ................................. 339 
Table 75 List of exclusion criteria applied to studies eighty-one to eighty-seven .................... 340 
Table 76 Definitions of stroke used across papers ................................................................... 341 
Table 77 The most common stroke mimic diagnoses and the frequency with which they occur 
across studies .................................................................................................................... 342 
Table 78 Frequency of functional disorder synonyms across studies ...................................... 343 
Table 79 Studies reporting zero functional disorder patients as stroke mimics ...................... 344 
Table 80 Age and gender profile of medical mimic and functional disorder patients from 
individual papers reporting demographic details ............................................................. 345 
Table 81 Written survey responses to the question, “Patients with functional stroke symptoms 
should be managed” ......................................................................................................... 348 
Table 82 Written responses to the statement, “There are effective treatments for functional 
stroke patients”................................................................................................................. 348 
Table 83 Written response to the statement, “Patients with functional stroke symptoms are 
difficult to manage ............................................................................................................ 349 
Table 84 Responses to, “Which setting currently provides the most effective treatment?” ... 349 
Table 85 Written responses to the statement, “Patients with functional symptoms have an 
undiagnosed physical illness” ........................................................................................... 349 
Table 86 Written responses to the statement, “Patients with functional stroke symptoms have 
a psychiatric disorder” ...................................................................................................... 349 
Table 87 Written responses to the statement, “What is the role of the doctor or health care 
team in managing functional stroke symptoms?” ............................................................ 350 
Table 88 Written responses to the statement, "Physiotherapy could prove an effective 
treatment for some functional stroke patients"............................................................... 350 
Table 89 Written responses to the statement, “Patients with functional stroke symptoms have 
personality disorders” ....................................................................................................... 350 
Table of Tables 
18 
 
Table 90 Written response to the statement, "There are clear guidelines on how to manage 
patients with functional stroke symptoms” ..................................................................... 350 
Table 91 The number and frequency of SLaM diagnoses given across time to FMD and control 
group ................................................................................................................................. 368 
Table 92 List of teams giving first SLaM diagnoses to FMD and control groups ...................... 369 
Table 93 Employment rates in functional motor and control groups according to the 
International Standard Classification of Occupations (ISCO-08) ...................................... 370 
Table 94 Rate of disease in functional motor and control group patients ............................... 371 
Table 95 Rate of disease in functional motor and control group patients ............................... 372 
Table 96 Breakdown of types of congenital malformations, deformations and chromosomal 
abnormalities for functional motor and control group patients ...................................... 373 
Table 97 Rate of tuberculosis, hepatitis, HIV and mycoses and protozoal disease in the 
functional motor and control groups. ............................................................................... 373 
Table 98 Table showing breakdown of familial mental health issues according to group and 
relative type ...................................................................................................................... 374 
Table 99 Socio-demographic differences in functional motor and control group patients with 
two complete HoNOS scores versus patients with one or no complete HoNOS scores .. 375 
Table 100 Binary logistic regression model showing the relationship between independent 
variables and the likelihood of a functional motor patient having a comorbid functional 
disorder ............................................................................................................................. 376 
Table 101 Binary logistic regression model showing relationship between independent 
variables and the likelihood of a psychiatric inpatient admission .................................... 376 
Table 102 Binary logistic regression showing associations between independent variables and 
FND membership after the removal of any patients with a schizophrenia diagnosis ...... 377 
Table 103 Reasons for early therapy cessation ........................................................................ 378 
Table 104 Missed treatment sessions and mean number of days between appointments .... 379 
Table 105 Socio-demographic differences between patient groups who improved, got worse or 
remained the same after CBT treatment .......................................................................... 380 
Table 106 Characteristics of FMD patients with two available CORE-OM scores versus those 
with one or no available CORE-OM scores ....................................................................... 381 
Table 107 Characteristics of FMD patients with two available HoNOS-ABI scores versus those 
with one or no available scores ........................................................................................ 382 
Table 108 Characteristics of FMD patients with two available PHQ-9 scores versus those with 
one or no available scores ................................................................................................ 383 
Table of Figures 
19 
 
Table of Figures 
Figure 1 ‘A Clinical Lesson at the Salpêtrière’ by Pierre Brouillet depicting Charcot 
demonstrating hypnosis on a female patient ..................................................................... 28 
Figure 2 Campaign poster from the UK’s Department of Health (2007) public awareness of 
stroke campaign .................................................................................................................. 44 
Figure 3 Increases in internet interest in the signs of stroke. Graph A shows increases in 
frequency of UK Google searches for the terms ‘FAST’ and ‘stroke’ between 2008-2017, 
Graph B shows increases in worldwide Google searches for the term ‘stroke’ over the 
same period ........................................................................................................................ 45 
Figure 4 Flowchart displaying the systematic review’s search strategy ..................................... 50 
Figure 5 Geographical distribution of regions in which studies were based .............................. 52 
Figure 6 Forest plot displaying the proportion of stroke mimic patients diagnosed at acute 
stroke unit, ambulance, emergency department (ED), emergency medical services (EMS), 
hospitals, mixed settings, primary care or outpatient settings, stroke unit, and telestroke 
settings ................................................................................................................................ 59 
Figure 7 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to medical setting ........................................................... 60 
Figure 8 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to medical setting with papers removed which report no 
functional disorder cases, but do give an ‘other’ category ................................................ 60 
Figure 9 Forest plot displaying the proportion of stroke mimic patients according to studies’ 
study design ........................................................................................................................ 61 
Figure 10 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to study design ............................................................... 61 
Figure 11 Forest plot displaying the proportion of functional disorder patients according to 
study design with papers removed which report no functional disorder patients but which 
list an ‘other’ category ........................................................................................................ 62 
Figure 12 Forest plot displaying the proportion of stroke mimic patients according to whether a 
sample exclusion criterion was applied .............................................................................. 63 
Figure 13 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to study design ............................................................... 63 
Figure 14 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to exclusion criteria with papers removed which report a 
zero functional disorder rate but an ‘Other’ category ........................................................ 64 
Table of Figures 
20 
 
Figure 15 Forest plot displaying the proportion of stroke mimic patients according to the 
economic status of the country in which the study was based .......................................... 64 
Figure 16 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to economic status of the country in which the study was 
conducted ........................................................................................................................... 65 
Figure 17 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to economic status of the country in which the study 
took place with papers removed which report a zero functional disorder rate but also an 
‘other’ category ................................................................................................................... 65 
Figure 18 Forest plot displaying the proportion of stroke mimic patients according to whether 
they received thrombolysis treatment ............................................................................... 66 
Figure 19 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to whether the patients received thrombolysis treatment 
or not ................................................................................................................................... 66 
Figure 20 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to whether patients were given thrombolysis with papers 
removed which report no functional disorders but list an ‘other’ category ...................... 67 
Figure 21 Forest plot displaying the pooled proportion of stroke mimic patients by publication 
year ..................................................................................................................................... 67 
Figure 22 Forest plot displaying the pooled proportion of functional disorder patients from 
stroke mimic patients by publication year .......................................................................... 68 
Figure 23 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to the year category in which the paper was published 
with papers removed which report no functional disorder rate but include an ‘other’ 
category .............................................................................................................................. 68 
Figure 24 Forest plot displaying the pooled prevalence of stroke mimic patients according to 
the intended aim of study papers ....................................................................................... 69 
Figure 25 Forest plot displaying the pooled prevalence of functional disorder patients 
according to the intended aim of studies ........................................................................... 69 
Figure 26 Forest plot displaying the proportion of functional disorder patients according to the 
papers’ reported aim with papers removed which report no functional disorder rate but 
include an ‘other’ category ................................................................................................. 70 
Figure 27 Forest plot displaying the pooled prevalence of stroke mimic patients according to 
the quality category into which they fell ............................................................................ 71 
Figure 28 Forest plot displaying the pooled prevalence of functional disorder patients 
according to their quality category ..................................................................................... 71 
Table of Figures 
21 
 
Figure 29 Forest plot displaying the proportion of functional disorder patients according to 
papers’ assigned quality score with papers removed which report no functional disorder 
patient rate but an ‘other’ category ................................................................................... 72 
Figure 30 Flow chart showing functional motor disorder patients recruitment ...................... 177 
Figure 31 Frequency of symptom types in functional motor disorder patients ....................... 192 
Figure 32 Functional motor and control group HoNOS scores and their change over time .... 211 
Figure 33 The five areas assessment model (reproduced courtesy of Kent and McMillan (2009))
 .......................................................................................................................................... 228 
Figure 34 Flowchart showing total number of patients considered for study inclusion 
throughout study .............................................................................................................. 236 
Figure 35 Paired dotted line graphs showing change in clinical mean CORE-OM scores for the 
functional and control groups at the start and end of treatment .................................... 265 
Figure 36 Line graph demonstrating change in overall mean CORE-OM scores between F44.4 
and control groups pre- and post-CBT .............................................................................. 265 
Figure 37 Paired dotted graph showing each participants’ change in HoNOS-ABI scores pre- and 
post-CBT ............................................................................................................................ 268 
Figure 38 Figure showing change in mean HoNOS-ABI scores between F44.4 and control groups 
before and after CBT treatment ....................................................................................... 269 
Figure 39 Paired dotted graph showing each participants’ change in PHQ-9 scores pre- and 
post-CBT ............................................................................................................................ 271 
Figure 40 Figure showing change in mean PHQ-9 scores between F44.4 and control groups 
before and after CBT treatment ....................................................................................... 271 
Figure 41 Forest plot displaying the proportion of patients with an eventual stroke mimic 
diagnosis from medical services. The size of each square is proportional to the weight 
given to the study in the summary statistics. ................................................................... 346 
Figure 42 Forest plot displaying the proportion of stroke mimic patients with functional 
disorder diagnosis by service setting. The size of each square is proportion to the weight 






This PhD was generously funded by the National Institute for Health Research’s Biomedical 
Research Centre (BRC) at South London and the Maudsley (SLaM) NHS Foundation Trust and 
the Institute of Psychiatry, Psychology and Neuroscience at King’s College London.  
Thank you to Drs Robert Weeks and Najma Kahn-Bourne for their assistance in the design and 
completion of the qualitative stroke study. I would like to thank the stroke clinicians who took 
part in the study and who gave their time generously. In particular, I would like to thank the 
patients on the stroke ward who agreed to participate and for their willingness to tell their 
stories.  
Many thanks the CRIS team at the BRC Nucleus, particularly Meghan Pritchard, Amelia Jewell, 
Craig Colling, and Debbie Cummings for their assistance throughout this PhD.  
Thank you to the staff at SLaM’s outpatient neuropsychiatry clinic who welcomed me and 
offered insight into the functioning of their clinic. In particular, I would like to thank Dr Clare 
Grey and Gillian Watson who were very helpful and supportive. 
Thanks to my neuropsychiatry colleagues for their friendship and comradery. In particular, I 
would like to thank Drs Timothy Nicholson, Leon Fonville, Manuela Russo, Elaine Hunter, 
Graham Blackman, and Javier López-Moríñigo for their technical and clinical acumen, as well as 
their valuable advice at different stages of this PhD.  
I would especially like to thank my supervisor, Professor Anthony David from whom I have 
learned a great deal. I am extremely grateful for the time, expertise, and support he has given 
throughout this process, as well as his calm manner, pragmatism, and clear-headed insight. 
Finally, I would like to thank Mary Sloan, John O’Connell, Tim O’Connell, and Janosch Heller for 







The research questions and study designs in this thesis were proposed by Prof Antony David 





Thesis Outline  
Chapter 1 is a general introduction to functional neurological disorders, outlining its history, 
prevalence, socio-demographic features, comorbidities, and economic costs. This chapter then 
outlines the specific aims of this thesis.  
Chapter 2 describes a systematic review and meta-analysis investigating the prevalence of 
stroke mimic patients and patients with unexplained or functional stroke symptoms who 
present to medical and stroke settings. Potential moderating factors associated with 
prevalence are explored.  
Chapter 3 explores hyper acute stroke staffs’ views on diagnosing, treating and referring 
patients with functional stroke symptoms. The study uses a survey method and semi-
structured interviews to explore these topics.  
Chapter 4 assesses the views and experiences of functional stroke mimic patients admitted to 
one hyper acute stroke ward. This study employs semi-structured interviews and the Brief 
Illness Perception Questionnaire to examine admission experiences, symptomology, illness 
beliefs, attitudes to clinicians, perceptions of control, and views on the future. Interviews were 
conducted at patients’ bedsides and were repeated two months after patients’ discharge.  
Chapter 5 describes a case-control study utilising a large anonymous medical database 
examining the socio-demographics, health and life events of patients with an FMD diagnosis in 
SLaM NHS Trust. Patients are compared to a control group constituting a random sample of 
patients from SLaM. The factors associated with an FMD diagnosis are presented and 
discussed.  
Chapter 6 describes a study assessing the clinical outcomes of FMD patients who received CBT 
from a neuropsychiatry outpatient clinic in South London and the Maudsley NHS Trust. 
Patients are compared to a control group of patients with organic disorders who received CBT 
at the same clinic. Physical improvement, dropout rates, and clinical outcomes are examined 
and compared.  
Chapter 7 is a general discussion of the results of this thesis and an attempt to integrate 
findings within existing epidemiological and psychological models of FND. Recommendations 
for future service provision and treatment are made.   
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Functional neurological disorder (FND) comprises a spectrum of disorders defined by 
neurological symptoms for which no organic cause can be found. Symptoms include weakness, 
motor and movement disorders, dizziness, blackouts, seizures, and disrupted sensory 
symptoms. Symptoms are incongruous and inconsistent with organic neurological disease.  
The disorder has multiple synonyms such as hysteria, conversion, psychogenic, psychosomatic, 
somatisation, non-organic, and medically unexplained neurological symptoms. This thesis 
adopts the most recent nomenclature, ‘functional neurological disorder’, but when discussing 
the historical development of the disorder in this chapter, we adopt the historical term 
‘hysteria’1.  
The diagnostic definition of the disorder has changed through the last two centuries. Its 
copious diagnostic iterations are beyond the scope of this thesis but the current Diagnostic and 
Statistical Manual of Mental Disorders, version 5 (DSM-5) (American Psychiatric Association, 
2013) defines FND as:  
 One or more symptoms of altered voluntary motor or sensory function; 
 Where physical findings show evidence of incompatibility between the symptom and 
neurological or medical conditions; 
 The symptom is not better explained by another medical or psychological disorder 
and; 
 The symptom causes clinically significant distress or impairment in social, occupational 
or other areas of functioning.  
The International Statistical Classification of Diseases - 10th edition (ICD-10) (WHO, 1992) 
classifies FND as a dissociative disorder while in the DSM-5 it is defined as a somatoform 
disorder. Older versions of the DSM required the clinician to identify a potential psychological 
stressor but such requirements have since been removed as it was deemed both a clinically 
difficult observation and potentially irrelevant to the diagnosis. 
This chapter provides an introduction to FND. It outlines the history and theories of the 
disorder, its epidemiology, and discusses the aims of this PhD.  
                                                          
1 Throughout this thesis I will use the term ‘FND’ and ‘FMD’. ‘FND’ is the more general term, preferred 
in the neurological and psychiatric literature, referring to the disorder as a whole. ‘FMD’ refers 




1.2 Historical overview 
Functional neurological symptoms have a long and varied history, dating back to ancient Egypt, 
Greece and Rome.  
Hippocrates used the term hysteria in the 5th Century BC and claimed the disease related to 
movement of the uterus (Sigerist, 1951). He distinguished hysteria from epilepsy. The latter he 
believed was compulsive and the result of brain pathology while hysterical movements 
originated in abnormal movements caused by uterine problems.  
The Romans also believed hysteria was womb-related. Aulus Cornelius Celsus, a Roman 
encyclopaedist, writing in the first century BC wrote, “Sometimes it so completely destroys the 
senses that on occasions the patient falls, as if in epilepsy. This case, however, differs in that 
the eyes are not turned, nor does froth issue forth, nor are there any convulsions” (Penso, 
2002).  
While Celsus associated symptoms with epilepsy, Claudius Galen, a Greek physician and 
philosopher agreed that while hysteria originated in the womb, there were various symptoms, 
besides convulsions. His treatments included purges, the administration of various herbs, and 
marriage (Sigerist, 1951). 
1.2.1 Jean-Martin Charcot 
The modern history of the disorder began in Paris with the neurologist, Jean-Martin Charcot 
(1825-1893). Charcot opened a laboratory in the Parisian hospital, the Salpêtrière, and set out 
to establish what he termed ‘a museum of living pathology’. He made detailed observations of 
nervous diseases. He defined hysteria as a physical disease caused by hereditary deficits or 
trauma to the central nervous system. He believed hysteria was a brain disorder that could 
affect men and women and that it was caused by ‘functional’ rather than structural lesions, a 
physiological alteration of the nervous system with unknown pathogenesis. He identified a 
range of symptoms including pain, visual disturbance, motor symptoms, and numbness 
through to convulsions. He termed convulsions or non-epileptic seizures (NES) ‘grande 
hysteria’ or ‘hysteria major’, the classical hysterical sign. 
Charcot was at the forefront of modern attempts to classify nervous disease (Bouchara, 2014), 
a method he applied to hysteria. As the disorder precluded the simple identification and 
classification of pathogenesis and structural abnormalities, he classified it by its symptom 
clusters, a tradition that continues today. He also viewed hysteria as separate from 
malingering or feigning. Given the difficulties in establishing a diagnosis, he photographed 




patterns and phases of the disorder, hoping these photographs would form a physiological 
map of the disorder. He has been described as taking the ‘wastepaper basket’ of hysterical 
symptoms and replacing it with ‘a coherent and conceptually elegant array’ (Goldstein, 1987).  
Charcot had an idiosyncratic style of treatment and hospital management. He prepared weekly 
lecture-demonstrations, attracting large audiences. His pupil, the neuropsychiatrist Pierre 
Janet (1859 – 1947) wrote, ‘Everything in his lectures was designed to attract attention and to 
captivate the audience by means of visual and auditory impressions’ (Guillain, 1959). With a 
sense of the theatrical, he often imitated the behaviour of patients he was about to present. 
There is evidence that female patients were ‘prepped’ by assistants before they appeared and 
were rewarded for good performance (Ellenberger, 1981).  
 
 
Figure 1 ‘A Clinical Lesson at the Salpêtrière’ by Pierre Brouillet depicting Charcot 
demonstrating hypnosis on a female patient 
His public platform may have helped bring the disorder to public attention, and there is a 
suggestion that his fame was responsible for a rise in the rate of hysteria, which rose from a 
prevalence of 1% in 1841 to 17% in 1883 (North, 2015).  
Showalter (1997) and Appignanesi (2008) argue that the socio-political context of France at the 
time affected Charcot’s work. Paris had experienced a surge in anticlerical and anti-
establishment sentiment and Charcot’s political views are believed to have influenced his 
approach where he strove to ‘reclaim hysteria from religious interpretation…[such as] diabolic 
possessions or saintly ecstasy’ (Ellenberger, 1994). Two-thirds of Charcot’s hysteria patients 
were working-class women and while he was a practising neurologist, there was huge internal 
migration from rural to urban French settings. Many of the new arrivals to Paris were women 
who moved to find work and they often lived alone, on subsistence wages, unsupported by 




The rise in the prevalence of hysteria at the time could represent increased awareness of the 
disorder, increased help-seeking behaviour within the population, or growth in distress due to 
the social and economic upheavals of the time. Social and cultural theorists argue however 
that the fluctuations in prevalence highlight the social malleability of hysteria as a diagnosis 
and question its validity. Appignanesi (2008) writes, ‘doctors and patients collaborated in 
creating that pattern of illness and discontent’, arguing that since Charcot’s time, the disorder 
has all but disappeared. Shorter (1992) and Showalter (1997) don’t go so far as to claim 
hysteria has disappeared. Instead they argue that the traditional, ‘grande hysterie’ like 
paralysis and convulsions have vanished, making way for new manifestations such as chronic 
fatigue syndrome (CFS), with symptoms ‘amplified by modern communications and fin de siècle 
anxiety’ (Showalter, 1997). 
The view that the disorder never really existed but instead emerged and grew as a means to 
define or undermine women, particularly working class women, is common place. While it is 
possible that the disorder was used as a societal tool, and emerged and was maintained by the 
specific social, economic, and medical circumstances of the time, the evidence suggests that 
far from disappearing, its prevalence in fact remained relatively stable through the 20th 
century. Stone et al. (2008) argue that hysteria did not disappear but due to the fracturing of 
neurology and psychiatry into separate disciplines, declines in neurologists’ interest in non-
organic symptoms, continual changes to the name and definitions of ‘hysteria’, coupled with 
clinicians’ concern regarding misdiagnosis, hysteria cases no longer presented to psychiatrists, 
giving only the appearance of its disappearance.  
Towards the end of his life, Charcot regretted the biological emphasis he had placed in his 
theory of hysteria. Many of his ideas were dismissed immediately after his death as a new 
emphasis on traumatic experience developed. While the hereditary basis of his theories have 
been largely discredited, more recent evidence suggests FND patients often have a family 
history of psychogenic blindness or NES (Mattoo et al., 2002), and brain imaging studies in 
functional visual loss show alterations in the visual association cortex (Okuyama et al., 2002).  
1.2.2 Pierre Janet 
Charcot’s student, Pierre Janet (1859-1947) studied and treated hysteria. He conceived 
hysteria as a disorder in which disturbance in conscious awareness manifests in physical 
disability (Haule, 1986). He argued that hysteria patients were preoccupied with fixed ideas, 
and that their “attention is altogether the most difficult to fix, and that but a few can succeed 




Underlying this inability to attend to new sensory information was a process he called 
‘dissociation’, a discontinuation of consciousness. His theory of dissociation involved a 
‘splitting off’ of one part of the nervous system from the central system due to a postulated 
neurophysiological mechanism (Janet, 1907).  
Dissociation also involved the fragmentation of parts of personality into separate 
compartments; a process he suggested was triggered by extreme stress or emotion. He 
believed the tendency towards dissociation was an individual predisposition, and symptoms 
were maintained due to secondary gain for the patient.  
He viewed Charcot as placing too strong an emphasis on the physiological underpinnings of the 
disorder but he was critical of his contemporaries who he believed overstated the disorder’s 
psychological mechanisms. He called for a unification of both approaches, “Hysteria, they say, 
is a psychic disease, it is the disease of suggestion…there is some truth in this view, for it brings 
into relief psychic character of affection; but it is quite insufficient. We should, in my opinion, 
retain something of the precise method of Charcot, of the search after the determination and 
the laws of hysteria, and apply it only to psychological facts” (Janet, 1907).  
Modern research supports many of Janet’s theories. A number of studies have identified 
attentional disturbances in patients with NES (Liepert et al., 2011; Pareés et al., 2013). 
Functional neurological symptoms are classified in the ICD-10 as dissociative and while 
dissociative mechanisms may be particularly relevant to certain functional disorders such as 
NES, dissociation is not a process that can in itself account for all functional disorder symptoms 
(Stone, 2006). 
1.2.3 Sigmund Freud 
Sigmund Freud (1856 – 1939) was also briefly a student of Charot in 1885. While Charcot had 
identified and categorised elaborate behaviours, Freud’s interest was broader including 
everyday symptoms, such as headaches, limps, loss of voice and coughs, which he termed 
‘petite hysterie’.  
He and his colleague Joseph Breuer formulated psychological theories and wrote, “in what 
follows, little mention will be made of the brain and none whatever of molecules. Physical 
processes will be dealt with in the language of psychology; and indeed it cannot possibly be 
otherwise” (Breuer & Freud, 1974). They argued that all hysteria had traumatic origins and 
these traumas were not related to injury or disease. They suggested hysteria resulted from 
traumatic experiences and memories repressed from consciousness. The memories are highly 




their theory, healthy people could get rid of the cerebral excitation associated with emotion, 
for example through physical movement like shouting, jumping, or crying. If these physical 
responses were repressed, emotion could persist and become associated and linked to the 
negative memory. 
Freud distinguished between hysterical and psychosomatic symptoms. He believed migraine, 
headache and stomach pain were psychosomatic but leg paralysis, a classic hysterical 
symptom, represented the conversion of psychic energy into physical symptoms. In Freud’s 
theory, classic hysterical symptoms held symbolic meaning, with leg paralysis symbolising 
castration, and blindness representing a wish to look at something forbidden. Dreams for 
Freud were a way to understand the symbolism of these symptoms.  
Their most famous patient, Bertha Pappenheim (1859 – 1936), Anna O., experienced 
symptoms such as contractions of the right arm and leg, severe cough, mood swings, 
headaches, sleepwalking, and a loss of voice. They offered hypnosis as a treatment. Under 
hypnosis, she could provide detailed accounts of the circumstances in which her symptoms 
had arisen and following hypnosis her symptoms were said to abate. Later they developed 
psychoanalysis, a talking therapy in which patients told stories, often from dreams or 
daydreams with the aim of reconstructing the repressed memories through interpretation and 
free-association.  
Freud initially theorised that the repression of childhood sexual abuse from consciousness 
caused hysteria, writing, ‘at the bottom of every case of hysteria there are one or more 
occurrences of premature sexual experience’. As the incidence of hysteria grew, he abandoned 
this view, writing, “surely such widespread perversions against children are not very probable” 
(Freud, 1984). Instead, he favoured a seduction theory that highlighted patients’ unconscious 
sexual and Oedipal fantasies. The change in his causal theory led to heated debate amongst 
psychoanalysts. The psychoanalyst Jeffrey Masson wrote, ‘by shifting the emphasis from an 
actual world of sadness, misery, and cruelty to an internal stage on which actors performed 
invented dramas for an invisible audience, Freud began a trend away from the real world, that 
it seems to me, is at the root of present-day sterility of psychoanalysis” (Kelly, 1995).  
Carson et al. (2016) note that Freud’s reversal in thinking should be considered within the 
context of a broader shift in his views away from defining hysteria as a specific set of 
symptoms to a disorder that represented global psychological distress. Nonetheless, his 
Oedipus theory remained and today holds little influence in much modern psychotherapy, 
viewed both as a misogynistic anachronism and a kind of historical joke. Freud’s theories were 




The essential diagnostic criterion for the identification of psychological stressors at the time of 
symptom onset was removed from the DSM-5 (APA, 2013). Purely psychological 
interpretations of the disorder have more recently been challenged on the basis of a lack of 
evidence for associations between psychological stressors and the disorder (Stone & Edwards, 
2011). 
1.2.4 World War One 
The outbreak of World War One saw a resurgence of interest in hysteria with the return of 
British soldiers from the front with unexplained limps, loss of voice, headache, pain, mutism, 
emotional distress and insomnia. Charles Myers (1873 – 1946), a physician and psychologist, 
encountered British soldiers in France in 1914 and made associations between their symptoms 
and hysteria (Myers, 1915). Reluctant to employ the term ‘hysteria’, instead he used ‘shell 
shock’. Initially, Myers had believed the mental distress was a result of soldiers experiencing 
shells bursting near them but later found these symptoms appeared in soldiers who, “had 
never been near an exploding shell, had not been under fire for months, or had never come 
under fire” (Myers, 2012). He admitted ‘shell shock’ was a ‘singularly ill-chosen term’ and later 
advocated use of the terms ‘concussion’, ‘nervous shock’ or ‘war neuroses’.  
Gordon Holmes, a neurologist at Queen Square, London, viewed shell shock as the result of 
weak character and demoted Myers. His views reflected broader public opinion at the time. In 
the ‘Evening Standard’, shell shock soldiers were called ‘degenerates’. By the 1930s however, 
such views began to change and psychological symptoms became more accepted as their 
incidence rose. A psychologist in 1935 wrote, ‘In the military hospitals, the study of so-called 
shell shock revealed that symptoms quite as serious as the well-defined psychoses might arise 
through simple stress and strain and yet prove quickly curable by psychotherapeutic means” 
(Burt, 1977). 
After World War One, the huge incidence in shell shock, which saw 80,000 soldiers afflicted, 
had consequences for theories of hysteria. Perhaps most importantly, the rise of shell shock 
suggested, as Charcot had argued previously, that hysteria was not a disorder afflicting only 
women and that sexual trauma and repression alone could not account for its symptoms. 
Broader accounts of the disorder were needed. 
1.2.5 Modern accounts 
As noted, through the 1930s to the 1960s, Freudian theories saw a resurgence in popularity in 
psychological practice, particularly in the United States. By the end of the 1960s however, due 




medical models within psychiatric training, and advances in the philosophy of science (Popper, 
1963), psychodynamic theories lost favour. Psychoanalytic theory was robustly criticised for 
being immune to scientific testing as nothing could, in principle, falsify them. Wittgenstein 
(1966) likened Freud’s theory to a form of mythology whereby psychoanalysis could provide 
helpful explanations to patients but could not scientifically justify its practices. 
Psychiatry and neurology had fractured as disciplines and in 1959, the Archives of Neurology 
and Psychiatry separated. The new ‘American Medical Association Archives of General 
Psychiatry’ stated the decision was a recognition of “neurology and psychiatry as distinct 
clinical specialities” (Grinker, 1959). For most of the second half of the century, both disciplines 
ignored each other and that schism has mostly continued. Its separation has meant FND 
patients can be left in a kind of medical no-man’s land whereby they may move back and forth 
between neurologists and psychiatrists with little continuity of care and neither clinician 
accepting primary clinical responsibility.  
Along with this institutional and academic separation, hysteria began to fracture as a unified 
diagnosis and differing iterations emerged. In the 1960s, Samuel Guze distinguished between a 
‘conversion reaction’ and ‘hysteria’ writing, ‘conversion symptoms are individual symptoms 
while hysteria is a polysymptomatic disorder’ (Guze, 1967). He defined hysteria as 
‘somatisation disorder’ or ‘Briquet’s syndrome’ and argued that a diagnosis should be based 
on a personal history of at least 25 physical symptoms, beginning before the age of 35. In the 
latest DSM-5 (APA, 2013), somatisation disorder was combined with undifferentiated 
somatoform disorder and is called ‘somatic symptom disorder’, no longer requiring a specific 
number of somatic symptoms for a diagnosis.   
Through the 1950s and 1960s, neurologists grew concerned with the issue of misdiagnosis. 
Eliot Slater, a psychiatrist, argued that misdiagnosis could be as high as 60%, implying that the 
hysteria diagnosis was often one made in error (Slater, 1965). This view has been robustly 
refuted. Stone (2016) argues that Slater confused presumed misdiagnosis with incidental 
diagnoses in his analyses. Nonetheless, Slater’s contribution led to a genuine concern that 
clinicians might misdiagnose FND patients, a concern that continues today (Kanaan, 2009). A 
neurologist contemporary of Slater, argued that his position was adopted so he could avoid 
contact with these patients, “when presented with an essentially curable clinical state that we 
still cannot banish, we suggest to ourselves that there is no such illness” (Walshe, 1965).  
Other theories that developed through the 20th century that have relevance for current 





Illness behaviour theories are sociological accounts of illness which state that different people 
and groups perceive, evaluate and act upon illness in different ways, and these actions are 
influenced by cultural and social expectations (Mechanic, 1962). These sociological accounts 
were the first to help situate illness behaviour within a wider social network while retaining 
the importance of individual belief and behaviour.  
Such theories can be overextended however. This is exemplified in the anthropological work of 
Mark Zborowski (1969). He classified ethnic responses to pain writing, “The Irish display a 
denial of pain, they equate pain with illness and death and so are unwilling to admit to its 
presence and exhibit some degree of martyrdom. Italians suffer loudly and want everyone to 
know about the pain they are experiencing. They enjoy the sympathy of secondary gains 
associated with their verbal reports of pain. Jewish people suffer pain loudly, and family are 
often closely involved with the suffering. Most are concerned with the meaning of pain”. An 
anachronism, Zborowski’s work seems derived from cultural stereotypes rather than evidence.  
Other theories emphasising social context are behavioural learning theories such as classic and 
operant conditioning which have relevance to the treatment of FND today. Pavlov’s (1927) 
classic conditioning theory and Skinner’s (1938) operant conditioning model showed how 
conditioning can create automatic biological and behavioural responses. In FND, anxiety and 
panic may come to signal imminent physical symptoms and patients may take steps to avoid 
situations that believe might heighten such anxiety. These theories are of particular relevance 
to cognitive behavioural therapy (CBT) treatments of FND where patients are taught how to 
recognise avoidant behaviours, as well as other therapies like physiotherapy where clinicians 
adopt positive reinforcement techniques (Nielsen et al., 2014). 
Many psychological theories have been posited over the last two centuries, each with useful 
components. However, like with most psychological disorders, no single framework manages 
to competently explain the disorder and, as discussed, many have limitations. The current, 
most commonly held, medical and psychological explanatory model of FND is the 
‘biopsychosocial’ model (Engel, 1977). This model acknowledges the role of biological and 
psychosocial characteristics but does not assign importance to any single characteristic. One 
criticism of this theory is that in its attempt to explain everything, instead it explains very little. 
However, given the continual theoretical and definitional revisions of FND, and the often 
contentious nature of the disorder itself, a broad, non-prescriptive, agnostic account may be 






Many of the large population-based epidemiological studies of psychiatric morbidity do not 
measure the prevalence of functional disorders due to the difficulty and cost involved in 
excluding neurological disorders on the basis of a questionnaire or interview alone. Studies 
that do attempt this often rely on patients’ recall or GPs’ reports which introduce the 
possibility of recall bias. The expertise of the person making the diagnosis also affects the rate 
of the disorder. Carson et al. (2000) compared GPs’ diagnoses to diagnoses made in neurology 
clinics. GPs’ diagnoses had only slightly better reliability than chance. 
Sar et al. (2009) reported a lifetime prevalence rate of conversion disorder of 48.7% in women 
in the general Turkish population. A one-month prevalence rate of 0.006% was reported in a 
large survey of the Chinese public using the Structured Clinical Interview for DSM-5 (Phillips et 
al., 2009). A one-year prevalence rate in the Italian public was estimated at 0.3% (Faravelli et 
al., 1997). The annual incidence of conversion reactions was 22 cases per 100,000 per year in 
the US and 11 cases per 100,000 in Iceland (Stefansson et al., 1976). Stefansson et al. used a 
psychiatric case register; however the other studies used surveys of the general population 
with no neurological testing, and again are open to biases in recall and reporting.  
Within hospital settings, rates are evidently higher. In a retrospective cohort study of frequent 
attenders in England, Reid et al. (2001) report that 27% of these patients had one or more 
medically unexplained symptoms. In neurology outpatient settings, the rate varies between 
15-35% (Ahmad & Ahmad, 2016; Carson et al., 2000; Fink et al., 2003; Snijders et al., 2004; 
Stone et al., 2009b; Stone et al., 2010a). These studies assessed patients whose symptoms 
could not be fully explained by organic disease but when researchers use official diagnoses 
from the DSM or ICD-10, prevalence rates reduce. One study found 61% of new neurology 
inpatients had at least one medically unexplained symptom, but 35% fulfilled diagnostic 
criteria for an ICD-10 somatoform disorder (Fink et al., 2005).  
There are limited data available on the prevalence of FND in psychiatric settings. Hafeiz (1980) 
report a ‘hysterical conversion’ rate of 7.4% in a psychiatric clinic in Khartoum, Sudan. Liaison 
psychiatrists in general medicine consistently treat functional disorder patients and referral 
rates to them vary between 8 - 16% (Clarke & Smith, 1995; Hyphantis et al., 2009; Lipowski & 
Wolston, 1981). A large study spanning 20 general hospitals found somatoform disorders 
accounted for 4.1% of referrals to liaison psychiatrists of which FND made up 40%, with the 




1.3.2. Socio-demographic factors 
Previous research has highlighted the clinical characteristics linked to FND. These include 
female sex (Ahmad & Ahmad, 2016; Carson et al., 2000; Feinstein et al., 2001; Kim et al., 1999; 
Lempert et al., 1990), lower socioeconomic status (Deka et al., 2007; Maxion et al., 1989; 
Stefansson et al., 1976), exposure to physical and sexual abuse in childhood (Nicholson et al., 
2016; Roelofs et al., 2005), as well as other traumatic life events such as bereavement or 
parental rejection during childhood (Binzer & Eisemann, 1998; Creed et al., 2012; Duncan et 
al., 2006). Patients frequently experience physical precipitating events like head injuries or 
trauma (Binzer et al., 1997; Pareés et al., 2014). Patients may have been exposed to family or 
friends with an organic movement disorder (Pellicciari et al., 2014) and neurological disease 
has been estimated to affect one in ten cases of FND (Stone et al., 2012a). 
1.3.3 Comorbidity 
Psychological comorbidities are high in FND and consistently higher than rates seen in 
equivalent organic disorders. Depression and anxiety are consistently reported and the rates 
vary between 20-40% (Binzer et al., 1997; Carson et al., 2011; Defazio et al., 2017; Lempert et 
al., 1990; Marsden, 1986; Raskin et al., 1966). It is important to note that depression does not 
affect all patients. Feinstein et al. (2001) reported rates of depression similar to those seen in 
healthy controls. Depression can be difficult to ascertain in FND however as patients may be 
concerned clinicians might dismiss organic illness if they disclose psychological symptoms 
(Stone et al., 2010b).  
Personality disorders are a controversial area in the field. Given their potential lack of clinical 
utility many clinicians may wish to avoid giving a personality disorder diagnosis altogether. 
Despite this, in studies that have measured personality disorder, rates are relatively high, 
ranging between 16-50% (Binzer et al., 1997; Defazio et al., 2017; Folks et al., 1984; Ljungberg, 
1957; Scévola et al., 2013).  
1.3.4 Cost and disability 
The cost of FND to the exchequer is substantial. A study by Barsky et al. (2005) reported 
patients with somatisation disorder in the US have more primary care, emergency department, 
and hospital visits, higher inpatient costs, and higher outpatient costs with the total cost, at 
the national level estimated to be $256 billion a year.  
In the UK, patients with FND, admitted to a district general hospital, stay for an average of 17 
days and have up to eleven scans during that period. The average cost to the hospital over two 




to be €5429 per patient and the national annual cost of these conditions to the Irish exchequer 
is €27 million annually (Magee et al., 2014). A systematic review on the economics of FND 
reported significant expenditure, with excess costs ranging from $430 to $5300 per patient 
(Konnopka et al., 2012).  
The cost to the individual is also high with high levels of disability experienced by patients and 
has been reported to be comparable with severe neurological disorders. Many patients remain 
chronically ill after a diagnosis (Feinstein et al., 2001; Williams et al., 1995), leading to 
continued disability at work and home. Carson et al. (2011) report that 50% of patients with 
unexplained symptoms in a neurology outpatient clinic were unemployed and 20% received 
income support or unemployment benefits, and 27% received incapacity benefits. The receipt 
of benefits was significantly higher in these patients than in patients with organic neurological 
disease. The burden of the disorder is therefore high, both for health care systems and 
patients themselves.  
In conclusion, FND is a disorder with a rich and varied history, and perhaps the first modern 
psychological syndrome. Theoretical understanding and scientific accounts of the disorder 
have suffered due to the separation of neurology and psychiatry as disciplines and modern 
dualistic conceptualisations of the mind and body. Despite this, it is a disorder that exists in the 
modern world, with a high cost and disease burden. It has its own socio-demographic profile, 
albeit one that may vary depending on the settings and the techniques used to identify it.  
1.4 Aims of thesis 
Our historical description of FND, through its various nosological forms, highlights the changes 
in medical and psychological accounts of the disorder and its relative stability as a reliable 
diagnosis. Unexplained physical symptoms are common and they occur in every known 
medical setting from dentistry through to cardiology and gastroenterology (Nimnuan et al., 
2001). While these patients might not necessarily qualify for an FND diagnosis, their presence 
suggests that regardless of speciality, physicians routinely encounter patients with unexplained 
or functional symptoms.  
Medicine, in response to advances in medical science and technology has become more 
specialised and, with exceptions like primary care and general medicine, most physicians and 
surgeons are trained in only some kinds of medical care. In 1960 for instance there were 18 
speciality medical boards in the US, and by 2011 there were 158 (Detsky et al., 2012).  
The development of specialised services and accompanying medical subspecialties along with a 




in newly developed services. Recent examples of this include the presentation of patients with 
medically unexplained visual loss to a specialist neuro-ophthalmology clinic (O'Leary et al., 
2016) and a study which reported that 84% of patients who received an emergency lumbar 
magnetic resonance imaging (MRI) scan for suspected cauda equine syndrome did not have 
the disorder. Scan-negative patients were more likely to be female and younger, and a 
proportion went on to receive psychiatric follow-up (Gibson et al., 2017).  
Where new medical or neurological services are set up to accommodate the treatment of 
specific physical disorders or to improve access to new diagnostic techniques, it is likely that 
FND patients will form part of presentations to these services. One question related to this is 
whether the patients with unexplained neurological symptoms attending new types of services 
have similar symptoms to FND patients attending other services. Are their symptoms 
transitory for instance or do they follow a chronic course of the illness?  
A previously unexplored medical specialty in which new manifestations of FND may present is 
to hyper acute stroke care. Hyper acute stroke units (HASUs) were established in London in 
2010 in a bid to increase the application of stroke medicine, reduce admission times and 
mortality. Inevitably, FND patients enter the hyper acute stroke pathway. Stroke medicine 
routinely accounts for the rate of patients presenting to stroke services who have symptoms 
that mimic stroke, (‘stroke mimics’) but often give little detail regarding who these patients are 
and where they go after their admission. Apart from one previous paper by Garagalas et al. 
(2016), no research has specifically focused on the proportion of stroke mimics with a 
functional explanation for their symptoms. Anecdotally, clinicians were at a loss as to how to 
treat these patients as there are no guidelines on the treatment or referral of FND patients 
from HASUs. Chapter Two of this thesis aims to establish the prevalence rates of FND patients’ 
presentations to stroke settings and to investigate the socio-demographic and clinical factors 
associated with these presentations.  
Hyper acute stroke care is a relatively recent phenomenon. Chapter Three aims to investigate 
and describe the attitudes, opinions and experiences of hyper acute stroke clinicians towards 
FND patients in stroke settings through the use of a large survey and a series of semi-
structured interviews.  
While Freud was the first to emphasise the importance of listening to the stories and 
experiences of patients, surprisingly little research has focussed on FND patients’ voices or 
views, particularly regarding their own treatment. Chapter Four aims to investigate the 
attitudes and experiences of patients with unexplained stroke symptoms admitted to a HASU 




role that patients’ illness perceptions play in the maintenance of symptoms. This study uses 
semi-structured interviews and two-month follow-up interviews as well as the Brief Illness 
Perception Questionnaire. 
Pervasive throughout FND research is a lack of large sample sizes. The predominance of 
evidence comes from medical and neurology settings, often in the form of case studies. While 
there is some evidence to suggest that most FND patients consider that they have a 
neurological disease (Stone et al., 2004a), a proportion of these patients will be referred to 
psychiatric services. Little is known about who these patients are, whether they differ to other 
patients receiving psychiatric interventions, and how they respond to treatment. 
Chapter Five attempts to address the lack of statistical power in previous research by utilising a 
large retrospective database to assess the presentation of patients with FMD. We first 
established a cohort of patients with FMD and examined their socio-demographic, and health 
factors, as well as their life experiences, and clinical outcomes. The characteristics of this group 
were compared to a random sample of psychiatric patients derived from the same database, 
which allowed comparisons of clinical factors and the identification of risk factors in FMD 
presentations.  
The final study addresses the lack of existing research on the effectiveness of psychological 
treatments for FMD. Using the same database, Chapter Six assesses the effectiveness of CBT 
for FMD patients delivered in a neuropsychiatry outpatient clinic. The study aims to investigate 
the outcomes of FMD patients who received CBT treatment compared to patients with organic 
disorders treated in the same clinic. We also sought to compare CBT-uptake rates, dropout 
rates, the rate of physical symptom improvements and the change in acceptance of 
psychological explanations between the start and end of therapy, and clinical outcomes.  
Chapter Seven describes findings within the context of existing literature, compares findings 
from across the five studies and makes recommendations for future service provision and 




Chapter Two: A systematic review and meta-analysis of the prevalence of stroke mimics and 






Stroke is the world’s third most common cause of death after ischaemic heart disease and 
cancer (Warlow, 2003). In 2007, there were 125,945 reported strokes across England 
(Townsend, 2012). Of stroke patients, approximately 40,000 will die of the disease (Mackay, 
2004). In 1990, stroke accounted for 3% of the world’s disability burden (Warlow, 2003) and as 
the proportion of older adults across the globe increases, the rapid and accurate diagnosis of 
stroke has become increasingly important (Royal College of Physicians Sentinel Stroke National 
Audit Programme, 2014; Townsend, 2012).   
Given its worldwide burden, continual attempts are made to improve stroke detection and 
outcomes. This has led to an emphasis on rapid hospital admission and treatment. There has 
been a drive to both improve services and increase public awareness of symptoms. This has 
meant, inevitably, that patients, whose symptoms ‘mimic’ stroke, end up in stroke services. 
Many medical diseases and disorders can mimic stroke like headache, brain tumours, seizures, 
infection, and vertigo. A proportion of stroke mimic patients have a functional disorder and, 
potentially, a psychological explanation for their presentation.  
In this chapter, the term ‘medical mimics’ will be used to refer to differential stroke diagnoses 
which have a medical etiology, while ‘functional mimics’ will refer to patients with functional, 
psychological, or medically unexplained symptoms.  
This study is a systematic review and meta-analysis assessing the proportion of stroke mimic 
and functional mimic patients presenting with suspected stroke. This introduction outlines the 
diagnosis and treatment of stroke, the restructuring of stroke care in London, public health 
campaigns to increase awareness of stroke, existing literature on the demographic and clinical 
features of stroke mimic and functional stroke patients, before outlining the aims of this study. 
2.1.1 Stroke pathway 
2.1.1.1 Stroke definition  
Stroke is defined as the “rapid onset of focal or global cerebral deficit, lasting more than 24 
hours or leading to death, with no apparent cause other than a vascular one” (WHO, 1992). 
Stroke symptoms can include paralysis on one side of the body, sudden loss or blurring of 
vision, numbness, dizziness, confusion, difficulty understanding words, balance problems, 
difficulty swallowing, sudden severe headache, and loss of consciousness.  




Haemorrhagic strokes account for 20% of all strokes and are associated with a higher risk of 
mortality compared to ischaemic strokes (Royal College of Physicians, 2014).  
There are many stroke risk factors including older age, cigarette smoking, diabetes, and obesity 
(Prospective Studies Collaboration, 2002), a history of atrial fibrillation, hypertension, diabetes, 
coronary heart disease, and hyperlipidemia (Merino et al., 2013). 
2.1.1.2 Stroke diagnosis and treatment 
The stroke pathway has three distinct phases, the emergency setting, the acute phase, and 
rehabilitation.  
Paramedics are usually the first clinicians to assess stroke, attending up to 70% of patients 
eventually admitted to hospital (Lacy, 2001). They have an average diagnostic accuracy of 
between 80-95%, but often don’t correctly identify stroke mimic patients (Kothari et al., 1995). 
The Los Angeles Prehospital Stroke Screen, the Cincinnati Prehospital Stroke Scale, the 
Melbourne Ambulance Stroke Screen (Kidwell, 2000) and the Face Arm Speech Test (FAST) in 
the UK are some of the screening measures developed to improve paramedics’ identification 
of stroke, and to help standardise its evaluation.  
The FAST test is used by the London Ambulance Service. It assesses facial droop, arm drift and 
speech changes or slurring of speech, emphasising the importance of time. The Recognition of 
Stroke in the Emergency Room (ROSIER) scale (Nor et al., 2005) was developed for use in the 
emergency room but is also currently being trialed by ambulance services in North East 
London in attempts to improve the diagnosis of stroke.  
Once relayed to hospital, brain imaging is the most common method of diagnosis. Computed 
tomography (CT) is the gold standard diagnostic tool for the diagnosis of acute haemorrhage 
within the first week of stroke onset (Warlow, 2003). A normal CT scan does not immediately 
imply stroke-free status. Even though CT scans can detect haemorrhagic strokes, they only 
have 40% sensitivity for the confirmation of acute ischaemic stroke (Mullins et al., 2002).  
Brain MRI with diffusion weighted imaging is highly sensitive and specific for the detection of 
early cerebral ischaemic stroke (van Everdingen, 1998) and is more sensitive than a CT scan 
(Brazzelli, 2009). MRI scans are costly however and take time to administer (Vymazal et al., 
2012). In addition, they may not identify an acute haemorrhage within the first hours of onset 
as a hematoma can be mistaken for a tumour (Warlow, 2003). They are often ordered for 
patients with more complex symptoms where the potential location of the stroke is unknown. 
The sensitivity of both CT and MRI techniques decreases as time passes. A combination of 




Stroke treatments include surgical interventions, reversal of anticoagulation and most 
commonly, the administration of the clot-busting medication, thrombolysis. Like the receipt of 
a diagnosis, these treatments are time-critical. Thrombolysis should ideally be given within 3 
hours, but not after four and a half hours of symptom onset (Wardlaw et al., 2014).  
The detection of stroke is not straightforward. Fast diagnosis and treatment is paramount to 
survival and future outcomes. The risk threshold for a clinician to admit and treat a potential 
stroke will generally be low, and as a result, patients with differential diagnoses can enter the 
stroke system.  
2.1.1.3 Restructuring stroke care in London 
Prior to 2010, London’s stroke system was underperforming in comparison to the rest of the 
UK. The system included 30 local hospitals providing care for acute stroke and there was wide 
variation in the number of patients treated across London. While most strokes occur in the 
outskirts of the city where more elderly and poorer populations live, at the time, most stroke 
beds were located within inner London.   
In 2006, a report recommended greater specialised acute stroke care through dedicated, high-
volume, specialised stroke units providing care to patients in the 72 hours after stroke onset 
(Healthcare for London, 2007). The overall aim was to provide rapid assessment and treatment 
for stroke patients in London, regardless of their location within the city, or the time of stroke 
onset. In July 2010, services were restructured and eight HASUs were established.  
The change in stroke care led to improvements in stroke patients’ outcomes. The thrombolysis 
rate in 2013 in London increased to 17% compared to an English average of 12% (Royal College 
of Physicians, 2014). The stroke survival rate also increased from 87.2% to 88.7% (Hunter et al., 
2013) and this decline in mortality was sustained 90 days after discharge. Additionally, the 
length of hospital stay reduced (Morris et al., 2014). The HASU model’s success has led to its 
uptake in urban regions outside London including Manchester, Newcastle, and Southampton.  
While the restructuring of services has brought positive change for stroke patients, functional 
patients also enter the hyper-specialised pathway but are often promptly discharged from 
services and are provided with little support or aftercare.  
2.1.1.4 Public awareness campaigns 
In conjunction with the re-organisation of stroke services, there has been a global drive to 
improve the public’s awareness of the signs of stroke. A public health campaign run by the 




through national media campaigns, community stroke screening events and patient 
education2. Figure 2 displays an example of a poster used by the campaign.  
 
Figure 2 Campaign poster from the UK’s Department of Health (2007) public awareness of 
stroke campaign 
Following the campaign, a time trend analysis showed increased public interest in stroke-
related information through access to resources like websites, webpage views, and calls to 
stroke helplines (Flynn, 2014). There were increased stroke-related emergency admissions and 
increased thrombolysis administration. Mass media campaigns targeting the public’s 
awareness of stroke in Ireland in 2010 demonstrated a significant increase in the attendance 
to emergency departments after the campaign (Mellon, 2013), although a study in the Czech 
Republic demonstrated less success in the improvement of public awareness of stroke 
(Mikulik, 2011).  
Publicly available data from ‘Google Trends’ shows searches for terms like ‘stroke’ have 
increased over the past decade on the search engine3. Figure 3 shows (A) a steady increase in 
the proportion of UK Google searches for the terms ‘FAST’ and ‘stroke’ from January 2008 to 
January 2017 and (B) an increase in the proportion of worldwide searches for the term ‘stroke’ 
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   (A)                                                                                 (B)  
Figure 3 Increases in internet interest in the signs of stroke. Graph A shows increases in 
frequency of UK Google searches for the terms ‘FAST’ and ‘stroke’ between 2008-2017, Graph 
B shows increases in worldwide Google searches for the term ‘stroke’ over the same period 
It is possible that these trends reflect an increased interest in medical terms and symptoms 
generally or increased access to the internet, rather than public knowledge or interest in 
stroke specifically. The results may also reflect increases in the global burden of diseases 
related to population ageing, however Google searches for Alzheimer’s disease, also a disease 
affected by ageing populations, do not show the same positive trend.  
It is likely that these public awareness campaigns have contributed, at least partly, to 
knowledge and interest in the signs and symptoms of stroke and this has led to increased help-
seeking from stroke services. This, in turn, may have led to higher rates of false positive 
admissions to stroke settings where people misinterpret physical symptoms as stroke and seek 
medical intervention. While the re-organisation of services has helped improve stroke 
outcomes, larger numbers of stroke mimic patients may be admitted to services (Kwan et al., 
2004). 
2.1.2 Stroke mimics   
Stroke mimic patients display stroke-like symptoms that are not explained by stroke. A 
systematic review by Gibson and Whiteley (2013) reported that stroke mimics make up 20-
25% of suspected stroke diagnoses and they present to primary care, emergency, secondary 
and acute settings, with the highest rate of stroke mimics found in ambulatory settings. They 
report that the most frequent stroke mimic diagnosis was seizure (19.6%), followed by 
syncope (12.2%). Functional patients made up 7.4% of stroke mimic patients.  
Diagnosing and treating stroke mimic patients is costly. In the United States, the excess direct 





Some studies have attempted to identify stroke mimics’ distinguishing features. Current data 
suggests stroke mimic patients are more likely to be female, African American rather than 
Caucasian, and more likely to arrive at the emergency department in a private vehicle than 
ambulance (Merino et al., 2013). Stroke mimic patients are also likely to be younger than 
stroke patients. Vroomen et al. (2008) reported that of patients aged under-50, the stroke 
mimic rate was 21%, but amongst patients aged over-50, the stroke mimic rate was much 
lower at 3%.  
Stroke mimics have less severe deficits at baseline and have a shorter symptom onset-to-
treatment time compared to stroke patients (Chen et al., 2011). Furthermore, they are more 
likely to have a history of cognitive impairment and to present with aphasia, but are less likely 
to have a history of hypertension or to display facial palsy, sensory loss or visuo-spatial neglect 
(Forster et al., 2012). Stroke mimics were less likely to have experienced a loss of 
consciousness or seizure when their symptoms began (Hand et al., 2006) and they have lower 
ROSIER scores than stroke patients (Edwards et al., 2015). 
The current protocol for the management of stroke mimic patients in HASUs is their 
repatriation to an ‘appropriate medical setting within 24 hours of the non-stroke diagnosis 
being made’ or direct discharge home (NHS London Strategic Clinical Networks, 2014). There 
are no specific guidelines on functional mimic patients. Patients with a non-stroke diagnosis 
and a non-medical explanation for symptoms who are admitted into a stroke pathway will 
likely be discharged quickly. Problems may further arise as the planning document for the 
restructuring of stroke services anticipated a stroke mimic rate to HASUs of 15%, a potential 
underestimate (Healthcare for London, 2009), substantially less than the 24% rate reported in 
Gibson and Whiteley’s (2013) paper.  
2.1.2.1 Functional stroke mimic patients 
Gibson and Whiteley’s (2013) systematic review was the first to provide an aggregated figure 
of the proportion of stroke mimics who have a functional disorder. As mentioned, they report 
that 7.4% of stroke mimic patients have FND, and a further 5% have ‘non-specified’ symptoms.  
From individual studies, the rate of functional stroke patients has been reported to be as high 
as 38 - 41% (Gargalas et al., 2015; Scott & Silbergleit, 2003; Vroomen et al., 2008). These high 
rates might be partly explained by the fact Gargalas et al. (2015) specifically aimed to assess 
the stroke mimic rate, making use of neuropsychiatry experts to make the functional diagnosis, 
while Vroomen et al. (2008) listed no ‘other’ or miscellaneous category.  




of functional patients’ attendance at differing medical services, they included only prospective 
studies and reported only one moderating factor, the influence of the medical setting on the 
stroke mimic rate.  
Little is known about the demographic or clinical features of FND patients who present to 
stroke settings, with most information coming from case series. Gargalas et al. (2015) 
examined the distinguishing features of functional mimic patients. Functional patients were 
younger than both medical stroke mimics and stroke patients, were most likely to present with 
isolated weakness followed by slurred speech and compared to medical mimics were more 
likely to have symptoms of depression, back pain, migraine, and asthma. Functional mimic 
patients were more likely to be discharged directly home compared to medical mimics and 
stroke patients. After follow-up, they reported that of those patients for whom data were 
available, 59% of patients had been referred to another service after their admission, and this 
was most frequently to the ‘Improving Access to Psychological Therapies’ (IAPT) service.  
2.1.3 Study aim 
The care pathway for stroke patients is established and effective but there is little clinical or 
research interest in the treatment of patients with functional disorders who are admitted into 
the stroke pathway. With the exception of Gargalas et al.’s (2015) study, little is known about 
these patients, their prevalence, or their demographic features. 
Receiving invasive or unwarranted treatment may have harmful physical and psychological 
effects. Stroke mimic and functional patients may face negative consequences due to delays in 
receiving the correct diagnosis and treatment. Functional disorder patients have been treated 
with thrombolysis, and while the medication appears safe, the lack of guidelines on the care or 
appropriate referral of these patients within stroke centres is conspicuous.  
This chapter outlines a study on the prevalence of functional patients who are referred to 
stroke services. This systematic review and meta-analysis aims to:  
I. Review the literature on stroke mimic patients and functional stroke mimic patients;  
II. Establish the demographic and symptom profiles of functional patients;  
III. Determine the proportion of patients presenting to acute emergency, medical or stroke 
services who had a stroke mimic diagnosis;  
IV. Determine the proportion of stroke mimics who have a functional disorder diagnosis;  
V. Assess the effect of moderating factors on the rate of stroke mimic and functional 
diagnoses including the diagnosis site, study design, exclusion criteria, countries’ 





This review was registered with the National Institute for Health Research’s International 
Prospective Register of Systematic Reviews (PROSPERO) on the 31st October 20144.  
This study aimed to review all published reports of the prevalence and incidence of stroke 
mimic patients across all clinical settings.  
A literature search was performed in two stages. The first search took place in October 2014 
and a second search, using more comprehensive search criterion, began in June 2015 and was 
completed in April 2016.  
2.2.1 First literature search 
The first literature search was performed using the following databases: CINAHL, PubMed, 
OvidSP and Google Scholar. The search term “stroke mimic*” was used. Grey literature and 
conference proceedings were excluded.  
The first database searched was CINAHL. CINAHL is an index of English-language journal 
articles about nursing and biomedicine. This search began on 21st October 2014 and returned 
62 papers. After a review of abstracts, 27 papers were chosen for further review on the 21st 
October 2014.  
OvidSP was searched on 22nd October 2014. OvidSP is a gateway programme for the databases 
Embase (searched from 1980 to October Week 2, 2014), PsychINFO (searched from 1806 to 
October Week 3, 2014) and Ovid Medline (searched from 1946 to October Week 2, 2014). The 
search term produced 397 papers. On 21st November 2014, 144 papers were chosen which 
met the inclusion criteria.  
PubMed was searched on 27th November 2014. PubMed accesses the MEDLINE database 
which comprises abstracts on life-sciences and biomedical topics. The search resulted in 173 
papers. A total of 44 papers were chosen for inclusion on 27th November 2014.  
The final database searched was Google Scholar. Google Scholar includes most peer-reviewed 
online journals of Europe and America’s largest publishers. The search engine does not publish 
the exact size of the search. Of 200 relevant search results reviewed, 29 were chosen for 
inclusion on 28th November 2014.  
The total number of papers at this stage of the review was 244. The full version of each study 
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was read and reviewed and 210 papers were excluded based on the inclusion criteria. Figure 4 
shows a flow chart displaying the first search strategy as well as the reasons for papers’ 
exclusion.  
2.2.2 Second literature search 
To ensure a comprehensive search, a second search began in June 2015.  
The search strategy used here was: [(Suspect* adj (((Cerebr* or intracerebral or brain) adj 
(ischem* or haemorrhage* or hemorrhage or bleed* or infarct*)) or (Stroke or brain attack or 
cerebrovascular attack or cva))).tw.] or [((Mimic* or differential or misdiagnos*) adj3 
(((Cerebr* or intracerebral or brain) adj (isch?em* or haemorrhage* or hemorrhage or > 
bleed* or infarct*)) or (Stroke or brain attack or cerebrovascular attack or cva))).tw.] or 
[*stroke/di]. The search results were limited to humans. 
This search utilized OvidSP searching the databases PsychINFO, Embase and Ovid Medline. The 
search returned a total of 11,915 papers. The title and abstracts of these papers were read and 
311 were chosen for more in-depth reading. 109 of these papers were then chosen as 
potential papers for inclusion. 53 papers were then chosen and 56 excluded.  
The total number of papers included from both search one and search two in this study is 87.  











































2.2.3 Inclusion and exclusion criteria 
 
The following inclusion and exclusion criteria were applied at each reviewing stage during the 
search process:  
Studies were included if:  
I. They reported the proportion of patients with a final diagnosis of stroke mimics 
from a sample of suspected or confirmed stroke patients; and 
II. They reported on a series of consecutively eligible patients. 
Studies were excluded if:  
I. They were not available in English; 
II. They were ‘grey’ literature’; or 
III. The sample included Transient Ischemic Attack (TIA)-only patients. 
832 titles returned 




Reasons for exclusion:  
Conference abstract: 96 
Duplicate: 75 
Not relevant to review:  29 
Only in foreign language: 6 
Not available: 2 
Emailed author, no reply: 1 









Reasons for exclusion:  
Not relevant to review: 
34 
Not available: 12   
Only in foreign 
language: 7 
Conference abstract: 1 
Dataset used in a paper 













2.2.4 Data extracted 
Data were extracted on country, study design, data collection, time period, sample size, 
average age of sample, gender of sample, stroke prevalence, stroke mean age, gender of 
stroke sample, number of reported stroke mimics, proportion of stroke mimics, mean age of 
stroke mimics, gender of stroke mimics, proportion of stroke mimics who have a functional 
disorder, gender of functional disorder patients, mean age of functional patients, the most 
common stroke mimic diagnosis, site of diagnosis, the method used to diagnose stroke mimics, 
and whether thrombolysis was administered to stroke mimics.  
A quality score was calculated for each study. These were based on a criterion outlined by 
Kmet et al. (2004) who developed a checklist for judging the quality of quantitative studies. 
Table 70 (“Appendix 2.1: Checklist for the assessment of quality of quantitative studies”) gives 
this checklist.  
There are 14 items scored depending on the degree to which each specific criteria was met 
(“yes” = 2, “partial” = 1, “no” = 0). Items not applicable to the study design in question were 
marked “NA” and were not included in the summary score. A summary score was calculated 
for each paper by summing the total score obtained across all relevant items and dividing by 
the total possible score. 
2.2.5 Statistical analysis 
The systematic review data were analysed using Excel Version 14 and SPSS Version 22 
(Chicago, IL, USA). Data are expressed as numbers and proportions. Independent sample t-
tests were used to compare age data between groups and chi-square tests compare gender 
proportions. P-values less than 0.05 were considered statistically significant. Comprehensive 
Meta-Analysis (CMA) Version 3.3 (Biostat Inc., Englewood, NJ, USA) was used to conduct the 
meta-analysis. Random-effects models were used to calculate prevalence and summary 
statistics. This model was used as it assumes variance in effect sizes between studies and 
makes inferences about the parameters of the population of studies that is likely larger than 
the set of observed studies (Hedges & Vevea, 1998). The I2 statistic was used to assess 







2.3.1 Systematic review 
The search returned 87 relevant papers. The average sample size was 808.4 patients. The 
largest study was a prospective quality improvement initiative at two hospitals in the US with a 
sample size of 8187 patients (Merino et al., 2013). The smallest study was conducted by 
Dassan et al. (2012) with 44 patients in total, a prospective study testing the utility of a 
biomarker in the assessment of stroke.  
Articles originated from twenty-two countries, with the US contributing the most studies 
(n=33), followed by the UK (n=16) and Germany (n=8). Six of the included papers were 
published in low-income countries. Figure 5 shows the distribution of studies according to their 
country of origin.  
 
Figure 5 Geographical distribution of regions in which studies were based 
75% of studies (n=65) were published after 2008, possibly reflecting increasing interest in the 
topic of stroke mimic patients, government responses’ to ageing populations, the increasing 
economic cost of cardiovascular disease, and the push to improve stroke services. The 
remaining studies (n=22) were published between 1982 and 2007.   
Of the medical settings in which studies were based, the most common was the emergency 
department (n=28), followed by stroke units (n =15), acute stroke centres (n=11), and hospitals 
(n=11). One paper reported stroke mimic rates across three settings (Harbison et al., 2003a) 
and five papers reported stroke mimic rates across two medical settings (Berglund et al., 2014, 
El Husseini & Goldstein, 2013, Ferro et al., 1998, Karlinski et al., 2015, & Ramanujam et al., 
2008). The rest reported rates from one setting alone.  
A prospective study design was employed in 46 (53%) studies and the remainder utilised a 




four papers were validation studies of screening tools of which five aimed to assess the 
efficacy of biomarkers in assessing stroke. Twelve studies were audits of services; six 
investigated the validity of clinicians’ diagnostic skills, while the remaining three were 
descriptive studies.  
Data were extracted on whether stroke mimic patients in the study had received thrombolysis 
treatment. Most commonly, no information was available on whether stroke mimic patients 
had received thrombolytic treatment (n = 54). In 19 studies, all stroke mimic patients received 
tissue plasminogen activator (rt-PA). In ten studies, stroke mimic patients did not receive any 
thrombolysis treatment and in four papers, some stroke mimics received treatment while 
others did not.  
The mean quality score was 69.3% (SD: 17.1%, range: 16.6 – 94.4). The paper with the lowest 
score (16.6%) was Martínez Fernández et al.’s (2012) paper, a prospective paper investigating 
emergency doctors’ diagnostic accuracy. The highest scoring paper (94.4%) was by Foerch et 
al. (2012), a study investigating the diagnostic accuracy of plasma glial fibrillary acidic protein 
in distinguishing intracerebral haemorrhage from cerebral ischemia.  
2.3.1.1 Exclusion criteria 
Exclusion criteria of some kind were applied to study samples in 63 papers, leaving 22 with no 
recruitment restrictions, and two papers not stating whether they used selection criteria.    
The most common exclusion criterion was patients not given thrombolysis treatment (applied 
in 17 papers), patients with incomplete data (applied in 16 papers), and patients aged under-
18 (applied in ten papers). Moeller et al. (2008) excluded patients aged under-16. One paper 
reported stroke mimic rates in a paediatric sample (Shellhaas et al., 2006) and one study 
investigated rates in a sample restricted to the over 65’s (Kose et al., 2013). Herzberg et al. 
(2014) excluded patients whose initial clinical exam showed no sign of stroke, potentially 
leading to a reduced rate of stroke mimic patients.  
Table 71-75 (see “Appendix 2.2: Exclusion criteria applied across all studies”) outlines all of the 
exclusion criteria applied in each study.  
2.3.1.2 Stroke definitions 
Stroke is a heterogeneous disorder and case definitions of stroke and stroke mimics varied 





Twenty papers compared stroke mimic patients to stroke and TIA patients. Fifteen papers 
classified strokes as ‘stroke’ with no further detail, twelve examined only ischemic stroke and 
five examined ischemic stroke, TIA and intracranial haemorrhage patients combined. The rest 
used a variety of stroke definitions and combinations of stroke types.  
In studies where TIA and subarachnoid haemorrhage patients were categorised as stroke 
mimic patients, these patients were reclassified as stroke for the purposes of this review and 
meta-analysis (see Table 76, “Appendix 2.3 Definitions of stroke across papers”).  
2.3.1.3 Stroke mimic diagnoses 
Seventy-one papers listed stroke mimic diagnoses.  
The stroke mimic diagnosis which was frequently the most common across all studies was 
seizure (across 22 papers, it was the most frequent diagnosis), followed by functional disorder 
(the most frequent diagnosis in 14 papers), and migraine (the most frequent diagnosis in 
eleven papers). See Table 77, “Appendix 2.4: Most common stroke mimic diagnoses across 
studies” for a breakdown of the most frequently occurring stroke mimic diagnoses. 
2.3.1.4 Functional disorder definitions 
A range of terms were used to describe patients with functional symptoms. Table 78 
(“Appendix 2.5: Functional disorder synonyms across studies”) lists the terms used and their 
frequency of use. The most commonly used term was “conversion disorder” appearing 19 
times across studies, followed by the term “functional”, occurring ten times, and “psychiatric”, 
which occurred seven times.  
One study used the terms “anxiety” and “depression”, as well as “conversion disorder” (Ferro 
et al., 1998). In this study, two patients referred from the emergency department with 
suspected stroke were later given a diagnosis of anxiety, one was given a diagnosis of 
depression, and two were given a diagnosis of conversion disorder. While the paper 
distinguished between these diagnoses in their table, in the text the authors refer to all 
patients as ‘psychiatric’. For the purposes of our review, all three terms were regarded as 
functional mimic cases. 
2.3.1.5 Stroke and stroke mimic demographics 
The total number of patients with suspected stroke was 70,333 of whom 55,625 had a stroke 
diagnosis confirmed and 14,708 were diagnosed with conditions mimicking stroke. Of patients 




Fifty papers reported their entire samples’ average age, giving a weighted mean of 68.2 years 
of age (SD: 3.8). Thirty-five papers reported stroke patients’ mean age, giving a weighted mean 
of 69.7 years (SD: 2.2). Thirty-four papers reported stroke mimics’ mean age, giving a weighted 
mean of 63 years (SD: 6). A t-test for unequal variances found stroke mimic patients were 
statistically significantly younger than stroke patients (t = 87.3, df = 6801, two-tailed p = 0.001). 
Fifty-one papers gave a gender breakdown of all patients. The total rate of all female patients 
was 50.2%. Thirty-four papers reported the rate of female stroke patients (46.3%) and 38 
papers reported the rate of female stroke mimic patients (56.8%), a significant difference (χ² = 
227.6, df = 1, p = 0.001).  
Table 1 outlines the age and gender of stroke and stroke mimic patients. 
Table 1 The age and gender characteristics of stroke and stroke mimic patients 
 














68.2 (40,859) 69.7 (26,017) 63 (6,363) 0.001 
Female rate (%)
b
 20887/41610 (50.2) 9296/20082 (46.3) 3945/6944 (56.8) 0.05 
a 
Stroke v. stroke mimic patients: t = 87.3, df = 6801, two-tailed p = 0.001. 
b
 Stroke v. stroke mimic patients: χ² = 227.6, df = 1, p = 0.001 
 
2.3.1.6 Functional disorder demographics and symptoms 
In 16 papers, there was no breakdown of stroke mimic patient diagnoses at all. In five, only a 
partial account of stroke mimic diagnoses was given. Of the 66 papers giving some form of 
stroke mimic diagnosis breakdown, in eight, functional disorder was not listed as a diagnosis 
but the disorder may be masked within the catch-all, miscellaneous categories, termed ‘other’. 
Three papers gave full accounts of stroke mimic patient diagnoses but did not list a functional 
disorder (signifying a true rate of ‘zero’ functional disorder events). In total, this left 55 papers 
reporting positive functional disorder event rates.  
One would expect functional disorders to feature as a diagnosis amongst stroke mimic 
patients. Because of this, the three papers reporting a zero functional disorder rate with no 
‘other’ category were carefully assessed. These are outlined in Table 79 (see “Appendix 2.6: 
Studies reporting no FND patients in their stroke mimic breakdown”). Two of the three studies 
(Bray et al., 2005; Kothari et al., 1995) were from ambulatory settings where clinicians may feel 
less informed or less willing to give a functional diagnosis, particularly given the potential risk 
in misdiagnosing stroke. Foerch et al.’s (2012) study reported only three stroke mimic patients 




Of the 55 papers reporting a positive functional disorder rate, ten reported the gender profile 
of functional patients (n=173), eleven reported functional patients’ ages (n = 177), and nine 
gave information on presenting symptoms (n = 160). From the same pool of participants, data 
from medical mimics were extracted (i.e. stroke mimic patients with a medical explanation for 
their symptoms).  
Of these patients, the weighted mean age of functional disorder patients was 51.6 (SD: 6.5) 
while the weighted mean age of medical mimics was significantly higher at 63.8 years (SD: 4.7) 
(t = 22.8, df = 246, p = 0.001). The pooled proportion of female functional disorder patients 
65.9% while the pooled rate of female medical mimic patients was 50.6%, a statistically 
significant difference (χ² =12, df = 1, p = 0.005).  
Information on functional patients’ presenting symptoms was available from nine papers. The 
types of symptoms that functional and medical mimics presented with were examined. 
Patients in both groups could present with more than one symptom. Symptoms were grouped 
in categories and necessarily, symptom categories became broader so some nuance was lost.  
Weakness and numbness were the most common symptom for both functional (63.3%) and 
medical mimic patients (48.6%), but functional disorder patients were significantly more likely 
to present with weakness or numbness, and significantly less likely to present with reduced 
consciousness. From these nine papers, there were no reports of functional mimic patients 
presenting with seizures or convulsions. Disorders of speech and language comprehension, 
such as dysarthria, dysphasia and aphasia were the second most common symptom type in 
both groups.  
Table 2 below gives a breakdown of age, gender and symptoms across these studies while 
Table 80 (“Appendix 2.7: Age and gender of medical mimic and functional mimic patients from 




















Total n  482 177 
 Mean age (SD)
a
 63.8 (4.7) 51.6 (6.5) 0.05 
Females
b
 243 (50.6) 114 (65.9) 0.05 
Symptoms
b
    
 
Weakness or numbness  287 (48.6) 167 (63.3) 0.05 
 
Reduced consciousness  46 (7.8) 7 (2.7) 0.001 
 




 35 (5.9) 11 (4.2) > 0.05 
 
Dysarthria, dysphasia, aphasia or anomia  101 (17.1) 41 (15.5) > 0.05 
 
Seizures or convulsions  2 (0.3) 0 (0) > 0.05 
 
Cognitive impairment, confusion, or memory loss  40 (6.8) 14 (5.3) > 0.05 
 






Age data available in 11 papers, symptom data available from 9 papers 
2.3.1.7 Accounting for ‘other’ categories 
In 33 papers, a full breakdown of stroke mimic diagnoses was not given and the miscellaneous 
category ‘other’ was used. It was hypothesized that papers which did not list functional 
disorder at all might have counted the disorder within the diagnostic category, ‘other’. In order 
to examine this, the ‘other’ rate was compared in papers listing both a functional disorder rate 
and an ‘other’ rate to papers listing an ‘other’ rate but no functional disorder rate.   
Twenty-one papers listed both categories. In these papers, the average functional disorder 
rate was 12.5% and the average ‘other’ rate was 17.05%. Twelve papers listed an ‘other’ rate 
but no functional disorder rate. The mean ‘other’ rate in these papers was significantly higher, 
nearly twice as high at 31.6% compared to the 17.05% in papers listing both ‘other’ and 
functional disorder rates, representing a significant difference (χ² = 116.4, df = 1, p < 0.001) 
(see Table 3).  
Table 3 Difference in average rates of ‘other’ categories between papers listing an ‘other’ 








‘Other’                                           
rate 
 % 
Papers with a ‘functional disorder’ category & an 
‘other’ category listed  
21 12.5 17.05* 
Papers with no ‘functional disorder’ category 
listed, but ‘other’ category listed  
12 - 31.6* 
*Significant difference between ‘other’ rates (χ² = 116.4, df = 1, p < 0.001) 
This supports the hypothesis that functional disorder patients may be hidden within the 





Three meta-analysis calculations were conducted:  
I. Analysis one assessed the proportion of suspected stroke patients who were later 
confirmed as stroke mimic patients (n included studies = 87); 
In the calculation of the functional disorder rate, papers with no stroke mimic breakdown at all 
(n = 16) and papers with only partial accounts of stroke mimics (n = 5) were excluded. Further 
calculations were as follows:  
II. Analysis two included all studies, including the eight papers which listed no functional 
disorder rate but where it is possible functional disorders were hidden within papers’ 
self-described ‘other’ category (n studies = 66); 
III. Analysis three excluded the eight papers where functional disorders are not listed but 
which have an ‘other’ category (n studies = 58).  
Random effects models were used and included the three papers which gave full accounts of 
stroke mimics, did not include an ‘other’ category but where functional disorder was not listed. 
The findings were as follows: 
I. Analysis one: There were 70,333 suspected stroke patients and 14,708 of these were 
stroke mimic patients. Using a random effects model from all 87 papers, the pooled 
proportion of stroke mimic patients was 17.9% (95% CI: 15.5% to 20.6%), with high 
between study heterogeneity (I2: 98.6%).  
II. Analysis two: The total number of suspected stroke patients eventually diagnosed with 
a functional disorder was 691. The pooled prevalence of functional disorder as a 
proportion of all suspected stroke patients was 1.7% (95% CIs: 1.3% - 2.2%, I2: 89.7%). 
The pooled proportion of functional disorders as a proportion of stroke mimic patients 
was 11.8% (95% CIs: 9.3% - 14.9%, I2: 86.9%).  
III. Analysis three: With the removal of the eight studies with an ‘other’ category, the 
pooled prevalence of functional disorders as a proportion of stroke mimic patients 
increased to 13.9% (95% CIs: 11% - 17.4%, I2: 87%).  






2.3.2.1 Diagnosis site 
I. Analysis one 
When taking the diagnostic setting into account the pooled proportion varied. The overall 
heterogeneity remained high. The highest proportion of stroke mimic patients were diagnosed 
in primary care or outpatients setting (36.4% of suspected stroke patients, 95% CI: 21% - 
55.3%), followed by the ‘EMS’ setting (emergency medical services) (35.1%, 95% CI: 21.5% - 
51.7%), ambulances (28.8%, 95% CI: 19.2% – 40.7%), and the lowest rate of stroke mimic 
patients were diagnosed at stroke units (6.5%, 95% CI: 4.3%- 9.9%). Figure 6 displays the stroke 
mimic rates across settings.  
Figure 41 (See “Appendix 2.8: Stroke mimic forest plot”) displays a forest plot showing the full 
breakdown of rates from individual studies according to the study setting.  
 
Figure 6 Forest plot displaying the proportion of stroke mimic patients diagnosed at acute 
stroke unit, ambulance, emergency department (ED), emergency medical services (EMS), 
hospitals, mixed settings, primary care or outpatient settings, stroke unit, and telestroke 
settings 
II. Analysis two 
Analysis two included papers which reported no functional disorder but which reported an 
‘other’ category. The setting from which functional disorder patients were most frequently 
diagnosed was the stroke unit (25.3% of stroke mimics, 95% CIs: 15.6% - 38.3%, I2: 77.7%). The 
setting with the least frequently diagnosed functional disorder patients was the ‘EMS’ setting 
(2.4%, 95% CIs: 0.3% - 16.4%, I2: 77.1%).  
Figure 7 outlines the proportion of functional disorder patients diagnosed from stroke mimic 
patients according to the medical setting in which they were diagnosed.  
Group by
Study Setting
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Acute stroke unit 0.176 0.114 0.261
Ambulance 0.288 0.192 0.407
ED 0.245 0.191 0.309
EMS 0.351 0.215 0.517
Hospital 0.152 0.097 0.231
Mixed 0.089 0.035 0.210
Primary care or outpatients 0.364 0.210 0.553
Stroke unit 0.065 0.043 0.099
Telestroke 0.158 0.082 0.284
Overall 0.190 0.125 0.278




Figure 42 (Appendix 2.9: Functional stroke mimic forest plot) displays the proportion of 
functional stroke mimic patients and the individual studies from which rates were taken.  
 
Figure 7 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to medical setting 
III. Analysis three 
With the removal of the eight papers reporting no functional disorder cases but which 
included an ‘other’ category, functional disorder rates increased slightly (with the exception of 
the ‘EMS’ setting). See Figure 8 for a breakdown of each functional disorder rate according to 
the setting in which the study took place.  
 
Figure 8 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to medical setting with papers removed which report no 





Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Acute stroke unit 0.138 0.079 0.232
Ambulance 0.057 0.024 0.129
ED 0.099 0.066 0.146
EMS 0.024 0.003 0.164
Hospital 0.085 0.041 0.167
Mixed 0.246 0.059 0.631
Primary care/outpatients 0.089 0.029 0.240
Stroke unit 0.253 0.156 0.383
Telestroke 0.037 0.007 0.160
Overall 0.103 0.062 0.165
-1.00 -0.50 0.00 0.50 1.00
Group by
Service Setting
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Acute stroke unit 0.139 0.081 0.227
Ambulance 0.070 0.030 0.155
ED 0.113 0.077 0.164
EMS 0.024 0.003 0.158
Hospital 0.120 0.058 0.231
Mixed 0.557 0.163 0.891
Primary care/outpatients 0.124 0.041 0.321
Stroke unit 0.280 0.177 0.411
Telestroke 0.063 0.012 0.281
Overall 0.131 0.080 0.208




2.3.2.2 Study design 
I. Analysis one 
The effect of study design on the rate of stroke mimic patients was investigated. Studies were 
categorised as utilising either prospective or retrospective designs; 46 (52.9%) papers were 
prospective and 41 (47.1%) were retrospective.  
The pooled proportion of stroke mimic patients from studies using a retrospective design was 
lower (12.6%, 95% CIs: 10.1% – 15.6%, I2: 98.8%) than studies using prospective methods 
(23.9%, 95% CIs: 19.9% - 28.4%, I2: 98.2%). Figure 9 shows the rate of stroke mimic patients 
according to the study design used.  
 
Figure 9 Forest plot displaying the proportion of stroke mimic patients according to studies’ 
study design 
II. Analysis two 
Taking the 66 papers reporting a functional disorder rate, there were similar proportions of 
prospective (48.5%) and retrospective studies (51.5%).  
The pattern was reversed as papers employing retrospective study designs had a higher rate of 
functional disorder (15.7%, 95% CIs: 11.3% - 21.3%, I2: 89%) than prospective studies (8.9%, 
95% CIs: 6.3% - 12.5%, I2: 81%). Figure 10 displays the forest plot of functional disorder rates, 
as a proportion of stroke mimics, according to study design. 
 
Figure 10 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to study design  
Group by
Study Design
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Prospective 0.239 0.199 0.284
Retrospective 0.126 0.101 0.156
Overall 0.175 0.090 0.313
-1.00 -0.50 0.00 0.50 1.00
Group by
Study Design
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Prospective 0.089 0.063 0.125
Retrospective 0.157 0.113 0.213
Overall 0.119 0.067 0.201




III. Analysis three 
When the eight studies reporting no functional disorder rates but ‘other’ categories were 
removed, again rates in both groups increased, with the retrospective studies reporting a 
functional disorder rate of 18.5% (95% CIs: 13.5% - 24.8%, I2: 89%). The prospective studies 
reported a rate of 10.3% (95% CIs: 7.4% - 14.3%, I2: 80.8%). Figure 11 displays the overall forest 
plot for studies.  
 
Figure 11 Forest plot displaying the proportion of functional disorder patients according to 
study design with papers removed which report no functional disorder patients but which list 
an ‘other’ category 
 
2.3.2.3 Exclusion criterion  
Some studies applied exclusion criteria to the sample under investigation (see “Appendix 2.2: 
Exclusion criteria applied across all studies”). Sixty-three papers (72.4%) applied some form of 
exclusion criterion to their overall sample, 22 applied no exclusion criteria (25.3%) and two 
papers (2.3%) gave no information on exclusion criteria. 
I. Analysis one 
Studies applying exclusion criteria to their sample had a lower pooled stroke mimic prevalence 
at 16.4% (95% CIs: 13.7% - 19.4%, I2: 98.7%) than the 22 papers with no exclusion criteria at 




Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Prospective 0.103 0.074 0.143
Retrospective 0.185 0.135 0.248
Overall 0.139 0.077 0.239





Figure 12 Forest plot displaying the proportion of stroke mimic patients according to whether 
a sample exclusion criterion was applied 
II. Analysis two 
The trend was reversed when the rate of functional disorder patients amongst stroke mimic 
patients was investigated. Forty-eight studies (72.7%) applied exclusion criteria while 16 
(24.2%) did not. Studies applying no exclusion criteria had an overall functional disorder 
prevalence of 9.2% (95% CIs: 5.5% - 14.7%, I2: 89.5%). The studies applying one or more 
exclusion criterion to the study sample reported a functional disorder rate of 13.2% (95% CIs: 
9.9% - 17.4%, I2: 85.4%). This is outlined in Figure 13. 
 
Figure 13 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to study design  
III. Analysis three 
When the eight studies were removed, again, functional disorder rates increased slightly with 
studies applying no exclusion criteria reporting a prevalence rate of 10.8% (95% CIs: 6.6% - 
17.1%, I2: 89.7%). Papers in which one or more exclusion criterion was applied had a functional 
disorder rate of 15.6% (95% CIs: 11.8% - 20.4%, I2: 85.8%), see Figure 14. 
Group by
Exclusion Criteria Applied
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
No 0.211 0.159 0.274
None stated 0.373 0.160 0.650
Yes 0.164 0.137 0.194
Overall 0.200 0.141 0.277
-1.00 -0.50 0.00 0.50 1.00
Group by
Exclusion Criteria
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
No 0.092 0.055 0.147
None stated 0.078 0.021 0.252
Yes 0.132 0.099 0.174
Overall 0.112 0.077 0.159





Figure 14 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to exclusion criteria with papers removed which report a zero 
functional disorder rate but an ‘Other’ category 
2.3.2.4 Countries’ economic status 
I. Analysis one 
Stroke mimic prevalence rates were compared based on whether they were conducted in high 
or low income countries. Seventy-seven papers (88.5%) were published in countries with high 
income economies. Six originated in low income economies (6.9%). Three (3.4%) were 
categorised as ‘mixed’ meaning their rates came from more than one country which included 
both high and low income states and one was not known (1.1%). 
Rates in both high and low income groups were very similar with a slightly higher pooled 
proportion of 19.4% for stroke mimic patients (95% CIs: 16.9% - 22.1%, I2: 98.3%) from higher 
income countries compared to lower income countries at 18.9% (95% CIs: 11.5% - 29.5%, I2: 
98.9%), see Figure 15. 
 
Figure 15 Forest plot displaying the proportion of stroke mimic patients according to the 
economic status of the country in which the study was based 
II. Analysis two 
In high income countries the pooled rate of functional disorder amongst stroke mimics was 
12.4% (95% CIs: 9.7% - 15.7%, I2: 86.7%), almost four times higher than the rate in studies from 
low income countries at 3% (95% CIs: 1.1% - 8%, I2: 25.3%). In two papers, studies were from 
Group by
Exclusion Criteria
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
No 0.108 0.066 0.171
None stated 0.078 0.022 0.241
Yes 0.156 0.118 0.204
Overall 0.128 0.085 0.188
-1.00 -0.50 0.00 0.50 1.00
Group by
Economic Status 
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
High income country 0.194 0.169 0.221
Low Income Country 0.189 0.115 0.295
Mixed 0.021 0.009 0.049
Not Known 0.101 0.023 0.352
Overall 0.103 0.040 0.239




mixed settings and these reported the highest pooled prevalence rate at 43.2% (95% CIs: 
15.3% - 76.1%, I2: 78.4%), see Figure 16. 
 
Figure 16 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to economic status of the country in which the study was 
conducted 
III. Analysis three 
When the eight studies were removed from the analysis, all functional disorder rates 
increased, with high income countries with a functional disorder rate of 14.1% (95% CIs: 11.1% 
- 17.8%, I2: 86.8%) and low income countries with a functional rate of 4.2% (95% CIs: 1.5% - 
11.7%, I2: 0%), see Figure 17. 
 
Figure 17 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to economic status of the country in which the study took 
place with papers removed which report a zero functional disorder rate but also an ‘other’ 
category 
2.3.2.5 Thrombolysis treatment 
Studies were categorised based on whether stroke mimic patients had received thrombolysis 
or not. Fifty-four studies did not state whether this treatment had been given. In four studies, 
some stroke mimic patients received the treatment while others did not. In 19 papers, all 
stroke mimic patients received thrombolysis.  
Group by
Economic Status
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
High Income Country 0.124 0.097 0.157
Low Income Country 0.030 0.011 0.080
Mixed 0.432 0.153 0.761
Not known 0.111 0.008 0.653
Overall 0.119 0.038 0.317
-1.00 -0.50 0.00 0.50 1.00
Group by
Economic Status
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
High income country 0.141 0.111 0.178
Low income country 0.042 0.015 0.117
Mixed 0.428 0.158 0.748
Not known 0.111 0.009 0.641
Overall 0.137 0.050 0.326




I. Analysis one 
In studies where stroke mimic patients received thrombolysis, the pooled prevalence of stroke 
mimic patients was 5.9% (95% CIs: 4.2% - 8.1%, I2: 95.5%) but higher in studies where stroke 
mimic patients did not receive thrombolysis (22.6%, 95% CIs: 15.6% - 31.5%, I2: 96.7%), see 
Figure 18. 
 
Figure 18 Forest plot displaying the proportion of stroke mimic patients according to whether 
they received thrombolysis treatment  
II. Analysis two 
There was a considerable difference in rates of functional disorder based on whether 
thrombolysis had been given. In studies where stroke mimic patients had received 
thrombolysis, 33.3% (95% CIs: 24.2% - 43.7%, I2: 71.1%) of patients had a functional disorder 
diagnosis. In studies where patients had not received thrombolysis the functional disorder rate 
was 5.5% (95% CIs: 3% - 9.8%, I2: 9.4%), see Figure 19. 
 
Figure 19 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to whether the patients received thrombolysis treatment or 
not 
III. Analysis three 
With the removal of the eight papers reporting no functional disorder but which included an 
‘other’ category, the functional disorder rate for patients who received no thrombolysis 
Group by
Thrombolysis Received?
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Mixed 0.181 0.098 0.310
No 0.226 0.156 0.315
Not stated 0.239 0.205 0.276
Yes 0.059 0.042 0.081
Overall 0.158 0.072 0.311
-1.00 -0.50 0.00 0.50 1.00
Group by
Thromboloysis Received?
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Mixed 0.209 0.111 0.359
No 0.055 0.030 0.098
Not stated 0.074 0.055 0.099
Yes 0.332 0.242 0.437
Overall 0.136 0.051 0.313




treatment increased to 6% (95% CIs: 3.3% - 10.6%, I2: 0%), but remained the same for those 
who did receive thrombolysis at 33.1% (95% CIs: 24.4% - 43.2%, I2: 71.1%), see Figure 20. 
 
Figure 20 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to whether patients were given thrombolysis with papers 
removed which report no functional disorders but list an ‘other’ category 
2.3.2.6 Year of publication 
The year of studies’ publication was categorised by decade: ‘1980 to 1989’, ‘1990 to 1999’, 
‘2000 to 2009’ and ‘2010 to 2016’.  
I. Analysis one 
The pooled prevalence of stroke mimic patients was highest in the years between 2000 and 
2009 (23.2%, 95% CIs: 18% - 39.4%, I2: 98.5%). The lowest rate was reported from papers 
published between 1990 and 1999 (9.3%, 95% CIs: 5.2% - 16.1%, I2: 96.3%). See Figure 21 for 
more details. 
 






Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Mixed 0.209 0.115 0.349
No 0.060 0.033 0.105
Not stated 0.091 0.068 0.121
Yes 0.331 0.245 0.431
Overall 0.145 0.061 0.308
-1.00 -0.50 0.00 0.50 1.00
Group by
Year of publication
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
1980-1989 0.170 0.062 0.388
1990-1999 0.093 0.052 0.161
2000-2009 0.232 0.180 0.294
2010-2016 0.170 0.140 0.204
Overall 0.166 0.114 0.237




II. Analysis two 
The rate of functional disorder as a proportion of stroke mimic patients increased over time 
(Figure 21). Between 1980 and 1989, two papers reported functional disorder rates at 2.8% 
(95% CIs: 0.6% - 13.3%, I2: 86.5%), between 1990-1999 the rate increased to 8.2% (95% CIs: 
3.3% - 19.1%, I2: 70.2%), between 2000-2009 it was at 10.1% (95% CIs: 6.5% - 15.5%, I2: 80%) 
and between 2010 and 2016 it was 14.2% (95% CIs: 10.5% - 19%, I2: 89%), see Figure 22. 
 
Figure 22 Forest plot displaying the pooled proportion of functional disorder patients from 
stroke mimic patients by publication year 
 
III. Analysis three 
With the removal of the eight studies with no functional disorder rates but ‘other’ categories, 
all functional disorder rates increased and there was an increasing trend over time with the 
rate of functional disorders at 7.4% (95% CIs: 1.3% - 33.5%, I2: 0%) in studies published 
between 1980 and 1989 and at 17.3% (95% CIs: 12.9% - 22.8%, I2: 89.7%) in published papers 
between 2010 and 2016. The overall functional disorder rate was 12.1% (95% CIs: 7.4% - 
18.9%, I2: 87.2%), see Figure 23. 
 
Figure 23 Forest plot displaying the proportion of functional disorder patients diagnosed from 
stroke mimic patients according to the year category in which the paper was published with 
papers removed which report no functional disorder rate but include an ‘other’ category 
Group by
Year Category
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
1980-1989 0.028 0.005 0.133
1990-1999 0.082 0.033 0.191
2000-2009 0.103 0.066 0.157
2010-2016 0.142 0.105 0.190
Overall 0.101 0.062 0.161
-1.00 -0.50 0.00 0.50 1.00
Group by
Year Category
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
1980-1989 0.074 0.013 0.335
1990-1999 0.083 0.034 0.188
2000-2009 0.106 0.069 0.160
2010-2016 0.173 0.129 0.228
Overall 0.121 0.074 0.189




2.3.2.7 Study aim 
The overall aim of each study was categorised into six categories to assess the effect of 
studies’ aims on the variability of prevalence rates.  
I. Analysis one 
The highest proportion of stroke mimics was reported from studies which had more than one 
aim, categorised as ‘mixed’ (n studies = 3) at 38.8% (95% CIs: 20.8% - 60.4%, I2: 96.5%). The 
lowest rate was reported from descriptive studies at 13.9% (95% CIs: 11.2% - 17%, I2: 98.7%), 
see Figure 24. 
 
Figure 24 Forest plot displaying the pooled prevalence of stroke mimic patients according to 
the intended aim of study papers 
II. Analysis two 
The highest functional disorder rate, as a proportion of stroke mimic patients, was reported in 
descriptive studies at 15.1% (95% CIs: 11.1% - 20.2%, I2: 89.5%) and the lowest in clinician 
diagnostic validation studies 6.1% (95% CIs: 1.9% - 18.2%, I2: 82.5%), see Figure 25. 
 
Figure 25 Forest plot displaying the pooled prevalence of functional disorder patients 





Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Descriptive study 0.139 0.112 0.170
Diagnostic val idation study of cl inicians 0.278 0.170 0.419
Mixed 0.388 0.208 0.604
Screening tool  val idation study 0.188 0.139 0.250
Screening tool  val idation study - biomarker 0.230 0.130 0.373
Stroke service audit 0.224 0.156 0.312
Overal l 0.218 0.158 0.292
-1.00 -0.50 0.00 0.50 1.00
Group by
Study Aim
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Descriptive study 0.151 0.111 0.202
Diagnostic val idation study of cl inicians 0.061 0.019 0.182
Mixed 0.064 0.018 0.198
Screening tool  val idation study 0.076 0.043 0.131
Screening tool  val idation study - biomarker 0.069 0.021 0.206
Stroke service audit 0.142 0.076 0.250
Overal l 0.099 0.062 0.154




III. Analysis three 
Removing the eight studies with an ‘other’ category saw a slight increase in all rates with 
descriptive studies reporting the highest functional disorder rate at 17.6% (95% CIs: 13.1% - 
23.2%, I2: 89.8%) and clinician diagnostic validation studies also showing a slight increase in 
proportion at 10.1% (95% CIs: 3% - 28.6%, I2: 78.5%) (see Figure 26). 
 
Figure 26 Forest plot displaying the proportion of functional disorder patients according to the 
papers’ reported aim with papers removed which report no functional disorder rate but 
include an ‘other’ category 
2.3.2.8 Quality score 
Quality scores were categorised into nine groups (11-20%, 21-30% etc.). The mean quality 
score was 69.3% (SD: 17.1%, range: 16.6 – 94.4).  
There was no correlation between studies’ sample size and their quality score.  
I. Analysis one 
There was no clear trend in prevalence rates according to quality score. Only one study was 
given a rating between 11-20% and one study was rated between 21-30%. The highest 
reported stroke mimic rate came from studies rated between 21-30%. The lowest stroke mimic 




Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
Descriptive study 0.176 0.131 0.232
Diagnostic val idation study of cl inicians 0.101 0.030 0.286
Mixed 0.064 0.020 0.189
Screening tool  val idation study 0.087 0.050 0.150
Screening tool  val idation study - biomarker 0.104 0.030 0.298
Stroke service audit 0.143 0.078 0.245
Overal l 0.118 0.076 0.178





Figure 27 Forest plot displaying the pooled prevalence of stroke mimic patients according to 
the quality category into which they fell 
II. Analysis two 
The same calculations were conducted for rates of functional disorder patients amongst stroke 
mimic patients. The highest rate of functional disorder were in papers rated between 51-60% 
(95% CIs: 5.9% - 34.8%, I2: 85.8%). The lowest rate was in studies rated 21-30% at 9.9% (95% 
CIs: 4.5% - 20.4%, I2: 0%) (although only one study scored within this quality category). See 
Figure 28 for a full breakdown of prevalence rates according to quality score categories.  
 
Figure 28 Forest plot displaying the pooled prevalence of functional disorder patients 
according to their quality category  
III. Analysis three  
With the removal of the eight studies reporting no functional disorders but listing an ‘other’ 
category, the lowest rate of functional disorder were those given quality scores between 41-
50% group with a prevalence rate of 9.9% (95% CIs: 4.6% - 19.9%, I2: 84%). The highest rate of 
functional disorder patients were from those studies rated between 51-60% group at 19.1% 
(95% CIs: 7.3% - 41.2%, I2: 83.3%). See Figure 29. 
Group by
Quality Score Category
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
11-20 0.244 0.062 0.611
21-30 0.345 0.096 0.724
31-40 0.179 0.095 0.311
41-50 0.200 0.127 0.300
51-60 0.083 0.044 0.150
61-70 0.135 0.092 0.193
71-80 0.246 0.194 0.306
81-90 0.141 0.099 0.196
91-100 0.192 0.113 0.306
Overall 0.172 0.127 0.229
-1.00 -0.50 0.00 0.50 1.00
Group by
Quality Score Category
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
21-30 0.010 0.000 0.237
31-40 0.106 0.036 0.277
41-50 0.099 0.045 0.204
51-60 0.155 0.059 0.348
61-70 0.130 0.065 0.244
71-80 0.122 0.076 0.192
81-90 0.103 0.055 0.184
91-100 0.128 0.057 0.262
Overall 0.116 0.085 0.156





Figure 29 Forest plot displaying the proportion of functional disorder patients according to 
papers’ assigned quality score with papers removed which report no functional disorder 
patient rate but an ‘other’ category 
2.4 Discussion 
2.4.1 Main findings 
This chapter aimed to estimate the prevalence of stroke mimic patients who present to stroke 
services and the proportion of these patients who have a functional explanation for their 
symptoms. 
Stroke mimic patients make up a significant proportion of patients with suspected stroke at 
17.9% (95% CI: 15.5 to 20.6%). Of stroke mimic patients, 11.8% (95% CIs: 9.3 - 14.9%) are 
functional disorder patients. When studies with an ‘other’ category and no functional diagnosis 
are removed from the analysis, the rate of functional disorders increases to 13.9% (95% CIs: 11 
- 17.4%). Functional patients represent 1.7% of all suspected stroke patients. Our functional 
disorder rates are likely an underestimate as many studies do not report functional cases but 
provide ‘other’ or ‘unknown’ categories, among whom a proportion are likely to be functional.  
Our stroke mimic rate is lower than the 26% reported in Gibson and Whiteley’s (2013) paper 
while our functional rate is higher. Gibson and Whiteley (2013) restricted their analysis to 
prospective research and included only 29 studies. Our stroke mimic rate from prospective 
studies alone was 23.9%. Our review also extends the definition of functional disorders, 
including patients with depression and anxiety diagnoses.  
Stroke patients were less likely to be female than stroke mimic patients (46.3% versus 56.8%) 
and medical mimics were less likely to be female than functional mimic patients (50.6% versus 
65.9%) both representing significant differences in proportions.  
Group by
Quality Category
Study name Event rate and 95% CI
Event Lower Upper 
rate limit limit
31-40 0.106 0.037 0.269
41-50 0.099 0.046 0.200
51-60 0.191 0.073 0.412
61-70 0.152 0.077 0.277
71-80 0.146 0.091 0.224
81-90 0.128 0.070 0.224
91-100 0.174 0.080 0.337
Overall 0.139 0.105 0.182




This finding is not unexpected. It is well established that stroke more commonly affects males 
than females. The global male stroke prevalence is 41% higher than female stroke prevalence 
(Appelros et al., 2009). In addition, there is consistent evidence that functional symptoms 
more commonly affect women, a finding replicated in most epidemiological studies and across 
multiple settings such as neurology (Stone et al., 2010a), general practice (De Waal et al., 
2004; El Husseini & Goldstein, 2013; Faravelli et al., 1997), and general hospitals (Deka et al., 
2007). Nimnuan et al.’s (2001) study found females were twice as likely as men to have 
medically unexplained symptoms across seven medical specialities.  
Stroke patients had an average age of 69.7 years while stroke mimic patients were on average 
seven years younger. Medical mimics’ mean age was 63.8 years while functional mimics were 
significantly younger with a mean age of 51.6 years. These findings correspond with previous 
findings. Appelros et al.’s (2009) study report a mean age of stroke onset of 68.6 years for men 
and 72.9 years for women, and functional disorder patients in neurology settings have a mean 
age of 43 years (Stone et al., 2010), although it is likely these symptoms begin earlier. 
Functional patients are more likely to present with weakness and numbness and less likely to 
have reduced consciousness or vertigo. Weakness and numbness are defined by absence of a 
function. It is plausible that a clinician, faced with an absence of physical function and no clear 
imaging evidence, might be more likely to classify these symptoms as functional despite more 
recent calls for positive signs to be employed when making a functional diagnosis (Stone, 
Carson, & Sharpe, 2005). 
The diagnosis of functional disorder, until recently, required clinicians to identify a potential 
psychological reason for symptoms and the disorder necessitates some kind of 
patient/clinician interaction. This may influence the kind of symptoms described as functional. 
A clinician assessing a potential functional patient with reduced consciousness won’t be able 
to gain a psychological history and such a patient may be less likely to receive the functional 
diagnosis.  
Vertigo, which can occur as part of a functional presentation, may be regarded by stroke 
clinicians as a stand-alone diagnosis and clinicians may feel making further investigations or 
exploring the possibility of a functional diagnosis may be unwarranted or unnecessary. 
A high proportion of studies included in this review list stroke mimic diagnoses but the primary 
purpose of these studies was to improve the accuracy and speed of the diagnosis and 
treatment of stroke. Of the 87 papers reporting stroke mimic rates, 24% gave no or only partial 
outlines of stroke mimic diagnoses. Even less information is available on functional disorders. 




was no consistent evidence on the type of symptoms functional patients presented with or 
their clinical outcomes. As a result, this study will be necessarily limited in its scope.   
Rates vary depending on the kind of setting in which you look, the kind of study used and the 
year in which the study took place. The following section discusses the results from the 
stratified analyses.  
2.4.2 Stratified analysis 
2.4.2.1 Diagnosis site 
There was considerable variability in the rate of stroke mimic patients depending on the kind 
of service making the diagnosis. As might be expected, stroke mimic patients are most 
commonly identified by clinicians at the early stages of the stroke care pathway, in the 
ambulatory, emergency and primary care settings. As the setting becomes more specialised, 
the rate of stroke mimic patients falls. It is likely that clinicians in the emergency and primary 
care settings act as barriers or filters to stroke mimic patients reaching more acute settings.  
The same process does not appear to be operating for functional disorder patients. In the 
identification of functional patients according to settings, there was a near reversal in 
prevalence rates. Stroke units identified the highest proportion of functional patients followed 
by mixed settings and acute stroke settings, with the lowest rates reported in emergency and 
ambulance settings.  
It is possible that of stroke mimic conditions, functional disorders are the hardest differential 
diagnosis for non-specialist clinicians to make. Functional disorders, perhaps due to a lack of 
knowledge, or due to its perceived difficulty in correctly identifying, mean clinicians in 
emergency and ambulatory settings and in general practice will not risk giving this diagnosis. 
The secondary and tertiary clinicians however appear more confident in giving that functional 
disorder diagnosis.  
2.4.2.2 Study design 
Retrospective studies report half the rate of stroke mimic patients compared to prospective 
studies. These studies may be subject to a higher degree of bias than prospective studies so 
the higher rate of stroke mimic patients from prospective research may in fact be more 
accurate. Moffitt et al. (2009) reported for instance that the lifetime prevalence rate of mental 
disorder in prospective studies was almost double compared to the rate reported in 




The results reported here are similar to those in Gibson and Whiteley’s (2013) review which 
included only prospective studies. They reported a stroke mimic rate of 26%, slightly higher 
than the 23.9% found in the prospective studies in this review. Their results also mirror the 
functional disorder rate from prospective studies. They report a functional disorder rate of 
7.4% while in this study it was 8.9%.  
It is unclear why the retrospective rate of functional disorder is almost double the rate 
reported in prospective studies. It is possible that in retrospective research, when authors 
were unable to give a positive differential diagnosis, they use functional diagnoses as an 
umbrella term for ‘unknown’.  
2.4.2.3 Exclusion criterion 
As expected, studies which applied no exclusion criterion to their study sample reported a 
higher rate of stroke mimic patients than those that did. The most common exclusions were 
patients who did not receive thrombolysis treatment and those with incomplete data. Stroke 
mimic patients are less likely to receive thrombolysis and may be more likely to have 
incomplete data, thereby lowering the stroke mimic prevalence rate.  
The rate of functional disorders was less in papers with no exclusion criteria. It is possible that 
studies applying exclusions to their study sample were more rigorous in their data collection 
methodologies and were more likely to define and count functional cases.  
The discrepancy in the number of studies applying exclusion criteria (72.4% of studies) 
compared to those applying no criteria (25.3% of studies) makes it difficult to draw substantive 
conclusions here.  
2.4.2.4 Countries’ economic status 
The incidence of stroke in low and middle income countries now exceeds the rate in high 
income countries (Feigin et al., 2009). The majority of studies in this review come from high 
income countries, likely reflecting the cost of doing this kind of research. Stratifying papers by 
countries’ economic development may be somewhat redundant however as the wealth of a 
nation or their healthcare spending often does not necessarily reflect the sophistication of 
their healthcare system (Anderson & Frogner, 2008).  
There was no difference in the rate of stroke mimic patients in high and low income countries 
but there was a lower rate of functional patients reported in low income countries than high 
income countries. This may reflect clinicians’ lack of knowledge or interest in functional 




about the prevalence of functional symptoms outside high-income countries (Brown & Lewis-
Fernández, 2011). A paper on unexplained fatigue found it was present in all cultures but 
people from middle and higher income countries may be more likely to report it to their GP 
(Skapinakis et al., 2003).  
2.4.2.5 Thrombolysis treatment 
As noted in the section on exclusion criteria, whether stroke mimic patients receive 
thrombolytic treatment will likely affect their prevalence. When no thrombolysis was given to 
stroke mimic patients, the stroke mimic rate was much higher. Clinicians will apply strict 
diagnostic criteria when they decide to give the thrombolytic drug and will be more likely to 
exclude stroke mimic patients at this stage.  
In studies where thrombolysis was given, the functional disorder rate was higher than in 
studies where it was not given. This again may reflect the fact that functional disorder is often 
seen as a diagnosis of exclusion rather than a disorder with positive symptoms of its own. It 
may be easier to exclude other types of stroke mimic patients like brain tumours from 
thrombolytic treatment, but in the absence of positive signs, a neurologist will likely give the 
treatment to a potentially functional patient rather than risk not treating a true stroke patient. 
There is evidence that thrombolysis is safe in patients with FND (Tsivgoulis et al., 2011), 
evidence that may influence doctors’ treatment decision making.  
2.4.2.6 Year of publication 
There was no distinct pattern in the rate of stroke mimic patients over time. The rate varied 
between 9% and 23.2%. There were, however, an increasing number of scientific papers 
published since the 1980s. Given the few papers published on stroke mimic rates in the 1980s 
and 1990s, it is difficult to draw definitive conclusions on functional presentations to stroke 
wards. While the interest in stroke research increases, the rate of stroke mimic patients shows 
no clear pattern. This is surprising as one might expect that as diagnostic methods improve 
over time in all settings, there would be a subsequent reduction in the rate of stroke mimic 
patients.  
The rate of functional patients presenting to stroke services increases minimally over time. 
Establishing a time trend in the prevalence and incidence of functional symptoms at all is 
difficult given the changes to case definitions and the rarity of studies reporting more than one 
rate over time. Evidence suggests that functional symptoms remain relatively stable over time. 




a five year period in Iraq while earlier research by Stefanis et al. (1976) reported the rate of 
‘hysteria’ increased over time.  
2.4.2.7 Study aim 
Descriptive studies reported the lowest rate of stroke mimic patients while studies with mixed 
aims reported the highest rate. It is worth noting however that descriptive studies were more 
likely to apply some kind of exclusion criteria (62%) than not (33.3%). The lower rate of stroke 
mimics might therefore be due to exclusion criteria rather than study design. The highest rate 
of stroke mimic patients was reported by studies with mixed aims, but definitive conclusions 
are difficult to draw as there were only three studies of this kind and the pooled prevalence of 
this finding has wide margins of error.  
The prevalence rate of functional patients was consistent across studies with the exception of 
descriptive studies and service audits where the rate was almost double. 
2.4.2.8 Quality scores 
The average quality score for studies was high but analysis of quality scores by stroke mimic 
and functional disorder prevalence showed no clear pattern.  
2.4.3 Limitations 
It is likely that the rate of functional disorder reported in this study is an underestimate. It is 
possible that clinical staff who assess newly referred patients may avoid giving a functional 
diagnosis completely or use other terminology, like migraine or ‘functional overlay’ to avoid 
potentially uncomfortable discussions with patients. Such a bias is likely to affect each setting, 
from emergency settings through to tertiary stroke care. We have attempted to address this 
by demonstrating that papers that do not list functional disorders have inflated numbers in 
their ‘other’ categories compared to studies which list functional disorder rates, a result which 
is strongly suggestive that a proportion of functional cases are hidden within the ‘other’ 
category. 
The stroke mimic rate varied widely. This may be partly explained by the variety of ways in 
which stroke mimic patients were defined. Commonly, no information was given on how 
stroke mimic patients were defined. Where information was available, some studies used a 
prospective medical follow-up by the clinical team or used the presence of an alternative 
diagnosis to indicate stroke mimic status. Other papers applied less stringent definitions 
relying only on a lack of positive findings from imaging results, counting stroke mimic patients 




found’. The multiplicity of stroke mimic definitions precluded the possibility of investigating 
their effect on our stroke mimic event rate.  
With the exception of Gargalas et al.’s (2015) paper, whose aim was specifically to quantify the 
functional mimic rate, papers included in this review were often unclear or vague regarding 
the functional disorder definitions they employed and none used structured interviews to 
make the diagnosis. Diagnoses were made by stroke clinicians, general practitioners (GPs) or 
emergency personnel. Some papers, like Ferro et al. (1998), used multiple terms to describe 
patients that in other studies were classed as one disorder but did not explain the differences 
in diagnoses employed.  
This review counted only the most frequent stroke mimic diagnosis from each study but did 
not count the total number of stroke mimic diagnoses from all studies. Given the 14,708 stroke 
mimic patients included with a potentially extensive number of stroke mimic diagnoses, this 
was beyond the remit of this paper, but may be a useful analysis in future research.  
Finally, there was a high level of statistical heterogeneity across studies. Due to the very little 
existing evidence on functional stroke patients, this review applied minimal exclusion criteria. 
While Gibson and Whiteley’s (2013) paper restricted their analysis to only prospective studies, 
papers in our review were not restricted by studies’ methods, design or quality. We attempted 
to account for heterogeneity by conducting comprehensive stratified analyses but such 
analyses can only go so far. It is likely that different services see different types of patients due 
to a large variety of reasons such as the expertise of clinicians within certain services or macro-
level differences like health insurance systems within different countries. Such processes may 
affect the prevalence of functional patients and stroke mimic patients but are difficult to 
measure and account for. 
2.4.4 Conclusions 
This review is the first of its kind to explore the rate of functional disorders and its associated 
demographic and symptom features in stroke settings. While many studies focus on the rate of 
stroke mimic patients, fewer have examined functional disorder patients in particular, and 
fewer again give information on their demographic or clinical features.  
Functional disorders may be the ‘Cinderella’ of stroke services. The disorder consistently 
appears as a differential stroke diagnosis but there are currently no protocols in the UK on how 
to effectively diagnose, treat or refer functional patients who appear within stroke settings. 
The lack of such information in this area is conspicuous. 
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Chapter Three: A qualitative study of stroke clinicians’ experiences treating stroke mimic 










Patients with functional disorders consistently present as stroke mimic patients across a range 
of stroke settings. Chapter Two established that functional disorder patients account for 11.8% 
(95% CI: 9.3 – 14.9%) of stroke mimic admissions to acute stroke wards. These patients are 
more often female and younger than medical mimics and they most commonly present with 
weakness.  
What happens once a functional patient is admitted to an acute ward is less well known. This 
and the following chapter investigate functional disorder admissions from clinicians’ and 
patients’ perspectives. This chapter adopts a mixed methods approach to assess clinicians’ 
experiences and attitudes towards functional patients in the hyper acute stroke setting. 
Clinicians’ views are themselves important as they can directly affect the outcomes of patients.  
Doctor-patient relationships can be fraught and this may be especially so in the case of 
functional patients. Clinicians and functional patients alike can find interactions both 
unsatisfactory and stressful and encounters can be characterised by misunderstandings and 
mutual distrust (Kenny, 2004). Medical consultations with patients with unexplained 
symptoms are associated with more unmet expectations, higher healthcare costs and higher 
patient dissatisfaction (Jackson & Kroenke, 1999). Research from primary care with patients 
with medically unexplained symptoms however found that if the first clinical encounter is 
positive, it is associated with fewer subsequent visits (Owens et al., 1995).  
Much of the research on doctor-patient interactions comes from primary care but it is likely 
that clinicians’ attitudes towards patients with unexplained symptoms in acute settings, may 
be more challenging and complex given the occupational pressures of working in these 
settings. The emergency department, general medical wards and intensive care units are 
demanding environments where staff may lack the time and resources to meet the needs of 
patients with specific mental health requirements (van der Kluit & Goossens, 2011). Evidence 
suggests some clinicians view functional patients as illegitimate recipients of care (Kirmayer et 
al., 1994) or as blocking beds for patients with physical disease. Consequently, functional 
patients may distrust physicians and believe their needs are not being met. 
3.1.1 Clinicians’ attitudes to unexplained syndromes 
Doctors and nurses in medical settings have described working with mental health patients as 
challenging. Medical staff in acute settings can feel a lack of positive reinforcement, a lack of 




all (Bailey, 1998). Foundation-year and trainee doctors have been shown to hold attitudes 
towards mental health patients on par with those held towards criminal populations (Noblett 
et al., 2015). Consultations with patients with unexplained symptoms have been described as a 
place of contest and likened to a ‘court of law, a medieval siege, a tug of war’ (Marchant-
Haycox & Salmon, 1997) or a ‘duet of escalating antagonism’ (Kleinmann, 1988). 
Clinicians’ attitudes form early in their careers and negative attitudes can extend to mental 
health professionals. Medical students can hold discriminatory views on the psychiatry 
profession and have been described believing psychiatrists have “a tendency to over-
conceptualise” (Nielsen & Eaton, 1981). When asked to compare psychiatrists to surgeons, 
physicians, and GPs, students believed psychiatrists were “confused thinkers” (Harris, 1981) 
and their patients were “not easy to like” (Wilkinson et al., 1983). A survey of medical students 
showed they hold the highest regard for pneumonia patients and the lowest for patients with 
long-standing, unexplained abdominal complaints (Korszun et al., 2012). 
These attitudes continue, even as careers develop and experience grows. Hartz et al. (2000) 
reported only 14% of GPs described ‘very good’ or ‘excellent’ satisfaction in managing 
unexplained symptoms. In an attitudinal study of neuroscience nurses in a neurology unit, 
Ahern et al. (2009) found 46% of nurses believed functional disorder patients were 
‘manipulative’. GPs described consultations with functional patients as ‘frustrating’, referring 
to them as ‘heart-sink’ patients (Wileman et al., 2002). In one survey, 44% of neurologists 
believed there was an overlap in the relationship between conversion disorder and feigning 
symptoms (Kanaan et al., 2011).  
Such negative views could be fostered and maintained by mechanisms like stereotyped 
thinking, a lack of interest, negative symptom attributions, poor mental health knowledge, a 
lack of belief in their own competence and incompatible perspectives between clinicians and 
patients when treating symptoms.  
Previous qualitative research found some GPs had a tendency to stereotype functional 
patients as having ‘undesirable traits’ and often believed they failed to conform to society’s 
work ethic (Raine et al., 2004). The stereotyping of patients can mean their condition becomes 
their defining characteristic. In surgery settings it was found nurses adopted a ‘risk attitude’ 
when looking after mental health patients and many held stereotyped perceptions such as a 
belief in their non-compliance to medical advice (MacNeela et al., 2012). 
A lack of interest in functional disorders may perpetuate attitudes. When compared to other 
patients with a clear somatic diagnosis, physiotherapists were found to have only a moderate 




Clinicians can feel like they have failed if they don’t find an organic cause for a presenting 
complaint. In a series of interviews with GPs in Iowa, 17% reported finding organic causes was 
their primary aim (Nordin et al., 2006). Potentially missing an organic cause can be worrying, 
but might also affect a clinician’s career. Doctors may also feel dissatisfied if they are unable to 
treat underlying functional symptoms. Ahern et al.’s (2009) study of neuroscience nurses 
found 75% of respondents believed their knowledge of functional symptoms was limited and 
clinicians have reported believing treatment for these patients to be pointless (Salmon et al., 
2007).  
Feeling incompetent may undermine professional identity and as a consequence clinicians 
might feel insecure or powerless (Woivalin et al., 2004). Nurses with mental health knowledge 
have a more positive attitude towards patients with comorbid mental health problems 
compared to those without such knowledge (Mavundla, 2000) and nurses with more 
professional experience generally had a more positive attitude towards these patients 
(Bjorkman et al., 2008). A large survey of UK medical schools examining the reasons doctors 
rejected psychiatry as a profession found it could be partly explained by trainees’ self-appraisal 
of their own occupational competence (Lambert et al., 2003). This may reflect a wider, 
endemic problem. For instance, a lack of managerial support for general ward nurses caring for 
mental health patients has been reported and many believed they lacked appropriate clinical 
supervision (Harrison & Zohhadi, 2005). Managerial and structured support in how to manage 
patients with mental health problems or functional symptoms might help reduce beliefs of 
professional ineffectiveness.  
Engaging with patients’ psychological motivations and personal experiences may be an activity 
some clinicians wish to avoid. GPs have been found to respond to patients with medically 
unexplained symptoms by trying to normalise their symptoms, providing reassurance, but they 
tend not to engage with their individual concerns (Fitzpatrick, 1996), even when patients give 
cues to their psychosocial problems (Ring et al., 2005). GPs are more likely to offer medical 
care like drugs, physical investigations and specialist referral to patients who do not discuss 
psychosocial difficulties (Salmon et al., 2006). Doctors have also been found to decline 
‘empathic opportunities’ and are less likely to explore the concerns of medically unexplained 
patients (Epstein et al., 2006). In contrast, research has shown patients want more emotional 
support from their clinicians and most will openly discuss their psychological symptoms if 
asked (Peters et al., 1998).  
Olde Hartman et al. (2009) argue that clinicians’ inability to engage with psychological 
symptoms comes from a lack of common epistemological understanding between clinicians 




these divisions can lead to the direct dissolution of the doctor-patient relationship. Asbring 
and Narvanen (2003) argue there is an incongruence between the objective methods of 
diagnosis and treatment taught in medical school and the realities of treating illness and 
distress within their social context, leaving many new doctors unprepared. Physicians are 
trained to refer to visible findings and test results while patients claim authority in the 
understanding of their own body and pain (Rhodes et al., 1999; Peters et al., 1998). Such 
incongruence in thinking can lead to contested diagnosis and conflict.  
Patients are not immune to clinicians’ attitudes and as a consequence of poor interactions, 
may become more entrenched in their idiosyncratic health beliefs. Negative emotions, like 
frustration, can be shared and escalate. This has been named the ‘looping effect’ where cycles 
of emotions worsen when a patient’s emotional response triggers and heightens emotions in 
the clinician (Kirmayer & Sartorius, 2007).   
How receptive the doctor views the patient to be to their guidance may play an important role. 
For many clinicians, it is important that the patient has insight into the nature of their own 
symptoms, is willing to share responsibility for their management (Nordin et al., 2006) and 
does not undermine the opinion of the doctor or lack trust in their abilities (Wileman, 2002). A 
large postal survey of 349 neurologists found that they were willing to discuss the 
psychological factors involved in functional disorder once they believed the patient was 
receptive to such a discussion (Kanaan et al. 2011). 
Contested authority and struggles for control often mark these medical consultations. As 
paternalistic models of doctor-patient relationships lose favour and non-hierarchical doctor-
patient interactions are advocated (Mead & Bower, 2000), clinician-patient relationships may 
improve. Reaching a shared understanding of the cause and treatment of symptoms is the first 
step in improving the relationship. Possible methods of improvement include encouraging 
patients to become an active participant in their own care, to voice their ideas while clinicians 
listen, reflect and offer collaboration.  
3.1.2 Improving the doctor-patient relationship 
A number of interventions have been proposed to improve the clinician-patient relationship to 
help improve attitudes to mental health patients generally.  
Working in mental health as an undergraduate medic is effective in fostering a positive 
attitude to psychiatry (Singh et al., 1998). A qualitative analysis of scientific and narrative 
reviews on positive consultations with patients with unexplained symptoms highlighted the 




therapeutic environment and the importance of giving reassurance and regularly scheduled 
appointments (Heijmans, 2011).  
Patients with medically unexplained symptoms found the most helpful explanations from 
clinicians were those that encouraged them to feel control over their symptoms (Salmon et al., 
1999). Other positive steps include taking a careful history at the first assessment, probing for 
recent stressors, completing physical examinations (Sharpe, 2002), giving positive 
explanations, indicating to patients that they believe the patient, emphasising the high 
prevalence of functional symptoms generally, and where appropriate, making psychiatric 
referrals (Stone, Carson, & Sharpe, 2005).  
There is evidence that formal training can improve clinicians’ attitudes. A trial testing a 
cognitive-oriented educational programme improved GPs’ attitudes towards patients with 
somatisation (Rosendal, 2005). Reattribution training where clinicians are taught how to 
provide psychological explanations to patients with medically unexplained symptoms also 
found improvements in doctor-patient communication (Morriss et al., 2007). An earlier study 
by the same authors found positive patient improvements when GPs were taught how to 
encourage patients to relate physical symptoms to psychosocial causes (Morriss et al., 1999). 
Interventions can improve the doctor-patient relationship but understanding attitudes and 
experiences within their clinical context is the first step in this process. 
3.1.3 Aim of research  
Much of the existing evidence on doctor-patient relationships comes from primary care. GPs 
have more time to develop relationships with their patients yet the majority find patients with 
unexplained symptoms difficult to manage (Reid et al., 2001). The time constraints and 
pressurised nature of acute care likely mean relationships between doctors and patients in 
acute settings are even more strained. There is little evidence on the experiences of clinicians 
in specialised, tertiary care settings with patients with functional diagnoses, and there is no 
existing research on stroke staffs’ attitudes to functional stroke patients.  
This study aimed to investigate and describe the attitudes, opinions and experiences of hyper 
acute stroke clinicians towards FND patients through the use of a large survey of hyper acute 
stroke settings in England and a series of semi-structured interviews with staff in one HASU. 






The first half of this section outlines the methods used to conduct the survey study. The 
second section outlines the methods used to conduct semi-structured qualitative interviews 
with stroke staff at one HASU site.  
3.2.1 Survey procedure 
Multi-disciplinary teams from twelve stroke settings were surveyed, eleven of which were 
HASUs and one was a stroke ward. The stroke ward was included as a comparator but due to 
the low response rate at this site, statistical comparisons were unfeasible.  
A snowball sampling method was chosen. Questionnaires were given to a manager or senior 
clinician in each stroke team. They were asked to distribute questionnaires to other stroke 
staff members. Most frequently, this person was the multidisciplinary teams’ lead such as the 
nurse consultant. At two settings the researcher attended multidisciplinary meetings in person 
and distributed questionnaires. See Table 4 for a list of the sites contacted for involvement and 
their response rates.  
Table 4 NHS stroke services participating in the survey 
Stroke sites n (%) 
Salford Royal  25 (20.4) 
Northwick Park 17 (13.9) 
Northumbria Emergency Specialist Hospital 14 (11.5) 
King’s College Hospital 13 (10.7) 
Barts and the London 12 (9.8) 
Southampton General Hospital 12 (9.8) 
St Georges 8 (6.6) 
Princess Royal University Hospital 6 (4.9) 
University College London Hospital 5 (4.1) 
Charing Cross Hospital 5 (4.1) 
Royal Hampshire County Hospital 3 (2.5) 
St Thomas’ (stroke ward) 2 (1.6) 
Total 122 (100) 
Any stroke clinician who had experience with functional stroke mimic patients was invited to 
complete the questionnaire. No exclusion criteria were applied to any staff members but some 
decided that they did not have enough experience to warrant involvement and self-excluded. 
The snowball sampling method employed in this study meant a non-response rate could not 
be ascertained. 
All questionnaires, both paper and electronic versions are stored in accordance with the Data 




3.2.2 Questionnaire  
Questionnaires were derived from a template used by Reid et al. (2001). These authors 
developed and piloted the questionnaire with a panel of GPs and it was designed to illicit GPs’ 
attitudes to patients with medically unexplained symptoms. Questions were adapted for 
stroke staff.  
All questionnaires were anonymous. Information on participants’ age, gender, speciality and 
grade was collected. Information was collected on participants’ attitudes to patients with 
functional stroke symptoms and treatment as well as views on their role in the management of 
the functional stroke patients. Questionnaires asked which setting functional stroke patients 
should be managed in and which setting currently provided the most effective management of 
patients. Additional questions, not in Reid et al.’s study, on clinicians’ attitudes to research in 
the area of functional symptoms and their view on guidelines were also collected.  
There were eleven survey questions, eight of which required participants to respond on a four-
point Likert scale from “strongly agree”, “agree”, “disagree” or “strongly disagree” to 
questions designed to elicit clinicians’ attitudes towards patients with functional stroke 
symptoms, where they believed patients should be treated and their view on the use of 
physiotherapy for this group.  
Staff were given no incentive in exchange for completing the questionnaire.  
The questionnaire was piloted at a research meeting of neuropsychiatrists at King’s College 
London on 16th February 2016. Participants completed the questionnaire and provided 
feedback which was incorporated into the questionnaire. The survey was distributed to HASUs 
by hand between February and November 2016. See “Appendix 3.2: Stroke staff 
questionnaire” for a copy of the questionnaire used.  
3.2.3 Survey analysis 
Statistical analysis was completed using SPSS (IBM SPSS for Windows, Version 22, Chicago, 
SPSS Inc.). Survey responses were re-coded from ‘strongly agree’ or ‘agree’ into one ‘agree’ 
category and the responses ‘strongly disagree’ or ‘disagree’ were re-coded into a ‘disagree’ 
category. Frequencies were used to compare differences between groups and where 




3.2.4 Qualitative study 
3.2.4.1 Qualitative study: setting 
The qualitative study took place at one HASU in London. The researcher was embedded at this 
site from 18th January 2016 until 19th October 2016 (with the exception of weekends and 
public holidays).  
As outlined in Chapter Two, HASUs are designed to provide rapid assessment and early 
treatment to stroke patients. They are open twenty-four hours a day. The ward is staffed by six 
consultants who work on rotation, each working four weeks at a time. There are three 
specialist registrars attached to the unit who share responsibility for both the outpatient clinics 
and the inpatient ward. The ward is also staffed by multidisciplinary clinicians who include 
specialist nurses, occupational therapists, dieticians and physiotherapists. The HASU also 
employs a neuropsychologist who meets patients if any psychological issues arise. Occasionally 
a patient with functional symptoms will be meet the psychologist on the ward.  
3.2.4.2 Qualitative study: procedure 
The semi-structured interview script was developed in partnership with the study’s chief 
investigator.  
Staff members at the HASU were contacted and asked if they would like to participate in an 
interview. No staff member who was approached refused to participate. Recruitment was 
purposive to ensure gender and job specialities were representative. The HASU’s clinical 
neuropsychologist was not interviewed. Although they would have been useful in the kind of 
psychological insights they could give, this clinician was aware of the study and partially 
contributed to its design.  
There was no monetary payment for participation but participants were given a box of 
chocolate after the interview as a gesture of gratitude. Interviews were held in a private office 
on the HASU ward at a time of participants’ choosing and were conducted in private.  
Participants were given the study’s information sheet (see “Appendix 3.3: Information sheet 
for NHS staff”) and information about the study was also given verbally. Participants were 
asked to sign the consent form prior to their participation (see “Appendix 3.4: Consent form 
for NHS staff”).  
At the start of each interview, as a way of introduction, each interviewee was told that the 
interviews would discuss functional stroke patients’ presentations to the HASU. It was 




a type of stroke mimic presentation whereby there was no medical explanation for the 
symptoms presented and that these patients could be distinguished from another type of 
stroke mimic, namely ‘medical mimics’ where there was a medical explanation for the 
symptoms. The interviewer did not mention the role that psychological processes may or may 
not play in symptom presentation as this was a topic to be elicited in the interview itself.  
See “Appendix 3.5: Interview schedule for NHS stroke staff” for the semi-structured interview 
schedule used.  
3.2.4.3 Qualitative study: analysis 
Interviews were analysed using thematic analysis which allows for the identification, 
classification and organisation of themes (Braun & Clarke, 2006). Unlike Grounded Theory 
(Glaser et al., 1968) or Discourse Analysis (Foucault, 1972), thematic analysis is atheoretical. 
Themes within thematic analysis are considered to capture something important about the 
data.  
There is debate regarding the type of quality criteria which can and should be applied to 
qualitative research. The traditional concepts of reliability, validity and objectivity are often 
rejected, with the argument that unlike quantitative research, qualitative studies rely on non-
numerical information and phenomenological interpretation, therefore requiring different 
quality checks (Leung, 2015).  
Qualitative researchers have instead proposed alternative concepts to assess quality such as 
consistency, neutrality, confirmability, applicability, credibility, coherence, generalisability, 
trustworthiness and authenticity (Guba, 1989; Lincoln & Guba, 1985; Noble, 2015). As 
theoretical terms have developed, there has been a drive to develop quality checklists such as 
the NICE quality guidelines (NICE, 2012). Checklists recommend techniques like purposive 
sampling, grounded theory, triangulation, and respondent validation.  
The reliance on such checklists has been criticised as counterproductive in that they can 
reduce qualitative research to a list of prescriptive technical procedures which in themselves 
do not confer rigour (Barbour, 2001). These checklists can be useful as frameworks by which to 
guide the research. In this study, three approaches were adopted to help enable 
methodological rigour.  
Firstly, to enable a reflexive approach, the researcher kept a field diary on each day of the 
study where observations on the ward and the researcher’s experience interviewing 
participants were recorded. This approach helps foster critical self-reflection (Ortlipp, 2008). In 




of the ward helped enable a broader understanding of the processes at play as prolonged 
involvement in the community of interest may enhance sensitivity and validity (Kirk & Miller, 
1986).  
Secondly, all interviews were recorded using a Dictaphone. The researcher transcribed all 
interviews. This helped improve familiarity with the data. Names and any identifying 
information such as place or person’s names were removed from transcripts. Transcripts can 
provide a good record of naturally occurring interactions and are a reliable record of those 
interactions (Seale & Silverman, 1997).  
Finally, all transcripts were read, re-read and analysed using thematic analysis and the 
qualitative programme ATLAS.ti (version 7.5.12, Berlin, Scientific Software Development). 
Using qualitative software packages has been welcomed as an important development in 
improving rigour (Pope et al., 2000). Transcripts were coded by labelling each line of dialogue 
with a basic descriptive code.  
Throughout the analysis an iterative process took place with codes added, removed, merged 
or split. Each line of data was given a code which formed a coding framework. This coding 
framework was made up of one hundred and ten codes. All codes were grouped into ‘thematic 
families’. These families represent clusters of similar issues. Thematic families were then 
further grouped into four ‘global themes’.  
3.2.4.4 Qualitative study: ethical considerations 
Ethical approval was granted by the Queen Square Research Ethics Committee (REC) 
(15/LO/1914) on the 6th January 2016 and local research and development (R&D) approval was 
received on the 15th January 2016. The study received approval from the hospital site’s 
Neurosciences Research and Advisory Group (RAG) on the 13th January 2016.  
The main ethical concerns in this study were the maintenance of privacy and confidentiality. 
Due to the relatively small size of the HASU team, and the potentially sensitive nature of the 
interviews, it was important that staff interviews were conducted in private and all 
information was confidential. All data collected from the qualitative interviews, both audio and 
transcript materials were stored under the Data Protection Act of 1998. Only the research 
team alone had access to de-identified information which was kept in a locked drawer or in its 





3.3.1 Survey results 
3.3.1.1 Participants 
In total, 122 questionnaires were returned. Across the twelve sites, the mean number of 
completed surveys was 10.3 (SD: 6.4). Of survey respondents, the most common occupation 
type was physiotherapy (n = 27).  
Additionally, 15 stroke consultant doctors completed the survey, twelve junior doctors, sixteen 
occupational therapists, seven neurologists and eight nurses. Twenty-two respondents did not 
state their job titles (see Table 5).  
Six participants did not give information on their gender. Of those who did, 87 were women 
(75%) and 29 were men (25%). 
The mean age was 34.5 years (SD: 9.1, range 22 – 61). When age and gender were explored 
according to participants’ occupation, all occupational therapists were women and the lowest 
proportion of female respondents was amongst stroke consultants (33.3%). Stroke consultants 
were on average the eldest participants (mean age 46.7, SD: 8.6) while occupational therapists 
were the youngest (mean age 30.8, SD: 7.8).  







 n (%) 
Physiotherapist 27 (22.1) 31 (5.2) 21 (77.8) 
OT 16 (13.1) 30.8 (7.8) 16 (100) 
Consultant 15 (12.3) 46.7 (8.6) 5 (33.3) 
Junior doctor 12 (9.8) 31.7 (5.5) 8 (66.7) 
Neurologist 7 (5.7) 31.3 (3) 6 (85.7) 
Nurse 8 (6.6) 32 (4.7) 6 (75) 
Other
1
 15 (12.3) 36.2 (12.2) 11 (73.3) 
Not stated 22 (18) 38.3 (9.2) 14 (63.6) 
Total 122 (100) 34.5 (9.1) 87 (75)
2 
1
‘Other’ category includes therapy assistants, clinical 
psychologists, speech and language therapists, 
neuroscientists and allied health professionals 
2
Six participants did not report their gender 





3.3.1.2 Survey results: attitudes to functional patients  
The frequency of agreement to statements related to the possible cause of functional stroke 
symptoms and clinicians’ belief of how easy or not these patients are to manage was analysed 
(see Table 6).   
Respondents were more likely to agree or strongly agree that patients with functional stroke 
symptoms are “difficult to manage” (77.9% agreed with this statement). Most respondents 
(75.4%) disagreed or strongly disagreed that patients with functional stroke symptoms have an 
undiagnosed physical illness. Participants were also more likely to disagree that patients with 
functional stroke symptoms have a personality disorder (69.7% disagreed). There was no 
difference between the rate of respondents agreeing and disagreeing with the statement that 
‘patients with functional stroke symptoms have a psychiatric illness’ (54.1% disagreed). 
Table 6 Table displaying agreement to statements on patients with functional stroke 
symptoms 
Patients with functional stroke 
symptoms are:  
Agree & 
strongly 












 95 (77.9) 26 (21.3) 1 (0.8) 0.001 
“Have an undiagnosed physical illness”
a
 23 (18.9) 92 (75.4) 7 (5.7) 0.001 
“Have personality disorders”
a
 34 (27.9) 85 (69.7) 3 (2.5) 0.001 
“Have a psychiatric illness”
a
 53 (43.4) 66 (54.1) 3 (2.5) > 0.05 
a 
Chi-square test comparing ‘agree or strongly agree’ with ‘disagree or strongly 
disagree’ rates 
 
Agreement and disagreement to these statements were assessed according to profession, 
gender and age profile. Age was transformed from an integer into a categorical variable and 











Table 7 Table displaying frequency of ‘agree’ or ‘strongly agree’ responses to statements by 




















In response to the statement “Patients with functional symptoms are difficult to manage”, the 
professions displaying the most frequent agreement were neurologists followed by 
physiotherapists. The profession least likely to agree were those grouped in the ‘other 
category’.  
In response to the statement, “Patients with functional stroke symptoms have an undiagnosed 
physical illness”, neurologists were most likely to disagree while 37.5% of nurses agreed or 
strongly agreed with the statement.  
In response to the statement, “Patients with functional stroke symptoms have personality 
disorders”, there were consistently low rates of agreement, with the ‘Other’ category and 
neurologists most likely to disagree and the highest rate of agreement amongst nurses and 
stroke consultants. Fifty per cent of nurses surveyed agreed with the statement although the 
total number of nurses responding to this statement was only eight.  
In response to the statement, “Patients with functional stroke symptoms have a psychiatric 

































n (%) n (%) n (%) n (%) 
Overall 95 (77.9) 23 (18.9) 34 (27.9) 53 (43.4) 
Profession     
Consultant 12 (80) 3 (20) 6 (40) 8 (53.3) 
Junior doctor 10 (83.3) 3 (25) 3 (25) 3 (25) 
Neurologist 7 (100) 0 (0) 1 (14.3) 2 (28.6) 
Nurse 5 (62.5) 3 (37.5) 4 (50) 2 (25) 
OT 13 (81.3) 3 (18.8) 4 (25) 12 (75) 
Other 9 (60) 3 (20) 1 (6.7) 4 (26.7) 
Physiotherapist 23 (85.2) 5 (18.5) 7 (25.9) 13 (48.1) 
Unknown 16 (72.7) 3 (13.6) 8 (36.4) 9 (40.9) 
Gender     
Female 69 (79.3) 17 (19.5) 24 (27.6) 39 (44.8) 
Male 23 (79.3) 6 (20.7) 8 (27.6) 13 (44.8) 
Age     
21-30 28 (77.8) 5 (13.5) 5 (13.5) 17 (45.9) 
31-40 35 (83.3) 10 (23.8) 14 (34.1) 20 (47.6) 
41-50 7 (87.5) 2 (25) 1 (12.5) 3 (37.5) 
51-60 8 (88.9) 1 (12.5) 3 (37.5) 2 (22.2) 




frequently agreed with the statement and the profession most likely to disagree were junior 
doctors and nurses.    
There was no statistical difference in agreement to any statement according to age.  
3.3.1.3 Survey results: attitudes to treatment  
In response to the statement, “Patients with functional symptoms should be managed in…”, 
the majority of participants said primary care (32.8%), mental health settings (27.9%) and 
‘other settings’ (27%).  
In response to the question, “Which setting currently provides the most effective treatment 
for patients with functional stroke symptoms?”, the majority of respondents again chose 
primary care (44%), followed by ‘other settings’ (24.6%). The lowest proportion of participants 
chose ‘outside the NHS’ for both statements.  Response rates are outlined in Table 8.  
Table 8 Breakdown of responses on where functional stroke patients should be managed and 









managed in”  
“Which setting 
currently provides 






n (%) n (%) 
Primary care 40 (32.8) 54 (44.3) 
Medical/surgical outpatients 9 (7.4) 11 (9) 
Mental Health 34 (27.9) 19 (15.6) 
Outside the NHS 1 (0.8) 2 (1.6) 
Other settings 33 (27) 30 (24.6) 
No response 5 (4.1) 6 (4.9) 
Total  122 (100) 122 (100) 
 
Participants were asked “What is the role of the doctor or health care team in managing 
functional stroke symptoms?” and were asked to select up to three responses. The responses 
chosen most frequently were “To provide reassurance and support” (34.5%), “To provide 
counselling and appropriate psychological management” (30.7%) and “To act as a gatekeeper 
preventing inappropriate investigation” (19.1%). No respondent agreed with the statement 
that their role was “To prescribe psychotropic medication” or “To have no involvement at all”. 




Table 9 The rate of agreement to statements regarding the doctor or health care team’s role in 
managing functional stroke symptoms. Participants could choose up to three.  
“What is the role of the doctor or health care team in managing 
functional stroke symptoms?” n (%) 
“To provide reassurance and support” 110 (34.5)  
“To provide counselling and appropriate psychological management”  98 (30.7) 
“To act as a gatekeeper preventing inappropriate investigation”  61 (19.1) 
“To refer for further investigations to identify a cause”  46 (14.4) 
“Not to get too involved in their management” 4 (1.3)  
“To prescribe psychotropic medication” 0 (0) 
“To have no involvement with them at all”  0 (0)  
Total 319 (100) 
 
3.3.1.4 Survey results: attitudes to further research in the area 
The majority of respondents (95.8%) agreed or strongly agreed with the statement that further 
research is needed in the area of functional stroke symptoms. Answers were evenly divided in 
response to the statement: “There are effective treatments for functional stroke patients” 
with 50.9% of respondents agreeing with the statement. The majority of respondents (83.9%) 
agreed or strongly agreed that “Physiotherapy could prove an effective treatment for some 
functional stroke patients” and 89.9% of respondents disagreed or strongly disagreed with the 
statement “There are clear guidelines on how to manage patients with functional stroke 
symptoms”. Responses are outlined in Table 10 below.  
Table 10 The frequency of responses to survey statements on research and treatments for 












“Further research is needed into the area of 
functional stroke symptoms” 
115 (95.8) 5 (4.2) 2 (1.6) 
“There are effective treatments for functional 
stroke patients” 
59 (50.9) 57 (49.1)  6 (4.9) 
“Physiotherapy could prove an effective 
treatment for some functional stroke patients” 
99 (83.9) 19 (16.1) 4 (3.3) 
“There are clear guidelines on how to manage 
patients with functional stroke symptoms” 
12 (10.2) 106 (89.9) 4 (3.3) 
Responses were compared according to profession, age and gender categories. A Chi-square 
test found no statistically significant difference between men or women’s responses to any of 
the four statements.  
When examined by profession, all consultants, junior doctors, neurologists and 
physiotherapists agreed or strongly agreed that, “Further research is needed into the area of 




In response to the statement, “There are effective treatments for functional stroke patients” 
there was a more varied response pattern. The profession most frequently agreeing or 
strongly agreeing with this statement were neurologists. The professional group which was 
least likely to agree or strongly agree with the statement were consultants at 40%.  
In response to the statement “Physiotherapy could prove an effective treatment for some 
functional stroke patients”, all consultants and neurologists agreed or strongly agreed with the 
statement. The professional groups agreeing least with this statement were nurses and the 
‘Other’ group at 66.7%.  
Agreement to the statement, “There are clear guidelines on how to manage patients with 
functional stroke symptoms”, no neurologist or profession labelled ‘other’ agreed. Agreement 
to this statement was low across all professions with the highest rate of agreement amongst 
neurologists at 100%. Table 11 displays agreement to statements regarding treatment by 
profession type. There was no significant difference in responses with regards age or gender.  
Table 11 Table displaying percentage of ‘strongly agree’ or ‘agree’ responses to statements 







































“There are clear 
guidelines on 





 n (%) n (%) n (%) n (%) 
Overall 115 (95.8) 59 (50.9) 99 (83.9) 12 (10.2) 
Profession     
Consultant 15 (100) 6 (40) 14 (100) 1 (6.7) 
Junior doctor 12 (100) 5 (41.7) 11 (91.7) 1 (9.1) 
Neurologist 7 (100) 5 (71.4) 7 (100) 7 (100) 
Nurse 6 (85.7) 4 (57.1) 4 (66.7) 1 (14.3) 
OT 15 (93.8) 9 (56.3) 15 (93.8) 2 (12.5) 
Other 14 (93.3) 7 (50) 10 (66.7) 14 (100) 
Physiotherapist 27 (100) 13 (54.2) 24 (88.9) 3 (11.5) 
Unknown 19 (90.5) 10 (47.6) 14 (66.7) 4 (18.2) 
Gender     
Female 81 (95.3) 40 (49.4) 72 (84.7) 8 (9.6) 
Male 29 (100) 14 (48.3) 22 (81.5) 4 (13.8) 
Age     
21-30 35 (94.6) 18 (51.4) 30 (81.1) 4 (11.4) 
31-40 42 (100) 21 (51.2) 37 (92.5) 4 (9.5) 
41-50 7 (87.5) 5 (71.4) 6 (75) 1 (12.5) 
51-60 9 (100) 4 (50) 7 (77.8) 2 (25) 




Some participants wrote additional comments on the paper survey. These were collected and 
are outlined in Table 81 – Table 90, (see “Appendix 3.1: Qualitative survey responses).  
 
3.3.2 Qualitative results 
3.3.2.1 Participants 
In total, 14 staff members were recruited to the qualitative study. Seven female and seven 
male staff members were interviewed. Five senior house officers, three nurses (one nurse 
manager, one TIA nurse specialist and one nurse consultant), one physiotherapist, two 
neurology registrars, two stroke registrars, and one geriatrics registrar were interviewed.  
The average length of interviews was 25 mins 43 secs (range: 16 – 41 minutes). See Table 12 
for a list of the clinical staff interviewed according to profession, ethnicity and gender. Age 
information was not collected.  
Table 12 List of qualitative interviewees  
Position Ethnicity Gender 
Senior house officer Mexican Female 
Senior house officer Romanian Female 
Locum senior house officer White British Male 
Nurse Black British Male 
Physiotherapist White British Male 
Registrar British other Male 
Senior house officer Singaporean Male 
Senior house officer Other Female 
Geriatrics registrar White British Female 
TIA/thrombolysis  nurse specialist Black British Female 
Neurology registrar British other Male 
Neurology registrar White British Male 
Registrar White British Female 
Nurse consultant White British Female 
In total, 110 were created from the interview data. These codes were grouped into ‘thematic 
families’ which were then grouped by ‘global themes’. Global themes and their constituent 








Table 13 Table outlining the themes from qualitative staff interviews and their constituent 
thematic families 











































The following sections outline the results of the interviews according to the four main global 
themes identified. 
3.3.2.2 Symptom attributions 
This section explores staff members’ illness attributions towards patients with functional 
stroke symptoms. Attribution theory attempts to explain how people understand the causes of 
events and behaviour (Weiner, 1980). An external attribution will link the cause of an event to 
an external source; for example a traumatic life event. Internal attributions are those where 
cause is ascribed an internal characteristic, for instance linking depression to personality traits. 
There is evidence that when people attribute mental health symptoms in others to 
mechanisms beyond that person’s control they will display more acceptance and tolerance and 
be less likely to blame the person for their symptoms (Corrigan et al., 2001).  
Some research suggests a belief in stress or anxiety as a causal factor is associated with greater 
tolerance (Schnittker, 2008). Psychosocial attributions like abuse can help reduce the 
perception of personal responsibility but may increase the sense of otherness, ‘them’ versus 
‘us’ (Schomerus, 2014). Attributions can vary depending on clinicians’ speciality. A study on 
clinicians’ beliefs on the cause of ‘Gulf War Illness’ found internal medicine clinicians were 
more likely to believe mental health problems or stress was the cause of the problem while 
mental health clinicians attributed the illness to viruses, bacteria and exposure to toxins 
(Richardson et al., 2001). Gaining insight into clinicians’ attributions may therefore help predict 
attitudes and behaviour. 
In these interviews, two attribution types emerged. The first aligned with current psychological 
models of functional symptoms where cause was seen as complex and multi-dimensional. A 




ascribed blame to the individual patient. Such attributions may reflect stereotyped thinking 
and emotional responses to occupational pressures as well as genuine uncertainty as to the 
role of volition in functional disorders.   
All staff members were asked directly what they believed caused patients’ functional 
symptoms but, in many instances, attributions emerged unprompted such as anxiety, 
interpersonal conflict, pre-existing physical conditions and attention-seeking. Participants were 
not asked whether they believed symptoms were consciously simulated but this emerged 
nonetheless as an important tenant in their understanding.  
A variety of views aligned to psychological models of functional patients emerged. 
Misinterpretations of normal physiological problems, anxious personality types and 
environments leading to stress were all examples of possible predisposing factors in the 
emergence of functional symptomatology.  
A number of participants argued that some functional stroke mimic patients have anxious 
personalities and over-interpret natural physiological changes within their bodies. This is the 
view that tendencies to be overly-primed to normal somatic processes can lead to 
misinterpretations and catastrophic construals of minor illnesses:  
“I think a lot of these patients, whatever is going on in their life, they do maybe have a 
virus, a bit of an inner ear problem and all of a sudden they sleep funny on their arm or 
wake up with pins and needles, and it just sort of rolls out of control. They end up 
coming to hospital because they’re dizzy, feel sick, they’ve got pins and needles in their 
arm or they are feeling a bit weak and lethargic, and they’re already down” (Nurse 
consultant, female) 
This view is echoed in the psychological literature where there is evidence that misdirected 
attentional processes and misinterpretations of normal somatic symptoms could be linked to 
patients’ symptom attributions (Brown, 2004). 
Some staff members believed that functional patients’ presentations were a manifestation of 
innate, essential processes like personality and that functional patients’ tendency to over-
interpret natural physiological changes within their bodies was the result of anxious 
personalities. In these instances it was therefore unlikely for a clinician to posit that these 
symptoms were within a patient’s control and blame was attenuated:  
“[They are] not just people who have clearly had psychological trauma, but also people 
who have maybe, their personality has always been to be quite anxious, very 




“I feel that those people are getting benefit from being in hospital, getting something 
out of it…but this girl, I felt that she genuinely, I felt she might have had some 
underlying psychological issue and this might have been a manifestation of anxiety or a 
mental health personality. But I just didn’t feel that she was doing it deliberately” 
(Registrar, female) 
The latter participant’s unwillingness to attribute blame to a patient with an anxious 
personality serves to highlight the attribution of blame to functional stroke patients where 
non-essentialist attributions have been made.  
Similar assumptions about the extent of the conscious production or control of symptoms are 
evident in the view that functional symptoms might be linked to inter-personal conflict. A 
number of staff members mentioned the possibility that problems within the family might 
account for symptoms: 
“They are worried about something and when you dig a little deeper, they are having 
stress back home or some difficulty” (Senior house officer, female) 
Another clinician believed functional symptoms could be a manifestation of both personality 
and difficult social situations but patients were not conscious of this:  
“I honestly think they have a lot of problems, socially and with themselves, that their 
body was projecting all these issues, but they were not aware of what they were 
actually doing” (Senior house officer, female) 
The proposals that functional symptoms might be caused by misinterpreting normal physical 
processes, anxious personality types or patients’ social environment mirror some of the 
current psychological literature on functional symptoms. As previously described, there is good 
evidence that misdirected attentional processes could be linked to misinterpretations of 
normal somatic symptoms. Erroneous symptom perceptions can emerge from biases in a 
person’s existing health knowledge (Brown, 2004) while distraction techniques can reduce the 
experience of symptoms (Barsky et al., 1988). Personality traits may also play a role. Watson 
and Pennebaker (1989) argue that functional symptoms may be linked to individuals’ general 
predisposition and affectivity. Childhood experiences of parental illness are linked to functional 
symptom onset (Hotopf, 2003) and there is evidence that traumatic events like childhood 
physical and sexual abuse are risk factors in the experience of medically unexplained 
symptoms (Lackner, 2005).  
While these clinicians’ attributions echo mainstream psychological literature, the symptom 




functional symptoms highlight the self-perpetuating and multi-factorial nature of symptom 
cause (Deary et al., 2007), best illustrated by Engel’s (1977) biopsychosocial model where 
symptoms emerge and are maintained by a multiplicity of environmental, cognitive, 
behavioural and physiological factors.  
A second, different view of functional symptom cause also emerged. Here, symptoms were 
attributed to conscious feigning for secondary gain – the benefits derived from being unwell. 
Staff members who expressed this view maintained that patients performed their symptoms. 
Staff often expressed anger and annoyance at the perceived dishonesty:  
 “It’s frustrating. Because why would you actually fake a stroke? A stroke is life 
changing…disables someone for the rest of their life…so imagine that person has a 
stroke when you’re there, thinking, “Oh well, I’ve got stroke” when you don’t really 
have. So it is frustrating” (Nurse, female) 
From this perspective, functional patients are explicitly compared to stroke patients. This view 
also implies that patients can control their symptoms and do so for secondary gains. A number 
of interviewees gave examples of potential advantages they believed patients sought. Financial 
remuneration was one:  
“The people who I think are getting some kind of benefit from the situation, the people 
who are trying to get you to sign benefit forms, or who are on the personality-disorder 
type spectrum, I feel quite annoyed with them and I know it’s not professional” 
(Registrar, female) 
Attention-seeking from staff, friends and family members was another causal attribution. 
Some staff believed these were conscious attempts to gain the sympathy derived from having 
a physical illness:  
“Sometimes they, how should I put it, they need attention, from other people. So they 
are complaining that they cannot move their legs and hands to get attention back from 
other people” (Senior house officer, male) 
 “What motivates them? Could be attention, eh, you know, maybe they’ve got their 
own personal reasons, you know, I don’t know but it could be financial, it could be a 
whole lot of things” (Nurse manager, male) 
Another staff member believed that while some patients engaged in conscious attempts to 




“In the textbooks, it’s called ‘gain’ but I don’t think it means as in, they are consciously, 
I mean there will be a small proportion who are, almost old fashionably, called 
‘malingering’. I don’t think that’s a very big proportion at all. But there are people who, 
it’s probably unconscious who, their whole life is wrapped around their illness…their 
partner has become their carer, not just financially, they are excused from tasks that 
they might have to do” (Registrar, male)  
Help-seeking behaviour and primary and secondary gain do feature in psychological models of 
functional symptoms. Help-seeking behaviour can increase when people misinterpret physical 
sensations as signs of illness (Kirmayer & Taillerfer, 1997). There is evidence that some patients 
with somatisation disorder may be more likely to have experienced threatening life events 
where their symptoms have the potential to illicit some secondary gain (Craig et al., 1994).  
Clinicians who believe functional symptoms are feigned however differ from the established 
literature on functional symptoms in two important ways: 
Firstly, to be diagnosed with functional symptoms under DSM-IV (APA, 1994) and ICD-10 
criteria (WHO, 1992), deliberate feigning of symptoms has to be ruled out. The interviews 
suggest that some clinicians have conflated feigning and functional symptoms. If a clinician 
concludes that a patient’s symptoms are intentionally produced, the diagnosis will change to 
factitious or malingering disorder. However, the evocation of ‘unconscious’ motivation is a 
common element in clinicians’ understanding of functional disorders since Freud. Stone et al. 
(2005) note that patients’ own awareness of their functional symptom control will fluctuate 
and while they may begin with little awareness they may gradually gain conscious control or 
vice versa. Given the complexity of this clinical picture, it is arguably futile for any clinician to 
accurately detect and delineate deception from unconscious processes. Despite this, clinicians 
in these interviews appear relatively preoccupied with the issue and it appears to play an 
integral role in their beliefs about functional patients.  
Secondly, when psychological theories do mention secondary gain, they often conceptualise it 
as a maintaining rather than explanatory factor, something which perpetuates an already 
existing symptom or arises due to stressful life events (Craig et al., 1994). While secondary gain 
may be part of a functional presentation, it is unlikely to be a simple connection between 
seeking advantages and simulating symptoms. 
In summary, while some clinicians hold varied, nuanced views on functional symptom cause 
and suggest personality, stress, traumatic life events and the misattribution of normal bodily 




suggesting that the need for money or attention from friends and family consciously motivates 
patients to perform their symptoms.  
3.3.2.3 Interactions with patients 
Participants were asked what kind of diagnostic labels they use when they diagnose functional 
stroke patients and how they approach such conversations.  
Two styles of interaction emerged; the first was characterised by clinicians who employed 
obscure terms when discussing functional symptoms with patients while the second group 
used a more advanced system of explanation reliant on metaphorical language or 
demonstrative techniques.  
The first category included clinicians who said they often use obscure language in order to 
avoid difficult conversations. When asked which terms they most commonly used, most 
mentioned the term ‘functional’ or ‘non-organic’. 
“We often use the word ‘functional’ 
Do you think [the patient] understands what that means? 
 
No. That’s part of the reason why we use it. When a healthcare professional says the 
word…it’s our way of telling them, without telling them” (Senior house officer, male)  
This clinician purposely avoided addressing the true nature of patients’ symptoms. From this 
perspective, the patient might be satisfied that they received a label with which they could 
categorise their symptoms but such an approach may cause problems in the longer term when 
patients seek help post-discharge without a clear understanding of symptom cause. 
Using an obscure label can operate as a means by which to avoid difficult conversations that 
require the use of psychological terminology, something a stroke clinician may feel unprepared 
for or believe is outside their field of expertise, competence, or responsibility.   
Clinicians may also worry when giving a functional diagnosis that they are labelling a person 
which could lead to stigma once the patient is discharged: 
“Families tend to come along with the whole, “So what’s causing this then?” and it’s a 
difficult one. We don’t want to say, “We think this is functional” because there’s a lot 
of stigma associated with that, that it’s a psychiatric problem, rather than an organic 
problem so you just have to phrase it like, “Well, sometimes we can’t really explain it”. 




problem and we can’t find anything wrong and there’s nothing here we can fix, from a 
medical perspective” (Senior house officer, male) 
‘Label avoidance’ is a key feature in Corrigan’s theory of self-stigma where a person with a 
mental health problem avoids seeking treatment because they wish to avoid receiving a 
stigmatising label. In this case, there is a kind of role reversal where the clinician is aware of 
the negative mental health stereotypes and wishes to avoid labelling the patient (Corrigan & 
Wassel, 2008). While the impulse might be commendable, avoiding the issue completely may 
indirectly reinforce stigma as patients can read anything into the resulting diagnostic vacuum. 
Whether they are given ‘functional’ or ‘conversion disorder’ labels, a watered down 
explanation of their symptoms, or none at all, they are inpatients on an acute ward and will 
expect the normal medical processes of assessment, diagnosis, and treatment to proceed.  
Stroke clinicians may avoid lucid explanations in order to avoid potential stigma but they may 
also feel restricted in the treatment they can offer. By withholding a diagnosis, clinicians may 
not feel as obliged to treat or give referrals:   
“We’re doctors. So if someone has a stroke, I know what the risk factors are. I have 
drugs I can give to that patient to minimise that risk. I feel much more comfortable 
speaking...once I explain, ‘You’ve had a stroke’, they understand. But once you go down 
the functional route and say to someone, ‘There is nothing wrong with your brain. 
Rather than a problem of the brain, this is a problem of the mind, this is a mental 
health issue or a psychiatric issue’ there is a lot of stigma attached to that” (Registrar, 
male).  
A possible alternative explanation is that staff might not know what caused a patient’s 
symptoms and are unwilling to give any diagnosis. Obscure language and terminology benefit 
clinicians who do not want to risk giving a misdiagnosis:  
 “The consultant will speak to the patient…you know they normally use words like, ‘We 
don’t think that this is stroke, it could be something else, but we don’t think you need 
to be in hospital and we would refer you to our colleagues’” (Nurse manager, male) 
Giving a negative diagnosis like ‘we found nothing wrong’, may be reassuring to the clinician – 
they have addressed the symptoms by conducting diagnostic tests and haven’t caused harm by 
recommending any treatment or tagged the patient with a potentially stigmatising diagnosis. 
In this sense, a non-diagnosis or a negative diagnosis mitigates risk and uncertainty: 
“You have to phrase it like, ‘Well, sometimes we can’t really explain it’ but what we can 




can’t find anything wrong and there’s nothing here we can fix, from a medical 
perspective’…If you sort of say to people, ‘Look’, they feel like we’re accusing them of 
making things up then it tends to be quite hostile” (Locum senior house officer, male) 
Some clinicians were aware that diagnostic vagueness could be discomforting or even 
upsetting and noted the importance of a positive explanation. Even clinicians who recognised 
the value of this, however, still resorted to slightly obscure explanations and appeared to 
approach their conversations with patients with the expectation of confrontation:  
“Functional illnesses are almost kind of like a diagnosis of exclusion because it’s very 
hard to do objective tests and say, ‘Yes, that’s functional’ so sometimes you’ve got a 
limited information exercise. You can only do a limited number of investigations…you 
try to reassure the patient and say, ‘Look, I don’t think it is an organic problem…’ but 
then using that term, ‘I think’ rather than ‘Everything shows’ gives them a way in that 
they sometimes can confront you, ‘Well, if it isn’t, what could it be?’ I try to explain 
that there are things such as functional problems, inorganic problems or a 
manifestation of an emotional or stress related problem” (Registrar, male) 
Obscure terms and diagnostic vagueness may serve a further purpose. In referral letters, they 
can act as signals to other clinicians in the care pathway. Obscure terms can suggest the 
presence of a functional aetiology without offending patients or running the risk of 
misdiagnosis.  
“The letter that the patient takes with them…we try not to write under diagnosis, 
‘Functional presentation’, although, that is probably better than, what’s the other one? 
‘Conversion disorder’, you know, so what do you put there? Sometimes I just tell the 
doctors to write, ‘Negative MRI with neurological presentation’ or something like that, 
which I know is woolly and fluffing it up a bit because we don’t know what to write and 
it is a very uncomfortable position to be in because you know there is something wrong 
with these people” (Consultant nurse, female)   
Similar methods were found to be employed in neurologists’ letters to GPs (Kanaan et al., 
2009). Letters written in the early stages of the diagnostic process often contain coded 
messages to GPs that attempt to balance neurologists’ duty to be honest and accountable 
while not offending patients. Codes used included ‘elaborated weakness’, ‘inconsistent’ and 
‘functional symptoms’.  




“We do do things like say, for example, “This is probably a migraineous phenomenon” 
which probably covers up likely functional things” (Neurology registrar, male) 
“You always want to try and get the best, as good a diagnosis as possible because, you 
know, mislabelling people can be really destructive and that’s as much giving 
somebody the label, ‘TIA’ which is attached to them for their life and you know, 
‘multiple TIAs’ is a common diagnostic label and it’s just not something, in real life, in 
actuality, it’s not common for people to have recurrent TIAs. But they get labelled with 
that and they pushed down a certain diagnostic pathway all the time…I think often it is 
just a catch-all term of ‘Well, we don’t really know what to call it’ or ‘We’d rather not 
broach the subject and call it TIA’” (Registrar, male) 
As this clinician points out, giving a vague or false diagnosis could be actively harmful to 
patients. TIAs are difficult to diagnose and a clinician might find it easier to give a TIA than a 
functional diagnosis. TIA patients’ quality of life scores are comparable to stroke patients, 
despite the temporariness of their symptoms (Franzen-Dahlin & Laska, 2012). Post-diagnosis, 
many TIA patients live in fear that an episode will reoccur and limit their everyday activities 
(Spurgeon et al., 2013) so it is a diagnosis that should not be given lightly.  
There may be something especially damaging about such a practice in an acute inpatient 
setting, where the patient may assume that due to the specialisation of skills there, a diagnosis 
given there might hold more weight than a diagnosis from elsewhere. They may be more likely 
to change behaviour or be emotionally affected by diagnostic information from these 
clinicians. In such a setting, diagnostic vagueness from acute care staff might be particularly 
worrying. 
The final part of this section discusses the more direct means of communication utilised as well 
as the use of metaphor and non-verbal techniques employed by stroke staff.  
Some staff described being direct in their approach to functional diagnoses:  
“Sometimes I think the truth is just better than not hearing it. So, if you have these 
functional patients coming in, you’ll always have them coming back in because if you 
don’t tell them, ‘Actually, this is functional’ then they will present with the same 
symptoms again, thinking, ‘I definitely am having a stroke’” (TIA nurse, female) 
Other participants described utilising more complex explanations when talking to patients, 
relying on metaphors and similes to help patients better understand their symptoms. This was 





“Spend time with them, sit down with them and talk about wires in the brain, that it’s a 
bit like a computer and the wires get crossed and things won’t work.…I don’t know how 
I put it but I put it in such a way as, ‘We believe you believe’” (Nurse consultant, 
female) 
The ‘mind as machine’ metaphor is not new in cognitive psychology (Pinker, 1999) or 
philosophy (Dennett, 1984; McCulloch & Pitts, 1943; Rumelhart, 1989) but more recently it has 
been proposed as a way of explaining functional symptoms without inferring blame or guilt. A 
Dutch survey of 343 neurologists found 38.8% used a computer metaphor telling patients their 
‘hardware’ (or brain tissue) was intact but they were experiencing a ‘software’ problem (de 
Schipper et al., 2014). GPs treating unexplained medical symptoms have reported relying on 
mechanistic metaphors like ‘load and capacity’ concepts (olde Hartman, 2009).  
While such explanations help facilitate discussion about psychological or psychosocial 
problems, it has also been suggested that reliance on metaphor can ignore the finer details of 
diagnosis (Mabeck & Olesen, 1997). The mechanistic metaphors may not be helpful to 
everyone and most patients will likely understand explanations within their own pre-
established cognitive schemas. By taking time to first understand patients’ own 
conceptualisations, clinicians might be able to offer explanations that best suit the patient.  
Some clinicians described how the content of their explanations was less important than the 
way in which information was communicated. Examples include highlighting neurological 
inconsistencies for the patient, a technique recommended for neurologists in their assessment 
of functional symptoms (Stone et al., 2005):  
“I try using formal tests like the Hoover test…I normally do talk to them. I do it in a non-
confrontational way. I say ‘The weakness, you maybe feel that the weakness is there, 
but when I was trying to distract you, when I pulled my hand away, the weakness is not 
as bad as you make it out to be but I don’t know if maybe you’re perceiving that it’s 
weak or it is actually that weak’” (Neurology registrar, male) 
Similarly, clinicians believed that the language used in the clinical consultation was less 
important than the confidence with which the clinician spoke:  
“I think a lot of the time it depends on your confidence as a clinician. If you make a 
confident diagnosis and they trust you, to me, that is the absolute core element…If they 
don’t trust you, it doesn’t matter what you say it is” (Neurology registrar, male).  
While the content and language a clinician chooses is important, their non-verbal 




doctors and patients on stroke wards may be impaired compared to interactions on general 
medical wards. They may be more likely to be ignored, less likely to be given eye contact and 
less likely to be given help if needed (Pound et al., 1999). Non-verbal communication like head 
nodding, uncrossed arms and legs (Beck et al., 2002), tone of voice and eye contact 
(Marcinowicz et al., 2010) have been highlighted by patients as important. This is an area that 
has been explored extensively in general practice with less known on its effects in relation to 
functional patients.  
In summary, there is evidence that less experienced clinicians resort to obscure language in a 
bid to avoid confrontation or labelling patients. In other cases it may be to convenience the 
clinician themselves and help avoid taking responsibility for the patient. More experienced 
clinicians, have developed nuanced modes of communication and use metaphor and positive 
non-verbal techniques to communicate with patients.  
3.3.2.4 Responsibility and risk 
The theme of risk and the accompanying responsibility was a subtext in the previous two 
sections. Some clinicians believed that patients were consciously producing symptoms and 
were personally responsible for their admission. Others described feeling responsible for how 
they interacted with patients and were worried they might imply blame, guilt or infer stigma if 
they used psychiatric labels. However, some staff members believed that they were not as 
clinically responsible for functional patients as they were for stroke patients.   
This section examines how different clinicians prioritise patients and how they manage risk 
and uncertainty through diagnosis, treatment and referral patterns employed. Stroke clinicians 
continually deal with risk but it appears that once the risk of stroke has been mitigated, there 
is a deferral of clinical responsibility. 
There was a tendency for clinicians to view functional stroke patients as both outside their 
clinical remit and not a priority. This was likely due to the acute and specialised nature of the 
HASU and the clinical severity of stroke itself.  
“In a stroke unit, you’ve got to, you have such a high turnover and such a high volume 
of patients coming in who are really, really very sick patients, very unwell, and people, 
as soon as you say, “Okay, we can’t find an organic lesion for their problems”, everyone 
kind of loses interest a little bit and just like, ‘Yeah, it’s not for us, it’s not a neurological 




One doctor described feeling more at ease taking responsibility for stroke mimic patients with 
physical causes. This may be because doctors feel more competent treating physical symptoms 
but there was also a view that physical comorbidities were more important:  
“You know, I recognise what I can do and what I can’t do and psychiatry is something 
I’m not particularly interested in, I’ve not particularly got much skill so it’s a job for 
someone else…common stroke mimics, organic stroke mimics, things like Bell’s Palsy 
for example, we’ll often manage those ourselves” (Locum senior house officer, male) 
An unsympathetic view of this account is that the lack of priority is fuelled by a wish not to 
interact with people perceived as having mental health problems (Segal et al., 1980). The 
General Social Survey found half of adults surveyed in the US were unwilling to spend an 
evening socialising with or working next to a person with a mental illness (Martin, 2000). 
Such avoidance may directly affect the patient. Kirmayer and Taillerefer (1997) argue that 
negative doctor-patient interactions can increase the distress associated with symptoms and 
reinforce emotional arousal, illness worry and disability. Staff members however tended not to 
see themselves as part of patients’ interpersonal network and certainly not as potential 
contributors to or re-enforcers of distress.  
This attitude may result from a lack of interest in functional stroke patients generally, but it 
also reflects the specialisation of care on a HASU ward. Clinicians view the ward as a highly 
effective centre for stroke treatment and, from this perspective, functional stroke patients are 
usurpers of beds, time and resources.  
This view is likely tempered by the clinician’s role on the ward. Clinicians in managerial 
positions,  responsible for tracking the ward’s performance through reporting systems like the 
Sentinel Stroke National Audit Programme (SSNAP) may be more likely to see functional stroke 
patients as disruptive to the HASU and may be more acutely aware of the demand for beds 
and the costs involved in treating patients:  
“And I would never stand up there and say a patient doesn’t deserve a bed, but I’m 
really sorry but my acute stroke patient in A&E does deserve the HASU bed more than 
the mimic patients in there and you have to be realistic, and people can shoot me 
down, but obviously that patient can be managed elsewhere, whereas a HASU patient 
needs to come to HASU otherwise their outcomes are going to be terrible” (Nurse 
consultant, female) 
There is a high demand for HASU beds and a finite supply and this will inevitable place 




Their outcomes reflect HASU clinicians’ performance and the good management of a ward 
through the mandatory reporting in UK-wide stroke monitoring systems. SSNAP does not audit 
the outcome of functional stroke patients so the management adage ‘you can’t manage what 
you don’t measure’ may apply here.  
However, the monitoring of outcome may not always work against functional stroke patients. 
Physiotherapists abide by SNNAP guidelines and prioritise patients according to their time of 
arrival on the ward rather than their diagnosis:      
“We have to go by the SSNAP data. All the new patients have to be seen within 72 
hours. So over a weekend, we actually see those that come first…It’s a bit of a lottery, 
as in who has had scans, who has been washed, who is actually free” (Senior neuro-
physiotherapist, male) 
Functional patients will also be thoroughly examined. Under SNNAP standards, 90% of eligible 
patients must receive thrombolysis and 100% of patients must be scanned within 12 hours of 
symptom onset (London Strategic Clinical Networks, 2014). Because of the potential 
uncertainty and inconsistency in functional patients’ symptoms, their diagnostic assessments 
are often exhaustive. While a patient with haemorrhagic stroke might receive only a CT scan, a 
functional patient will often get both a CT and an MRI scan:   
“Sometimes we repeat the scan, just to make sure that we’re not missing anything” 
(Senior house officer, female) 
“The medical team, regardless of how unstroke-like the presentation might be, you 
know, ‘Drank six bottles of vodka’, ‘Patient had some cocaine’, ‘Heroin addict’, they all 
come back for an MRI…it’s the same treatment for everybody…the consultant…they’re 
still adamantly serious that every functional patient has an MRI. They cannot risk 
sending them home from the emergency department” (Consultant nurse, female) 
Being thorough may help reassure the patient but it also serves the purpose of protecting the 
hospital from any potential litigation. 
There were differences in the role personal intuition played in identifying functional patients 
and this tended to vary depending on the clinician’s experience. Some clinicians describe 
having an intuitive awareness of what non-stroke looks like:  
“When you’re a stroke nurse, or you work in stroke for a while, you automatically start 




presenting with symptoms that doesn’t match up with what they’re telling you, you 
start thinking, ‘You know what, this isn’t it’” (Nurse, male) 
Another clinician described identifying potential functional stroke by noticing idiosyncrasies in 
their presentations:   
“There is a lot of anecdotal evidence that things like dark glasses…for epileptic 
patients, if they came in with a teddy bear to telemetry then the likelihood of them 
being non-epileptic was statistically significantly high… you are probably 
subconsciously analysing lots of subtle aspects and cues, but you do get, I get an 
overarching sense of, ‘This doesn’t look like...it’s going to be a stroke’” (Neurology 
registrar, male) 
Some doctors argued that having less clinical expertise meant your personal threshold in 
accepting risk was lower and you were more thorough in your assessment.  
“The newer [doctors] are the ones that examine them more accurately, more in depth” 
(Senior house officer, female) 
Stroke is relatively easy to diagnose compared to other neurological disorders like Parkinson’s 
disease or multiple sclerosis. There may be a tendency to conflate diagnostic techniques like 
ordering assessments such as MRI and CT scans with good care and the administration of 
effective treatment. Clinicians were happy to discuss in detail how they ruled out physical 
diagnoses but gave little detail on the kind of treatment they would recommend or the 
referrals they make:  
“Most of the time they’re there, it’s just pat them on the back and off they go, that 
type of thing and I really don’t know what happens” (Consultant nurse, female) 
One clinician argued that not offering treatment was in itself useful and patients become more 
self-sufficient as a result:   
“Often it’s better to actually give them advice, discharge them without onward referral 
and sort of teach, show them how they can access services if they require it, advising 
them that they will improve spontaneously, that usually seems to work” (Neuro-
physiotherapist, male) 
Some clinicians described employing more positive strategies:  
“If you’re reassuring them that you have taken their ailment seriously and that you’re 




that, just by saying, ‘This is a functional hemiparesis. This is how we’re going to 
approach it, this is what we know about it’, things can get better” (Neurology registrar, 
male) 
Even if a clinician felt responsible for the care of the patient, many did not feel supported by 
the stroke system in making appropriate referrals. Many clinicians felt adrift when it came to 
knowing how to treat or where to refer functional patients: 
“It depends on the patient, if they ask to be referred. To my knowledge there’s no sort 
of protocol or pathway of whether you get referred for psychiatric or psychological 
treatment based on their functional symptoms” (Locum senior house officer, male) 
 “There doesn’t exist a clear pathway for patients who haven’t had a stroke. If we say 
this is a functional stroke mimic…there’s not a defined pathway on how we would go 
about managing that. It would literally just be a case of discharging them” (Senior 
house officer, male) 
One registrar believed referrals were difficult to make generally as they were reliant on who 
the referring clinician knew. Coupled with this, she believed mental health services were not 
well integrated within physical health care:  
“A lot of the time, making referrals in the NHS involves knowing who to email, who to 
call…because you have to know the services available. I’ve worked in this hospital for 
basically four years and I know a lot about the services here but I’m not sure about the 
mental health side of things and where that fits in” (Registrar, female) 
Some clinicians proposed concrete treatments for patients. Follow-up appointments in the 
setting in which patients were first admitted were recommended by one clinician arguing that 
continuity is important:  
“If they came in with a movement disorder that we thought was functional, then I 
would say that they should be seen in a movement disorder clinic for the first follow-
up…they may well go away and come back and they may have some questions that 
they need to go over things again, just to feel secure that you didn’t miss the diagnosis” 
(Neurology registrar, male) 
Continuity of care is valued by patients with medically unexplained symptoms (Hartz, 2000) 
but it has traditionally been seen as a responsibility for GPs rather than secondary services. 




“I really think that they need support groups and therapy, behavioural therapy, and 
unfortunately we just let them go and hope the GP will do that for them” (Senior house 
officer, female) 
There was a general tendency to describe or outline services that could be provided by other 
teams or departments rather than specific interventions that the stroke team or stroke 
clinicians themselves could provide. There appeared to be little desire to improve their own 
training or increase access to educational opportunities or a will to reorganise their own team.  
In summary, clinicians place a high degree of importance on the mitigation of risk associated 
with physical disease and it appears that once the lack of physical disease is firmly established, 
clinical responsibility is extenuated and the clinician’s priority becomes the discharge and 
referral of the patient.  
3.3.2.5 Systemic issues 
A number of clinicians described the institutional pressures of working within the NHS as a 
clear impediment in their day-to-day jobs. The high volume of admissions and the limited 
number of staff available was one such problem:  
“There is pressure to see the patients. They should all be seen every day and they 
should all get 45 minutes every day…there is one physio for 13 HASU beds. The maths 
doesn’t add up” (Physiotherapist, male) 
This was highlighted by another participant:  
“Our staff is not very big for the amount of patients that we get within a week. It’s not 
that they are inappropriately discharged, but they are discharged without all of their 
needs covered” (Senior house office, female) 
This was described elsewhere as a kind of supply/demand problem. The demand for beds was 
high with a limited supply:  
“We’ve got 12 beds, two are taken by tracheostomies and we have 250 admissions 
every month, now that’s 250 out. There’s not time. Average length of stay is 2.5 days 
for 40% of patients so turnover is massive” (Nurse consultant, female) 
“It is also the nature of doctors, the way you have a happy life as a doctor is if you can 
send patients home, you send them home because every single patient, even if there’s 




to your workload, so if someone is fit for discharge, you need to discharge them”. 
(Locum senior house office, male) 
The hierarchal nature of the acute stroke ward might aid its smooth running but it might also 
impede some staff members from being creative in their clinical response to functional stroke 
patients. One participant felt that nurses were constrained by doctors in how much 
information they could give to functional patients.  
“It’s not that nurses can’t do it, but if you’re being seen by a consultant on the ward 
round and the consultant isn’t really saying that you are functional but having a senior 
nurse or junior nurse going in and saying, ‘You’re functional’…I feel that it should be 
initiated by the consultant. Seeing that you’re the consultant, it’s your speciality” (TIA 
nurse, female) 
In summary, clinicians face impediments in the proper care and treatment of functional 
patients due to the high demand for beds and pressure to discharge patients promptly. Less 
senior members of staff also feel powerless in relation to the diagnosis of patients and the 
choice of treatment and referral pathways. 
3.4 Discussion 
3.4.1 Main findings 
The survey study suggests stroke clinicians believe their role is to provide reassurance and 
support to functional patients and that they view the primary care setting as the most 
appropriate for the treatment of patients. These findings correspond to results from surveys of 
GP attitudes who also saw their main role as providing reassurance and support to functional 
patients (Reid et al., 2001b; Sirri et al., 2017). GPs themselves endorse primary care as the 
most appropriate setting in which to treat patients. 
Like Reid et al.’s study, our survey results found stroke clinicians believe functional stroke 
patients are difficult to manage and don’t believe that they have an undiagnosed physical 
illness. Stroke staff felt functional stroke symptoms have been neglected by research and there 
should be more guidelines available to staff. Unlike Reid’s survey, stroke clinicians don’t 
believe functional symptoms can be explained by personality disorders and fewer agree that 
these patients have a psychiatric illness (43.4% of stroke clinicians versus 63.5% of GPs). It is 
possible that stroke clinicians were unaware or unsure what personality disorders were and as 




individual patients so they may be less likely to suspect an underlying psychological or 
psychiatric aetiology.  
The qualitative interviews reveal more varied and nuanced attitudes towards patients. 
Firstly, when asked about the possible cause of functional stroke symptoms, clinicians make 
multiple symptom attributions like the seeking of financial gain, requiring attention from 
family and friends and the misinterpretation of normal physical problems. In contrast to the 
survey findings, the qualitative results indicate that some clinicians believe personality does 
play a role in the emergence of functional symptoms.  
In making these attributions, clinicians revealed the extent of volition they believed patients 
had over their symptom production and how much blame they apportioned to individual 
patients for their admission. Clinicians who made internal or essentialist causal attributions 
like personality seemed less likely to ascribe blame to the individual patient. Where clinicians 
believed symptoms were consciously produced, there was a sense that patients were culpable 
for their admission. 
This, in part, echoes existing literature highlighting the often entrenched negative attitudes of 
doctors towards patients with unexplained or functional symptoms where patients are 
characterised as self-focused, irritable, difficult and demanding (Engel, 1959; Friedman et al., 
1963). The current work suggests a shift in attitudes wherein a degree of responsibility or 
motivation is ascribed to patients, but this does not inevitably lead to rejection and blame. This 
is compatible with our survey results where clinicians stated they felt their primary role was to 
provide reassurance and support, followed by counselling and appropriate psychological 
management for these patients. More education on the current causal models of functional 
disorder might help reduce misconceptions and potential stigmatising behaviour. 
Two styles of clinician/patient interaction emerged. The first type saw the clinician attempt to 
address the functional diagnosis but avoid direct conversations through the adoption of vague 
terms. Doctors feared misdiagnosing patients and also stated they did not want to use a 
potentially stigmatising label. There may be a certain level of psychological projection here 
whereby the clinician themselves has endorsed negative stereotypes of functional patients and 
is concerned patients will respond badly to the label. Using vague language helps protect the 
clinician from difficult bedside conversations but may leave the patient confused and in a 
diagnostic limbo.  
A second style of interaction saw clinicians employ a range of techniques to try to convey the 




techniques to try to give positive diagnoses. This is a positive finding as there have been 
attempts in recent years for clinicians to use positive assessments and diagnoses when 
treating functional patients (Stone et al., 2005). Clinicians are advised to try to reduce patients’ 
anxiety, make positive functional diagnoses, to explain the diagnosis as much as possible, and 
if the clinician feels there is a co-occurrence of physical and psychological symptoms, to discuss 
this (Reuber, 2005). How to adapt these steps to the specific needs of the HASU would be 
helpful for future research.  
Risk and responsibility was a prominent theme throughout our interviews. Coping with risk is 
an integral part of a stroke clinicians’ job where the consequences of giving a false negative 
stroke diagnosis could be severe. Clinicians felt responsible for functional stroke patients up to 
the point they could definitively rule out stroke. The diminution in clinicians’ sense of 
responsibility for functional patients is fortified by systemic issues like the lack of available 
beds and staff shortages, but this may be somewhat of a pretext when shirking responsibility. 
Once the risk of stroke is mitigated, the sense of responsibility for the patient fades. While 
clinicians were happy to discuss the diagnostic tests they used and the ways in which they 
imparted diagnostic information they were often vague when it came to discussing their 
treatment and referral approaches. Many mentioned the lack of guidelines and referral 
options for these patients, corresponding with the survey results where respondents all agreed 
that there was a lack of available guidance on how to refer functional stroke patients.  
Functional disorder patients in neurology outpatient settings report impairment similar to 
patients with physical symptoms and experience more distress than neurology patients 
(Carson et al., 2011). In acute settings like the HASU, it is likely that distress is even higher. The 
diagnosis of functional disorders deserves the same degree of effort and care as a physical 
disorder and when the diagnosis is reached, clinical responsibility should not be abdicated. 
HASU guidelines direct staff to discharge stroke mimics within 24-hours of their admission. 
While this might be straightforward for medical mimic patients, functional disorder patients 
may be left in treatment limbo. While an educational programme for stroke staff might help 
improve clinicians’ understanding of and ability to convey a functional diagnosis, guidelines are 
needed to improve the systemic care and referral of functional patients across HASU sites. 
Such calls have been made elsewhere and have increased in recent years (Caruso & 
Manganotti, 2016; Segal et al., 2012). 
Finally, it is worth considering these findings within the context in which clinicians work and 




of the stroke cases they see. In this light, staff often see functional patients as healthy and 
extremely lucky.  
Clinicians don’t live in a social vacuum and the wider cultural importance bestowed on ‘being 
healthy’ is worth mentioning. Some sociologists have described the ideological pursuit of good 
health in high income countries as morally and ideologically driven. In capitalist economies, 
self-control and responsibility for one’s own health are increasingly valued (Crawford, 2006). 
To some clinicians, functional patients violate these social norms and may be seen to directly 
contravene and undermine these moral virtues.  
3.4.2 Strengths and limitations  
Our survey study is the first to assess stroke clinicians’ views on and experiences with 
functional stroke patients. The questionnaire sampled a wide geographical area within the UK, 
including rural and urban regions and surveyed a range of disciplines and grades. While our 
semi-structured interviews were based in one HASU and may therefore have limited 
representativeness, our survey study addresses this concern.  
The survey has a number of limitations. Firstly, there were not enough survey respondents to 
allow for robust statistical comparisons between urban and rural sites or staff members’ years 
of experience. Secondly, a more extensive questionnaire might help tease apart engrained 
attitudes towards functional stroke patients. Attitudinal questionnaires assessing mental 
health literacy like the ‘Mental Health Literacy Questionnaire’ (Jorm et al., 2006) or social 
stigma scales (Modgill et al., 2014) would have been interesting additions. It was important 
however that the questionnaire was completed quickly as staff were asked to complete 
questionnaires during work hours. The number of response scales we could include was 
therefore necessarily restricted.   
The method we employed to distribute the questionnaire could limit the extent of 
interpretation in three ways. Firstly, a clinician within the stroke team was asked to distribute 
surveys and given a number of weeks to complete the task. Given staff members’ busy 
schedules, this request often had to be repeated. Despite this, the response rate at some sites 
was low. Some stroke sites are therefore under-represented in our survey. It is possible that 
the sites with higher response rates have well-established procedures and clinical insight into 
how to treat functional stroke patients, potentially biasing our results. However, given that 




Secondly, asking a senior clinician within the team to distribute questionnaires meant it was 
difficult to assess the non-response rate or to investigate whether those not responding were 
systematically different to those that did.  
Thirdly, as the staff member in each team who agreed to distribute surveys often held a senior 
position, it is possible that their influence affected some responses. Though surveys were 
confidential, it is possible staff members were worried that their views might be noted by the 
person collecting their questionnaires and they may have given more socially-desirable 
answers as a result. 
The qualitative interviews allowed for a more in-depth analysis of the issues and allowed for 
the elicitation of a richer breadth of information. The interviews took place at one urban site 
so representativeness may be limited. The response rate to the qualitative study was high and 
recruitment of different disciplines was representative of the staff working at this ward. The 
interviewer was embedded on the ward which allowed her to gain greater insight into its 
culture and the procedures employed there.  
Spending a substantial block of time on the ward was helpful for the researcher but it may 
have had a disadvantage. Clinicians knew the researcher was researching functional 
presentations on the ward. It is possible that there was an observer effect whereby staff 
became primed to the topic of functional symptoms as a result of knowing research was being 
conducted on the issue and may have changed or adapted their clinical behaviour as a result of 
the presence of the researcher.  
There may also have been a kind of ‘contamination’ within the stroke team. Clinicians who 
were interviewed may have discussed the topic of functional symptoms or the content of the 
interviews with other clinicians on the ward who were then subsequently interviewed. This 
might have influenced their view of the subject. Social desirability bias can also not be ruled 
out. All interviewees were assured that the interviews were private and confidential and were 
encouraged to speak freely without fear of judgement.  
It is also possible that the researcher, in the use of interviewing techniques and thematic 
analysis, exhibited a form of observer bias in the style of questioning or became primed to 
notice certain themes more acutely than others. We tried to reduce this by using the same 
semi-structured interview schedule for all participants, avoiding leading questions and in the 
presentation of results, giving counter-examples.  
The setting of the interviews may have affected the kind of results gained. Interviews did not 




A more neutral setting, for example within the university, might have helped mitigate any such 
bias although within the bounds of the time available, this would not have been a practical 
solution. Doctors kept their emergency pagers on them during interviews. In one case, an 
interview came to an end because of an emergency call. In another case, an interview was 
postponed for another day. The presence of the pager might have influenced some responses 
as the researcher and participants were aware that it could go off at any time. Conducting the 
interviews on the ward however was an advantage however as it gave the interviewer insight 
into the ward’s procedures and protocols.  
In the period that the interviews took place, there were a number of junior doctor and hospital 
porter strikes. It is possible that some of the systemic issues raised as concerns in the 
qualitative interviews were heightened due to these industrial disputes at the time. However, 
given that these interviews happened over the relatively long course of ten months, the 
interviews are less likely to be biased by any single source of industrial or occupational dispute.  
3.4.3 Conclusions 
Clinicians display some conflicted views on functional stroke patients. They are concerned with 
the potential misdiagnosis of these patients and show concern about mislabelling or 
stigmatising patients. Clinicians have varying views on the potential cause of these symptoms 
but most feel their primary role is the diagnosis and treatment of stroke and the immediate 
discharge of functional stroke patients. Few have any fixed view on the best referral or 
treatment option for functional patients but both quantitative and qualitative studies showed 
stroke clinicians want more information on treatment guidelines and referral options. There is 
a paucity of treatment and referral guidelines for functional stroke mimic patients and our 
survey found stroke evidence that staff would like more guidance in this area. 
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Chapter Four: Qualitative interviews with patients with unexplained stroke symptoms in a 








The previous chapter explored the experiences and attitudes of stroke clinicians in diagnosing 
and treating functional stroke patients. This study explores the experiences of functional 
stroke patients after their admission to a HASU and again two months after their discharge.  
There is evidence to suggest that those who experience physical symptoms for which there is 
no obvious biological cause or where there is ambiguity or uncertainty around their diagnosis 
can endure physiological and psychological consequences. Patients can experience high levels 
of depression (Henningsen et al., 2003), disability, and distress (Carson et al., 2011).  
Diagnostic uncertainty has been linked to heightened sensitivity to pain and a reduced quality 
of life (Wright et al., 2009).  
Understanding how a person represents and understands their functional symptoms and 
experiences during an acute stroke admission is not just a pedagogical exercise. It may help 
predict their future behaviour and their recovery trajectory. Patients who attribute 
unexplained symptoms to physical causes are more likely to make frequent visits to doctors 
while those who make psychological attributions are more likely to experience comorbid 
depression and anxiety (MacLeod et al., 1998; Rief et al., 2004). Understanding the 
experiences of functional stroke patients on the stroke ward and after discharge is the first 
step in the development of theoretical and treatment models.  
Previous qualitative research investigating the experience of patients with unexplained 
symptoms has focused on general practitioner (Ring et al., 2005) or neurology settings 
(Nettleton et al., 2005). There is considerable evidence on patients’ perspectives living with 
CFS (Broughton et al., 2017; Parslow et al., 2017), chronic pain (Osborn & Smith, 1998; Werner 
& Malterud, 2003), and irritable bowel syndrome (IBS) (Farndale & Roberts, 2010; Jakobsson 
Ung et al., 2013) but currently no literature on the experiences of patients with unexplained or 
functional neurological symptoms admitted to stroke settings.  
This introduction provides an overview of the existing literature on patients’ own accounts of 
unexplained syndromes, outlining evidence on the illness narratives patients employ to 
describe and understand their symptoms, the attributions and illness perceptions they make 





4.1.1 Previous qualitative findings 
4.1.1.1 Illness narratives  
Through the course of getting ill, being ill and recovering or getting worse, patients adopt ways 
of understanding and describing the experience, known as illness narratives. Narrative is 
employed by patients and clinicians and it can be helpful when trying to understand the 
meaning people ascribe to experience. Taking histories and writing formulations are an 
important part of a physician’s role. The clinical consultation could be seen as a collaborative 
attempt to construct a narrative and in itself can be therapeutic. Psychotherapy, for instance, 
is a formal collaboration between therapist and patient where both attempt to construct a 
narrative through which to understand past experiences. 
Traditional illness narratives often take the form of symptom onset experiences, seeking a 
diagnosis, receiving treatments and eventual recovery. For patients with unexplained or 
functional symptoms, such narratives may be harder to construct and patients can be left in 
‘semantic no man’s land’ (Kirmayer et al., 2004) or ‘diagnostic limbo’ (Corbin & Strauss, 1985). 
Chapter Three highlighted the tendency for stroke clinicians to avoid using formal diagnoses 
and the lack of treatment referrals for patients with unexplained or functional symptoms. In 
the absence of the normal medical treatment course and, given the often contested nature of 
functional diagnoses, it is important to understand the ways in which these patients 
understand their experience.  
Frank (1995) proposed three common types of illness narratives, ‘restitution’, ‘chaos’ and 
‘quest’. He argues that patients with unexplained symptoms commonly adopt ‘chaos 
narratives’ where patients describe symptoms which have no clear beginning, where disability 
is conceptualised as something that gets progressively worse, pain is unremitting and 
physicians are viewed as incompetent. Other qualitative research has highlighted the 
fragmented or chaotic accounts of unexplained symptoms by patients (Peters et al., 2008).  
That patients’ narratives can be chaotic is understandable given the frequent lack of guidance 
offered by doctors within consultations (olde Hartman et al., 2013). Chaotic or fragmentary 
accounts may arise as patients become aware of the time-limitations on their medical 
consultations and patients can feel frustration when GPs don’t or can’t appreciate the extent 
of their problems (Peters et al., 2008). Patients have often seen multiple clinicians and had 
many tests, and as a result may find it hard to recall specific elements of their medical 
histories. Patients with NES often struggle to retain information from doctors and many felt 





unable or unwilling to help reattribute their symptom experiences or guide their 
understanding (Peters et al., 2008).  
The lack of a clear narrative or structure with which to think about symptoms may have 
negative consequences for patients. A study of patients with chronic back pain found patients 
were relieved when they secured an identifiable organic cause and those with no diagnosis felt 
shame and guilt (Rhodes et al., 1999). While clinicians may view diagnostic uncertainty as an 
opportunity, for patients, this uncertainty can be disturbing and distressing (Kang, 2005). 
4.1.1.2 Illness attributions and perceptions 
Closely linked to illness narratives are the causal attributions made by patients. Attributions 
are the beliefs held by patients about the origins of their symptoms. There is evidence from 
medicine on how conflicting beliefs on the origins of symptoms between doctors and patients 
can negatively affect patients’ health care (Kaba & Sooriakumaran, 2007; The Lancet, 2013) 
through competing therapies, inducement of fear in the healthcare system and distrust in the 
discipline of medicine generally (Diette & Rand, 2007). Physicians operate within the 
biomedical model but patients may be influenced by their own behavioural and social beliefs 
(Platt & Keating, 2007). In unexplained or functional cases, patients may be convinced there is 
a medical explanation while doctors proffer psychosocial explanations.  
Robbins and Kirmayer (1991) identified three symptom attribution types. The first are 
normalising attributions where a person looks for an external or environmental account of 
their bodily sensations. If they find no external evidence for the symptom they may turn to the 
second attribution type; physical or biomedical explanations; and thirdly, they might adopt a 
psychological explanation where the symptom is attributed to psychological states like worry 
or anxiety.  
Other attribution theories do not depart greatly from Robbins and Kirmayer’s account. Young 
(1976) classified lay understandings of illness as either internalising or externalising while 
Helman (2000) described four attribution types: beliefs about cause located within the 
individual, the natural world, the social world, or the supernatural world.  
Patients with functional or medically unexplained symptoms may make multiple symptom 
attributions. Rief et al. (2004) reported that primary care patients with unexplained symptoms 
most frequently believe their symptoms were a result of ‘vulnerability to infection or 
environmental factors’. These patients were more likely to make organic illness attributions 
compared to patients with other physical disorders. A study of patients with chronic disorders 





mentioning physical, psychological and social causes like personality, genetics, organs behaving 
‘beyond their control’, poor relationships, and stress (Helman, 1985).  
Illness beliefs can affect illness behaviour and health outcomes. Belief in somatic causes can 
result in more requests for investigations and medications, increased disability at work and the 
avoidance of physical activity and more visits to GPs (Barsky et al., 1993; Ford, 1992; Sensky et 
al., 1996). Compared to patients who adopt psychological or social explanations, people who 
believe a physical cause accounts for their symptoms were less likely to experience stress 
(Bridges et al., 2009), more likely to have had childhood experiences of illness, and have had 
parents with a history of physical illness (Craig et al., 1994). Belief may also affect the 
chronicity of symptoms. Sharpe et al. (2010) reported that patients with unexplained 
symptoms in neurology who were unwilling to attribute their symptoms to psychological 
causes had poorer outcomes. For patients with chest pain, the persistence of pain was 
predicted by their earlier belief that they were prone to serious heart disease (Wielgosz & 
Earp, 1986). 
Different types of functional disorders may give rise to different illness beliefs. Ludwig et al. 
(2015) found patients with functional limb weakness were more likely to reject psychological 
causes than NES patients and less likely to consider their treatment effective. A study by Stone 
et al. (2004) found patients with functional weakness were more likely to find their symptoms 
mysterious compared to patients with organic weakness.  
There is an inherent dualism in these theories regarding patients’ illness beliefs. The 
conceptualisation of lay belief as wholly internal or external, psychological or physical may be 
overly simplistic and fails to account for the multiple and potentially contradictory causal 
attributions patients can hold and that beliefs may change over time.  
Leventhal et al. (1980) outlined a more pragmatic framework for understanding beliefs, based 
on illness perceptions. They noted how illness beliefs differ depending on the symptom label a 
person adopts, whether they believe their symptoms are acute or chronic, their perception of 
the consequences of their illness on everyday life and their views on curability and 
controllability. They propose that people are active problem solvers and try to avoid or treat 
illness depending on how much they perceive the illness to be a threat. There is consistent, 
though somewhat tautological evidence that frequent health care users believe that their 
symptoms have serious consequences, that they will continue indefinitely and report high 
rates of illness worry (Frostholm et al., 2007; Petrie et al., 2007). A systematic review showed 
an association between illness perceptions and survival in patients with end-stage renal 





2016). A systematic review concluded that there is a moderate to strong relationship between 
illness cognitions, coping and illness outcomes (Hagger & Orbell, 2003). 
Just as illness narratives can be complex, ambiguous and amorphous, illness attributions are 
likely to be multiple, and even contradictory. The kind of illness beliefs a patient holds and the 
strength of that belief will be influenced by many factors including the type of referrals they 
receive, the length of time they have experienced the symptoms, resistance to their beliefs 
from family and friends, how their symptoms progress over time and the kind of interactions 
patients have with the medical profession. The latter issue is explored in the next section. 
4.1.1.3 Attitudes to clinicians 
The previous chapter examined the attitudes and views clinicians hold towards functional 
stroke patients. This section explores existing evidence on the attitudes patients hold towards 
clinicians.  
Functional disorder patients can view consultations with trepidation. Qualitative studies of 
functional patients’ experiences found patients often fear the judgement of their clinician and 
worry that their doctor will view their symptoms as ‘all in their mind’ or worry that they will be 
seen as fraudulent or time-wasting (Nettleton et al., 2005; Peters et al., 2008). Back pain 
sufferers also expressed fear that the reality of their pain would be denied and their motives 
questioned (Glenton, 2003). In these instances, a physical diagnosis is akin to ‘absolution’ or a 
legitimation of symptoms. With the conferral of a physical diagnosis, patients can feel exempt 
from accusations of malingering, hypochondria and mental illness.  
Patients may hold differing attitudes to clinicians depending on the doctor’s speciality or 
experience. A study of NES patients found the type of health professional with whom they had 
had their single worst healthcare interaction were neurologists who did not specialise in 
seizures. They also reported these clinicians were lacking in knowledge and awareness, that 
they did not take the patient seriously and their personal perspectives were marginalised 
(Robson & Lian, 2017). Disagreement regarding symptom cause often lies at the heart of these 
interactions were a lack of trust and defiance can pervade interactions (Karterud et al., 2010).  
A study of patients with persistent somatising symptoms in Liverpool categorised patients’ 
responses to doctors’ explanations into three categories; clinicians who patients believed 
denied the reality of their symptoms; clinicians who sanctioned their own symptom beliefs and 
a third, less common type were doctors who offered explanations that attributed symptoms in 





perceiving doctors’ views to be in opposition to their own, suggesting the views of the doctor 
and patient not only differ but can be in active conflict (Salmon et al., 1999).  
Such conflict is reinforced when patients believe a doctor is incompetent and the information 
they hold is limited or wrong (Toombs, 1993). The perception of the fallible doctor can stem 
from a view that doctors are over-reliant on medical and technical investigations, and that 
they deny the reality of patients’ symptoms (Peters et al., 1998). Unsurprisingly, in cases where 
patients believe doctor’s knowledge to be fallible, patients display a greater readiness to reject 
their advice (Hunt et al., 1989).   
Positive engagement with patients emerges as an important part of the patient-doctor 
interaction. A study of primary care patients with somatoform symptoms found between 40 - 
50% of patients felt their physicians showed only moderate concern for their symptoms. 
Patients who perceived their physicians as caring about their unexplained symptoms were 
more likely to rate physicians as having shown respect for what they said, spending a suitable 
amount of time with them and receiving the best possible health care (Hartz, 2000).  
These findings suggest that the non-specific effects of the medical consultation are important. 
Improving communication skills, collaboration techniques, conflict management skills and 
addressing patients’ health beliefs directly might improve these doctor-patient interactions. 
The warmth of the relationship, the experience of being listened to and taken seriously and 
the sense that a doctor takes responsibility for the patient’s care are important for recovery.  
4.1.2 Aim of research 
Much of the existing research on experiences of functional patients comes from primary care 
and neurology outpatient settings but there are fewer accounts regarding the experiences of 
patients in acute inpatient settings, and less again on the experiences of these patients 
admitted to acute stroke wards. Like Chapter Two and Three, this study defines functional 
stroke patients as those patients who have not had a stroke and do not have any other medical 
aetiology for their symptoms but who may have a functional or psychological reason for their 
symptoms. 
This chapter aimed to investigate and describe the attitudes and experiences of patients with 
unexplained stroke symptoms admitted to one HASU. We aimed to understand patients’ 
experiences of symptom onset, the emotional and psychological effects of these admissions 
and to understand the role that patients’ illness perceptions play in their admissions and 







4.2.1 Brief Illness Perception questionnaire  
The Brief-IPQ was completed with all participants at the end of each baseline and follow-up 
interview (Broadbent et al., 2006). Questionnaires were completed at participants’ bedsides 
and via Skype at their two-month follow-up interview5.  
4.2.1.1 Questionnaire 
The Brief-IPQ measures illness representations. The scale is derived from Leventhal’s (1980) 
self-regulatory model which identifies five types of illness cognitions; consequences of being ill, 
timeline, personal control, treatment control and identity. 
The scale has been used successfully in many illness populations including mental and 
behavioural disorders (Wiborg, 2015) and stroke (Sjölander et al., 2013). The questionnaire 
assesses illness perceptions on a 0-10 point Likert scale with higher scores indicating a stronger 
endorsement of that item. Sample items include, “How much does your illness affect your 
life?” and “How concerned are you about your illness?” (Broadbent et al., 2006). See “Appendix 
4.1: Brief Illness Perception Questionnaire” for the questionnaire used in this study.  
The last item assesses the person’s view of the cause of the illness. This was not used in this 
study as it was a question explored in-depth within the qualitative interviews and one which a 
number of participants could not answer as they had not had formal discussions with their 
consultant at the time of the interview.  
The questionnaire has good concurrent validity when compared to the Illness Perception 
Questionnaire-Revised and shows good test-retest reliability (Broadbent et al., 2006).  
The questionnaire uses the word ‘illness’. Due to the functional nature of participants’ 
symptoms, ‘illness’ was not deemed a suitable term. Broadbent (2006) has noted that it is 
possible to replace the word ‘illness’ with the particular term of interest to the researcher 
while maintaining the questionnaire’s psychometric properties. In this case, the term 
‘symptom’ was used.  
4.2.1.2 Survey analysis 
An overall illness perception score was calculated for each participant. This represents the 
degree to which the illness is perceived as threatening or benign. To calculate this, scores on 
the ‘personal control’, ‘treatment control’ and ‘coherence’ items were reversed and added to 
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the ‘consequences’, ‘timeline’, ‘identity’, ‘concern’ and ‘emotional response’ scores. A higher 
score reflects a more threatening view of the illness.  
Repeated-measures Wilcoxon signed ranks tests compared the mean score of each item at 
baseline with the follow-up. These were used to investigate whether changes in illness 
perceptions from the baseline to follow-up assessments were statistically significant. P-values 
and confidence intervals were calculated. Cohen’s d was also calculated to examine whether 
effect sizes were potentially clinically relevant. Analysis was completed using SPSS (IBM SPSS 
for Windows, Version 22, Chicago, SPSS Inc.) 
4.2.2 Qualitative interviews 
4.2.2.1 Qualitative interviews: setting 
A handover meeting takes place at 8.30am each weekday morning on the HASU prior to the 
morning’s ward round. This meeting is attended by all doctors working on the HASU. 
Occasionally the ward’s matron or nurse consultant attends. At the diagnosis meeting, patients 
admitted to the hospital overnight are handed over to the clinical team by the night staff. 
Information on the handover includes their working diagnosis, symptom history, vascular risk 
factors, the results of any reports of diagnostic tests like ECGs, CTAs or MRIs as well as any 
remaining clinical tasks. Each patient is discussed by the clinical team.  
Each day at 11 am the multidisciplinary therapy team meets. The progress of each patient is 
noted.  These meetings are attended by the clinical psychologist, speech and language 
therapists, occupational therapists, physiotherapists, dieticians and often a junior doctor or 
registrar. Therapists discuss the progress of patients in relation to their movement, speech and 
functional outcomes such as their ability to cook, write, and the safety of their swallowing. 
Discharge decisions are often made at these meetings.  
In addition to hyper acute stroke care, the ward also provides a TIA service and several weekly 
stroke clinics where patients are reviewed who have previously been discharged from the 
service.  
With 15 beds on the ward, there can be up to 15 patients at any one time. Some patients came 
under the care of the stroke team but were located on different wards, for example in 
neurology. These patients were not approached for participation in this study. 





4.2.2.2 Qualitative interviews: procedure 
Baseline qualitative interviews took place in the same HASU setting as the qualitative 
interviews with stroke staff outlined in Chapter Three. The researcher was embedded on this 
HASU from 18th January 2016 until 19th October 2016 and attended the 8.30am diagnostic 
morning meetings at the HASU ward each working day and the 11am multidisciplinary meeting 
(with the exception of public holidays and weekends). 
Any patient with possible functional symptoms was identified from the handover sheet or by a 
clinician. The researcher spoke to the doctor to assess how likely the particular patient might 
be to have a functional explanation for their symptoms. The 11am meeting was also useful in 
discussing the potential diagnosis of individual patients.   
The researcher discussed with the doctor whether it was possible to consent the patient into 
the study. In some cases, doctors advised this would not be feasible as the patients’ diagnosis 
was unknown or there was likely a medical explanation for their symptoms.  
If a patient was recently admitted to the ward, for example, the previous evening, they were 
often given an MRI that morning. The results of the MRI were usually known by between 2 and 
3pm that day. If the MRI was clear, doctors often made the decision to discharge the patient 
immediately. In such cases, the researcher waited until the results of the MRI were known 
before approaching the patient. Patients were also included who had had a stroke but had 
‘functional overlay’; some symptoms that were not explained by stroke. 
When stroke was definitively excluded by the team, and there was no other likely medical 
explanation for symptoms, the researcher approached the patient at their bedside. A 
description of the study was given and patients were asked if they consented to take part. An 
information and consent sheet was given. Interviews took place at their bedside. All interviews 
were recorded with a Dictaphone. Interviews were transcribed by the researcher. The 
transcription helped improve the researcher’s familiarity with the data. See “Appendix 4.2 
Information sheet for patients” and “Appendix 4.3: Consent sheet for patients” for a copy of 
the information and consent form used with participants.  
Patients were also asked if they consented to be contacted in two months’ time. All patients 
agreed. At the two-month follow-up date participants were phoned via Skype. At the follow-up 
stage, participants were again asked to give informed consent. All interviews were recorded.  
Interviews took the form of semi-structured in-depth interviews and the interview schedule 





of the interview schedule used. Interviews were conducted in a non-judgemental, open style 
of questioning and participants were asked at the end of the interview to contribute anything 
extra they wished to add that had not yet been covered during the interview or to withdraw 
any information they had given that they did not wish to be included.  
Of note, when approached by the researcher, patients often had had different types of 
conversations with the medical team or individual staff members. Some for instance had been 
told that there was no explanation for their symptoms, while others were awaiting an 
explanation. Due to this variability, the interviewer did not imply or bring up the functional 
nature of patients’ symptoms but patients were asked what they believed caused their 
symptoms.  
Patients were contacted via Skype two months after their baseline interview and the interview 
was conducted again. The same interview schedule was used in order to assess change over 
time.  
4.2.2.3 Qualitative interviews: analysis 
Baseline and follow-up interviews were analysed using a separate thematic analyses (Braun & 
Clarke, 2006). Data from interviews at both time points were coded and themed separately. 
The analytic approach here was the same as that taken in the analysis of clinicians’ interviews. 
See Chapter Three, Section 3.2.4.3 for a detailed description of the approach used.  
4.2.2.4 Qualitative interviews: ethical considerations 
Ethical approval was granted by the Queen Square REC (15/LO/1914) on the 6th January 2016.  
The study’s recruitment began on the 18th January 2016. By the 15th February 2016, a slower 
recruitment rate than expected was noted and the process of applying for a non-substantial 
amendment from the Queen Square REC began. This application sought an extension of the 
recruitment period and was granted on the 24th February 2016.  
There were a number of ethical considerations prior to the initiation of this study. Baseline 
interviews were conducted at the HASU bedside. As beds were on shared wards, to ensure 
privacy, each participant was offered a private room on the ward in which to conduct the 
interview if they wished. No participant took up this offer.  
Each participant was asked to read the study information sheet. Participants were told that 
participation was voluntary and they could withdraw from the interview at any stage and that 
all information held was private and confidential. Once they understood the procedure and 





The follow-up interviews were conducted via telephone using Skype software. Participants 
were re-consented into the study. Consent was this time given verbally and consent sheets 
were signed by the researcher on behalf of the participants.  
All baseline interviews were recorded with an encrypted Dictaphone. Participants were given a 
study ID and participants’ names and contact information were stored on an encrypted 
spreadsheet with information stored in a locked file in a secure research unit. Any city names, 
person names or any other identifiable information was removed from the interview 
transcripts. 
Other ethical dilemmas are inherent within qualitative research such as this. The researcher 
attended the doctors’ diagnostic meetings and multidisciplinary staff meetings. Information on 
participants not in the study was commonly discussed. By attending these meetings, the 
researcher was party to conversations between doctors and clinicians about patients who later 
became participants in the study. In some instances, the researcher was aware of diagnostic 
test results before a doctor had conveyed that information to the patient. It was important in 
these cases that the researcher remained neutral throughout interviews.   
By taking part in qualitative research, individuals can be given a voice, many of whom can find 
this therapeutic and beneficial. There is however also the possibility that such information, 
once published, can be used against certain groups or negative stereotypes can be reinforced 
(Finch, 1993). In the results of this study, a range of views are given to discuss each theme, 
rather than just the most common view, in the hope of avoiding simplistic generalisations.   
It is increasingly common practice in qualitative research to involve participants in the analysis 
process (Tong et al., 2007), for example to return transcripts to participants for comment or 
correction or feedback on the results. While time constraints in this study rendered this 
difficult, some participants did agree that they would like to read the final version of this study 
when written and published.  
4.3 Results 
4.3.1 Participants 
Over the ten months the researcher spent embedded on the hospital ward, 41 patients were 
considered as potential participants.  
Six of these patients were discharged before the researcher could meet them at the bedside 
(for instance, they were admitted and discharged on the weekend or overnight). In each case 





Three patients joined the study and were interviewed but were later excluded as they received 
a stroke diagnosis that explained their symptoms.   
Two patients were approached but did not have capacity to consent to the study. 
In total, 30 functional stroke patients were interviewed at baseline and 25 were interviewed at 
the two-month follow-up, giving a follow-up rate of 83.3%. The five participants who did not 
take part in follow-up interviews were uncontactable despite repeated attempts. Table 14 
outlines the gender, age, ethnicity and occupation of participants as well as the symptoms with 
which they were referred.  
Four participants (13%) had a history of previous stroke but after admission, no new stroke 
was found on their MRI scan. Two participants (6.7%) had confirmed stroke but their doctors 
believed their symptoms did not entirely correspond to their diagnostic tests and therefore 
some symptoms could be classified as ‘functional overlay’.  
Age data were known for 26 participants. The mean age of participants was 48.9 years of age 
(SD: 15.8). There were 22 females (73.3%) and 8 males (26.7%) in total.  The most common 
ethnicity was white British (56.7%).  
Baseline interviews took an average of 26.2 minutes (SD: 14.8 minutes) while follow-up 
interviews took on average 12.5 minutes (SD: 8.2 minutes) 
The time between baseline and follow-up interviews varied depending on how easy it was to 
contact participants via Skype. The number of days set out in the study protocol between 
baseline and follow-up interviews was sixty-one, but it often proved difficult to contact 
participants after their discharge. In addition, there was only one researcher so interviews 
could be delayed due to holidays and bank holidays. The average number of days that passed 












Table 14 Sex, age, ethnicity, occupation and admission symptoms of qualitative participants 
ID Sex Age Ethnicity Symptom Occupation 
1 M NK White British Left sided facial weakness, left arm weakness Medically retired 
2 M 23 British Expressive dysphasia Business owner 
3 F 29 Eastern 
European 
Facial numbness Waitress 
4 F 20 Black British Severe headache and dysarthria Student 
5 F 65 Black British Frontal bilateral headache; right-sided pain & 
mild disequilibrium 
Retired 








9 M 67 British Light-headed. History of previous stroke  Former carer, retired 
10 F NK British Left-sided pain Stay at home mother 
11 F 62 British Rotatory vertigo, chronic fatigue and depression Unemployed 
12 M 53 White British Left-sided facial droop and slurred speech Employed, unknown 
13 F 33 Pakistani Dysphasia and headache  Office worker 
14 F 64 Portuguese Left hand numbness and expressive dysphasia Retired teaching 
assistant 
15 F NK Black British Right sided weakness, headache, photophobia.  
History of bipolar disorder 
NHS receptionist 
16 F 21 British Light-headed and syncope Volunteer mental  
health researcher 
17 F 88 British Left-sided weakness. History of previous stroke.  
Possible functional overlay  
Retired 
18 M NK British Reduced finger movements in both hands and 
muddled speech 
Fire service officer 
19 F 53 Jamaican Sudden onset speech disturbance. History of 
anxiety 
Old age carer in 
nursing home, on 
leave 
20 F 31 White British Left-sided weakness and facial droop Special needs  
assistant 
22 F 59 Black British Left-sided weakness and numbness - previous 
stroke, symptoms indicate overlay  
Unemployed 
23 F 38 British Migraine, left face and arm weakness. History of 
previous stroke and CFS  
Church worker 
24 F 52 Finish Dysarthria, dysphasia, dizziness and posterior 
headache 
Call centre worker 
25 F 53 Black British Left-sided weakness and frontal-post headache; 
multiple supra and infratentorial acute posterior 
circulation infarction with functional overlay 
Nurse 
26 M 50 White British Left-sided weakness. History of depression Unemployed 
27 F 58 Iranian Hyperventilation and shaking of upper and lower 
limbs following local dental anaesthetic  
Engineer 
28 M 55 British Right-sided weakness. History of PTSD Army officer,  
on medical leave 
29 F 51 British Left-facial droop and speech slurring Child minder 
30 F 49 Spanish Left-sided headache, dizziness and diplopia. 
History of depression and fibromyalgia 
Former cleaner, 
receives DLA 
31 F 49 British Left-facial weakness, dysarthria and left facial  
paraesthesia 
Unemployed 
33 F 51 German Left-facial droop, left arm and face paraesthesia.  
Confirmed stroke with overlay  
Psychotherapist 





Two participants did not complete a Brief-IPQ at baseline or at follow-up. In total there were 
28 baseline questionnaires and 23 follow-up responses. The follow-up response rate was 
82.1%.  
Of the 28 questionnaire responders, 20 (71.4%) were female and 8 were male (28.6%). Age 
data were available for 26 participants. The average age was 48.9 (SD: 15.8).  
The age and gender of respondents who completed only one survey was compared to those 
who completed the survey at both baseline and follow-up. There were no statistical 
differences in the gender profile of either group. Those who completed only one survey were 
slightly younger than those who completed two but no statistical difference was found (mean 
age: 47 years (SD: 15.8) versus 49.4 years, (SD: 16.2), t = 0.30, p = 0.77). Table 15 outlines the 
age and gender profile of participants who completed both baseline and follow-up 
questionnaires with those who completed only one questionnaire. 
Table 15 Age and gender profile of Brief-IPQ survey completers versus those that completed 
one or no survey 
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Total 28 (100) 23 (82.1) 5 (17.9)   
Female
1
 20 (71.4) 16 (69.6) 4 (80) > 0.05 
Male
1
 8 (28.6) 7 (30.4) 1 (20) > 0.05 
Mean age (SD)
2
 48.9 (15.8) 49.4 (16.2) 47 (15.8) > 0.05 
*comparison between those completing both surveys with 
those completing only one 
1




4.3.2 Brief Illness Perception questionnaire results 
The mean total Brief-IPQ score at baseline was 49.3 (SD: 9.9) and at two-months’ follow-up the 
score reduced to 39 (SD: 20.1) suggesting participants’ perceptions of their symptoms went 
from being seen as threatening to more benign with time (total possible score: 80). Males and 
females did not differ in their scores at baseline or at follow-up.  
Higher values imply worse outcomes. The highest mean scores at baseline were the ‘emotional 
response’ item (mean 7.8, SD: 2.6) and ‘concern’ regarding symptoms (mean: 8.2, SD: 1.8). 
Lowest mean scores were for perceptions of treatment control (mean: 2.9, SD: 3.2) suggesting 
participants were emotionally affected and concerned by their admission but relatively 
optimistic that treatment would help. Table 16 outlines baseline and follow-up mean scores 





Two months later all mean scores had dropped. The highest score was now personal control 
(mean: 5.9, SD: 3.9) and the lowest was treatment control (mean: 2.5, SD: 3), suggesting 
participants felt they did not have personal control over their symptoms but believed the 
treatment they received could help.  
Repeated-measures analyses were conducted to assess changes in mean scores over time. 
‘Consequences’, the self-reported effect of symptoms on the person’s life (Z = -3.4, p = 0.001), 
’identity’ denoting the number of symptoms a person experienced (Z= -2.1, p = 0.04), ‘concern’ 
(Z = -2.7, p = 0.01), and the mean ‘emotional response’ (Z = -2.0, p = 0.05) saw a significant 
decrease in scores over time. There was no statistically significant change in responses to the 
‘timeline’ question (how long they expected to experience symptoms), the degree of personal 
control patients felt they had over symptoms, the degree to which they believed treatment 
might help their symptoms or how much patients felt they understood their symptoms. The 
disparity in the gender ratio of participants did not allow for gender to be accounted for in this 
study.  













Consequences 7.33 (2.8) 3.3 (3.6) -3.4 0.001 1.25 
Timeline
1
 5.83 (2.9) 5.2 (4.3) 0.42 0.68 0.18 
Personal control 7 (3.4) 6.2 (4.1) -0.49 0.62 0.21 
Treatment control 2.9 (3.4) 2.2 (3.1) -0.85 0.39 0.22 
Identity 4.95 (2.9) 3.5 (3.6) -2.1 0.04 0.44 
Concern 8.2 (1.8) 5.6 (4) -2.7 0.01 0.84 
Understanding 5.2 (3.7) 4.9 (4.6) -0.47 0.64 0.07 
Emotional response 7.8 (2.6) 5.6 (3.7) -2.0 0.05 0.69 
1 
Normally distributed data so statistic reported here is a t-test 
Scores range from 0 to 10. A higher score indicates a more negative 
response 














4.3.3 Baseline qualitative interview results 
The results of global themes from the baseline interviews are presented in Table 17. 
Table 17 Thematic framework derived from baseline qualitative interviews  
 
Global themes 









Symptom onset & 
experience 
Common attributions Views on recovery 
Locus of control Attitudes to research 
Help-seeking Authenticity Views on treatment 
Inpatient experience   
Emotional response   
Three global themes emerged with corresponding sub-themes. The first theme relates to 
phenomenological experiences such as symptom onset, admission and inpatient experiences, 
and emotional reactions. The second theme deals with symptom attributions; the common 
attributions made by staff, perceptions of control, and the issue of authenticity. The third and 
final theme deals with issues related to patients’ future; their views of recovery, attitudes to 
research and views on treatment. The final section explores results from the follow-up 
interviews and the themes of symptom experience and attributions.  
4.3.3.1 Phenomenological experiences 
4.3.3.1.1 Symptom onset and experience 
Two distinct types of symptom onset occurred. In the first type, participants experienced a 
sudden onset of somatic symptoms that seemed to occur without warning. The second type 
was inconspicuous and more dissociative in nature, i.e. the feeling of altered awareness.  
The patients who experienced a sudden onset of somatic symptoms described a range of 
everyday activities they were engaged in when their symptoms began. Symptoms were 
unexpected, often disturbing and often were accompanied by sensations of panic. These 
symptoms represented an abrupt interruption to everyday life: 
“I was just on the underground. And, I, it was just a normal day really. I felt fine the 
whole day. Yeah, and I just started to lose, my vision started going...I just wasn’t with 
it. I felt really ill and then my speech was going” (Participant 2, male, 23) 
“I was in a bus. And I suddenly couldn’t remember where I was going or what bus I was 
on, ’I can’t remember what I’m meant to be doing’” (Participant 15, female) 
Memory failure was mentioned by another participant who described being unable to recall 





“I collapsed whilst I was in the toilet…It’s disturbing. It’s frightening not knowing what I 
have or haven’t done. What makes it worse, because it happened in the pub, I don’t 
know whether I’ve upset anyone, or what, to be quite honest” (Participant 1, male) 
Panic was a frequent response to symptom onset:  
 “I couldn’t lift my arms, I couldn’t lift my fingers, I couldn’t lift up my head…by then I 
was panicking so I started to cry. Even that was an effort” (Participant 15, female)  
Another participant acknowledged the possibility that the panic itself might have served to 
worsen her symptoms:  
“It lasted about one hour. It was not very, it was a slight sensation, maybe because I 
became panic-y as well” (Participant 14, Female, 64) 
Five participants described how their symptoms began while commuting. Being in crowds 
seemed to be at least a partial mediator in the experience of panic. Feelings of agoraphobia on 
public transport could serve to worsen already existing symptoms or promote 
misinterpretation and an intense focus on physical sensations which could lead to the 
emergence of somatisation (Tomasson et al., 1991). There can be unpleasant consequences to 
experiencing such symptoms while travelling. Being away from home, feeling ridiculed, or 
unable to ask for help could intensify already existing symptoms and anxiety. Being 
surrounded by people could be also prove useful as a number of participants described how 
other passengers called for medical help.  
While the circumstances in which symptoms began varied, there were a variety of symptom 
types. These ranged from dizziness, disorientation, weakness, numbness, pain, visual 
disturbance, headache, memory disturbance, changes to or the loss of speech, fatigue and 
facial droop (see Table 14 for a list of symptoms).  
The second type of symptom onset represented a more insidious onset, one marked by a shift 
in phenomenological experience, often characterised by discomfort and which frequently had 
dissociative qualities which could feel strange and unusual. This type of experience seemed to 
have a less well defined onset:  
 “I couldn’t talk. My legs were feeling jelly-ish. I couldn’t walk. I was stumbling. I had to 
hold walls to walk. My arms had no coordination. I was slurring. You could not 
understand what I was saying” (Participant 13, female, 33)  
 “I was beginning to feel very fuzzy headed. You know, it was sort of as if I’d had a good 





through my head, the sea. When you pick a seashell up off the beach and put it to your 
ear, you hear the sea and that was what I was feeling in my head…I felt a bit drained. I 
decided to go to bed” (Participant 9, male, 67).  
Other participants also likened the experience to being drunk:  
“I felt as though I was drunk. Apart from my head. My head felt ok but my body wasn’t 
responding. And I felt as though I was being enclosed in my body” (Participant 18, 
male) 
Dissociative processes may help explain these experiences (Spitzer et al., 1999). A large study 
of NES patients found over 60% experienced depersonalisation and derealisation immediately 
before, during or after the attacks. Symptoms in this study included shortness of breath, 
dizziness, sweating, heart palpitations amongst others (Hendrickson et al., 2014). In our study, 
patients who experienced these symptoms often did not seek immediate help. These 
symptoms, while strange, were not experienced acutely and did not seem to be particularly 
painful. One participant who commonly suffered from headache did not feel immediately 
concerned by the experience and did not seek immediate help: 
“My head was hurting but I thought it was just a normal headache so I didn’t think to 
alert anyone. I didn’t take any medications. All I done was went to sleep” (Participant 4, 
female, 20) 
This lack of concern, or potential ‘la belle indifference’, was similarly described by a male 
participant who resisted the urge to phone for help and believed it was something he could 
control and treat himself:  
“I had a couple of beers. I was lying on the sofa and then I woke up at two in the 
morning. I was lying on the floor. I couldn’t move my side. I couldn’t swallow. And I just 
thought it was something brief so I just thought, ‘I’ll just carry on’ and I thought ‘I can 
heal myself’ if you like because I started doing weights with my hand. And I went on 
for, like, three weeks” (Participant 26, male, 50) 
The types of symptoms themselves appear to affect one or many neurological functions and 
ranged from distinct deficits like weakness or visual disturbance through to amorphous and 
strange experiences which appeared to represent an experiential interruption to everyday life. 
When symptoms occurred unexpectedly and acutely, they caused distress and panic.  
Slower, more inconspicuous onsets were associated with dissociative experiences and might 





however that la belle indifference is a term usually used by clinicians to describe a patient’s 
attitude rather than a subjective experience. It has previously been reported in approximately 
21% of functional patients’ presentations but it has not been shown to be a clinically useful 
sign (Stone et al., 2006).  
 
The symptom onset described in this study align closely with that reported by Stone et al. 
(2012b) in patients with functional weakness recruited from a neurology service in Scotland. 
This study categorised three distinct modes of onset including sudden (accounting for 46% of 
the group), present on waking (13%) and a gradual onset (39%).  
4.3.3.1.2 Help-seeking 
How participants experienced the onset of the symptom was mediated by the kind of help 
they received from those around them at the time. Having symptoms taken seriously by others 
was important, but this might have served to reinforce feelings of panic and concern. One 
participant described realising that his symptoms might be stroke only after an ambulance 
driver made a stroke assessment:  
“A couple of minutes later the ambulance crew turned up. I heard the handover, ‘He’s 
FAST negative’ so I know that now he is checking for stroke and the signs and 
symptoms of normal stroke are negative. I got into the ambulance and they said, 
‘We’re going to take you to the hospital for precaution’. I felt very silly, very upset, very 
emotional” (Participant 18, male) 
While receiving help could be anxiety-provoking, for some, the perception of not being taken 
seriously at the time of symptom onset was also worrying. Some participants described not 
being taken sufficiently seriously by ambulance crew and medics. This may have led to concern 
that they wouldn’t receive appropriate treatment and their symptoms would get worse: 
“Somebody called an ambulance and the first responder came. He was as helpful as a 
lump of coal. And, that experience, I wanted to throttle him. Because he was like, ‘How 
are you feeling?’ and I was like, ‘Listen, how is this going to help me? I don’t think I can 
hold my head up much longer.’ And the next thing I knew I was on the floor. I couldn’t 
lift my arms. I couldn’t lift my fingers. I couldn’t lift up my head” (Participant 15, 
female) 
In some cases, the act of seeking help seemed to reinforce or intensify the experience of 





an ambulance worker or emergency call worker, participants’ symptoms intensified or 
worsened and in some cases they were unable to communicate at all:  
“[The paramedic] did some tests. He called the ambulance. He said, ‘Because 
something’s not right. You’re not. I can see you’re not right and I’m not finding 
anything in the normal realm of things that would tell me why’. And then the 
ambulance crew came and it got more and more difficult to concentrate and keep my 
speech fluid…I don’t know…I don’t really do panic, you know?” (Participant 8, female, 
43) 
It is possible that when receiving help, the self-reflection and concentration needed to focus 
on the symptom, recall its onset and describe the somatic symptoms was in itself anxiety-
provoking and upsetting:  
“So I’m on the phone with my son. I feel different in my body. I feel sick. I said to my 
son, ‘I don’t like how I feel, I’m going to call ‘111’ and speak to them’…The doctor did 
call and I’m explaining what happened. He was saying he should send a doctor or an 
ambulance out. I’m saying, ‘Send a doctor out please’. And I feel a terrible pain come 
down sharp, come down my neck” (Participant 19, female, 53). 
Help-seeking is an inherently social act and it is likely that the initial response of friends, family 
and medics to the patient may influence the experience of the symptoms themselves.  
4.3.3.1.3 Inpatient experience 
Most participants described a swift admission to the HASU. There was often a short waiting 
period in an emergency room but most had scans almost immediately after their arrival and in 
some cases they were also thrombolysed. A sense of urgency from staff characterised their 
initial experiences on the stroke ward:  
“[The ambulance] brought me here right away. When I arrived they saw me straight 
away, after five minutes or so and after the scan and everything, they sent me here” 
(Participant 14, female 64) 
One participant describes being left alone briefly before the stroke team descended and their 
care escalated:  
“I was in a hallway. A nurse came and took some bloods and I thought, ‘Well, where 
are the people?’ All of a sudden and it got, all, very hectic and all, ‘Oh my god’ and then 





about the blood clotting stuff…so it was then clear to me what was going on. 
(Participant 33, female, 51) 
During this period participants described feeling confused by the tests and believed the 
medical team were also confused. He describes receiving mixed messages regarding his 
possible diagnosis:   
“I remember meeting doctors and them trying to get me to do things, like different 
tests and they weren’t sure what was happening. They weren’t sure what it was and 
then they said, ‘You’ve had a stroke’ or ‘You’ve had a minor stroke’ or something like 
that” (Participant 2, male, 21) 
It is possible that the urgency and effort in trying to diagnose and treat the presumed stroke 
reinforces or contributes to beliefs that symptoms have a physical explanation which may 
escalate existing panic or worry. Once stroke has been ruled out however, the sense of 
urgency abated and some patients begin to feel less like a clinical priority:  
“There are some, very focused, very clever, but neurology-only doctors, where I think 
they sort of want to send you out because you’re not dying…I felt a bit patronised” 
(Participant 33, female, 51) 
It may be at this juncture the relationship between the patient and staff becomes problematic. 
Feeling like an uninteresting patient is not uncommon for patients with unexplained 
symptoms. A similar sentiment was described by men living with unexplained pain who 
described how clinicians lost patience and interest once a physical cause was not found 
(Paulson et al., 2002). Such concerns are likely not unfounded as doctors themselves often 
describe their lack of interest in these patients (Garcia-Campayo, 1998). 
4.3.3.1.4 Emotional response 
Patients experienced a variety of symptoms and a range of emotional reactions in response to 
these symptoms. Patients’ emotional responses differed depending on the kind of interactions 
they had had prior to their admission or once on the ward.  
Most participants described feeling worried, fearful or upset during their admission. Some 
were articulate and insightful when describing their emotional response and they were often 
aware of their own ability to control their emotions. For others, emotions felt overwhelming 
and unbound, a reaction over which they did not feel they could exercise any control. 





“I seem to get upset, I don’t know whether it’s this or not, but I get upset very easily 
recently, over the silliest little things that before wouldn’t have bothered me” 
(Participant 11, female, 62) 
The experience on the ward itself was most often characterised by feeling anxious and upset:  
“Just depressed. It makes me feel sad and depressed” (Participant 27, female 58).  
Another participant, who had had a stroke but experienced additional functional overlay, 
described how the experience on the ward had been disturbing due to being exposed to 
people with serious illness: 
“There were three old women there [on the ward] and one of them was sort of on 
death’s door and I found that hugely distressing because she was screaming all the 
time…I could hear everything and I just felt myself getting more and more anxious and 
going downhill” (Participant 33, female, 51) 
These negative emotional experiences were echoed by other participants:  
“It makes me quite irritable. I don’t like to say angry, but it makes me feel angry” 
(Participant 17, Female, 88) 
 “There is of course some underlying anger about it, ‘Why me?’” (Participant 24, 
female, 52) 
 “After this happened, I’m very disappointed and now I’m very depressed” (Participant 
10, female) 
Stoicism was also commonly expressed: 
“All I’m concentrating on is happy thoughts and things that make me happy” 
(Participant 22, female, 59) 
 “You can’t sit there and bawl your eyes out” (Participant 18, male)  
 “They send me home not knowing what’s gone on but there’s still a bit of tingling and 
weakness. I’m just going to have to take it in my stride” (Participant 22, female, 59) 
These stoical responses serve to highlight the extent of the emotional impact of the experience 
itself. While negative emotions were experienced as something beyond the patient’s control, 
stoicism was a coping strategy employed to deal with the severity of the emotions experienced 





Participants described other attempts to control their emotional responses. One of the 
participants gave a multifaceted account of her emotional response:  
“There are certain things which, unless you can think your way around them, are going 
to take their toll in a more comprehensive way than others…I have to say the biggest 
part, the most destructive part for me was guilt. You know, ‘I’ve got absolutely no right 
to be feeling like this. Why am I feeling like this?’” (Participant 8, female, 43) 
Another participant with stroke and functional overlay described how she would first deal with 
her physical symptoms before trying to tackle the emotion by her diagnosis: 
“I deal with the physical symptoms first and then at some point it will filter 
through…When you have anxiety, you’re anxious… but at least I recognise a bit more 
what I’m doing with it and know that I’m pushing it to one side because I have to, but I 
have to concentrate on the other side first” (Participant 33, female, 51) 
Participants who had no stroke aetiology expressed relief when told they had not had a stroke:  
“I was very relieved. Because what I didn’t realise was the impact of having had a 
stroke. This sounds silly, not just on my body, but also the repercussions for me as an 
individual, sort of things like driving restrictions” (Participant 18, male) 
 “Happy that it’s not anything serious” (Participant 20, female, 31) 
While some participants were relieved, others were concerned that they had not received a 
positive diagnosis and were left wondering what had in fact caused their symptoms. As one 
participant described:  
“I take the positive and tend to take the middle road and if it gets sorted then it’s going 
to be brilliant, but if they don’t find out what is causing it and then I just have to put up 
with this, then I won’t be happy” (Participant 29, male, 55) 
This point was reiterated by another participant who argued that not knowing what caused his 
symptoms was more worrying than receiving a concrete diagnosis:  
“They said [the medical team] ‘You were lucky, it was nothing’. Yeah, I’m lucky it was 
nothing, but who wants that answer?” (Participant 27, female, 58) 
Participants react to their admission with fear, worry and mood lability. Some described coping 
styles such as stoicism in response to the belief they had experienced a stroke. For those who 
knew there was no underlying stroke aetiology, participants tended to either express relief 





4.3.3.2 Symptom attributions 
4.3.3.2.1 Common attributions 
When participants were asked what they believed caused their symptoms, not unlike the 
stroke clinicians’ responses in Chapter Three, their responses ranged from uncertainty to 
mentioning potential biological, psychological and social causes. Many of the views expressed 
were mediated by the kind of conversations participants had had at the bedside with their 
stroke physician prior to the interview. Participants, not surprisingly, aligned their attributions 
with what they had been told by the doctor.  
Frequently, doctors had told participants that they were unsure about symptom aetiology, and 
participants, in turn, said that they did not know what had caused their symptoms. Amongst 
these responses was a pervasive sense of confusion:  
“I’m still not convinced that I’ve had a stroke of any kind. And it’s very confusing. Some 
say I have and some say I haven’t…” (Participant 8, female, 43) 
“The MRI showed up fine, everything showed up fine…they just kind of said they don’t 
think it’s a stroke, it could have been a small stroke but they don’t think that it is. They 
don’t know what it is. And that was a little bit worrying…They didn’t tell me anything 
they could do really. They didn’t suggest anything else” (Participant 2, male, 23) 
“I said, ‘What happened then? It must be something’ because I’ve never, I’ve never 
witnessed that before. She [the nurse] said she don’t know…They did some scanning. 
They said they’re going to do an MRI. I had no doctor come back to me to say, ‘Well, 
it’s not a stroke but it’s…whatever’ because it must be something, causing that” 
(Participant 19, female, 53)  
The uncertainty and lack of concrete information was uncomfortable for patients and some 
described feeling uneasy due to the lack of information they had been given: 
“Don’t ask me why. I don’t know why. I’m the kind of person that likes to know if it is 
one thing or another. Not in between…I’d rather they said it, come out straight with it” 
(Participant 11, female, 62) 
“They don’t know what’s causing the symptoms so I’m going home without any 
information and that doesn’t make me feel confident” (Participant 22, female, 59) 
One participant described how the lack of a formal diagnosis meant that her treatment options 





“First of all, I was relieved that it is nothing very serious. Second, not relieved because I 
would like to know what’s causing all this. Because if the cause is clear and known, 
then there is at least a chance that there would be a treatment or preventative 
treatment that would keep it at bay, whatever it is” (Participant 24, female, 52) 
Some participants had beliefs about the cause of their symptom but felt their knowledge was 
limited:  
“You understand to a certain extent what is going on, but you don’t really know why. 
Do you know what I mean, because you know that you’re feeling unwell and it 
frustrates you a bit when you come to hospital, where you can’t stick a sticky plaster on 
and say, ‘All better’” (Participant 9, male, 67) 
Uncertainty was not the only response. Two participants believed there was a potential 
biological cause for their symptoms but were unclear as to whether the symptoms themselves 
were stroke or not. One participant believed her symptoms might be the result of side-effects 
from antibiotics while another felt it might be linked to weight. The assumption of an 
underlying biological explanation is implicit here:  
“Well, I’m overweight…I’m still not sure why this happened. With my hands [referring 
to numbness] there’s a suggestion it could be a virus. It could be carpel tunnel, they’re 
not sure” (Participant 18, male) 
Psychological and psychosocial accounts of symptoms were common but beliefs about 
whether the symptoms themselves were stroke or not were rarely clear. Participants 
frequently suggested potential psychological stressors like anxiety were a potential causal 
factor, but were unclear about their beliefs regarding the aetiology of their symptoms: 
“It can be stress because I heard news about my dad’s [sickness] so maybe I was 
thinking too much. So they were saying it can be stress” (Participant 3, female, 29) 
The possibility of a psychological cause was echoed by another participant who felt her 
symptoms could be attributed to a busy life with many responsibilities:  
“I’ve just got a lot going on in my personal life. A lot of major milestones. Children 
doing important exams, getting married…so all those things at once, has just caused a 
huge amount of stress” (Participant 29, Female, 51) 
Another participant attributed his symptoms, or at least the worsening of symptoms, to a 





“My condition overall I think might have been a bit, how do you say, exasperated by 
the fact my wife passed away last May” (Participant 9, male, 67) 
Another participant rejected a psychosocial account, but did not have any defined views on an 
alternative cause:  
“My mum thinks that I was stressing because of my exam results but I wasn’t stressing. 
I’m a very positive and happy person so nothing comes to mind. I wouldn’t want to be 
sick right now. It’s very sunny outside” (Participant 4, female, 20)  
While these quotes highlight the acknowledgment by patients that psychological factors may 
play a part in the expression of their symptoms, it was unclear whether participants believed 
psychological factors were the entire explanatory cause of their symptoms or whether 
psychological problems were a moderating factor, partially contributing to the onset of an 
actual organic stroke.  
Another participant, for instance, described how psychological factors helped moderate a 
biological trigger which led to the onset of an organic stroke. She did not however believe that 
her physical symptoms were themselves psychological:  
“I’m assuming it could just be all the stress building up and then the stroke” 
(Participant 13, female, 33) 
Another participant was strongly convinced that psychological factors had not caused her 
stroke, but rather the stroke had caused psychological symptoms:  
“He said [referring to an ambulance worker] ‘Oh she’s just upset, once she calms down 
she’ll be able to get up...sometimes when young people are upset, they just collapse’. 
And I’m trying to say, ‘I didn’t collapse because I’m upset, I collapsed because I got 
upset after I collapsed’” (Participant 15, female) 
In summary, patients make a number of attributions from identifying biological to psychosocial 
causes like anxiety, stress and external social factors like family life. Commonly participants are 
uncertain about the cause of their symptoms, a fact reflected by the lack of information 
participants receive from their clinicians. While some participants mention the role of 








4.3.3.2.2 Locus of control  
Locus of control is the degree to which a person attributes events and actions in their life to 
internal factors such as their own behaviour or ability, as opposed to external factors like 
chance or the environment.  
Almost uniformly, participants believed they had no control over the course of their 
symptoms: 
“I didn’t have control. Like it happened and that’s it” (Participant 3, female, 29) 
While participants often felt they did not have control over symptom onset, similar to their 
emotional responses, some believed that they might have control over symptom progression:  
“One doesn’t really have control over symptoms. One has control over the reduction of 
symptoms” (Participant 8, female, 43)  
Linked to this sense of a lack of control was a degree of fatalism or at least resignation. 
Maintaining an external locus of control regarding the onset of the symptoms could be a 
means of protecting oneself psychologically, avoiding self-blame and helping to reduce any 
tendency to engage in counter-factual thinking. This may be a manifestation of the stoicism 
described earlier. In this particular instance, the participant had had a previous stroke but after 
admission, no new stroke was found:   
“These things happen and you can’t alter it. So in that sense I find that I don’t have 
control” (Participant 17, female, 88) 
Participants felt they had some control regarding their future preventative behaviour, and 
mentioned taking approaches like taking more trips to the doctor, taking the correct 
medication and losing weight as ways in which they might prevent a re-occurrence of 
symptoms. Others described how they would not try to change their health behaviour as 
symptoms were beyond their control: 
“Whatever is causing it is nothing I’m doing. I’m not going to fret about it. I will simply 
stick to my medical regime and hope for the best because I’m not going to worry about 
something I can’t change” (Participant 24, female, 52) 
Another participant mentioned his family history as the reason she had so little control over 






“My dad died with a heart attack and my mum with stroke. Cerebral stroke. But there 
is nothing that I can do. Like I feel now that the best way is to take more care of myself 
which is what I’ve been trying” (Participant 14, female, 64) 
A lack of internal locus of control is therefore pervasive throughout these interviews and 
echoes our findings from the Brief-IPQ.  
4.3.3.2.3 Authenticity 
While participants felt that the onset of their symptoms was been beyond their control, a small 
number expressed worry that clinical staff believed their symptoms were volitional and were 
concerned that they might be viewed as malingerers or as performing symptoms for some 
gain:  
“I was very angry at first because it’s as if you’re putting it on and wasting people’s 
time but I’m not that sort of person. I don’t like hospitals” (Participant 6, male, 56) 
Another participant felt judged by staff and that they were not deserving of treatment:  
“I feel like if I call them to say something to them, I feel like I’m bothering them” 
(Participant 19, female, 53) 
Participants are concerned that the legitimacy of their experiences was questioned by staff. 
Throughout interviews, participants expressed concern that their motivations might be 
misconstrued and were concerned that their experiences might be undermined, denied or 
dismissed: 
“I feel like a bit of a fraud sitting here” (Participant, 11, female, 62) 
 “People think that, ‘Oh, he’s had the medical book out, what page is he on today? 
What does he have wrong today?’…they think you’re a pest at hospitals…you’re just 
pestering people and you’re looking for something that is not really there. You’re not 
having the confidence in what the doctors are telling you. And you feel as though, oh, 
‘They’re going to get fed up with me’ You know? ‘They’re going to blacklist me’” 
(Participant 9, male, 67) 






“It’s frustrating…when I get any type of treatment and they’re saying, ‘Oh, she doesn’t 
want to work’ but people who know me know that that’s not true because I work very 
hard” (Participant 19, female, 53) 
This fear of judgement is pervasive throughout interviews and participants are particularly 
concerned that they will be viewed as illegitimate recipients of care.  
4.3.3.3 Views on the future 
4.3.3.3.1 Views on recovery 
While on the stroke ward, participants had varied opinions on life once discharged. While 
some participants’ symptoms abated during their admission, they were nonetheless concerned 
that symptoms might return in the future:  
“I’m so scared it’s going to happen a second time and a third time” (Participant 3, 
female, 29) 
 “I don’t feel a thing, but I can’t say if the symptoms will come back. They could come 
back next week. I don’t know” (Participant 13, female, 33)  
 “It could have been worse, but you know, the doctors can’t tell me if it is going to 
happen again. There’s a likelihood of it happening again. They’ve done all the 
investigations which shows up okay, but in the future they don’t know” (Participant 25, 
female, 53) 
This concern about the future and the difficulty in coping with uncertainty was made more 
acute by a fear that their ability to work might be restricted. This worry about potentially 
losing their livelihood was a source of distress:  
“I don’t want to be disabled like this. I am very active with my kids and I’m new here [to 
England] and I want to start my life. I don’t want to lose work” (Participant 10, female) 
 “I’m just hoping that this doesn’t continue and I can come out of here and go back to 
work the next day and carry on as before. That’s what I’m really hoping for” 
(Participant 15, female) 
 “I’m extremely concerned because I have to work. If I am not working, I am not 
earning. I have to work. So that is extremely concerning about my health…I’m working 
as a contractor. One important meeting, I lost it. And no one is bothered about that 





This point regarding participants’ concern about their employment status is worth reiterating. 
Some clinicians interviewed in Chapter Three expressed the view that patients might be 
wilfully producing symptoms in an effort to avoid work or gain benefits. These quotes highlight 
that at least a proportion of participants are in fact keen to work and work appears to be 
important to their identity and self-worth. 
A number of participants were hopeful that if they made lifestyle changes, their symptoms 
might improve and they would make a full recovery. It is likely that these views emerge from 
biological causal attributions:  
“If I can get the physio in and get moving I think I might be able to get going again” 
(Participant 22, female, 59)  
 “If I change my lifestyle completely. I think that will help. Get my blood pressure down, 
although I take blood pressure medication, I take diabetes medication but I think in 
terms of eating and exercise…” (Participant 25, female, 53) 
Regardless of whether patients believe their symptoms were caused by biological or 
psychosocial factors, expressing the view that their symptoms might respond to lifestyle 
changes highlights a certain degree of control that patients feel over their symptoms, 
something that they were often unwilling to admit when asked directly. 
4.3.3.3.2 Views on research 
One of the original purposes of this study was to gauge participants’ views on taking part in 
research generally and physiotherapy specifically.  
All of the participants were happy to be involved in research but gave different reasons. Some 
felt that taking part in a physiotherapy trial would directly benefit them:  
“I would be happy to take part in and do that because whatever it takes to get me back 
on my feet” (Participant 19, female, 53) 
Another participant felt that the social nature of being involved in research might be beneficial 
in itself:  
“We could as a group, as a club, we could exchange views and ideas and problems, all 
that” (Participant 9, male, 67)  





“I’m a big proponent of learning hospitals and learning in general so if there’s anything 
I can do, I’ll always jump in” (Participant 8, female, 43) 
Altruistic reasoning was also evident in other participants’ responses:  
“It may not necessarily help me, but if it’s going to help others in the future and maybe 
a learning basis on both sides of the coin” (Participant 9, male, 67) 
“If my experiences can help somebody else, that would be really great” (Participant 24, 
female 52) 
Others felt that answering the semi-structured interviews had in itself been beneficial in 
helping patients examine their own personal response to their admission when they hadn’t 
had an opportunity to do so previously:  
“It’s really helpful to go through these questions, realise myself how I’m thinking and 
how I’m feeling because I don’t, I don’t stop and go, ‘How do I think about this?’” 
(Participant 26, male, 50) 
 “It does help, talking to other people. If it’s not family. I think it’s important to share 
these things because if you bottle them up inside, it’s like a bomb waiting to explode. 
And there’s not many people you can talk to about it, you can’t talk to your own wife” 
(Participant 6, male, 56) 
Most participants agreed that they would be happy to travel to take part in research. Some 
expressed a preference for engaging in research in their home but another participant saw a 
benefit in travel in itself:  
“I don’t mind travelling. It would get me out, wouldn’t it?” (Participant 11, female, 62) 
Asked whether they would be willing to wait to receive an intervention, for example if they 
were randomised to a waiting arm of a trial, some said they would still take part, provided they 
still needed the intervention while others expressed a preference for such an intervention to 
start immediately. 
4.3.3.3.3 Views on an ideal treatment 
Participants were asked whether they would be happy to try physiotherapy as an intervention. 
Although some participants did not have symptoms that might directly respond to 





“To strengthen my limbs…If I can get the physio in and get moving I think I might be 
able to get going again” (Participant 22, female, 59) 
The non-specific benefits of physiotherapy tended to be acknowledged by participants rather 
than the specific features of the therapy. As one participant noted:  
“So physio, I don’t mind because if it’s going to help to rehabilitate me, of course, I’m 
interested in it. So something like that, or maybe talking about your experience” 
(Participant 15, female) 
Another participant mentioned the possible benefits of talking therapy:  
“My motor function wasn’t affected at all, only my senses. I would like some sort of 
help with how to manage that, how to think about it…if there is anything I can do to 
make it better, if I just, if I know I just have to be patient then I just have to be patient, 
but I don’t want to miss a chance, if I can do something” (Participant 33, female, 51) 
Patients describe a will to get better and are open to physiotherapy or any other intervention 
to try to improve.  
4.3.4 Two-month follow-up interview results 
Follow-up interviews were completed two months after the baseline HASU interview. This 
section discusses the changes over time in symptom experience and attributions.  
4.3.4.1 Symptom experience 
Two months after their discharge from the HASU, participants’ symptoms had remitted 
completely, partially improved or they continued to experience symptoms with some new 
symptoms emerging. Information on symptom progression was available for 25 participants of 
whom 10 (40%) saw no improvement, 4 (16%) saw partial improvements and 11 (44%) saw 
improvements in their symptoms or a complete resolution. 
Patients who no longer experienced symptoms tended not only to describe their symptom 
remission but an overall improvement in their general health also. This improvement likely 
occurred because participants became more health conscious and made lifestyle changes:  
“I feel fine. I play tennis every week and I run so I kind of, that’s keeping me as fit as I 
can. I mean, to be honest, if something is going to happen to me, something is going to 
happen to me so I kind of work on that basis and just carry on as normal” (Participant 





Others had seen an improvement in their initial symptoms and the emotional intensity which 
accompanied the symptoms had dissipated:  
“I can do more. When I first left hospital I was almost bed ridden, I was so tired. I 
developed a headache, I felt tired, I felt dizziness, my balance was out of kilt, a whole 
ream of things. Definitely, over time, I can do more. I can actually go to the bus. I can 
work…before I used to get anxious…and I was speaking to the nurse about a problem, I 
would fall down. I’m feeling better, more active” (Participant 23, female 38) 
The group who continued to experience residual symptoms found these symptoms difficult to 
expunge: 
“The migraines started before I was in hospital and they haven’t stopped to date and 
medication that I have tried hasn’t worked and I’ve tried different ones so far” 
(Participant 15, female) 
“My mouth is shaking. I’ve got tingling down the side of my head” (Participant 31, 
female, 49) 
“My head goes really funny, I get a really bad headache, I feel sick, I start struggling to 
breathe. Whether that’s stress or anxiety, I don’t know and then I feel really dizzy…that 
lasts for about ten minutes and I go into seizure. All I know is that it’s pretty violent, 
that’s all I’ve been told” (Participant 16, female, 21) 
For some of this group, they went on to develop new somatic symptoms. These symptoms 
may be functional, but it is also possible that being admitted to hospital had enabled the 
detection and diagnosis of other underlying health problems. One participant described being 
referred for memory problems:  
“I’m going to see my GP this week because the consultant that I saw said he’s going to 
make a few recommendations plus I had seen a mental health nurse earlier because 
my memory was a bit shoddy at best” (Participant 15, female) 
4.3.4.2 Symptom attribution 
At the baseline interview, most participants were confused about their symptom onset and 
were unable to account for a possible cause. Of patients who held causal explanations, many 
believed they had experienced some kind of stroke event. Some participants believed that 





causal mechanisms and it was often hard to ascertain whether they viewed these factors as 
directly causal, or as moderators of their symptoms.  
Two months later, the majority of participants had been told definitively that they had not 
suffered a stroke via a GP referral letter or in a follow-up stroke clinic. Not having had a stroke 
was something most accepted and most expressed relief. With stroke definitively ruled out, 
the question was then what had caused symptoms. Different causal explanations were 
proposed. Many participants adopted a psychological account of their symptoms mentioning 
stress and exhaustion:  
 “Every day I’m a little bit better, so I think of the reasons I wound up at the hospital in 
the first place is because I was just exhausted…it has been an on-going thing with me. I 
tend to overdo it…my mental energy is such that my physical energy hasn’t yet sort of 
caught up with it” (Participant 8, female, 43) 
While reflecting on her admission, another participant also felt her symptoms had started 
because of a stressful period in her life and she should not have been brought to the hospital 
at all:  
“It was just a very stressful time. I wouldn’t have gone if they hadn’t made me” 
(Participant 29, female, 51) 
Avoiding making causal attributions seemed to be an active coping strategy. There was a sense 
that some participants preferred not to ruminate on possible cause: 
“I’m fine. I don’t have any problems. I’ve had a check-up and they’ve said that I don’t 
have stroke…It doesn’t affect my life because I knew it was not a stroke. Maybe it was 
just that I was stressed” (Participant 5, female, 65) 
Some participants acknowledged that they had not suffered a stroke but nonetheless gave an 
opaque neurological account of their symptoms. These accounts were often lacking in detail: 
“They said they didn’t think it was stroke at all, in the end and that it was just factors, 
factors of stuff going on in my body, like I say, it could be a nervous thing in the body, 
the nerves in the body that, ehm, are playing up and can give other symptoms” 
(Participant 9, male, 67) 
Some participants remained uncertain regarding cause two-months later and had no lay 





“They suspected that I had mini stroke, but later, when they discharged me, that’s why 
I’m still confused, they said, ‘No, you have not had a mini-stroke’…it seemed to me that 
they couldn’t give me the right information and I was discharged without being, 
without knowing exactly what happened” (Participant 14, female, 64) 
Participants are most frequently given only a negative diagnosis and told only of the lack of 
stroke aetiology. The lack of clarity from staff was a direct source of uncertainty for 
participants, with many noting that staff and by extension, they themselves, do not know what 
caused their symptoms:  
“They don’t know what happened. They know that it happened but they don’t know 
why” (Participant 33, female, 51) 
“There’s nothing they can do about it. They said that they can’t see any reason for it” 
(Participant 22, female, 59)   
A sense of frustration due to the lack of a clear explanation from doctors regarding symptom 
cause was expressed by another participant. This participant was still searching for a positive 
diagnosis, having had only stroke ruled out:  
“I didn’t get an answer from the stroke ward, except to say, ‘We don’t think you’re 
having a stroke. We think its migraine related’…I’ve had all the stroke-like symptoms, 
eh, but nothing definitive. I don’t think there was anything definitive on the scan…but 
even speaking to my doctors, they’ve never heard of anyone just losing the use of all 
their limbs, even temporarily as the result of a migraine…it’s like learning to walk 
again…and I had to fight to get an ambulance to come home because I couldn’t walk 
five paces on my own, you know?” (Participant 15, female) 
One participant described how he feared the lack of a diagnosis meant there may be a more 
severe underlying cause:  
“If I experience it again, then I will be back to the doctor. For it to be a reoccurring 
thing, it’s possible that what was going on was stress and I get that but if it reoccurs 
then, it would be more of a concern for me. And I think, in the back of my mind, when I 
have, I call it a funny turn, I suppose that’s what’s going through my mind, is this 
something like an MS attack? I’ve got nothing to base it on if I’m being absolutely 
honest, but I’d be lying if I said it didn’t concern me” (Participant 18, male) 





“I’m very worried about it because I don’t know what can happen…I don’t know if it will 
affect me later on or what” (Participant 10, female) 
For other participants, they were more easily able to accept this uncertainty and it did not 
invoke anxiety or concern:  
“Occasionally I might feel, if I have a similar symptom like if you close your eyes for a 
while and open them and the lights goes funny then I think, ‘Oh shit, is this happening 
again?’ or something like that, occasionally I get a little bit anxious about it but not 
really, not to the point where it stops me living my life. Brains are complex things, 
that’s the only thing I’d say” (Participant 2, male, 23) 
One participant, who had had a previous stroke but was admitted with functional overlay, had 
come to realise that uncertainty was inherent in modern medicine and doctors were fallible, a 
way of thinking she found useful when she encountered the health care system:  
“My outpatient appointment was very brief…if I have learned anything from this 
experience it’s that we assume that medicine knows quite a lot, if I can give medicine 
an identity, because doctors actually don’t know and so often times they cannot say 
what has caused certain things to happen…I just carry on. You know, it’s better if you 
know what’s caused it, then you can try to limit it but if you don’t know what that’s 
based on, what can I do? There’s nothing I can do” (Participant 23, female, 38) 
This participant had a history of CFS so it is possible that her ability to cope with uncertainty 
within the medical system was more developed than others as a result of her experience with 
the diagnosis. 
Other participants coped with the uncertainty, incorporating it into their understanding of 
their symptoms:  
“It wasn’t under my control, it was absolutely something I couldn’t control myself, but 
when it finished, it finished and perhaps it is coming back, I don’t know…the consultant 
that explained everything, he couldn’t say what happened to me and he just said, ‘I 
don’t know what happened to you. No one knows what happened to you. What 
happened is finished and now you are ok’ and I thought, ‘Okay’” (Participant 27, 
female, 58) 
In summary, two months after discharge from the HASU, equal proportions of participants 
have seen their symptoms abate or continue. Consistent across most participants however was 





occurred in the first place. Some participants seem to accept this uncertainty, but for others, 
the lack of understanding is problematic and remained a source of anxiety.  
4.4 Discussion 
4.4.1 Main findings 
4.4.1.1 Questionnaire findings 
Results from the Brief-IPQ indicate that while admitted to the stroke ward, participants believe 
their symptoms severely affect their life; they have little control over these symptoms; they 
are concerned about their symptoms; and these symptoms have a high negative emotional 
impact on their life. Participants believe that the treatment they receive on the ward will help 
improve their symptoms. On average, they are neutral in their response to questions related 
to the extent of their understanding of symptoms, how long they think symptoms will continue 
and how much it will affect their life.  
The mean emotional response score (How much do your symptoms affect you emotionally? 
e.g. feeling angry, scared, upset or depressed) reported by functional stroke participants was 
high and similar to responses from patients with type two diabetes (Vedhara et al., 2012), 
bipolar disorder (Lobban et al., 2013) and women with depression (Brown et al., 2010). 
Functional stroke patients reported a strong belief in the consequences of their symptoms 
(How much do your symptoms affect your life?) similar to responses reported in patients with 
breast cancer (Kaptein et al., 2013), lung cancer (Kaptein et al., 2011) and patients with 
depression in advanced disease stage palliative care (Price et al.). Functional stroke patients 
report that they had little personal control over their symptoms with a mean ‘personal control’ 
score on par with patients with ankylosing spondylitis (Hyphantis et al., 2013) and type two 
diabetes (Bean et al., 2007). The baseline questionnaire results suggest that functional stroke 
patients have strong negative emotional responses to a HASU admission and feel a lack of 
control over their symptoms, similar to the experiences of patients with serious physical 
maladies.  
Two months later, there is an improvement in some symptom perceptions. Patients’ view of 
the consequences of their symptoms, the extent that they experience symptoms, their 
concern about the symptoms and their emotional response all significantly improved with 
time. There was, however, no significant improvement in the length of time patients believed 
their symptoms would continue, the amount of personal control they felt they had over their 
symptoms or their understanding of their symptoms. Patients were hopeful that treatment 





Patients with strong illness identities, who predict long illness timelines and severe 
consequences have higher future healthcare use, independent of doctors’ ratings of illness 
severity (Frostholm et al., 2005). In a prospective study of CFS, the strength of patients’ belief 
in a somatic cause for their symptoms predicted poorer symptom outcomes (Wilson et al., 
1994). The finding here that some perceptions improve over time with no psychosocial 
intervention is encouraging, particularly as previous research is mixed on the ability of 
psychosocial interventions to improve illness perceptions. Some psychosocial interventions 
intended to improve illness perceptions in physical disease found no change for instance 
(Skovbjerg et al., 2012; Welschen et al., 2012). 
While some aspects of patients’ illness perceptions may improve on their own, an intervention 
addressing patients’ perception of personal control over their symptoms and their 
understanding of the nature of functional symptoms might be fruitful for future research. 
Examples of interventions which have improved patients’ sense of personal control include a 
psychological, family-based intervention with motivational interviewing methods for type two 
diabetes patients (Keogh et al., 2011), a cognitive behavioural intervention for cardiac 
outpatients (Jonsbu et al., 2013) and an 18-week text-messaging programme for patients with 
asthma  (Petrie et al., 2012).  
These interventions were designed to improve the outcomes of patients with physical health 
disorders. While one study testing an online psycho-education programme reported 
improvements in personal control perceptions of bipolar disorder patients (Proudfoot et al., 
2012) an intervention designed specifically to improve the symptom perceptions of FND 
patients would be worthwhile.  
4.4.1.2 Qualitative findings 
Results from qualitative findings were classified into three thematic families, namely 
‘phenomenological experiences’, ‘symptom attributions’, and ‘views on the future’. 
‘Phenomenological experiences’ were classified into four sub-themes, including patients’ 
experience of their symptom onset, their help-seeking behaviour prior to admission, their 
experiences as inpatients and their emotional responses to admission. The ‘symptom 
attributions’ theme was further classified into three sub-themes including patients’ common 
attributions, locus of control and authenticity. ‘Views on the future’ were further sub-divided 
into views on recovery, research and an ideal treatment. Two-month follow up interviews 






Some patients gave a detailed, thorough narrative of the onset of their symptoms and their 
arrival to hospital. Symptoms were an interruption to the normal course of their day. For 
participants with more insidious symptom onsets, many described out-of-body experiences 
and dissociative states, similar to symptom onset experienced by patients with functional 
weakness (Stone et al., 2012). Previous literature regarding patients with unexplained or 
functional symptoms suggests patients’ illness narratives are often chaotic with no clear 
beginning or end (Frank, 1995). In our study however, participants were consistently coherent 
in their descriptions of symptom onset. Previous research on illness narratives with patients 
with unexplained symptoms was often conducted in general practice where symptoms are 
more likely to be established and chronic. In this sample, perhaps because symptom onset was 
recent, patients’ demonstrated clarity in their recall and narration of events.  
Some participants described a phenomenon where, when seeking help, their symptoms often 
got worse. Salmon (2006) suggested that patients’ presentations might intensify if they sense a 
doctor’s reluctance to engage or to accept their symptoms at face value. Salmon argues that as 
doctors propose physical investigations and treatments in response to the escalating severity 
of functional symptoms, they can inadvertently induce and entrench somatisation. It may also 
be possible that the act of describing symptoms could worsen symptoms as patients are forced 
to focus on symptoms themselves, something that may intensify the symptom experience 
(Barsky et al., 1993). It is not possible to draw causal conclusions here, but it may also be the 
case that as medical care escalates, participants’ anxiety or panic increases and symptoms 
worsen. The escalation of care may also re-inforce participants’ pre-existing beliefs about the 
seriousness and potential somatic nature of their condition.  
Our qualitative findings regarding patients’ emotional responses mirror results from the Brief-
IPQ. Functional stroke patients describe an array of strong negative emotions in response to 
their HASU admission from feelings of depression, distress, anger, disappointment, as well as 
stoic resignation. Regarding stoicism, the minimisation of emotion has previously been 
reported in research with patients with FMD (Epstein et al., 2016). Participants in our study 
expressed apprehension that they might not find a potential cause for their symptoms, a 
reality that often remained two months later.  
Our findings somewhat contradict previous research suggesting that somatoform disorder 
patients have lower levels of emotional awareness (Subic-Wrana et al., 2005). The stoic 
response was in itself an acknowledgement of a potentially strong emotional reaction. A study 
of patients with medically unexplained symptoms in general practice found these patients 
were more likely to look for emotional support than patients with symptoms that had a 





unexplained symptoms deny their psychological needs. Stoicism, or at least professed stoicism, 
was common in our study however and this seemed to be a response to the strongly negative 
emotional experience of being admitted to the ward.  
Causal beliefs, uncertainty, control and coping styles were common inter-related themes 
throughout our interviews. Most participants were uncertain about the potential cause of their 
admission with many mentioning anxiety, psychological factors, and stroke itself. The 
uncertainty that emerged may be partly due to the context of the interviews – participants 
may have preferred to wait until they were discharged or to talk to their GP before deciding 
conclusively what they believed caused their illness. This is unlikely to have played a prominent 
role however as participants’ uncertainty remained in the two-month follow-up interviews.  
It is most likely that the lack of certainty reflects the lack of diagnostic information participants 
received from clinical staff. Clinical stroke staff appeared to adopt a dichotomised view of 
patients as stroke sufferers or non-stroke patients and non-stroke patients with potential 
functional aetiologies received little to no explanation from staff. Previous research suggests 
diagnostic uncertainty can lead to high emotional distress, anxiety and depression (Mischel et 
al., 1991; White & Frasure-Smith, 1995) and in our study, this lack of certainty may partly 
explain patients’ negative emotional responses.  
Not all participants were uncertain about the cause of their symptoms; some held psychosocial 
explanations. This contradicts Rief et al.’s (2004) primary care study where somatoform 
patients held exclusively physical attributions. It is possible that patients with unexplained 
symptoms seen in primary care have more chronic symptoms and as a result of the length of 
symptom experience, may be less open to psychosocial accounts. Our results corresponds with 
findings from a study of patients with somatoform disorders in an allergy clinic who also 
recognised the role of psychosocial factors (Groben & Hausteiner, 2011). Our results suggest 
that illness attributions may be multifactorial in nature and while some patients might be 
uncertain, others are open and receptive to psychosocial accounts.  
Illness beliefs affect the long term outcome of patients with both physical and mental health 
issues, for example patients who did not know that they were hypertensive showed a 
threefold increase in the days of work missed after they received a diagnosis (Haynes et al., 
1978). More research is needed to tease apart the causal explanations that patients with 
unexplained symptoms in stroke settings develop. In our study it was often unclear whether 
participants believe psychosocial factors modify, mediate or directly cause physical 
susceptibility to a somatic event or whether they believe their somatic symptoms can be 





Patients almost unanimously described experiencing little to no control over their symptoms, 
but many felt hopeful that they could control their recovery. These findings correspond with 
results from the Brief-IPQ where patients report low rates of personal control over symptoms. 
It is likely that a lack of perception of symptom control is linked to the uncertainty inherent in 
many patients’ symptom attributions. Individuals who perceive symptoms as beyond their 
control, have poorer health outcomes, poorer quality of life (Brown et al., 2015), report more 
somatic symptoms and higher rates of neuroticism and anxiety than patients with internal 
locus of control styles (Hoehn-Saric & McLeod, 1985). It is possible that learned helplessness 
arises when patients feel they lack control. A longer follow-up period and the inclusion of 
measures like the Generalised Self-Efficacy scale (Schwarzer & Jerusalem, 1995) and the 
Multidimensional Health Locus of Control scale (Wallston et al., 1978) might help account for 
such factors in future studies.   
Throughout interviews, participants expressed concern that they might not be taken seriously 
by stroke clinicians. They were often acutely sensitive to perceived negative inferences made 
about them by clinical teams. This is a feature of much of the qualitative literature on patients 
with contested diagnoses like unexplained physical symptoms (Nettleton et al., 2005; Peters et 
al., 2008; Salmon et al., 1999; Stone, 2014), chronic pain (Osborn & Smith, 1998), CFS (Clarke, 
2000) and fibromyalgia (Cunningham & Jillings, 2006; Sturge-Jacobs, 2002). These papers 
highlight how individuals’ lack of outward signs of illness or disability can arouse suspicion in 
others causing patients’ credibility to be questioned. Results from our study depart from these 
findings somewhat. Illegitimacy is experienced only in relation to staff members. Patients have 
short, acute symptoms which have often not yet become chronic. Patients describe having 
their legitimacy as patients questioned by doctors but do not mention their wider social circle 
of friends or family. Instead, friends and family appear supportive in response to symptom 
onset, often seeking medical care and visiting the patient on the ward.  
The findings from clinicians’ interviews in Chapter Three suggest that patients’ concerns about 
being viewed as legitimate recipients of care may not be entirely unwarranted. The results of 
our study suggest that patients are not immune to the views of their clinicians and these 
results reinforce the need for clinicians to avoid making moral judgements at the patient’s 
bedside (Raine, 2004).   
Two months after their discharge, some participants continued to experience symptoms while 
some had had a complete remission. This was reflected in the Brief-IPQ results where there 
was a significant drop in participants who described experiencing many severe symptoms. 
Those who recovered completely tended to have made lifestyle changes and described 





disorder patients in a tertiary referral clinic, 9.5% had a complete abatement of symptoms, 
33.3% of participants improved but 57.2% of patients’ symptoms were the same or worse 
(Feinstein et al., 2001). In our study, a higher proportion of patients improved (44%) and a 
lower proportion worsened (40%), at least in the short-term. Our follow-up period of only two-
months however may not capture the true chronicity of these symptoms.  
Symptom attributions changed to some degree two months after their discharge but most 
participants were still unsure of the cause. There is conflicting evidence on whether or not 
receiving a diagnosis or label is helpful in the treatment of functional symptoms. Huibers and 
Wessely (2006) have argued that being labelled with a functional diagnosis can lead to the 
reinforcement of illness beliefs and an acceptance of a fully-fledged sick role and the 
appropriation of a disease identity. The alternative argument is that receiving a label can be an 
empowering act, removing uncertainty and bringing relief and legitimacy. Patients with CFS, 
for instance have described receiving a diagnosis as the most helpful event in the course of 
their illness (Woodward et al., 1995). In our study, functional patients admitted to HASUs 
should, at the very least, receive a concise, honest explanation of the nature of functional 
symptoms, and if symptoms persist and become chronic, they should receive a prompt 
diagnosis that might help patients access future effective treatment.  
4.4.2 Strengths and limitations 
This study is the first to assess the experiences of patients with unexplained or functional 
symptoms admitted to a hyper acute stroke ward. The study period of ten months and the 
broad inclusion criteria allowed for the recruitment of a representative sample of participants. 
The use of the Brief-IPQ during the semi-structured interview was an attempt to achieve data 
triangulation, allowing for some cross-verification of our results.  
Results in this study correspond with results in Chapter Three. In Chapter Three, clinicians 
described how they avoided giving positive diagnoses or terms that might label participants 
and deliberately relied on obscure labels when discussing diagnosis. Results from the current 
study suggest that the resulting diagnostic uncertainty has negative psychological effects on 
patients who expect the normal process of diagnosis, treatment and referral to operate. This 
uncertainty persists two months after discharge.   
Participants interviewed in this study were only those admitted to the HASU, most commonly 
after assessment by a paramedic and a doctor in the Accident and Emergency department. 
These patients will be, at least symptomatically, different to functional disorder patients seen 
by a paramedic or A&E doctor but not admitted to the HASU. Their physical symptoms may 





patients who are not subsequently admitted. It may not be possible therefore to generalise 
the results of our study to functional disorder patients not admitted to acute settings.  
Related to this issue is the fact that interviews took place at one HASU site in a single NHS 
Trust. Further research is required to ascertain whether our results are generalisable to other 
HASU wards or acute care settings. Unexplained symptoms are common in nearly every 
medical setting (Reid et al., 2001a) but more research is needed on the specific experiences 
and processes related to patients’ admission to acute settings generally as these may differ to 
patients’ experiences in primary care or on non-acute wards.  
The transience of some patients’ symptoms is worth noting. Not all participants in this study 
would qualify for a diagnosis of functional neurological symptom disorder, or indeed any 
mental health diagnosis. Some participants experienced stoke along with functional overlay. 
Patients often experienced acute symptoms which resolved while on the stroke ward and 
which did not return. Others described what were likely to be chronic symptoms that would 
not meet the diagnostic threshold. This might be problematic in an epidemiological study 
measuring incidence but our study aimed to understand experiences, and the presence of 
unexplained symptoms. The finding that symptoms were often transient and sub-diagnostic is 
an important finding in itself with implications for future interventions in this area.  
Participants had a wide range of unexplained symptoms, some had previously experienced 
stroke in the months prior to their admission and some had had a stroke admission. The 
heterogeneity of symptoms has implications for the interpretation of the Brief-IPQ results. A 
larger sample size would have allowed for symptom type and length of symptom experience to 
be accounted for in the analysis of the questionnaire. Future research in this area would 
benefit from adopting a multi-site recruitment approach to increase the sample size. 
The researcher was embedded on the ward and in some cases participants sought reassurance 
and advice during the interview. As the researcher, I wished to remain impartial throughout 
the interviews although in some cases it was difficult to maintain this in the face of some 
patients’ clear distress. In some instances, it was necessary to speak to the ward’s clinical 
neuropsychologist after the interview to let them know the patient was experiencing 
difficulties.  
At the two-month follow-up, not every participant responded to the request for an interview. 
It is possible that non-responders were different to responders, they may have had worse 
outcomes or it is possible their symptoms completely resolved. Despite this, the follow-up rate 





Our follow-up interviews were conducted via Skype, but without video. While internet based 
methods of interviewing are increasingly common due to their efficiency and affordability, it 
was harder to establish rapport with participants during the follow-up interviews. As a result, 
some of the richness of the interaction may have been lost. This may be reflected in the fact 
that Skype interviews took less time than our face-to-face baseline interviews. However, using 
Skype allowed participants to be interviewed in their own home, at a time that suited them, 
with little interruption to their day and likely contributed to the high response rate.  
4.4.3 Conclusions 
Patients with functional stroke symptoms who are admitted to stroke settings have a strong 
negative emotional response to their admission. While inpatients, many believe they have had 
a serious cerebrovascular event and that there will be serious negative consequences in the 
future. Most do not feel they have any personal control over their symptoms. Two-months 
after their discharge from hospital participants continue to believe they have no personal 
control over their symptoms, have little understanding of the symptoms which brought them 
to the ward, and are uncertain as to the symptom cause. Most continue to feel they did not 
receive an adequate explanation from clinical staff.  
Patients might benefit from improved doctor communication through the use of well-
developed explanation and positive diagnoses but patients with higher rates of depression and 
















Functional motor disorders comprise symptoms such as weakness, numbness, tremor, gait 
disorders and paralysis which are not caused by neurological disease. Patients can present 
with abnormal motor symptoms which are incongruous with the motor disorders that occur in 
neurological disease.  
The previous three chapters outlined research examining functional neurological symptoms 
and their occurrence within stroke settings and the perspectives of patients and clinicians. This 
study and the proceeding chapter examine the occurrence of FMD symptoms in one large 
mental health trust.  
It is worth noting that the definition of FMD used in this and the subsequent chapter relates to 
functional motor disorder that includes, but is not restricted to functional movement 
disorders. Functional motor disorder is a broad category that in our chapters relates to 
abnormal movements like gait disorders and tremor but also includes weakness and any 
symptoms affecting motor faculties like speech, swallowing, visual, or urinary disturbances.  
This introduction outlines the epidemiology, clinical features, physical health comorbidities, 
life events, treatment, and prognosis of FMD before outlining our study’s aims. Evidence is 
drawn from functional disorders generally, and where possible, from evidence on FMD 
patients specifically.  
5.1.1 Prevalence 
As outlined in the introduction to this thesis, the frequency of FND varies depending on the 
setting, the case definitions employed and the methods used to ascertain cases. 
Epidemiological studies of FMD specifically are rare. Information on their prevalence comes 
from movement disorder and general neurology clinics. In movement disorder clinics in the US 
a rate of 3% has been reported (Factor et al., 1995; Thomas & Jankovic, 2004) but anecdotally 
it has been reported to be as high as 20% (Hallett, 2006). In a general medical setting, Portera-
Cailliau et al. (2006) reported a rate of 10%, and in general neurology clinics there are reports 
of rates between 1-9% (Lempert et al., 1990; Marsden, 1986).  
The differences in rates could reflect local referral patterns and clinicians’ specialities, clinic 
types, the diagnostic criteria and methods used to assess patients, and clinicians’ awareness of 
functional symptoms. A robust epidemiology of functional disorders has suffered due to the 






FMD patients have a socio-demographic profile that matches most other functional disorders. 
In Factor’s (1995) study of functional movement disorders, 61% of patients were women and 
most were young to middle-aged. Hinson and Haren (2006) reported a mean age of onset 
between 37-50 years but FMD may also affect children and the elderly. Batla et al.’s (2013) 
retrospective study of patients with functional movement disorders reported 21% of patients’ 
symptoms began after the age of 60 while Schwingenschuh et al. (2008) reported a mean age 
of onset in children of 12.3 years of age. In children with functional movement disorders, 
dystonia, tremor, and gait disorders were the most common symptoms.  
5.1.3 Clinical features   
Patients with FMD present with a range of symptoms. Symptoms can begin suddenly and 
without warning and unlike organic movement disorders, their progression is often fast 
(Williams et al., 1995). The phenomenology of the disorder can shift over time and symptoms 
can change form and type.  
Tremor is frequently reported as the most common type of functional movement disorder 
seen in movement clinics (Factor et al., 1995; Hinson & Haren, 2006). One such clinic in 
Toronto reported that tremor was the most common functional symptom, comprising 32.8% 
of presentations, followed by dystonia (25%) (Miyasaki et al., 2003). Batla et al. (2013) also 
found tremor was the most frequent symptom while a further study reported dystonia as the 
most common symptom, followed by tremor (Fahn & Williams, 1988). These symptom 
frequencies should be interpreted with caution given the possibility of referral bias affecting 
the type of patients seen in differing services. 
The following section outlines existing evidence on the individual features of specific motor 
symptoms.  
5.1.3.1 Tremor 
Functional tremor is often marked by its sudden onset, variability in severity, and variability in 
the part of the body affected. It commonly affects the arms but can reach all parts of the body 
including hands, legs, and head (Schwingenschuh & Deuschl, 2016). Maximum disability has 
been said to occur directly after onset and symptoms can follow a static or fluctuating course 
(Kim et al. 1999). It is often distinguished from organic disease as it can change or stop 
depending on the level of attention paid by the patient to the affected limb (van Poppelen et 
al., 2011). Distraction techniques are often employed by clinicians such as asking patients to 





Schwingenschuh et al. (2011) found no single test could adequately distinguish functional 
tremor from organic tremor seen in Parkinson’s disease, but employing a combination of 
electrophysiological tests has good sensitivity and specificity (Hallett, 2010).  
Functional tremor affects more women than men with rates of female morbidity ranging 
between 70 - 80% with a mean age of between 42 and 44 years (Deuschl et al., 1998; Jankovic 
et al., 2006). Jankovic et al.’s (2006) study reported that 24% of functional tremor patients had 
a psychiatric illness before their symptom onset and over half experienced comorbid somatic 
symptoms like pain.  
Patients have a poor prognosis; Janokovic (2006) reported that 85% of patients retired after 
the onset of their tremor, subsequently retired and McKeon et al. (2009) found that 64% of 
patients continued to experience moderate to severe symptoms after five years.  
5.1.3.2 Gait disturbance 
Normal gait is defined by two principles; equilibrium and locomotion. Equilibrium is the ability 
to assume and maintain an upright posture of the head and trunk, while locomotion is the 
body’s ability to propel itself forward (Nutt et al., 1993). This is disrupted in gait disorders. Gait 
disorders often occur due to arthritis or neurodegenerative disease. Functional gait disorder 
patients have no positive pathology or known pathogenesis. In general medical settings, 
functional gait disorders have been reported between 9-10% (Miyasaki et al., 2003; Stolze et 
al., 2005).  
Patients with abnormal functional gait disturbance can show an excessive slowing of 
movement and buckling of the knee (Baik & Lang, 2007). Symptoms may include veering from 
side to side when walking, limping on one leg, walking hesitantly as if on ice, and swaying 
erratically in the upper body  (Jordbru et al., 2012). Other movement patterns include 
tightrope walking, trembling walking, truncal jerking, and astasia-abasia, the inability to stand 
upright unassisted (Sokol & Espay, 2016). Falls and injury as a result of the disorder are 
reported to be rare (Jankovic, 2015). 
Other clinical signs have gained some attention such as ‘huffing and puffing’, grunting, 
grimacing, and breath-holding while moving. These have been described in 44% of patients 
with functional gait disorder (Laub et al., 2015), and are explained as the excessive 
demonstration of effort for the benefit of the clinician. Park et al. (2015) proposed ‘the whack-
a-mole’ sign where the suppression of movement in one body part is followed by the re-
emergence of the movement in another area. This was tested in a movement disorders clinic 





It can be difficult for clinicians to distinguish functional gait disorders from organic disease but 
Fung (2016) argued that if a single symptom is difficult to define, the combination of a 
patient’s clinical syndrome (for instance multiple medically unexplained symptoms) as well as 
inconsistencies in their presentation makes an organic diagnosis unlikely. 
5.1.3.3 Weakness 
Paralysis is a classic functional symptom. Functional weakness can occur in many 
manifestations such as paraparesis, hemiparesis, triparesis, etc., and complete paralysis 
(Lanska, 2006). Of new neurology outpatients, 1.5% had functional weakness (Stone et al., 
2009b), similar to the 2% rate from neurology inpatients (Parry et al., 2006). Functional 
paralysis in neurology inpatients may range between 1-18% (Metcalfe et al., 1988; Schiffer, 
1983) . 
A study by Stone et al. (2010b) reported hemiparesis was the most common type of functional 
weakness in a study of functionally weak patients referred to consultant neurologists, the leg 
was involved in 94% of cases. Symptoms lasted a mean of nine months, 79% of patients were 
women, and their mean age was 39 years. Comorbid symptoms included fatigue, pain, 
gastrointestinal symptoms, tremor, and NES. Patients had a higher frequency of psychiatric 
disorder such as depression and panic compared to controls with organic weakness and higher 
use of walking aids such as wheelchairs, bath chairs, Zimmer frames and stair lifts. Functional 
weakness patients were more likely to give up work as a result of illness than controls but both 
groups were as likely to receive disability benefits.  
Like tremor, weakness can have a sudden onset and has been likened to the onset of stroke. It 
can be accompanied by panic and dissociation and may begin after an injury to the affected 
limb (Stone et al., 2012b). Crimlisk et al. (1998) found 42% of FMD patients had a history of 
neurological disease.  
Common signs in the presentation include ‘la belle indifference’ although, as previously noted, 
its utility and validity has been questioned; ‘Hoover’s sign’, an involuntary extension of a weak 
leg when the healthy leg is forced to extend against resistance (Hoover, 1908); a dragging 
monoplegic gait, where one leg is dragged with the knee extended and hip rotated; and 
collapsing weakness. Stone et al. (2010) have discussed the possibility that patients have 
reduced ticklishness and can present with ‘arm protection’ where patients protect their arm in 
a flexed position in the absence of pain by laying it across their lap or holding it in a flexed 
position when walking. Other tests for upper limb weakness include ‘drift without pronation’ 
(Daum & Aybek, 2013). Patients are asked to keep their arms outstretched and to hold the 





drift of the arm without pronation. The ‘double crossed arm pull’ test is a sign for functional 
monoparesis (Biller et al., 2011). The patient’s wrists are grabbed when crossed across their 
chest. When asked to pull back as hard as possible the patient may pull both arms back.  
There are a large number of such tests and it has been advised that the purpose of the tests is 
shared with patients during clinical encounters to form part of their physical and psychological 
rehabilitation (Stone & Aybek, 2016). 
5.1.3.4 Sensory symptoms 
Functional sensory disturbance can affect any part of the body. Symptoms often include 
feeling that a limb is not part of the body; altered sensations on one side of the body or on the 
face, arm or leg; or fleeting bodily sensations such as buzzing sensations. Patients may present 
with a disturbance of pain sensation and reductions in the perception of touch and 
temperature. Some presentations can be extreme where a patient loses the sensation of an 
entire arm or leg (Stone & Vermeulen, 2016). Sensory disturbances often co-occur with 
functional weakness (Stone et al., 2002). Stone and Vermeulen (2016) note that impairment is 
often short in duration and commonly affects only half the body.  
Toth et al. (2003) reported that 74% of patients with hemisensory syndrome were female with 
a mean age of 35. In a cohort study by Stone et al. (2003), 60 patients with functional or 
sensory disturbance (it is unclear what proportion had only sensory symptoms) reported their 
symptoms continued for a median duration of 12.5 years. Where a whole limb is affected, 
studies have found the sensory disturbance is often demarcated along clear boundaries, most 
commonly the shoulder and the groin (Janet, 1907). Stone and Vermeulen (2016) describe a 
splitting where patients can feel they are ‘cut in half’ or ‘split down the middle’. In a study of 
405 patients with functional symptoms, the most common sensory symptoms were hypo- or 
anaesthesia followed by dysesthesia (Lempert et al., 1990). Numbness is said to more 
frequently affect the trunk than arms or legs and the disturbed sensation can flip from one 
side to the other (Stone & Vermeulen, 2016).  
One clinical sign of sensory loss is the ‘splitting of vibration sense’. Vibration is perceived 
mostly through bone conduction. By placing a tuning fork on the right or left of the forehead, 
the sensation should be felt identically on either side as the same bone is involved. This test’s 
sensitivity has been reported to be 95% in 19 patients with functional symptoms however it 





5.1.3.5 Other symptoms 
This section outlines the less common functional motor symptoms of speech, facial, and 
urinary disturbance. 
Functional speech disorders cover a range of abnormal speech patterns that cannot be 
accounted for by organic disease. These disorders often co-occur with other functional 
symptoms. “Hysterical mutism” was described by Charcot as “sudden onset, impossibility of 
speaking or crying out [but the] perfect preservation of intelligence”. Baizabal-Carvallo and 
Jankovic (2015) reported the most common functional speech disorder seen at the Mayo clinic 
over ten years was stuttering-like dysfluency followed by articulation deficits. Women 
accounted for 76.6% of these patients. Speech and language therapies show positive results. 
Duffy (2016) notes that when treating functional speech impairment with speech therapy, 
patients should be helped to develop an explanation they can provide to others about the 
nature of their symptoms.  
Functional facial movements can affect the eyelids, tongue, and muscles of the face. 
Uncontrollable and painful contractions of the eye can account for up to 7% of FMDs (Factor et 
al., 1995). Symptoms can be episodic in onset and inconsistent in their presentation and again, 
more commonly affect women and have been associated with migraine and facial weakness 
(Fasano et al., 2012). These authors also reported that symptoms most frequently affect lips, 
eyelids and nasal regions. Little is known about the treatment of the disorder but in Fasano et 
al.’s (2012) study, 21% of patients spontaneously recovered.  
Urinary dysfunction is another type of functional symptom and can present in a variety of 
ways. Functional urinary retention was described by Charcot as “hysterical ischuria” (Charcot, 
1877). This has been reported in young women and has been linked to urinary tract infections 
and early emotional deprivation (Wahl & Golden, 1963). In a retrospective review of patients 
with functional movement disorder, Batla et al. (2016) found 20% of patients had lower 
urinary tract dysfunction. Of these patients, overactive bladder symptoms were the most 
frequent and patients with fixed dystonia were most commonly affected. 
Other types of FMDs include jerking movement, tics, eye movements, swallowing difficulties, 
and some speech and voice disorders. Functional symptoms can affect a wide range of motor 
functions and they can be debilitating and disturbing. The following sections outline life 





5.1.4 Life events 
Functional disorders have been historically associated with traumatic life events or 
psychological stress. Up until recently, the identification of a psychological antecedent was a 
diagnostic criterion of functional disorder. This is no longer the case, but theories of functional 
disorders frequently link their development to psychosocial precipitants. Research in this area 
tends to classify life events into those occurring in childhood that relate to sexual, physical and 
emotional abuse, often classed as trauma, and events occurring in adulthood, precipitants 
occurring closer to the time of symptom onset.  
Sexual abuse is frequently described in FND presentations. Much of the research in this area 
focuses on NES. Of research that does not focus on NES alone, the rates of abuse vary. Roelofs 
et al., (2002) reported that in FND patients there was a 28% rate of physical abuse; a 24% rate 
of sexual abuse; a larger array of types of physical abuse; sexual abuse of a longer duration; 
and more frequent incestuous experiences compared to patients with affective disorders. Sar 
et al., (2004) reported a rate of childhood sexual abuse (CSA) of 26.3%, emotional abuse of 
34.2%, a physical abuse rate of 44.7%, and an overall neglect in childhood rate of 57.9%. In 
patients with medically unexplained gastrointestinal problems, 13% experienced physical 
abuse and 13% experienced sexual abuse (Reilly et al., 1999). In patients with functional voice 
disorder, 41% experienced physical abuse and 32% experienced sexual abuse (Baker et al., 
2013).  
A systematic review reported an average CSA rate of 33.2% in NES patients (Sharpe & Faye, 
2006). The incidence of CSA in functional motor disorder may be lower than NES patients with 
previous reports ranging from 3-12.5% (Binzer & Eisemann, 1998; Stone et al., 2004b; Voon et 
al., 2010). These studies recruited from neurology settings where the abuse incidence may be 
lower than that seen in psychiatry patients. Nicholson et al. (2016) reported a life time sexual 
abuse rate in FMD of 41.9%, while McCormack et al. (2013) reported a CSA rate of 36.4%. Life 
time experience of abuse will be higher than abuse experienced in childhood alone and both 
studies’ recruited from specialist tertiary services where patients may have more severe 
symptoms and more traumatic experiences.  
Life events, as distinct from childhood sexual and physical abuse, have also been explored in 
relation to the development of FND. Binzer et al. (2004) found no differences in the number of 
life events three months prior to symptom onset between NES and epileptic patients. Testa et 
al. (2012) found NES patients did not experience a higher frequency or severity of life events, 
but rated them as more distressing. Research specifically excluding NES patients found FND 





Roelofs et al. (2005) reported a link between childhood trauma and functional neurological 
symptoms but found that this was mediated by the occurrence of recent stressful life events. 
In their study, life events were most commonly related to work and relationships. A study by 
Kozlowska et al. (2011) found 27% of conversion patients had experienced recent 
bereavement.  
Patients frequently experience physical precipitating factors with rates varying from 24-100% 
(Baik & Lang, 2007; Fasano et al., 2012; Jankovic et al., 2006; McKeon et al., 2009; Ranawaya et 
al., 1990; Schrag et al., 2004; Stamelou et al., 2012). Common types of physical precipitants 
include injuries in work, back and neck injuries, surgery, motor vehicle accidents, and head 
injuries. A systematic review reported that 37% of patients had a physical injury prior to 
symptom onset (Stone et al., 2009a). A retrospective review of 151 patients with functional 
movement disorders found the most common type of precipitating events were physical 
trauma, followed by ‘emotional life events’ (Batla et al., 2013). Physical injury or trauma was as 
high as 80% in functional patients in a movement disorders clinic (Pareés et al., 2014), while a 
retrospective study from seven tertiary movement disorder clinics described stress as the most 
common precipitating factor (61%), followed by physical trauma (14.8%) (Fasano et al., 2012). 
In a study of functional tremor, half of participants with acute symptom onset mentioned a 
precipitant which included a medical procedure, an upper respiratory tract infection, and 
work-related pain (McKeon et al., 2009). Physical trauma and organic disease are therefore not 
uncommon experiences prior to a functional symptom onset. 
While the literature suggests that a substantial proportion of FND patients have experienced 
adverse life events, a proportion have not. The methods used to assess these life events and 
the position of the person will likely affect the rate itself and it is possible that under-reporting 
is common throughout.   
5.1.5 Diagnosis 
The diagnosis of individual functional symptoms and the use of positive physical signs have 
been mentioned in previous sections. In the diagnosis of FND generally, a thorough history and 
clinical examination is important and will often necessitate the use of special investigations.  
Three clinical criteria, developed to help formalise and assist the diagnosis. The Fahn-Williams 
criteria (Williams et al., 1995) are the most widely used. These categorise diagnostic certainty 
as: i) documented, ii) clinically established, iii) probable, and iv) possible.  The Shill-Gerber 
criteria (Shill & Gerber, 2006) rely on clinical elements that suggest inconsistency with an 





Fahn-Williams and Shill-Gerber criteria show poor inter-rater reliability when assessing cases 
with a high degree of uncertainty (Morgante et al., 2012). 
Improvements in the Fahn-Williams criteria have been proposed (Gupta & Lang, 2009). These 
authors argue that the ‘possible’ category should be removed and the diagnosis of FMD should 
be made on the basis of positive findings. In the case of functional tremor, for example, 
positive signs like lack of family history, sudden onset, spontaneous remission, shorter 
duration of tremor, suggestibility and distractibility could help inform the diagnosis (Kenney et 
al., 2007).  
There has been a drive in recent years to develop criteria which are based on positive signs in 
order to improve the reliability and validity of diagnosis. Such a task is not straightforward as 
any such criteria have to account for the possibility that patients may have both a functional 
and organic disorder.  
5.1.6 Prognosis  
The prognosis for FMD patients is relatively poor. A systematic review with a mean follow-up 
time of 7.4 years found 40% of patients were the same or worse at follow-up and for patients 
whose symptoms had resolved, many did not experience complete symptom remission 
(Gelauff et al., 2014). Anderson et al. (2007) found increased psychiatric morbidity, and similar 
levels of disability and quality of life when they compared functional motor and Parkinson’s 
disease patients, despite functional patients being younger, with a shorter disease duration.  
A range of clinical factors have been linked to patients’ long-term outcome. Factors associated 
with poorer outcomes in patients with functional movement disorder include a longer 
duration of symptoms, an insidious onset of symptoms, the presence of an Axis-1 psychiatric 
diagnosis (Binzer & Kullgren, 1998; Feinstein et al., 2001), higher age at symptom onset (Stone 
et al., 2003), and receipt of financial benefits (Crimlisk et al., 1998; Mace & Trimble, 1996). 
Improved outcomes have been linked to being female (Czarnecki et al., 2012), and a change in 
marital status during the follow-up period (Crimlisk et al., 1998). 
Gelauff et al.’s (2014) review indicates that there may be differences in patients’ outcomes 
depending on the functional motor symptom type. Patients with functional tremor generally 
had poor outcomes with 44-90% of patients remaining the same or worse at follow-up 
(Jankovic et al. 2006; McKeon et al., 2009). The prognosis of patients with weakness and 
paralysis appears to be better. Stone et al. (2003) found patients with only sensory symptoms 
at presentation had higher physical and social functioning, and reduced pain at follow-up 





cautiously that patients with sensory symptoms alone have a relatively good prognosis 
compared to those with a broader range of functional symptoms (Gelauff & Stone, 2016). 
5.1.7 Aim of study  
Current research on functional motor disorder is characterised by low sample sizes and case 
studies (Binzer et al. 1997). Control groups, if used at all, are often comprised of neurology or 
brain injury patients. This may lead to overestimates in the assessment of the risk of 
psychiatric comorbidities and underestimates in the risk of physical comorbidities. Functional 
disorder patents are often seen in physical health settings and, following the application of 
tests and clinical examinations, they are frequently discharged. A number will be referred for a 
psychiatric or psychological consultation but the demographic, social and clinical profile of 
these patients is poorly understood. Most research in this area comes from liaison psychiatry 
in general medical settings and little from psychological and psychiatric services.  
This study aimed to establish a cohort of patients with FMD in order to investigate patients’ 
socio-demographic and health factors, life experiences, and clinical outcomes. The 
characteristics of this patient group were compared to a random sample of psychiatric patients 




5.2.1 Study setting 
Data from this study were collected from the Clinical Record Interactive Search (CRIS) (Stewart 
et al., 2009).  
CRIS is a case register which provides de-identified information from electronic clinical records 
from secondary and tertiary mental health services provided by SLaM NHS Trust. The Trust 
provides mental health care in the London boroughs of Lambeth, Southwark, Lewisham and 
Croydon. Electronic clinical records have been used by the Trust since 2006 in the form of the 
electronic Patient Journey System (ePJS). This is a single system where daily activities, 
medication, diagnoses, correspondence, health scores and all patient information is recorded. 
CRIS was established in 2008 to allow the search and retrieval of de-identified ePJS information 





5.2.2 Data collection 
5.2.2.1 Inclusion criteria 
Inclusion criteria for cases in this study included:  
I. Patients who received a primary or secondary ICD-10 diagnosis of ‘Conversion disorder 
with motor symptom or deficit’ (F44.4); or 
II. Participants with any F44 diagnosis and evidence of FMD  symptoms; or 
III. Any patient with confirmed functional motor disorder symptoms but no ICD-10 
diagnosis marked in structured text; and included 
IV. Only patients aged over-18. 
For each potential patient, evidence was sought that their symptoms could not be entirely 
explained by a physical disorder (e.g. neurologists’ letters confirming a functional explanation 
for symptoms). If there was no sound evidence of a confirmed functional motor disorder, or if 
the clinician was not certain that symptoms could be explained by a functional neurological 
diagnosis, patients were excluded. Patients were included if they had functional motor 
symptoms as well as other mental health diagnoses or comorbid functional diagnosis like CFS 
or NES.   
5.2.2.2 Matching 
Once the search for FMD patients reached saturation, and all corresponding data were 
collected, the control group was established. Inclusion criteria for entry into the control group 
were:  
I. Receipt of a psychiatric diagnosis from SLaM on the succeeding day the FMD patient 
received their diagnosis; 
II. Only patients aged over-18 were included; 
III. No evidence of a neurodegenerative disease of old age such as Alzheimer’s disease or 
dementia; 
IV. No diagnosis or evidence of an intellectual disability (F70 – F79); and 
V. Patients were excluded who had only brief contact with mental health services but had 
no mental health diagnosis6.  
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The day after each FMD patient received their first SLaM diagnosis was searched in CRIS. This 
search returned any SLaM patient who had received a diagnosis on this particular day. A 
control group patient was then chosen at random from this list, using a random number 
generated from the website, random.org.  
If they did not meet inclusion criteria a second patient was chosen using the same method and 
this process continued until each FMD patient was matched with two control group patients. 
Control patients were not matched on socio-demographic details as we were interested in the 
differences between groups on these particular factors. 
5.2.2.3 Search strategy 
Any SLaM patient suspected of having an FMD presentation was searched using the free-text 
fields in CRIS and the structured diagnostic search fields. The structured diagnostic search 
allowed for the search of all F44.4 primary and secondary diagnoses in SLaM. The free-text 
search allowed for a search of words linked to an FMD diagnosis on notes from routine clinical 
contact, Care Plan Approach reviews and any corresponding letters. See “Appendix 5.1: CRIS 
search criteria” for the search strategies used in our CRIS search and the total number of 
associated patients returned with each search. CRIS returns patient-level information.  
Two points should be noted in relation to our search strategy. The first relates to the fact that 
one researcher read the detailed notes of all potential study participants. The most effective, 
but least efficient search strategy would be to read all 250,000 CRIS records. This would allow 
for a robust calculation of prevalence. Instead, given the time and resource limitations, as 
sensitive and specific a search as possible was employed. It is however possible, and indeed 
likely, that patients who did not receive an official diagnosis, or whose symptoms were 
described in the free-text with words not detected by our search, will not be included. In total, 
we conducted nine searches which appeared to reach saturation as new searches with 
additional terms did not return new patients. After each search, more duplicates were found 
until eventually no new search iteration produced new patients.  
A second issue relates to the nature of the database. CRIS is updated every night and this 
means recently diagnosed FMD patients arriving into SLaM may be added each day. Our search 
does not include any patients referred after December 31st 2016.  
677 potential functional motor patients were returned as possible participants. 208 (30.7%) of 






122 patients did not meet the study’s inclusion criteria. Half of these patients (46.3%) were 
excluded because they were aged under-18. Thirty-three patients were functional patients but 
there was no evidence that they displayed any motor symptoms, for example they 
experienced dissociative seizures only. In 32 patients, there was no evidence of any functional 
symptoms at all. Twenty-five patients were considered borderline cases. In these patients’ 
notes there was a suggestion that they had a functional motor symptoms but their notes were 
not comprehensive enough for inclusion or they were awaiting updates from a neurologist. 




Figure 30 Flow chart showing functional motor disorder patients recruitment 
In total, there were 322 functional motor cases for whom 644 control group participants were 
matched.  
5.2.3 Measures 
Data were taken from both unstructured and structured fields in CRIS. Unstructured fields 
include patients’ notes, correspondence and events while structured CRIS fields include 
variables such as date of birth, clinical outcome scores and diagnoses. 
Information was sought on the following variables: date of birth, gender, ethnicity, marital 
status, date of death, welfare benefits, housing status, employment status and title of most 
recently held job, pre-morbid employment status (yes, no, not known), age at psychiatric 





the nature of the motor symptoms (recorded qualitatively), lifetime use of mobility aids (yes, 
no, not known), psychiatric inpatient visits (number of inpatient spells and total number of 
days spent in hospital), Health of the Nation outcome scores (HoNOS) (first and last available 
from each record), Chronic Fatigue Questionnaire scores (first and last available), Physical 
Health Questionnaire (PHQ-9) scores (first and last available), comorbid physical conditions 
(experienced as an adult), exposure to childhood sexual and physical abuse (classified as abuse 
experienced under the age of 18; yes, no, not known), exposure to adult sexual or physical 
abuse (experienced over the age of 18; yes, no, not known), any comorbid functional motor 
symptoms, family history of mental health problems (yes, no, not known, type of relative and 
total number of relatives), complications at patient’s birth (yes, no, not known and type of 
complication), most recent available information on smoking status (yes, no, not known) and 
most recent information on body mass index (BMI). Descriptive information was taken on any 
possible precipitating factors linked to symptom presentation. Precipitating factors are those 
defined by a clinician as potentially linked to patients’ symptom onset and could include any 
event from childhood or adulthood.   
For variables that could change over time, like smoking status, marital status, welfare benefits, 
housing status, and BMI scores, the most recent available information was collected. 
The following sections outline more detail on some of the variables used in the study. 
5.2.3.1 Abuse 
Childhood sexual abuse (CSA) was classified according to the WHO Consultation on Child Abuse 
Prevention (1999) which states, “child sexual abuse is the involvement of a child in sexual 
abuse that he or she does not fully comprehend, is unable to give informed consent to, or for 
which the child is not developmentally prepared and cannot give consent, or that violates the 
laws or social taboos of society”. Childhood physical abuse was defined according to the 
WHO’s definition as “the intentional use of physical force against a child that results in, or has 
a high likelihood of resulting in, harm to the child’s health, survival, development or dignity” 
(Butchart et al., 2006). There were instances where a patient described corporeal punishment 
as a child but did not perceive this as abuse or as harmful. These instances were not recorded 
as abuse. Adult physical or sexual abuse was defined in the same way but was classified as an 
event that occurred to a patient over the age of 18.  
5.2.3.2 HoNOS  
The HoNOS (Wing et al., 1998) has twelve items, each rated on a five-point scale by the 





problems, physical illness and disability, hallucinations and delusions, depression, 
relationships, activities of daily living, residential environment and daytime activities. It 
includes five-point rating scales which range from ‘zero’ meaning ‘no problems’ to four, 
‘severe to very severe problems’. All items, with the exception of daytime activities, have 
shown good inter-observer agreement. The HoNOS are often operationalised as a composite 
twelve-item scale with a total HoNOS score ranging from 0-48. Internal consistency of the 
HoNOS is high and concurrent validity with other clinician-rated instruments is good (Pirkis et 
al., 2005). 
5.2.3.3 HoNOS-ABI 
HoNOS-ABI assesses the neuropsychiatric factors linked to brain damage. The scale correlates 
with established outcome measures such as post-injury employment (Coetzer & Toit, 2001). 
The inter-rater reliability for the HoNOS-ABI has been established as acceptable (Fleminger et 
al., 2005).  
5.2.3.4 PHQ-9 
The PHQ-9 allows clinicians to make diagnoses of depressive and other disorders. The 
questionnaire is used to monitor the severity of depression and patients’ response to 
treatment. The questionnaire has good internal consistency and a test-retest reliability of 0.87. 
It has shown criterion validity with the Beck Depression Inventory (r = 0.79) (Zhang et al., 
2013).  
5.2.4 Statistical analysis 
Descriptive statistics such as frequencies, means and standard deviations were used where 
appropriate. Normality of data was tested using histograms, box-plots, and the Kolmogorov-
Smirnov and Shapiro-Wilk tests. FMD and control group patients were compared using 
Student’s t-tests, Mann-Whitney-U tests, and Wilcoxon signed ranked tests to compare 
normally distributed and non-normal continuous data respectively. Odds ratios (OR) with 95% 
confidence intervals were used to compare groups where the rate of unknown information 
was known. Chi-square tests were used to compare frequencies between groups when the 
rate of unknown information was not known and differences in frequencies, rather than risk 
was assessed. A significance level of 5% (two-tailed) was used for all analyses. Separate binary 
logistic regression analyses were performed to assess the predictor variables related to a 
diagnosis of functional motor disorder, the variables related to the having a comorbid 
functional diagnosis in FMD patients alone and the variables related to a psychiatric hospital 





patient with a schizophrenia-related diagnosis and comparisons were re-conducted. A binary 
logistic regression analysis was again conducted with the removal of all patients with a 
schizophrenia diagnosis to identify the variables related to a diagnosis of FMD. 
All analyses were performed using Microsoft Excel (Microsoft Office Professional Plus 2010, 
Version 14.0.7015.1000) and SPSS V.21.0 for Windows (SPSS, Chicago, Illinois, USA). Graphs 
were created using GraphPad Prism (version 7.00 for Windows, La Jolla California, USA). 
5.2.5 Ethical considerations 
Ethical approval as an anonymised database for secondary analysis was granted in 2008, and 
renewed for a further five years in 2013 (Oxford C Research Ethics Committee, reference 
08/H0606/71+5). 
5.3 Results 
In total there were 322 FMD patients and 644 control group participants.  
5.3.1 Diagnoses 
ICD-10 diagnostic information was gathered from the structured text in CRIS. The main primary 
and secondary diagnosis given by SLaM clinicians were assessed for both FMD and control 
groups. The primary diagnoses are outlined in Table 18.For FMD patients, the most commonly 
received main diagnoses were neurotic, stress-related or somatoform disorder diagnoses (F40-
F48) (57.5% of patients), followed by an F99 ‘unspecified mental disorder’ diagnosis (12.7%) 
and ‘Z00-Z99’ diagnoses (11.8%). ‘Z00-Z99’ codes represent generic encounters a patient has 
with health services.  
 
The control group represents a random sample of SLaM mental health patients and their ICD-
10 diagnoses were distributed across a wider range of diagnostic categories. The most 
frequent diagnosis received by control group patients were mood disorders (F30 – F39) (22.7% 
of patients), followed by mental and behavioural disorders due to psychoactive substances 
(17.4%), and schizophrenia, schizotypal and delusional disorders (14%).   
Some participants had received more than one primary diagnosis during their time in SLaM. If 





collected. These diagnoses are outlined in Table 91 (See “Appendix 5.2: Main diagnoses given 
in CRIS for FMD and control group patients”)7.  
Table 18 Main SLaM diagnosis for functional motor and control groups 







group       
n (%) 
ICD-10 Diagnosis   
(F00-F09) Organic mental disorders 7 (2.2)  5 (0.8)  
(F10-F19) Mental & behavioural disorders due to psychoactive 
substances 
3 (0.9)  112 (17.4) 
(F20 – F29) Schizophrenia, schizotypal and delusional disorders 4 (1.2)  90 (14) 
(F30 – F39) Mood disorders 22 (6.8)  146 (22.7) 
(F40 – F48) Neurotic, stress & somatoform disorders 185 (57.5)  70 (10.9) 
(F50 – F59) Behavioural syndromes associated with physiological 
disturbances 
2 (0.6)  17 (2.6) 
(F60 – F69) Disorders of adult personality and behaviour 4 (1.2)  12 (1.9) 
(F70 – F79) Intellectual disabilities 0 (0)  1 (0.2)  
(F80 – F89) Disorders of psychological development 0 (0)  2 (0.3) 
(F90 – F98) Behavioural and emotional disorders with onset in 
childhood and adolescence  
0 (0) 14 (2.2) 
(F99) Unspecified mental disorder 41 (12.7)  73 (11.3) 
Other Diagnoses 
(FXX) 9 (2.8)  4 (0.6) 
No axis one disorder 0 (0) 3 (0.5) 
(Z00 – Z99) Factors influencing health status and contact in health 
services 
38 (11.8) 89 (13.8) 
(F00-F99) Mental, behavioural & neurodevelopmental disorders 2 (0.6) 2 (0.3) 
(G00-G99) Diseases of the nervous system 2 (0.6) 0 (0) 
(M00-M99) Diseases of the musculoskeletal system & connective 
tissue 
2 (0.6) 0 (0) 
(B20 – B24) Human immunodeficiency virus (HIV) 0 (0) 1 (0.2)  
(X60 – X84) Intentional self-harm 0 (0) 1 (0.2) 
(R00-R09) Symptoms, signs and abnormal clinical and lab findings 1 (0.3) 2 (0.3) 
Total 322 (100) 644 (100) 
All secondary diagnoses were recorded. Ninety-six FMD patients (29.8%) had a secondary 
diagnosis recorded in CRIS’s structured diagnostic fields and 19 patients had more than one 
secondary or additional diagnosis. 176 (27.3%) control group patients had a secondary 
diagnosis and 59 had more than one secondary diagnosis.  
Assessing the frequency of individual diagnoses, rather than individual patients, there was a 
statistically significant difference between rates of secondary diagnoses. There was a 
significantly higher proportion of psychoactive substance disorders in the control group than 
FMD group (38.3% versus 4.3%, χ2: 45, 95% CI: 25.7 – 41.2, p < 0.05), and a higher rate of 
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neurotic, stress-related and somatoform secondary diagnoses amongst FMD patients 
compared to control group patients (47% versus 18.3%, χ2: 31.6, 95% CI: 17.8 – 39.3, p < 0.05).  
There were no other significant differences in the occurrence of secondary diagnoses between 
patients. Table 19 outlines patients’ comorbid secondary diagnoses.  







group       
n (%) χ
2
 95% CI 
p 
value 
ICD-10 Diagnosis      
(F00-F09) Organic, including symptomatic mental 
disorders 
3 (2.6) 6 (2.6)  0 -5 – 3.6 > 0.05 
(F10-F19) Mental and behavioural disorders due to 
psychoactive substances 
5 (4.3) 90 (38.3) 45 25.7 – 41.2 0.001 
(F20 – F29) Schizophrenia, schizotypal & delusional 
disorders 
3 (2.6) 12 (5.1) 1.2 -2.9 – 6.7 > 0.05 
(F30 – F39) Mood (affective) disorders 33 (28.7) 51 (21.7) 2.1 -2.9 – 17.5 > 0.05 
(F40 – F48) Neurotic, stress-related and somatoform 
disorders 
54 (47) 43 (18.3) 31.6 17.8 – 39.3 0.001 
(F50 – F59) Behavioural syndromes associated with 
physiological disturbances and physical factors 
2 (1.7) 3 (1.3) 0.09 -2.4 – 4.9 > 0.05 
(F60 – F69) Disorders of adult personality and 
behaviour 
9 (7.8) 24 (10.2) 0.5 -5 – 8.6 > 0.05 
(F80 – F89) Disorders of psychological development 2 (1.7) 2 (0.9) 0.4 -1.9 -5.3 > 0.05 
(F90 – F98) Behavioural and emotional disorders with 
onset in in childhood and adolescence  
3 (2.6) 4 (1.7) 0.3 -2.4 – 5.9 > 0.05 
(F99) Unspecified mental disorder 1  (0.9) 0 (0) 2.1 -0.9 – 4.8 > 0.05 
Total 115 (100) 235 (100)    
19 functional motor patients and 59 control patients had more than one secondary diagnosis  
5.3.1.1 SLaM diagnostic teams 
The SLaM psychiatric services who first gave each ICD-10 diagnoses were assessed using 
structured field diagnostic data. This information was not available from structured fields in 
38.5% of FMD patient cases and 64.6% of control group participants, representing a significant 
difference in the rate of unknown information (χ2: 28.9, 95% CI: 16.4 – 35.3, p < 0.05). It is 
possible that this information was unknown in cases that dated back to the inception of CRIS.  
For FMD patients, the most common team giving the initial diagnosis were neuropsychiatry 
services in psychiatric and general hospital outpatients (39.9%), followed by neuropsychiatry 
liaison services in general hospital inpatient settings (17.7%) and liaison psychiatry services in 
inpatient settings (12.6%).  
For control patients, the most frequent teams to give the first diagnosis were liaison psychiatry 
services in inpatient settings (20.2%), A&E (14.9%), drug and alcohol intervention services 





teams (11%). The services from which patients received their first diagnosis are outlined in 
Table 92 (See “Appendix 5.3: List of teams giving first SLaM diagnoses”).  
5.3.2 Socio-demographics 
5.3.2.1 Gender, ethnicity and marital status 
There were 238 females (73.9%) and 84 males (26%) in the FMD group. FMD patients were 
more likely to be female than control group patients (OR: 2.52, 95% CI: 1.9 – 3.4, p = 0.001).  
British participants constituted 64.6% of the FMD group, compared to 53.3% of the control 
group (OR: 1.6, 95% CI: 1.2-2.1, p = 0.001). There were more Irish participants (OR: 0.15, 95% 
CI: 0.04 – 0.7, p = 0.01) and more African, Caribbean and Black participants (OR: O.5, 95% CI: 
0.3 – 0.7, p = 0.001) in the control than FMD group.  
In 6.2% of cases in the FMD and 4.5% of the control group, ethnicity was not recorded.  
The marital status of patients was compared. These data were the latest available from 
unstructured text within CRIS. Any changes in marital status were therefore not captured. In 
both the FMD and control groups, the marital status of 2.8% of the participants was unknown.  
FMD patients were more likely to be married or in a civil partnership (41.5%) than control 
group patients (15.2%) (OR: 4, 95% CI: 2.9 – 5.4, p = 0.001). When stratified by gender, both 
male and female FMD patients were more likely to be married than control group 
counterparts. 38.8% of female FMD patients were married compared to 16.7% of female 
control patients (OR: 3.2, 95% CI: 2.14 – 4.7, p = 0.001). 49.4% of male FMD patients were 
married compared to 13.5% of male control group patients (OR: 6.2, 95% CI: 3.6 – 10.8, p = 
0.001).  
Amongst non-married participants, the most common status amongst FMD patients was 
singledom (68.3% of unmarried functional participants), followed by divorcees (18.6%) and 
cohabiting participants (6%).  Table 20 outlines the gender, ethnicity and marital status of FMD 









 Table 20 Age, ethnicity and marital status for functional motor and control groups 







   
 
 
OR 95% CI 
p 
value 
Gender Female 238 (73.9) 341 (53) 2.52 1.9 – 3.4 0.001 
 Male 84 (26.1) 303 (47)    
Ethnicity British
1
 195 (64.6) 328 (53.3) 1.6 1.2 – 2.1 0.001 
 Irish
2
 2 (0.7) 22 (3.6) 0.15 0.04 – 0.7 0.01 
 Any other white background
2
 16 (5.3) 46 (7.5) 0.6 0.3 – 1.06 > 0.05 
 Any other mixed background
2
 0 (0) 3 (0.9) 0.2 0.01 – 4.7 > 0.05 
 African, Caribbean & Black
2
 43 (14.2) 152 (24.7) 0.5 0.3 – 0.7 0.001 
  African 16 (37.2) 63 (41.4)    
  Caribbean 13 (30.2) 38 (25)    
  Any other black background 14 (32.6) 51 (33.6)    
 Asian
2
 14 (4.6) 24 (3.9) 0.98 0.5 – 1.9 > 0.05 
  Indian 3 (21.4) 2 (8.3)    
  Pakistani 3 (21.4) 5 (20.8)    
  Bangladeshi 1 (7.1) 4 (16.7)    
  Chinese 1 (7.1) 2 (8.3)    
  Any other Asian background 6 (42.9) 11 (45.8)    
 Any other ethnic group
2
 32 (10.6) 40 (6.5) 1.3 0.8 – 2.2 > 0.05 
 Total 302 (100) 615 (100)    
 Not known 20 (6.2) 29 (4.5)    
Marital 
status 
Married or civil partner
3
 130 (41.5) 95 (15.2) 4 2.9 – 5.4 0.001 
Not married 183 (58.5) 531 (84.8)    
 Total  313 (100) 626 (100)    
 Married females
4
 90 (38.8) 55 (16.7) 3.2 2.14 – 4.7 0.001 
 Married males
5
 40 (49.4) 40 (13.5) 6.2 3.6 -10.8 0.001 
  Single 125 (68.3)  399 (75.1)    
  Divorced or civil partnership 
dissolved 
34 (18.6) 54 (10.2) 
   
  Cohabiting 11 (6) 16 (3)    
  Widowed or surviving civil 
partner 
9 (4.9) 27 (5) 
   
  Separated 4 (2.2) 35 (6.6)    
 Not known 9 (2.8) 18 (2.8)    
1 
Reference group: all other ethnicities 
2
 Reference group: British 
3
 Reference group: Not married 
4
 Reference group: Unmarried females 
5 
Reference group: Unmarried males 
5.3.2.2 Age and mortality 
Date of birth was collected from structured fields. For anonymity purposes, CRIS gives the 
month and year of birth but not the day of birth. Age at the time of analysis was calculated. In 
instances where a patient died, their age at death was used instead. When available, age at 
symptom onset was collected from unstructured text. 
Mean age at analysis for FMD patients was 46.1 years (SD = 13.4) while for control patients it 
was 47.6 years (SD = 16.2). There was no statistically significant difference in age at analysis 





Table 21 Age at analysis, age at psychological symptom onset and mortality rates for functional 
motor and control groups  




group OR 95% CI 
p 
value 
Age Mean age at analysis
1 
(SD) 46.1 (13.4) 47.6 (16.2)  -3.4 – 4.2 > 0.05 
 Mean age of symptom onset
1 
(SD) 33.2 (14.6) 32.5 (17.8)  -1.4 – 2.9 > 0.05 
 Female age of symptom onset
1
 mean (SD) 32.2 (14.6) 32.7 (18)  -3.3 – 2.3 > 0.05 
 Male age of symptom onset
1
 mean (SD) 35.9 (14.2) 32.2 (17.7)  -0.4 – 7.8 > 0.05 
Mortality Observed deaths
2
 n (%) 8 (2.5) 54 (8.4) 0.28 0.13 – 0.59 0.001 
 Standardised mortality ratio
3
 3.10 3.83    
 Female
4
 n (%) 5 (2.1)  25 (7.3)  0.27 0.1 – 0.7 0.009 
 Male
5
 n (%) 3 (3.6)  29 (9.6)  0.35 0.1 – 1.2 > 0.05 
 Married/civil partner
6
 n (%) 2 (1.4) 11 (9.9) 0.13 0.03 – 0.6 0.01 
 Single, divorced, widowed, separated
7 
n (%) 6 (3.5) 43 (8.3) 0.39 0.17 – 0.95 0.04 
 Physical health condition
8
 n (%) 7 (3.2) 45 (13.8) 0.2 0.09 – 0.5 0.0001 
 No physical health condition
9
 n (%) 0 (0) 3 (1.4) 0.41 0.02 – 8.1 > 0.05 
 Smoker
10
 n (%) 3 (4.3) 17 (8.3) 0.5 0.14 – 1.8 > 0.05 
 Non-smoker
11 
n (%) 2 (1.8) 13 (10.4) 0.16 0.03 – 0.7 0.02 
Age v 
mortality 
Mean age at death
1 
(SD) 58.7 (13.7) 65.7 (19)  -20.9 – 7.1 > 0.05 
 Female
1
 mean age (SD) 53.8 (15.6) 70.3 (20.4)  -36 - 3 > 0.05 
  Male
1 
mean age (SD) 67 (2) 61.7 (17)  -1.6 - 12 > 0.05 
1 
Independent samples t-test comparing mean age 
2 
Reference: Surviving participants 
3 
Standardised for gender and age using data from ONS 2015 for England and Wales 
4 
Reference: Surviving females 
5 
Reference: Surviving males 
6 
Reference: Surviving married/civil partnership patients 
7 
Reference: Surviving single/divorced/widowed/separated patients 
8 
Reference: Surviving patients with physical health condition 
9 
Reference: Surviving patients with no physical health conditions 
10 
Reference: Surviving smokers 
11 
Reference: Surviving non-smokers 
The mean age at which FMD patients first began experiencing psychiatric symptoms was 33.2 
years (SD: 14.6, range: 2 - 75) and for control patients it was slightly younger at 32.5 years (SD: 
17.8, range 5 - 96). This information was taken from unstructured fields in CRIS. The difference 
between these age groups was not statistically significantly different. There were no statistical 
differences in symptom onset when stratified by gender. Table 21 outlines the age of symptom 
onset for both patient groups.  
The proportion of participants who died in both groups was observed. This information was 
taken from the structured field in CRIS. In total, eight FMD (2.5%) and 54 control patients 
(8.4%) had died when data were collected. Using odds ratios to compare the mortality rates 
between groups, morality was higher in the control than FMD group (OR: 0.28, 95% CI: 0.13 – 
0.59, p = 0.001).   
Using indirect standardisation, a standard mortality ratio (SMR) was calculated for the FMD 
and control groups. The data were standardised by age and gender using Office for National 





3.10, three times higher than the mortality rate seen in the general public in England and 
Wales but control patients SMR was higher again, at 3.83.  
Mortality rates were explored further through the stratification of socio-demographic factors. 
When stratified by gender, females in the control group had a higher odds of mortality than 
females in the FMD group (OR: 0.27, 95% CI: 0.1 – 0.7, p = 0.009) but there was no significant 
difference in mortality risk between males in either group (OR: 0.35, 95% CI: 0.1 – 1.2, p > 
0.05). Control group participants had a higher mortality rate compared to their counterparts in 
the FMD group regardless of marital status. If a comorbid physical health condition was 
present, control group participants had a higher risk of mortality compared to FMD patients 
(OR: 0.2, 95% CI: 0.09 – 0.5, p = 0.001), but no differences emerged between patients with no 
physical health condition. For smokers, there was no difference in the mortality rates between 
groups, but for non-smokers, control group patients had a higher risk of mortality compared to 
the FMD group (OR: 0.16, 95% CI: 0.03 – 0.7, p = 0.02).  
The mean age at death in the FMD group was 58.7 years of age (SD: 13.7) and 65.7 years of 
age (SD: 19) in the control group but there was no statistically significant difference in age 
between groups. There were no statistical differences in mean age at death when stratified by 
gender. Table 21 outlines these morality rates.  
Information was not routinely available on the cause of death.  
5.3.2.3 Housing 
The most recent type of accommodation resided in by patients was recorded when available 
from unstructured fields in CRIS. This information was unavailable in 25.2% of functional 
disorder cases and 14.3% of control group cases.  
The most frequent type of housing in which FMD patients resided was privately owned 
accommodation, and FMD patients were significantly more likely to reside in a privately owned 
home than control group participants (OR: 2.8, 95% CI: 1.8 – 4.4, p = 0.001). Conversely, 
control group participants were more likely to be council tenants than FMD patients (OR: 0.6, 
95% CI: 0.4 – 0.9, p = 0.01). There were no other observed differences in the type of dwelling 
resided in by either group.  
There were no differences between groups in rates of patients living with families or friends or 
those privately renting or in sheltered or supported accommodation. Table 22 outlines the 





Table 22 Table showing housing type for functional motor and control group participants 
 
5.3.2.4 Employment and benefits 
The most recently available data on employment from structured fields was assessed. 
Structured employment fields in CRIS were often not up-to-date. This information was cross-
checked with information from unstructured fields and where there was no agreement 
between structured and unstructured fields, the most recently available information was used.  
Overall, the rate of unemployment was 60% in both groups but FMD patients were more likely 
to be in employment than patients in the control group (24.5% versus 17.4%, OR: 1.5, 95% CI: 
1.1 – 2.2, p = 0.02). Control patients were more likely to be retired (OR: 0.3, 95% CI: 0.2 – 0.7, p 
= 0.001) while FMD patients were more likely to be medically retired (OR: 5.2, 95% CI: 1.4 – 
19.4, p = 0.02).  
Employment was stratified by gender, but no differences between groups emerged.  
Information was collected on whether patients had been employed before their symptoms 
began (classified as pre-morbid employment). FMD patients were more likely to have been 
employed prior to the onset of their symptoms than control patients (OR: 2.34, 95% CI: 1.4 – 
19.4, p = 0.001). Rates of pre-morbid employment were examined in currently unemployed 
patients. Currently unemployed FMD patients were more likely to have been employed pre-
morbidly (82.9%) than currently unemployed control group patients (69.3%) (OR: 2.14, 95% CI: 
1.4 – 3.3, p = 0.001).  
Control group patients were more likely to receive welfare benefits (55.7%) than FMD patients 
(47.8%) (OR: 0.73, 95% CI: 0.55 – 0.96, p = 0.03). No differences emerged when stratified by 






n (%) OR 95% CI p value 
Housing type      
 Council tenant
1
 47 (19.5) 153 (27.7) 0.6 0.4 – 0.9 0.01 
 Homeless orhostel
2
 7 (2.9) 46 (8.3) 0.5 0.2 – 1.2 > 0.05 
 Living with family
2
 39 (16.2) 85 (15.4) 1.5 0.9 – 2.5 > 0.05 
 Living with friend
2
 4 (1.7) 7 (1.3) 1.9 0.5 – 6.6 > 0.05 
 Privately owned
2
 83 (34.4) 95 (17.2) 2.8 1.8 – 4.4 0.001 
 Privately rented
2
 53 (22) 117 (21.2) 1.5 0.9 – 2.3 > 0.05 
 Sheltered accommodation
2
 3 (1.2) 9 (1.6) 1.1 0.3 – 4.2 > 0.05 
 Supported accommodation
2
 5 (2.1) 40 (7.2) 0.4 0.2 – 1.1 > 0.05 
Total 241 (100) 552 (100)    
Not known 81 (25.2)  92 (14.3)    
1
 Council tenant versus all other groups 
2 





gender although FMD males had a higher rate of unemployment compared to FMD females. 
Table 23 outlines the employment and benefit status of FMD and control group patients. 
Table 23 Table showing employment and benefits status of functional motor control group 
patients 
Of patients receiving benefits, the type of benefit received by the patient was assessed 
whenever that information was available in either structured or unstructured CRIS text (see 
Table 24). FMD patients were more likely to receive Disability Living Allowance (DLA) (χ2 = 
17.7, df = 1, p = 0.001). DLA is a tax-free benefit for disabled people who need help with 
mobility or care costs. FMD patients were less likely to be in receipt of Income Support 
Allowance (χ2 = 4.9, df = 1, p = 0.03), a benefit commonly given to individuals who are 
pregnant, carers or lone parents with children under five or who are unable to work because 







Control                             
group 





 73 (24.5) 104 (17.4) 1.5 1.1 – 2.2 0.02 
 Unemployed 179 (60.1) 389 (60.4) 1   
 Retired
2
 15 (5) 62 (10.4) 0.3 0.2 – 0.7 0.001 
 Sick leave
2
 9 (3) 10 (1.7) 1.3 0.5 – 3.3 > 0.05 
 Student
2
 11 (3.7) 23 (3.9) 0.7 0.3 – 1.5 > 0.05 
 Voluntary work
2
 0 (0) 5 (0.8) 0.1 0.01 – 2.4 > 0.05 
 Medically retired
2
 11 (3.7) 3 (0.5) 5.2 1.4 – 19.4 0.02 
 Total 298 (100) 596 (100)    





 58 (30) 61 (23.5) 1.4 0.9 – 2.2 > 0.05 
Employed male
4






 246 (87.5) 385 (75) 2.34 1.6 – 3.5 0.001 




170 (82.9) 284 (69.3) 2.14 1.4 – 3.3 0.001 
Total 281 (100) 513 (100)    
 Not known 41 (12.7) 131 (20.3)    
Benefits Receives benefits
7
 143 (47.8) 337 (55.7) 0.73 0.55 – 0.96 0.03 
 Receives benefits-female
8
 98 (44.5) 160 (50.3) 0.79 0.56 – 1.12 > 0.05 
 Receives benefits-male
9
 45 (57)  177 (61.7) 0.82 0.5 – 1.4 > 0.05 
 Total  299 (100) 606 (100)    
  Not known 23 (7.1) 39 (6.1)    
1




 Reference: unemployed females 
4
 Reference: unemployed males
 
5
 Reference: not employed pre-morbidly
 
6 
Reference: unemployed now and unemployed pre-morbidly 
7
 Reference: not receiving benefits 
8
 Reference: females not receiving benefits 
9 

















The most recent information available on job type was assessed and categorised based on the 
industry in which the patient worked. Information on job type was collected for patients on 
their current role and, for patients now unemployed, information on their most recently held 
job was collected.  
The type of industry in which patients worked or had worked was known in 74% of FMD cases 
and 55.7% in control group patients. See Table 25 for a breakdown of employment across 
industries.  
The most common industry in which FMD patients were employed was administration, 
banking and project management. There were no differences in employment industries except 
for those employed or previously employed in the health industry and in social care. FMD 
patients were more likely to work in health industries (5.9% versus 2%, OR: 2.6, 95% CI: 1.2 - 













n (%) χ2 95% CIs p value 
Disability Living Allowance 75 (43.6) 71 (24.7) 17.7 9.6 – 28.1 0.001 
Employment Support Allowance
1
 44 (26.7) 84 (29.3) 0.4 -6.3 – 11.2 > 0.05 
Housing Benefit 20 (11.6) 48 (16.7) 2.2 -1.9 – 11.6 > 0.05 
Income Support Allowance 15 (8.7) 46 (16) 4.9 0.7 – 13.4 0.03 
Child Benefit 6 (3.5) 11 (3.8) 0.03 -4.1 – 3.9 > 0.05 
Carer’s Allowance 6 (3.5) 2 (0.7) - - - 
Job Seeker’s Allowance 5 (2.9) 16 (5.6) 1.8 -1.7 – 6.6 > 0.05 
Freedom Pass* 1 (0) 7 (2.4) - - - 
Personal Independence Payment* 0 (0) 2 (0.7) - - - 
Total 172 (100) 287 (100)    
 1
 Formerly Incapacity Benefit 














   
 n (%) n (%) OR 95% CI p value 
Art, music & sport
1 
 10 (3.1) 19 (3) 0.9 0.4 – 2.2 > 0.05 
Child care
1
 8 (2.5) 7 (1.1) 2 0.7 – 6 > 0.05 
Civil service
1
 10 (3.1) 10 (1.6) 1.8 0.7 – 4.7 > 0.05 
Cleaning services
1
 6 (1.9) 15 (2.3) 0.7 0.3 – 2 > 0.05 
Construction
1
 18 (5.6) 33 (5.1) 1 0.5 – 2 > 0.05 
Customer services
1
 5 (1.6) 4 (0.6) 2.4 0.6 – 8.8 > 0.05 
Design
1
 3 (0.9) 5 (0.8) 1.1 0.2 – 4.7 > 0.05 
Education
1
 23 (7.1) 20 (3.1) 2 0.99 – 4.2 > 0.05 
Factory
1
 5 (1.6) 10 (1.6) 0.9 0.3 – 2.8 > 0.05 
Food, Drink & Hospitality
1
 16 (5) 36 (5.6) 0.8 0.4 – 1.6 > 0.05 
Gardening
1
 1 (0.3) 4 (0.6) 0.4 0.05 – 4.1 > 0.05 
Hair & beauty
1
 4 (1.2) 12 (1.9) 0.6 9.2 – 1.9 > 0.05 
Health
1
 19 (5.9) 13 (2) 2.6 1.2 – 5.9 0.02 
Mental health
1
 5 (1.6) 6 (0.9) 1.5 0.4 – 5.2 > 0.05 
Nursing
1 





36 (11.2) 64 (9.9) 0.8 0.5 – 1.3 > 0.05 
Police, prison & army
1
 9 (2.8) 8 (1.2) 2 0.7 – 5.6 > 0.05 
Retail
1
 24 (7.5) 47 (7.3) 0.9 0.5 – 1.7 > 0.05 
Sex work
1
 0 (0) 1 (0.2) 0.6 0.02 – 14.8 > 0.05 
Social care
1
 20 (6.2) 16 (2.5) 2.2 1.02 – 4.8 0.04 
Transport
1
 5 (1.6) 19 (3) 0.5 0.2 – 1.4 > 0.05 
Total 239 (74.2) 359 (55.7)    
Not known 38 (11.8) 156 (24.2)    
Not applicable 45 (14) 129 (20)    
Total 83 (25.8) 285 (44.3)    
1 
Reference group: Administration, banking, project management 
2 
Reference group: all other industry professions 
 
In the categorisations outlined in Table 25, types of employment in the health care sector 
included healthcare assistants, physiotherapists, occupational therapists but also non-clinical 
positions such as employment in medical records or hospital administration. In order to assess 
the difference in rates of those employed specifically in caring roles, a further analysis 
established care-giving employment. This denoted employment in positions involving 
responsibility for the health or well-being of another person.  
In total, 19% of FMD patients and 8% of control patients were employed or had been 
employed in a care-giving role in health, social care, child care and mental health sectors, 
denoting a statistically significant difference (OR: 2.63, 95% CI: 1.73 – 4, p = 0.001).  
When data was stratified by gender, the difference was only significant for females (OR: 2.04, 
95% CI: 1.3 – 3.2, p = 0.003). Male FMD patients were proportionately more likely to work as a 





Patients were grouped according to whether they were carers to a family member or friend, 
either formally or informally. FMD patients were more likely to act as carers (9.8%) than 
control group participants (2.8%) (OR: 3.77, 95% CI: 2 – 7.1, p = 0.001). After stratification by 
gender, the significant difference remained for both males and females.  
38.8% of FMD patients had a carer compared to 23.5% of control group participants. There 
was a significant difference between groups (OR: 2.06, 95% CI: 1.5 – 2.8, p = 0.001) and again, 
when data were stratified by gender both male and female FMD patients were more likely to 
have a carer than their control group counterparts.  
Table 26 outlines the differences in social and health care work between groups as well as 
those working as carers to family and friends and the rates of patients with carers.  
Table 26 Proportion of functional motor and control group patients working in social or health 








n (%) OR 95% CIs p value 
Social or health care worker  54 (19) 46 (8.2) 2.63 1.73 – 4 0.001 
Not known 38 (11.8) 83 (12.9)    
 Female social or health worker
1
  48 (22.7) 37 (12.6) 2.04 1.3 – 3.2 0.003 
 Male social or health worker
2
  6 (8.2) 9 (3.4)  2.6 0.9 – 7.5 > 0.05 
Carer to family or friends 28 (9.8) 16 (2.8) 3.77 2 – 7.1 0.001 
Not known 37 (11.5) 75 (11.6)    
 Female carer
3
  22 (10.4) 10 (3.3) 3.4 1.5 – 7 0.002 
 Male carer
4
 6 (8.1) 6 (2.2) 3.9 1.2 – 12.4 0.02 
Patients with carers 107 (38.8) 128 (23.5) 2.06 1.5 – 2.8 0.001 
Not known 46 (14.3) 100 (15.5)    
 Females with a carer
5
  84 (41) 74 (26.2) 1.95 1.3 – 2.9 0.001 
 Males with a carer
6 
 23 (32.4) 54 (20.6) 1.85 1.0 – 3.3 0.04 
1
Reference: Females who are not social/health workers 
2
Reference: Males who are not social/health workers 
3
Reference: Females who are not carers 
4
Reference: Males who are not carers 
5
Reference: Females without carers 
6
Reference: Males without carers 
This study utilised the International Standard Classification of Occupations (ISCO-08), a system 
of employment categorisation developed by the International Labour Organisation. The 
criteria used are based on the skill level and specialisation required to perform tasks and duties 
of positions (International Labour Organisation, 2011). The system defines ten occupational 
groups, with each group assigned a skill level required to complete the job.  
FMD patients were more likely to be technicians or associate professionals (χ2 = 7.8, df = 1, p = 





work in elementary professions (χ2 = 7.8, df = 1, p = 0.005). See Table 93 (“Appendix 5.4: 
Employment rates categorised according to ISCO-08 criteria”).  
5.3.3 Health  
5.3.3.1 Functional motor symptomatology  
The type of motor symptom affecting FMD patients was collected. This information was 
collected from unstructured fields within CRIS. Based on the information collected, nine 
symptom categorises were created including, ‘weakness’, ‘tremor, spasms, jerks, and tics’, 
‘non-back pain’, ‘numbness, paraesthesia, sensory loss’, ‘gait disturbance and falls’, ‘paralysis’, 
‘back pain’, ‘urinary/faecal incontinence’ and ‘other sensory or motor issues’. The final ‘other’ 
group was a catch-all category which included issues which could not be easily defined by the 
other issues. Examples of ‘other’ symptoms included buzzing in the ear, restlessness, 
‘muzziness’ in the head, dizziness, fainting, aphonia, speech difficulties, anosmia, and visual 
disturbance.  
In nine cases, there was no information available on patients’ symptoms, despite them having 
an F44.4 diagnosis. Of the remaining 313 patients, the mean number of functional symptoms 
was 2.42 (SD: 1.1, range 1 – 6).  
The most commonly reported symptom was ‘weakness’, accounting for 50.3% of all reported 
symptoms, followed by ‘other sensory or motor issues’ (37.9%) and ‘tremor, spasms, jerks and 
tics’ (33.9%). See Figure 31 for a breakdown of the frequency of symptoms.  
 



















When assessed according to socio-demographic variables, non-back pain was associated with 
the highest proportion of females (79.6%). The eldest participants were those experiencing 
gait problems or falls (M: 50.7 years, SD: 13).  
Whether the patients had a comorbid physical health condition was assessed. The lowest rate 
of comorbid health conditions were amongst those with back pain (58.1%), while the highest 
rate was amongst patients with gait problems or falls.   
Psychiatric admission rates were highest in those with paralysis and urinary or faecal 
problems. Mobility aid use was highest in those with urinary/faecal incontinence, followed by 
back pain.  
When those who were bed-bound were assessed, the highest proportion was in those who 
were paralysed. Child abuse rates were highest in those with urinary or faecal problems, 
followed by paralysis.  
See Table 27 for a breakdown of socio-demographic variables associated with different 
functional symptoms.  

























Weakness 162 (50.3) 122 (75.3) 44.6 (13) 116 (75.8) 55 (34) 100 (69) 11 (7.5) 25 (19.1) 
‘Other’  122 (37.9) 92 (75.4) 48.6 (14) 86 (74) 31 (25.4) 53 (50.5) 6 (5.7) 17 (17.5) 
Tremor 109 (33.9) 82 (75.2) 45.3 (14) 74 (72.5) 41 (37.6) 48 (50.5) 6 (6.3) 21 (23.6) 
Non-back pain 103 (32) 82 (79.6) 46.9 (12) 75 (75) 37 (35.9) 64 (66.7) 7 (7.3) 18 (21.7) 
Numbness 81 (25.2) 60 (74.1) 43.5 (12) 53 (67.9) 24 (29.6) 47 (62.7) 2 (2.7) 14 (21.2) 
Gait problems 66 (20.5) 51 (77.3) 50.7 (13) 49 (80.3) 27 (40.9) 38 (65.5) 3 (5.3) 10 (19.2) 
Paralysis 46 (14.3) 34 (73.9) 40.8 (12) 33 (75) 30 (65.2) 30 (71.4) 5 (11.6) 10 (25) 
Back pain 44 (13.7) 30 (68.2) 46.9 (13) 25 (58.1) 19 (43.2) 30 (75) 3 (7.5) 5 (13.9) 
Urinary/faecal  24 (7.5) 20 (83.3) 44.4 (10) 18 (75) 15 (62.5) 20 (87) 1 (4.3) 6 (30) 
 
If there was any mention in the unstructured notes of fatigue, anxiety, low mood or depression 
this was noted and a comparison was made between the FMD and control groups. It is 
important to note that this was a qualitative, post-hoc analysis.  
Fatigue was more common in the FMD group (OR: 4.5, 95% CI: 2.7 – 12.8, p = 0.001) and this 
significant difference applied to males and females. There was no difference in the mean age 
of patients suffering from fatigue between the two groups.  
There was no difference in the rate of reported anxiety between the two groups and no 





Depression was higher in the control group than the FMD group (OR: 3, 95% CI: 2.7 – 12.8, p = 
0.001) and higher amongst female control group members. There was no difference when only 
males were examined. There were also no differences in the mean age of FMD and control 
group patients experiencing depression. See Table 28 for a breakdown of fatigue, anxiety and 
low mood in the FMD and control groups.  
Table 28 The rate of mentions of fatigue, anxiety and low mood as a comorbid symptom in the 














 25 (7.8) 9 (1.4) 4.5 2.7 – 12.8 0.001 
Female
2
 18 (7.7) 7 (2.1) 3.9 1.6 – 9.7 0.002 
Male
3
 7 (8.8) 2 (0.7) 14.4 2.9 – 71 0.001 
Mean age
4
 45.8 (11) 43.9 (15)  -7.5 -11.3 >0.05 
Anxiety
1
 56 (17.4) 98 (15.2) 1.2 0.8 – 1.7 > 0.05 
Female
2
 40 (17.2) 57 (16.7) 1.03 0.6 – 1.6 > 0.05 
Male
3
 16 (20) 41 (13.5) 1.5 0.8 -2.8 > 0.05 
Mean age
4
 43.7 (14) 45.5 (16)  - 6.7 -3 > 0.05 
Depression
1 5
 112 (34.8) 288 (44.7) 3.3 0.5 – 0.9 0.003 
Female
2
 81 (34.7) 158 (46.3) 0.6 0.4 – 0.9 0.006 
Male
3
  16 (19) 41 (13.5) 1.5 0.8 – 2.8 > 0.05 
Mean age
4
 46.8 (13.5) 48.6 (17)  -5 –1.4 > 0.05 
1 
Reference: patients with no mention of symptom in notes 
2 
Reference: females with no mention of symptom in notes 
3 




Includes low mood, suicide ideation and suicide attempts 
 
The rate of depression, anxiety and fatigue and their co-occurrence with functional symptoms 
was assessed (see Table 29 for all frequency rates). Depression was most likely to co-occur in 
back pain (43.2% of those with back pain also reported depression), while the lowest rate of 
depression occurred within gait problems and falls (31.8%).  
Regarding anxiety, there were lower rates generally than depression, with 17.4% of FMD 
patients with any mention of anxiety in their notes. For those with back pain, anxiety was the 
lowest rate (11.4% of those with back pain had a mention of anxiety), while the highest rate of 
anxiety was in patients with weakness and numbness (19.8% in both).  
Fatigue had the lowest frequency amongst paralysis patients when it was only mentioned in 
one case while it was most commonly reported in patients with urinary or faecal problems 

















Urinary or faecal problems 8 (33.3) 3 (12.5) 3 (12.5) 
Weakness 64 (39.5) 32 (19.8) 13 (8) 
Numbness 29 (35.8) 16 (19.8) 5 (6.2) 
Other sensory or motor issues 42 (34.4) 22 (18) 9 (7.4) 
Tremor, spasms, jerks and tics 39 (35.8) 20 (18.3) 8 (7.3)  
Back pain 19 (43.2) 5 (11.4) 2 (4.5) 
Non-back pain 33 (32) 16 (15.3) 11 (10.7) 
Paralysis 16 (34.8) 6 (13) 1 (2.2) 
Gait problems, falls 21 (31.8) 13 (19.7) 6 (9.1) 
5.3.3.2 Mobility  
The lifetime prevalence of any kind of mobility aid use was assessed for only FMD patients 
from the unstructured fields in CRIS.  
Over half the sample had in the past, or continued to use, a mobility aid (163 patients, 58.2%). 
Of these patients, 108 (66.3%) used a wheelchair while the remainder used a Zimmer frame or 
walking stick (33.7%). Of all FMD patients, 19 patients (6.7%) were or had been completely 
bedbound. Of the FMD patients who had received a psychiatric inpatient admission, 76.3% 
used a walking aid, while 23% did not. 
See Table 30 for an overview of the mobility aids and bedbound rates of FMD patients.  






Mobility aid 163 (58.2) 
 Wheelchair user 108 (66.3) 
 Zimmer frame or walking stick 55 (33.7) 
No mobility aid 117 (41.8) 
 Not known 42 (35) 
Total 322 (100) 
Bedbound 19 (6.7) 
Not bedbound 263 (93.3) 
 Not known 40 (12.4) 
Total 322 (100) 
5.3.3.3 Smoking rates and BMI scores 
The last recent information available on smoking status was collected from unstructured CRIS 
records. In practise, this meant that if a patient smoked for a number of years but gave up 
before the end of their CRIS record they were recorded as a ‘non-smoker’. Smoking status was 





From the available data, 38.5% of FMD patients were active smokers, less than the 62.2% of 
smokers amongst control group patients (OR: 0.38, 95% CI: 0.26 – 0.55, p = 0.001). This is 
higher than the rate within the English public which is 19% (Health and Social Care Information 
Centre, 2015). Both female and male control group patients were significantly more likely to 
smoke than their FMD counterparts. There was no difference in the age of smokers, smoking 
rates between employed patients or those with no comorbid physical condition. However, 
unemployed control group patients and those patients with a physical health condition were 
more likely to smoke than their FMD counterparts. See Table 31 for a breakdown of smoking 
rates between groups by socio-demographic variables.  














OR 95% CIs p value 
Smoking       
 Yes 70 (38.5) 206 (62.2) 0.38 0.26-0.55 0.001 19%* 
 No 112 (62.5) 125 (37.8)    81%* 
Not known 140 (43.5) 331 (51.4)     
Female smokers
1
  46 (34.6) 91 (53.8) 0.45 0.3 – 0.7 0.001 17%* 
Male smokers
2 
 24 (34.8) 115 (55.8) 0.4 0.2 – 0.8 0.005 24%* 
Mean age smokers
3
 (SD) 45.2 (12.3) 45.9 (14)  -4.5 - 3 > 0.05  
Employed 
4
  12 (32.4) 14 (32.6) 0.9 0.4 - 2.5 > 0.05 19%* 
Unemployed 
5
 46 (41.1) 165 (73.3) 0.25 0.2 – 0.4 0.001 35%* 
Physical health condition present  49 (35.3) 116 (60.7) 0.35 0.2 – 0.6 0.001  
No physical health condition  19 (50) 69 (62.7) 0.6 0.3 – 2.3 > 0.05  
BMI normal range (18.5 – 24.9)      
 Mean 
3
 (SD) 28.2 (8.8) 26.8 (6.7)  -1.1 – 3.9 > 0.05 25.6** 
Not known 260 (64) 486 (75.5)     
Female mean
3
 (SD) 27.7 (9) 27.7 (8)  -3 - 3 > 0.05 26.9 
Male mean
3
 (SD) 30.3 (6) 25.8 (5)  1.2 – 7.9 0.008 27.4 
Age (Pearson’s r) 0.19 0.022   > 0.05  
Employed mean
3
 (SD) 19.3 (2.9) 25.2 (8)  -12.3 – 0.5 > 0.05  
Unemployed mean
3 
(SD) 29.6 (9) 27.6 (7)  - 1 – 5.1 > 0.05  
Physical health condition mean (SD) 29.8 (9) 27.1 (7)  -0.08 – 5.4 > 0.05  
No health condition mean (SD) 21.4 (6) 26.5 (6)  -9 – (-1.2) 0.01  
1
 Female smokers versus female non-smokers
 
2
 Male smokers versus male non-smokers
 
3 
Independent samples t-test (unequal variance assumed) 
4 
Employed smokers versus employed non-smokers 
5 
Unemployed smokers versus unemployed non-smokers; excludes ‘retired’, ‘medically retired’, 
‘sick leave, ‘student’, & ‘voluntary work’ groups
 
* Health and Social Care Information Centre (2015) 
** Health Survey for England data from 2011 (Sperrin et al., 2016) 
The most up-to-date information was taken on BMI scores. This information was taken from 





There was no significant difference in mean BMI scores between FMD and control patients 
although both groups’ mean BMI scores were above the normal limit (t = 1.5, df = 90.8, two-
tailed p = 0.135). BMI scores were available for 62 FMD and 158 control group patients. 
There was no significant difference in BMI scores between females however male FMD 
patients had significantly higher BMI scores compared to male control patients (t = 2.7, df = 86, 
two-tailed p = 0.01). There was no correlation between age and BMI scores for the FMD group 
(r = 0.2, n = 62, p > 0.05), or for the control group (r =0.02, n = 158, p > 0.05). There was no 
difference in BMI scores between employed groups, unemployed groups, or between patients 
with a physical health condition. Amongst patients with no physical health condition, control 
group patients had significantly higher BMI (t = -2.6, df = 63, two-tailed p = 0.01). See Table 31 
for a breakdown of BMI scores between groups and their associated socio-demographic 
variables.  
5.3.3.4 Comorbid physical conditions 
Information from unstructured CRIS notes was taken on whether patients had a comorbid 
physical health condition. Physical health conditions were classified as any physical health 
problem the patient suffered from in their recent medical history.  
In total, 74.5% of FMD patients had a current or recent physical health problem compared to 
59.6% of control group patients (OR: 1.9, 95% CI: 1.4 – 2.7, p = 0.001).  
Information was stratified by socio-demographic variables. Female FMD patients were more 
likely to have a physical health condition than female control patients (OR: 2.2, 95% CI: 1.5 – 
3.3, p = 0.001), but there was no difference between male groups. The mean age of FMD 
patients with a physical health condition was 47.4 years (SD: 14), significantly younger than the 
mean age of control group patients with a physical health condition (mean: 53.2 years, SD: 17, 
df = 527, p = 0.001).  
Both employed and unemployed FMD patients were more likely to have a comorbid physical 
health condition compared to controls, as well as patients who had had a psychiatric stay and 
those who did not. Non-smoker FMD patients had a higher rate of physical health conditions 
than non-smoking control group patients but there was no difference in the rate of physical 
health conditions between smokers.  
The number of physical health conditions was counted for each patient. The mean number of 
physical health conditions for FMD patients was 2.27 (SD: 1.6) and this did not differ 
significantly from the control patients. When the mean number of physical symptoms was 





conditions was significantly positively correlated with age for both FMD (r = 0.34, p < 0.05) and 
control group (r = 0.38, p < 0.05). See Table 32 for a breakdown of the rate of physical health 
conditions and the associated socio-demographic factors.  
Table 32 Comorbid physical disease rates and mean number of comorbid physical conditions 







n (%) OR 95% CI p value 
Comorbid physical condition 219 (74.5) 326 (59.6) 1.9 1.4 – 2.7 0.001 
Not known 28 (8.7) 97 (15.1)    
 Females with physical condition
2
  168 (77.1) 173 (60.1) 2.2 1.5 – 3.3 0.001 
 Males with physical condition
3
  51 (67.1) 153 (59.1) 1.4 0.8 – 2.4 > 0.05 
 Physical illness mean age (SD) 47.4 (14) 53.2 (17)  -8.5 – (-3.3) 0.001 
 Employed  45 (70.3) 38 (40.9) 3.4 1.7 – 6.7 0.001 
 Unemployed  131 (76.6) 205 (59.8) 2.5 1.4 – 4.2 0.001 
 Psychiatric inpatient stay  84 (79.2) 155 (60.8) 0.7 0.48 – 0.97 0.03 
 No psychiatric inpatient stay  135 (71.8) 171 (58.6) 1.8 1.2 – 2.7 0.003 
 Smoker  49 (72.1) 116 (62.7) 1.5 0.8 – 2.8 > 0.05 
 Non-smoker  90 (82.6) 75 (64.7) 2.6 1.4 – 4.8 0.003 




2.27 (1.6) 2.12 (1.5)  - 0.12 – 0.4 > 0.05 
 Female
4
 mean (SD) 2.3 (1.5) 2.2 (1.5)  - 0.19 – 0.46 > 0.05 
 Male
4
 mean (SD) 2.08 (1.7) 2.04 (1.6)  - 0.5 – 0.6 > 0.05 
1
 Comorbid physical illness versus no comorbid physical illness 
2
 Females with comorbid physical illness versus females without comorbid physical illness 
3
 Males with comorbid physical illness versus males without comorbid physical illness 
4
 Independent t-test 
 
Types of physical health conditions were categorised and coded according to the ICD-10 
classification system. The most common type of physical health condition experienced by FMD 
patients was ‘diseases of the nervous system’ (22.2% of all physical conditions) followed by 
‘endocrine, nutritional and metabolic diseases’ (15.3%) and diseases of the circulatory system 
(12.4%). 
Statistically significant differences in rates occurred in three of the fifteen disease categories. 
Control group participants (6.8% of patients with a physical health condition) were more likely 
to experience ‘infectious and parasitic diseases’ than FMD patients (OR: 0.3, 95% CI: 0.14 – 0.6, 
p = 0.002). FMD patients were more likely to experience ‘diseases of the nervous system’ 
compared to 7% in the control group (OR: 1.9, 95% CI: 1.2 – 3.1, p = 0.007). FMD patients were 
also more likely to experience ‘congenital malformations, deformations and chromosomal 
abnormalities’ compared to control group patients (OR: 16.8, 95% CI: 2.1 – 132.5, p = 0.007). 
Table 33 outlines the breakdown of ICD-10 codes across both groups.  
Table 94 and Table 95 give a breakdown of socio-demographic differences between patients 





also a significant difference in rates between these groups (see “Appendix 5.5: Rate of diseases 
in functional motor and control groups”).  









 n (%) OR 95% CI p value 




10 (2.1) 46 (6.8) 0.3 0.14 – 0.6 0.002 
(C00-D49) Neoplasms
1
 15 (3.1) 32 (4.7) 0.7 0.3 – 1.3 > 0.05 
(D50-D89) Diseases of the blood and blood-




15 (3.1)  16 (2.4) 1.3 0.6 – 2.8 > 0.05 




74 (15.3) 104 (15.3)  1.1 0.8 – 1.5 > 0.05 
(G00-G99) Disease of the nervous system
1
 107 (22.2) 48 (7) 1.9 1.2 – 3.1 0.007 




9 (1.9) 12 (1.8) 1.05 0.4 – 2.6 > 0.05 
(I00-I99) Disease of the circulatory system
1
 60 (12.4) 105 (15.5) 0.8 0.5 – 1.2 > 0.05 
(J00-J99) Diseases of the respiratory system
1
 41 (8.5) 70 (10.3) 0.8 0.5 – 1.3 > 0.05 
(K00-K95) Diseases of the digestive system
1
 37 (7.6) 69 (10.2) 0.7 0.4 – 1.2 > 0.05 




19 (3.9) 31 (4.6) 0.8 0.5 – 1.6 > 0.05 
(M00-M99) Diseases of the musculoskeletal 
system and connective tissue
1
 
36 (7.5) 75 (11.1) 0.7 0.4 – 1.1 > 0.05 
(N00-N99) Disease of the genitourinary system
1
 31 (6.4) 31 (4.6) 1.4 0.8 – 2.5 > 0.05 
(Q00-Q99) Congenital malformations, 
deformations and chromosomal abnormalities
1
 
12 (2.5) 1 (0.15) 16.8 2.1 – 
132.5 
0.007 
(R00-R99) Symptoms, signs and abnormal clinical 
and lab findings, not elsewhere classified
1
 
16 (3.3) 31 (4.6) 0.7 0.4 – 1.4 > 0.05 
(S00-T88) Injury, poisoning and certain other 
consequences of external causes
1
 
1 (0.2) 7 (1)  0.2 0.02 – 1.7 > 0.05 
Total 483 (100) 678 (100)    
1 
Reference: Endocrine, nutritional and metabolic diseases 
2
 Reference: All other disorders 
 
Given the high proportion of nervous system diseases amongst FMD patients, a further 
analysis assessed the occurrence of diseases affecting the nervous system in more detail. 
Ninety-seven individual FMD participants experienced neurological disease, with a total of 107 
instances of neurological disease across patients.  
Amongst these patients, the most common type of disorder of the nervous system was 
headache, accounting for 61.7% of all 107 instances of nervous system diseases. Of patients 
with headache, 87.9% were women and the average age was 45.7 years (SD: 11). Within 
nervous system diseases no significant differences in gender rates or mean age were observed 
between functional motor and control group patients. Table 34 outlines the frequencies of 












group       
 n (%) OR 95% CI p value 
Diseases of the nervous system* 107 (22.2) 48 (7)    
 Female
1
  80 (82.5)  21 (48.8) 4.9 2.2 – 10.9 0.001 
 Mean age
2
 47.2 (13) 59.2 (19)  - 18.4 – (-4.7) 0.001 
(G20-G26, G30-G32) Extrapyramidal and 
movement disorders & other degenerative 
diseases  
1 (0.9) 7 (14.6)    
 Female
1
 1 (100) 4 (57.1)  2.3 0.07 – 76 > 0.05 
 Mean age
2
               - 3 (42.9)    
(G35-G37) Demyelinating diseases of the central 
nervous system 
3 (2.8) 4 (8.3)    
 Female
1
 3 (100) 3 (75) 3 0.1 – 102 > 0.05 
 Mean age
2
 59 (12.2) 50 (18)  -22 – 40 > 0.05 
(G40) Epilepsy 15 (14) 11 (22.9)    
 Female
1
 11 (73.3) 5 (45.5) 3.3 0.6 - 17 > 0.05 
 Mean age
2
 46.1 (11) 48.5 (16)  -13.2 – 8.6 > 0.05 
(G40-G47) “Non-specific seizures” 3 (2.8) 5 (10.4)    
 Female
1
 1 (33.3) 0 (0)    
 Mean age
2
 52 (13) 49 (13.5)  - 21 - 27 > 0.05 
(G43) Headache 66 (61.7) 7 (15.2)    
 Female
1
 58 (87.9)  5 (71.4) 2.9 0.5 – 17.5 > 0.05 
 Mean age
2
 45.7 (11) 52.9 (13)   -17 - 3 > 0.05 
(G45) Transient cerebral ischaemic attacks 2 (1.8) 3 (6.5)    
 Female
1
 2 (100) 1 (33.3) 8.3 0.2 – 320 > 0.05 
 Mean age
2
 63 (17) 79 (16)  -64- 31 > 0.05 
(G47) Sleep disorder 2 (1.8) 1 (2.2)    
 Female
1
 2 (100) 1 (100)    
 Mean age
2
 54 (8) 56  -134 - 130 > 0.05 
(G50-G59, G60-G65, G70-G73) Nerve, nerve root 
and plexus disorders, polyneuropathies and other 
disorders of the peripheral nervous system and 
diseases of myoneural junction and muscles 
6 (5.6) 9 (18.8)    
 Female
1
 1 (16.7) 3 (33.3) 0.4 0.03 – 5 > 0.05 
 Mean age
2
 52.5 (17) 60.1 (20)  -29.2 – 14 > 0.05 
(G80-G83) Cerebral palsy and other paralytic 
syndromes 
4 (3.7)              -    
 Female
1
 3 (75)              -    
 Mean age
2
 40 (14)            -      
(G89-G99) Other disorders of the nervous system 5 (4.7) 1 (2.1)    
 Female
1
 4 (80)              -    
 Mean age
2
 36.8 (9) 58  - 50 - 7 > 0.05 
* 107 neurological diseases across 97 FMD patients & 48 neurological diseases across 43 control 
patients 
1
 Reference: Males 
2
 Independent samples t-test 
 
5.3.3.5 Comorbid functional disorders 
Information on comorbid functional disorders was collected from unstructured notes and 
structured diagnostic fields. In total, 106 patients (32.9%) had a comorbid functional disorder, 





were more likely to have a comorbid functional disorder than control group patients (OR: 26, 
95% CI: 14 – 48.2, p = 0.001).  
Under half of FMD patients with a comorbid functional disorder had NES (41.2%). The next 
most common functional disorder was IBS (19.4%) followed by dissociative pain disorder (also 
often frequently described as somatoform pain disorder) in 11.3% of patients.  










n (%) OR 95% CI 
p 
value 
Comorbid functional disorder?*      
 Yes
1
 106 (33.8) 12 (1.9) 26 14 – 48.2 0.001 
 No 208 (66.2) 612 (98.1)    
 Total 314 (100) 624 (100)    
Not known 8 (2.5) 20 (3.1)    
Females with comorbid functional disorder
2
  81 (34.6) 10 (3) 17 8.6 – 33.8 0.001 
Males with comorbid functional disorder
3
  25 (31.3) 2 (0.7) 65 15.2 – 286.3 0.001 
If comorbid functional disorder, what?      
 Chronic fatigue syndrome 11 (8.9) 2 (14.3)    
 Irritable bowel syndrome 24 (19.4)  7 (50)    
 Fibromyalgia 11 (8.9)  3 (21.4)    
 Non-epileptic seizures 51 (41.2) 1 (7.1)    
 Dissociative pain disorder 14 (11.3) 0 (0)    
 Somatoform disorder 6 (0) 0 (0)    
 Other functional disorders 7 (5.6) 1 (7.1)    
Total 124 (100) 14 (100)    
* 18 FMD participants had more than one comorbid functional disorder; 2 control participants 
had more than one comorbid functional disorder 
1
 Comorbid functional disorder versus no comorbid functional disorder 
2 
Reference: females without comorbid functional disorder  
3 
Reference: males without comorbid functional disorder 
Assessing only FMD patients, a binary logistic regression analysis was conducted to assess 
whether there were any socio-demographic differences between FMD patients with a 
comorbid functional disorder and those who had functional motor symptoms only. Binary 
independent variables entered into the model included gender, ethnicity, marital status, 
psychiatric admission history, experience of CSA, comorbid physical health problems, smoking 
status, history of employment as a health or social care worker, having a carer, and 
employment status.  
None of these independent variables predicted a comorbid functional disorder amongst FMD 
patients. The Cox and Snell pseudo R-square was 0.064 indicating that the fit of the model to 
the data was poor. See Table 100, “Appendix 5.8: Logistic regression results” for a full 





5.3.3.6 Psychiatric inpatient stays 
Information on admissions to psychiatric inpatient settings was collected from structured 
fields. Whether the patient had had an admission, how many times they were admitted and 
the total number of days spent in hospital was assessed.  
In total, 107 (33%) FMD patients had received a hospital admission at the time of data 
collection compared to 43.5% of control group participants (OR: 0.65, 95% CI: 0.5 – 0.9, p = 
0.002). When stratified by gender, there was no difference in admission rates between 
females, though male control group participants were more likely to have had a psychiatric 
admission than male FMD patients (OR: 0.44, 95% CI: 0.3 – 0.7, p = 0.002). There was no 
difference in rates between patients with a carer, but control patients with no carer were 
more likely to have had an admission than FMD patients with no carer. Control group smokers, 
and control group patients both receiving and not receiving benefits were more likely to have 
had an admission than their FMD patient counterparts.  
Patients with no admissions were removed from the analysis and the number of days in 
hospital and the frequency of psychiatric admission spells were analysed. The number of days 
and the number of hospital spells data was positively skewed so a non-parametric analysis was 
conducted.  
The mean number of inpatient days spent by FMD patients was 130.3 days (SD: 124) (median: 
112 days, IQR: 89) but control group patients spent significantly more days in inpatient settings 
(mean: 143.4 days, SD: 209, median: 67, IQR: 155, U = 11944.5, p = 0.007). Control female 
patients spent significantly more days in inpatient settings than female FMD patients but there 
were no differences between male groups.  
The mean number of episodes in hospital for FMD patients was 1.8 (SD: 3.7), significantly less 
than the mean number for control group patients at 3.3 (SD: 3.4, U = 8618.5, p = 0.001). Both 
male and female control group patients had a significantly higher number of admissions than 
their FMD counterparts. See Table 36 for a breakdown of the psychiatric admission rates and 
socio-demographic rates between groups as well as the number of days and hospital 
admissions.  
Examining only FMD patients, a binary logistic regression model was employed and 
characteristics differentiating patients who had a psychiatric admission history were compared 
to those who had not been admitted to hospital. The regression model indicated being 
unemployed pre-morbidly (OR: 0.09, p = 0.01), using a walking aid (OR: 5.28, p = 0.002), not 





abuse as an adult (OR: 6.8, p = 0.007), and being a current smoker (OR: 3.05, p = 0.02) 
significantly predicted psychiatric inpatient admission at the 5% level. The Cox and Snell 
pseudo R-square was 0.32 indicating that the fit of the model to the data was only moderate. 
See Table 101 (“Appendix 5.8: Logistic regression results”). 
Table 36 Psychiatric inpatient rates, days in hospital and spells in hospital for functional motor 
and control groups 











  107 (33) 280 (43.5) 0.65 0.5 – 0.9 0.002 
Female
2
  82 (34.5) 131 (38.4) 0.85 0.6 – 1.2 > 0.05 
 Male
3
  25 (29.8) 149 (49.2) 0.44 0.3 – 0.7 0.002 
  Patient has carer
4
 46 (43) 63 (49.2) 0.78 0.5 – 1.3 > 0.05 




51 (30.2) 194 (46.6) 0.49 0.3 – 0.7 0.001 
 Receives benefits
6
 64 (44.8) 186 (55.2) 0.66 0.4 – 0.9 0.04 
 Doesn’t receive benefits
7






 130.3 (124)   143.4 (209) 11944.5  0.007 
Female mean (SD)
8
 138.2 (127.4) 154.8 (223) 4408  0.04 
Male mean (SD)
8






 1.8 (3.7) 3.3 (3.4) 8618.5  0.001 
Female mean (SD)
8
 2.01 (4.2) 3.5 (3.8) 3268  0.001 
Male mean (SD)
8
 1.1 (0.3) 3.0 (3.1) 1219.5  0.001 
1
 Reference: Patients with no inpatient stay 
2
 Reference: Females with no inpatient stay 
3 
Reference: Males with no inpatient stay 
4 
Reference: Patients with carers not admitted to psychiatric settings 
5 
Reference: Patients without carers not admitted to psychiatric settings 
6 
Reference: Patients receiving benefits with no inpatient stay 
7 
Reference: Patients not receiving benefits with no inpatient stay 
8 
Mann-Whitney U test 
 
5.3.3.7 Familial mental health 
From the unstructured CRIS text, any mention of family mental health problems was recorded. 
The information was not known in 82 (25.5%) FMD and 315 (49%) control patients.  
There was a positive history of familial mental health problems in 52.1% of FMD patients, less 
than the 60% found for control patients. No statistical difference was observed between 
groups.  
The maximum number of relatives with a reported mental health issue for control patients was 
five, and four for FMD patients. The mean number of relatives with a mental health disorder 
for FMD patients was 1.59 (SD: 0.9) and for the control group, the mean was slightly higher at 





Relatives with a reported mental health problem were compared between the groups. The 
most common relative reported to have mental health problem amongst FMD patients were 
mothers (accounting for 30.4% of relatives with a mental health problem), followed by fathers 
(18.2%) and patients’ sons (6.1%). Similar patterns were observed in the control group and no 
differences in the rates were seen between groups. See Table 98 (“Appendix 5.6: History of 
familial mental health issues”). 
5.3.4 Life events  
5.3.4.1 Physical and sexual abuse  
Information on childhood and adulthood sexual or physical abuse was taken from unstructured 
text in CRIS.  
No information was available on the presence or absence of CSA for 22.4% of FMD patients 
and 39.9% of control group patients. The rate of CSA in the FMD group was 20% which did not 
differ significantly from the rate of abuse reported in the control group at 21.9% (OR: 0.9, 95% 
CI: 0.6 – 1.3, p > 0.05).  
Information on the presence or absence of childhood physical abuse (CPA) was lacking in 22% 
of FMD patients and 40.2% of control patients. The rate of CPA (22.7%) was slightly higher in 
the FMD group than that of sexual abuse within that group, but it did not differ significantly to 
the rate of CPA reported in the control group (21.8%) (OR: 1.05, 95% CI: 0.72 – 1.5, p > 0.05).  
No information was available on adult physical or sexual abuse (APSA) for 20.2% of FMD 
patients and 37.9% of control group patients. The rate of APSA in FMD patients was 27.2% 
which did not significantly differ from the rate in the control group of 21% (OR: 1.4, 95% CI: 0.9 
– 2, p > 0.05).   
Each abuse variable was stratified for gender, employment, history of mental health problems 
in the family and patients’ status as carers. There were no significant differences between 
groups on any of these variables, with the exception of APSA as control patients experienced 
more abuse if they also had a family history of mental health problems and FMD patients were 
more likely to experience ASPA if they had a carer.  








Table 37 History of childhood sexual and physical abuse and physical or sexual abuse in 







n (%) OR 95% CI 
p 
value 
History of child sexual abuse 50 (20) 85 (21.9) 0.9 0.6 – 1.3 > 0.05 
Not known 72 (22.4) 257 (39.9)    
 Female
1
 43 (22.8) 66 (30.3) 0.7 0.4 – 1.1 > 0.05 
 Male
2
 7 (11.3) 19 (11.2) 1 0.4 – 2.5 > 0.05 
 Employed
3
 7 (11.9) 12 (16.9) 0.7 0.2 – 1.8 > 0.05 
 Unemployed
4
 43 (23.1) 72 (23.1) 1 0.7 – 1.5 > 0.05 
 Family mental health history
5
 29 (69) 39 (83) 0.46 0.17 – 1.2 > 0.05 
 Patient has a carer
6
 18 (20.9) 21 (22.8) 0.9 0.44 – 1.8 > 0.05 
 Patient doesn’t have a carer
7
 28 (18.8) 55 (19.8) 0.94 0.57 – 1.6 > 0.05 
History of child physical abuse 57  (22.7) 84 (21.8) 1.05 0.72 – 1.5 > 0.05 
Not known 71 (22) 259 (40.2)    
 Female
1
 46 (24.3) 58 (27.1)  0.9 0.6 – 1.4 > 0.05 
 Male
2
 11 (17.7) 27 (15.8)  1.2 0.5 – 2.5 > 0.05 
 Employed
3
 10 (16.9) 14 (19.7) 0.8 0.3 - 2 > 0.05 
 Unemployed
4
 45 (24.2) 70 (22.7) 1.1 0.7 – 1.7 > 0.05 
 Family mental health history
5
 32 (71.1) 39 (79.6) 0.6 0.24 – 1.6 > 0.05 
 Patient has a carer
6
 19 (21.8) 12 (13.3) 1.8 0.82 – 4 > 0.05 
 Patient doesn’t have a carer
7
 33 (22.1) 66 (23.8) 0.9 0.6 – 1.4 > 0.05 
History of adult physical or sexual abuse 70 (27.2) 84 (21) 1.4 0.9 – 2 > 0.05 
Not known 65 (20.2) 244 (37.9)    
 Female
1
 65 (33.9) 75 (32.8)  1.1 0.7 – 1.6 > 0.05 
 Male
2
 5 (7.7) 9  (5.3) 1.5 0.5 – 4.7 > 0.05 
 Employed
3
 13 (21) 14 (18.7) 1.2 0.5 – 2.7 > 0.05 
 Unemployed
4
 53 (28.2) 68 (21.4) 1.4 0.9 – 2.2 > 0.05 
 Family mental health history
5
 26 (50) 33 (75) 0.3 0.14 – 0.8 0.014 
 Patient has a carer
6
 25 (29.4) 15 (16.5) 2.1 1.0 – 4.4 0.04 
 Patient doesn’t have a carer
7
 37 (24) 56 (19.6) 1.3 0.8 – 2.1 > 0.05 
1 
Reference: Females not experiencing the relevant abuse 
2
 Reference: Males not experiencing the relevant abuse 
3 
Reference: Employed patients not experiencing the relevant abuse 
4 
Reference: Unemployed patients not experiencing the relevant abuse 
5 
Reference: Patients with family mental health history not experiencing the relevant abuse 
6 
Reference: Patients with carers not experiencing the relevant abuse
 
7 
Reference: Patients without carers not experiencing the relevant abuse
 
5.3.4.2 Early life events 
Information on possible symptom precipitants was collected from unstructured text in CRIS. 
Precipitants constituted any information written in the clinical notes that might explain 
symptom onset. No exclusion criteria were applied and similar to information on functional 
motor symptoms, events were categorised after data collection was complete. If there was any 
reference in a patient’s clinical records of any possible precipitant, at any stage of their life, 
this was recorded and categorised. These categories were sub-divided into events that 
occurred in a patient’s early life and those that occurred after the age of 18. As this analysis 





records, it is not possible to entirely ascertain whether an event did not occur at all or whether 
the information was not known. These results should therefore be viewed as preliminary. 
Early life events included, ‘left or abandoned by a parent as a child’, ‘witnessing violence 
between parents’, ‘parents divorcing or separating’, ‘in care, fostered or adopted as a child’, 
‘experiencing bullying in primary or secondary school’ and ‘taking drugs under the age of 18’.   
Statistically significant differences in the frequency of reported events were found in the 
experience of bullying in primary or secondary school where the rate was higher in the FMD 
(17.8%) than the control group (9.1%) (OR: 2.16, 95% CI: 1.4 – 3.3, p = 0.001). Following 
stratification, this significant effect remained for both men and women.  
A significantly lower proportion of FMD patients reported taking drugs under the age of 18 
(1%) than the rate reported amongst control group patients (6.6%) (OR: 0.15, 95% CI: 0.05 – 
0.5, p = 0.002). This effect was significant only between female groups, not between men.  
Table 38 outlines the rates in the type of early life events for functional motor and control 
group participants.  







n (%) OR 95% CI p value 
Left or abandoned by a parent as a child
1
 30 (10.5) 37 (7.1) 1.5 0.9 – 2.5 > 0.05 
 Female
2
 25 (11.8) 24 (8.6) 1.4 0.8 – 2.6 > 0.05 
 Male
3
 5 (6.7) 13 (5.5) 1.2 0.4 – 3.6 > 0.05 
Violence between parents
1
 15 (5.3) 31 (6) 0.87 0.46 – 1.6 > 0.05 
 Female
2 
 12 (5.7) 19 (6.8) 0.8 0.4 – 1.8 > 0.05 
 Male
3
 3 (4) 12 (5) 0.8 0.2 – 2.9 > 0.05 
Parents divorced or separated
1
 38 (13.2) 63 (12.2) 1.1 0.7 – 1.7 > 0.05 
 Female
2 
 29 (13.6) 34 (12.1) 1.1 0.7 – 1.9 > 0.05 
 Male
3 
 9 (12) 29 (12.2) 0.98 0.4 – 2.2 > 0.05 
In care, fostered or adopted as a child
1
 14 (4.9) 35 (6.8) 0.7 0.4 – 1.3 > 0.05 
 Female
2 
 10 (4.7)  20 (7.1) 0.6 0.3 – 1.4 > 0.05 
 Male
3 
 4 (5.3) 15 (6.3) 0.8 0.3 – 2.6 > 0.05 
Bullied in primary or secondary school
1
 51 (17.8) 47 (9.1) 2.16 1.4 – 3.3 0.001 
 Female
2 
 37  (17.5) 26 (9.3) 2.1 1.2 – 3.5 0.008 
 Male
3 
 14 (18.6) 21 (8.8) 2.4 1.1 – 4.9 0.02 
Took drugs under-18
1
 3 (1) 34 (6.6) 0.15 0.05 – 0.5 0.002 
 Female
2 
 2 (0.9) 15 (5.4) 0.17 0.04 – 0.7 0.02 
 Male
3 
 1 (1.3) 19 (8) 0.2 0.02 – 1.2 > 0.05 
1 
Reference: patients not experiencing the same event 
2 
Reference: females not experiencing the same event 
3 





5.3.4.3 Adult life events 
Adult life events were categorised and explored in more detail. These categories include 
experiencing ‘financial difficulties’, ‘bereavement’ categorised as either a likely or unlikely 
symptom precipitant, ‘workplace, school or university issues’, ‘involvement in a legal dispute’, 
‘problems within a sexual relationship’, ‘experiencing an accident or assault’ classed as either a 
likely or unlikely precipitant, ‘being affected by war or political turmoil’, ‘being socially 
isolated’, ‘abusing drugs or alcohol’, ‘having a family member who is unwell’, ‘experiencing a 
physical symptom’ classified as either a likely or unlikely precipitant or ‘experiencing a 
complication before, during or after giving birth’. These categories were constructed after all 
data on precipitants was collected and are post-hoc and non-standardised.  
There were no differences in rates between groups experiencing financial difficulties, social 
isolation, bereavement classified as either a likely precipitant (occurred shortly before the 
onset of psychiatric symptoms) or an unlikely precipitant (e.g. did not occur close to the onset 
of psychiatric symptoms), or the experience of a traumatic or complicated birth or post-natal 
complication like post-natal depression.  
FMD patients experienced higher rates of workplace, school or university issues (22.6%) 
compared to control group participants (6.9%) (OR: 3.9, 95% CI: 2.5 – 6.1, p = 0.001), were 
more likely to be involved in a legal dispute (7% versus 0.8%, OR: 9.6, 95% CI: 3.3 – 28, p = 
0.001), to report problems within a sexual relationship (32.1 versus 23.2%, OR: 1.6, 95% CI: 1.1 
– 2.2, p = 0.006), to have experienced an accident or assault when it was classified as either a 
likely precipitant (15.3% versus 2.3%, OR: 7.6, 95% CI: 3.9 – 14.7, p = 0.001) or an unlikely 
precipitant (6.6% versus 1.7%, OR: 4, 95% CI: 1.8 – 8.9, p = 0.001), to be affected by war or 
political upheaval (6.9% versus 3.3%, OR: 2.2, 95% CI: 1.13 – 4.3, p = 0.02), to report a family 
member as being unwell (22% versus 6.4%, OR: 4.1, 95% CI: 2.6 – 6.5, p = 0.001) and to have 
had a physical symptom precipitating their symptom onset (23.3% versus 7.3%, OR: 3.8, 95% 
CI: 2.5 – 5.9, p = 0.001). FMD patients were significantly less likely to report abusing drugs or 
alcohol compared to the control group (8% versus 29%, OR: 0.2, 95% CI: 0.13 – 0.3, p =0.001).  
















n (%) OR 95% CI p value 




35 (12.2) 59 (11.4) 1.08 0.7 – 1.7 > 0.05 
 Female
2
  22 (10.4) 29 (10.3) 1 0.6 – 1.8 > 0.05 
 Male
3
 13 (17.3) 30 (12.6) 1.5 0.7 – 3 > 0.05 
Bereavement but unlikely a precipitant
1
 49 (17.1) 64 (12.4) 1.5 0.97 -2.2 > 0.05 
 Female
2
 35 (16.5) 38 (13.6) 1.3 0.8 – 2 > 0.05 
 Male
3
 14 (18.7) 26 (10.9) 1.9 0.9 – 3.8 > 0.05 
Bereavement as likely precipitant
1
 54 (18.8) 75 (14.5) 1.4 0.9 – 2 > 0.05 
 Female
2
 43 (20.3) 45 (16.1) 1.3 0.8 – 2.1 > 0.05 
 Male
3
 11 (14.7) 30 (12.6) 1.2 0.6 – 2.5 > 0.05 
Workplace, school or university issues
1
 65 (22.6) 36 (6.9) 3.9 2.5 – 6.1 0.001 
 Female
2
 43 (20.3) 19 (6.8) 3.5 1.9 – 6.2 0.001 
 Male
3
 22 (29.3) 17 (7.1) 5.4 2.7 – 10.9 0.001 
Involved in a legal dispute
1
 20 (7) 4 (0.8) 9.6 3.3 – 28 0.001 
 Female
2
 15 (7.1) 2 (0.7) 10.6 2.4 – 46.8 0.002 
 Male
3
 5 (6.7) 2 (0.8) 8.4 1.6 – 44.4 0.01 




92 (32.1) 120 (23.2) 1.6 1.1 – 2.2 0.006 
 Female
2
 77 (36.3) 84 (30) 1.3 0.9 – 1.9 > 0.05 
 Male
3
 15 (20) 36 (15.1) 1.4 0.7 – 2.7 > 0.05 




19 (6.6) 9 (1.7) 4 1.8 – 8.9 0.001 
 Female
2
 14 (6.6) 3 (1.1) 6.5 1.9 – 23 0.004 
 Male
3
 5 (6.7) 6 (2.5) 2.8 0.8 – 9.3 > 0.05 
Accident or assault a likely precipitant
1
 44 (15.3) 12 (2.3) 7.6 3.9 – 14.7 0.001 
 Female
2
  30 (14.2) 2 (0.7) 22.9 5.4 – 97 0.001 
 Male
3
 14 (18.7) 10 (4.2) 5.2 2.2 – 12.4 0.001 
Affected by war or political turmoil
1
 20 (6.9) 17 (3.3) 2.2 1.13 – 4.3 0.02 
 Female
2
 12 (5.6) 5 (1.8) 3.3 1.1 – 9.4 0.03 
 Male
3
 8 (10.7) 12 (5) 2.2 0.9 – 5.7 > 0.05 
Socially isolated
1
 5 (1.7) 9 (1.7) 1 0.3 – 3 > 0.05 
 Female
2
 5 (2.4) 4 (1.4) 1.7 0.4 – 6.3 > 0.05 
 Male
3
 0 (0) 5 (2.1) 0.3 0.02 – 5.1 > 0.05 
Abusing drugs or alcohol
1
 23 (8) 150 (29) 0.2 0.13 – 0.3 0.001 
 Female
2
 13 (6.1) 56 (20) 0.3 0.1 – 0.5 0.001 
 Male
3
 10 (13.3)  94 (39.5) 0.2 0.1 – 0.5 0.001 
Family member unwell
1
 63 (22) 33 (6.4) 4.1 2.6 – 6.5 0.001 
 Female
2
 45 (21.2) 21 (7.5) 3.3 1.9 – 6 0.001 
 Male
3
 18 (24) 12 (5) 5.9 2.7 – 13 0.001 




67 (23.3) 38 (7.3) 3.8 2.5 – 5.9 0.001 
 Female
2
 53 (25) 17 (6.1) 5.2 2.9 – 9.2 0.001 
 Male
3
 14 (23) 21 (8.8) 2.4 1.1 – 4.9 0.02 
Complication in pregnancy (e.g. 




22 (10.4) 33 (11.7) 0.88 0.5 – 1.6 > 0.05 
1 
Reference: patients not experiencing the event 
2 
Reference: females not experiencing the event 
3 






5.3.5 Outcome scores 
5.3.5.1 HoNOS 
An analysis was conducted comparing overall HoNOS scores between FMD and control group 
patients. Participants from both groups were included in the analysis if they had two available 
HoNOS scores. The earliest and latest scores were used for each participant.  
The first analysis assessed any potential within-group differences between participants who 
completed two HoNOS scores and those with one or no HoNOS scores. Most FMD patients had 
one or no scores (78.6%), while 69 patients (21.4%) had at least two available scores. 49.6% of 
control group participants had two available scores, while 50.3% of control group participants 
had one or no HoNOS score.   
An analysis compared whether there were any within-group socio-demographic differences 
between patients with two complete HoNOS scores and those with one or none. No significant 
differences emerged for FMD patients, except for ethnicity. British FMD patients were more 
likely to have one or no complete HoNOS score than two or more (χ2 = 12.6, 95% CI: 9.6 – 36.8, 
p = 0.0004). No within-group differences for control participants emerged when the same 
analysis was conducted (see Table 99, “Appendix 5.7: Socio-demographic differences between 
groups”). 
The mean number of days that passed between the first and last available HoNOS score was 
assessed. For FMD patients, the mean number of days were 1001.5 (SD: 1255, range: 12 – 
5848), while the mean for control group patients was 1654.8 (SD: 1347, range: 1 – 5843), a 
statistically significant difference (t = -3.9, df = 104.7, p = 0.001). This suggests control patients 
were in the Trust for a longer period of time.  
A repeated measures t-test found no statistically significant difference between the first 
HoNOS score (mean = 13.8, SD = 6.6) and last available mean HoNOS score (mean = 12.8, SD = 
6.2) for the 69 FMD patients (t = 1.0, 95% CI -0.98 – 2.9, df = 68, p > 0.05). Results were 
stratified by gender, ethnicity, experience of CSA, employment and comorbid physical health 
problems and no differences over time emerged.  
Control group participants saw a significant drop in mean scores over time (t = 6.4, 95% CI: 1.9 
– 3.6, df = 319, p < 0.01). When control group participants’ results were stratified by gender, 
ethnicity, experience of CSA employment and health, all HoNOS scores improved significantly 
according to these variables over time. However, control patients who were carers had no 





Table 40 shows the change in HoNOS scores for FMD and control group participants as well as 
their socio-demographic variables.  





















  value 
Functional motor group (n = 69) 13.8 (6.6) 12.8 (6.2) 1 1.0 > 0.05 
Gender Female (n = 52) 14 (6.8) 13.1 (6.3) 1 0.81 > 0.05 
 Male (n = 17) 13.4 (6.2) 12.1 (6.2) 1.3 0.63 > 0.05 
Ethnicity British (n = 29) 15.2 (7.7) 13.8 (6.3) 1.4 0.93 > 0.05 
 Other ethnicity (n = 40) 12.9 (5.6) 12.2 (6) 0.7 0.53 > 0.05 
CSA Experienced CSA (n = 10) 14.9 (9.3) 13.5 (8.7) 1.4 0.7 > 0.05 
 Didn’t experience CSA (n = 41) 13.9 (6.9) 12.2 (5.1) 1.7 1.3 > 0.05 
Work Employed (n = 12) 10.3 (4.6) 10.9 (6.3) - 0.7 -0.4 > 0.05 
 Unemployed (n = 49) 14.5 (6.3) 13 (6.1) 1.4 1.1 > 0.05 
 Patient is a carer (n = 7) 12.9 (3.2) 15 (4) -2.1 -2.1 > 0.05 
 Patient is not a carer (n = 56)  13.9 (7) 12.6 (6.2) 1.3 1.1 > 0.05 
 Patient is a social/health worker (n = 7) 15.9 (7) 15.5 (7.5) 0.34 0.7 > 0.05 
 Patient not a social/health worker (n = 54) 13.7 (6.7) 12.8 (5.8) 0.93 0.86 > 0.05 
Health Physical health problem (n = 46) 13.9 (6.1) 13.9 (6) 0 0.02 > 0.05 
 No physical health problem (n = 22) 13.8 (7.8) 11 (6.3) 2.8 1.3 > 0.05 
Control group (n = 320) 12.5 (6.2) 9.8 (5.8) 2.7 6.4 0.001 
Gender Female  (n = 174) 12.2 (6.2) 9.5 (5.5) 2.7 4.8 0.001 
 Male (n = 146) 12.8 (6.2) 10.1 (6) 2.7 4.3 0.001 
Ethnicity British (n = 158) 12.4 (6) 10.5 (6) 1.9 3.3 0.001 
 Other ethnicity  (n = 162) 12.5 (6) 8.98 (5.4) 3.52 5.8 0.001 
CSA Experienced CSA (n = 54) 12.5 (6) 10.1 (5.3) 2.4 2.5 0.006 
 Didn’t experience CSA (n = 172)  12.4 (6) 9.5 (5.6) 2.9 5.3 0.001 
Work Employed (n = 48) 12.5 (6.5) 8 (5.4) 4.5 4 0.001 
 Unemployed (n = 236) 12.6 (6.4) 10.3 (5.7) 2.3 5.2 0.001 
 Patient is a carer (n = 8) 13.8 (4.9) 13 (7) 0.8 0.3 > 0.05 
 Patient is not a carer (n = 301) 12.4 (6) 9.6 (5.7) 2.8 6.4 0.001 
 Patient is a social/health worker (n = 22) 14.2 (4.9) 7.7 (4.6) 6.5 4.6 0.001 
 Patient not a social/health worker (n=287) 12.3 (6.2) 9.9 (5.8) 2.4 5.3 0.001 
Health Physical health problem (n = 167) 12.5 (5.8) 10 (5.6) 2.5 4.4 0.001 
 No physical health problem (n=121) 12.1 (6.6) 9.4 (5.7) 2.7 3.7 0.001 
Range: 0 (best) - 48 (worst) 
A repeated measures one-way ANOVA was conducted to assess whether there was a change 
over time in HoNOS scores between groups. This test showed no significant interaction 
between FMD and control groups’ adjusted HoNOS scores over time (F (1, 387) = 2.83, p = 







Figure 32 Functional motor and control group HoNOS scores and their change over time 
5.3.5.2 HoNOS-ABI scores 
Fifty-four FMD patients had two available HoNOS-ABI scores. Only two control group 
participants had two available HoNOS-ABI scores, so FMD patients’ scores alone were 
analysed. The mean number of days between the first and second HoNOS-ABI score was 187.8 
(SD: 262.3, range: 4 – 1209).  
There was a significant drop in HoNOS-ABI scores over time from an overall mean of 13.9 (SD: 
5.7) to 11.9 (SD: 6.2) (t =2.9, df = 53, p = 0.005). Data were stratified by gender, ethnicity, 
employment, health, and experiences of CSA. There was a significant drop in HoNOS-ABI 
scores for men only, both British and non-British patients, patients who did not experience 
CSA, patients who did not work as carers, those that worked in social or health care, and 
patients with a comorbid physical health problem. Table 41 outlines HoNOS-ABI scores for 
functional motor patients.  
Table 41 First and last available HoNOS-ABI scores in functional motor disorder group 















   t  
 test 
     p  
  value 
Functional motor group (n = 54) 13.9 (5.7) 11.9 (6.2) 1.99 2.9 0.005 
Gender Female (n = 43) 13.6 (5.7) 12.2 (6.2) 1.35 1.78 > 0.05 
 Male (n =11) 15.2 (6.1) 10.7 (6.1) 4.5 3.34 0.007 
Ethnicity British (n = 37) 14.6 (5.7) 12.5 (6.2) 2.1 2.25 0.03 
 Other ethnicity (n = 17) 12.5 (5.8) 10.8 (6) 1.76 2.22 0.04 
CSA Experienced CSA (n = 13) 14.3 (6.7) 11.6 (6.7) 2.7 1.4 > 0.05 
 Didn’t experience CSA (n = 35) 13.9 (5.5) 12.3 (6.2) 1.63 2.2 0.04 
Health Physical health problem (n = 43) 14 (5.8) 11.5 (6.4) 2.5 3.3 0.002 
 No physical health problem (n = 8) 14.2 (6.1) 13.6 (5.3) 0.6 0.5 > 0.05 
Range: 0 (best) - 48 (worst) 













5.3.5.3 PHQ-9 scores 
In total, 20 FMD participants had two PHQ-9 scores. In groups populated by less than five 
patients, no comparisons were conducted. No PHQ-9 information was available on control 
group patients. The mean number of days between the first and last PHQ-9 score for 
functional motor patients was 162 days (SD: 195.3, range: 30 – 925).  
FMD patients showed a statistically significant reduction in PHQ-9 scores over time from a 
mean of 14.3 (SD: 7.7) to a mean of 11.1 (SD: 6.6) (t = 2.6, df = 19, p = 0.02). Data were 
stratified by socio-demographic variables. Female, and British patients, those not working as 
carers, and those who did not experience CSA showed a significant improvement in scores 
over time. For all other groups, there was no significant change in PHQ-9 scores. See Table 42 
for the first and last available PHQ-9 scores for FMD patients.  



















Functional motor group (n = 20) 14.3 (7.7) 11.1 (6.6) 3.2 2.6 0.02 
Gender Female (n = 18) 13.6 (7.5) 10.7 (6.1) 2.8 2.2 0.04 
 Male (n =2) 21 (7.1) 14.5 (13.4) - - - 
Ethnicity British (n = 15) 15.5 (7.4) 11.9 (7.1) 3.7 2.4 0.03 
 Other ethnicity (n = 5) 10.6 (8.2) 8.8 (5.1) 1.8 0.9 > 0.05 
CSA Experienced CSA (n = 3) 8 (3.5) 6.7 (2.5) - - - 
 Didn’t experience CSA (n = 15) 16.9 (6.8) 12.7 (6.7) 4.1 2.7 0.02 
Work Employed (n =2) 16.5 (7.8) 14.5 (7.8) - - - 
 Unemployed (n =16) 14 (8.3) 11.1 (6.8) 2.9 2 > 0.05 
 Works as carer (n = 4) 10.3 (11) 10 (10.2) -  - 
 Not a carer (n = 16) 15.3 (6.7) 11.4 (5.9) 3.9 2.7 0.02 
 Patient is a social/health worker (n = 4) 16.5 (5) 14.5 (6.7) - - - 
 Patient not a social/health worker (n = 16) 13.8 (8.3) 10.3 (6.6) 3.5 1 > 0.05 
Health Physical health problem (n = 14) 12.6 (7.8) 10.4 (7.3) 2.2 1.6 > 0.05 
 No physical health problem (n = 6) 18.3 (6.2) 12.8 (5) 5.5 2.4 > 0.05 
Scoring guide: ‘0-4’ no depression; ‘5-9’ mild; ‘10-14’ moderate; ‘15-19’ moderately severe; ‘20-27’ 
severe 
Two participants had two HoNOS-ABI scores so no control group analysis was conducted 
5.3.6 Logistic regression 
Using a binary logistic regression model, characteristics differentiating FMD and control group 
patients were investigated. The regression model indicated that being female (OR: 2.04, p = 
0.008), married (OR: 4.02, p = 0.001), employed pre-morbidly (OR: 2.08, p = 0.045), having a 
physical health condition (OR: 2, p = 0.02) and having a carer (OR: 2, p = 0.007) were associated 
with status as an FMD patient. Being British, a health or social care worker, smoker, having had 
a psychiatric inpatient admission, being a carer, and having experienced sexual or physical 





Cox and Snell pseudo R-square was 0.21 indicating that the fit of the model to the data was 
poor. The model correctly predicted 51% of FMD patients and 82.4% of control group patients. 
Table 43 outlines the regression model. 















Female  0.71  0.27  6.95  0.008  2.04  1.2 – 3.5 
British  0.19  0.25  0.62  0.43  1.22  0.75 – 2 
Married  1.4  0.28  25.3  0.001  4.02  2.3 – 6.9 
Employed pre-morbidly  0.73  0.37  4  0.045  2.08  1 – 4.3 
Health or social worker  0.24  0.36  0.46  0.50  1.28  0.6 – 2.6 
Smoker  -0.28  0.25  1.26  0.26  0.76  0.5 – 1.2 
Psychiatric inpatient stay  -0.28  0.24  1.3  0.25  0.76  0.5 – 1.2 
Physical health problem  0.69  0.28  6.3  0.01  2.0  1.2 – 3.5 
Carer to family or friend  0.76  0.58  1.73  0.19  2.15  0.69 – 6.7 
Has a carer   0.69  0.26  7.24  0.007  2.0  1.2 – 3.3 
Abuse experience*  0.29  0.17  3.03  0.08  1.3  0.96 – 1.9 
             
Model χ2 = 93.6, p < 0.001            
Pseudo R
2 
= 0.21             
n = 966             
The dependent variable is membership of the functional motor disorder group coded as 0 = 
control group and 1 = functional motor disorder patient 
*Abuse experience: collation of CSA, CPA and ASPA categories resulting in three point Likert 
scale (1-3) 
 
5.3.7 Sensitivity analysis  
Schizophrenia patients account for at least 23.1% of the control group in this study. One 
hypothesis is that the severity of a disorder like schizophrenia may account for some of the 
statistically significant differences seen between the FMD and control groups.  
In order to explore this possibility further, any patient with a schizophrenia, schizotypal or 
delusional disorder diagnosis (F20 – F29) in either the FMD or control groups was removed and 
univariate analyses assessing socio-demographic associations were conducted. 
With the removal of any patient with a schizophrenia diagnosis from either group, the total 
number of FMD patients was now 312 (removal of 3.1% of patients) while the control group 
total number was now 495 (removal of 23.1% of patients).  
After their removal from the analysis, there remained a significantly higher proportion of 
female FMD patients (χ2 = 31.6, p <0.05). The higher rate of British FMD participants 
disappeared but the control group still had a higher proportion of Irish participants (χ2 = 8.2, p 





FMD patients were still more likely than control group patients to be married (χ2 = 66.8, p 
<0.05). The significant difference in employment rates disappeared but FMD patients were still 
more likely to have been employed pre-morbidly (χ2 = 9.4, p <0.05). Differences in smoking 
rates remained, with control group patients still more likely to smoke than functional patients 
(χ2 = 21.8, p <0.05). With the removal of schizophrenia patients from the analysis, control 
patients were now more likely than FMD patients to have a relative with a mental health 
problem (χ2 = 7.7, p <0.05). There remained no difference in the rates of abuse between 
groups. 
Table 44 outlines the differences between functional motor and control groups after the 
removal of patients with a schizophrenia (F20-F29) diagnosis.  
Table 44 Socio-demographic comparisons with removal of all cases of schizophrenia, 
schizotypal, delusional, and other non-mood psychotic disorders 












 95% CI 
p 
value 
Gender Female 232 (74.4) 271 (54.7) 31.6 12.8 – 26.2 0.001 
 Male 80 (25.6) 224 (45.3)    
Ethnicity British 194 (66.4) 284 (60.8)  2.6 -1.5 – 12.9 0.10 
 Irish 2 (0.7) 20 (4.3) 8.2 1.2 – 5.9 0.004 
 Any other white background 13 (4.5) 38 (8.1) 3.7 -0.2 – 7.1 0.054 
 Any other mixed background 0 (0) 2 (0.4) 1.17 -0.9 – 1.5 0.28 
 African, Caribbean & Black 40 (13.7) 79 (16.9) 1.4 -2.4 – 8.5 0.23 
  African 13 (4.5) 36 (7.7) 3.04 -0.6 – 6.7 0.08 
  Caribbean 13 (4.5) 19 (4.1) 0.07 -2.6 – 3.8 0.79 
  Any other black background 14 (4.8) 24 (5.1) 0.03 -3.3 – 3.5 0.85 
 Asian
2
 11 (3.8) 13 (2.8) 0.58 -1.7 – 4.2 0.45 
  Indian 2 (0.7) 1 (0.2) 1.15 -0.6 – 2.3 0.28 
  Pakistani 1 (0.3) 2 (0.4) 0.05 -1.5 – 1.2 0.82 
  Bangladeshi 1 (0.3) 2 (0.4) 0.05 -1.5 – 1.2 0.82 
  Chinese 1 (0.3) 1 (0.2) 0.08 -0.9 – 1.6 0.78 
  Any other Asian background 6 (2.1) 7 (1.5) 0.38 -1.4 – 3.1 0.53 
 Any other ethnic group 32 (11) 31 (6.6) 4.6 0.13 – 9 0.03 
 Total 292 (100) 467 (100)    
 Not known 20 (6.4) 28 (5.7)    
Marital 
status 
Married or civil partner 139 (47.3) 93 (19.5) 66.8 20.8 – 34.6 0.001 
Not married 155 (52.7) 385 (80.5)    
Work Employed 72 (25) 90 (19.9) 2.7 -1.2 – 11.6 0.10 
 Unemployed 216 (75) 363 (80.1)    
 Employed pre-morbidly 240 (87.9) 307 (78.7) 9.4 3.2 – 14.9 0.002 
Health Smoker 67 (38.1) 142 (61.5) 21.8 13.3 – 33 0.001 
 Mean BMI
1
 28.6 (8.9) 25.98 (6.7) 1.9  0.06 
 History of psychiatric admission 101 (32.4) 169 (34.1) 0.25 -5.2 – 8.5 0.61 
 Complication at birth 38 (29.5) 28 (34.1) 0.5 -8.7 – 18.3 0.48 
 Family mental health history 121 (51.9) 159 (64.4) 7.7 3.4 – 21.4 0.006 
Life 
events 
CSA 48 (19.6) 70 (23.5) 1.2 -3.4 – 11 0.27 
CPA 57 (23.2) 70 (23.6) 0.01 -7 – 7.7 0.91 







With the removal of all patients with a schizophrenia diagnosis, a binary logistic regression 
analysis was repeated to assess the variables that predict membership to the FMD group. The 
Cox & Snell R Square was 33.7% and the model correctly predicted 78.8% of cases. Some of the 
significant associations with FMD membership disappeared with the removal of the 
schizophrenia patients.  
Variables that were no longer associated with FMD patients included gender, pre-morbid 
employment and having a carer. The variables that were significantly associated with FMD 
membership were being married (OR: 4.6, p = 0.02) and having a physical health problem (OR: 
11.8, p = 0.001), see Table 102, (“Appendix 5.8: Logistic regression results”).  
5.4 Discussion 
5.4.1 Main findings 
This study identified 322 FMD patients from a database holding 250,000 patients’ records. The 
associations between FMD and demographic, social, occupational, health and life events were 
investigated using a large number of control patients drawn from an extensive mental health 
case register (Stewart et al., 2009). 
4.4.1.1 Socio-demographics 
In our univariate analyses, FMD was associated with higher rates of female patients, British 
patients, private home ownership, employment, pre-morbid employment and employment in 
health and social care. FMD was associated with lower rates of Irish, African, Caribbean and 
black ethnicities, mortality, council tenancy occupancy, and the receipt of benefits.  
The predominance of females in our study endorses existing evidence on the gender ratio of 
functional motor symptoms. The rate in this study of 73.9% is lower than the rate of 80% 
reported in Stone et al.’s (2009b) neurology outpatient study, the 79% reported by consultant 
neurologists in Scotland (Stone et al., 2010b), and the 78.8% in a neuropsychiatric inpatient 
unit (McCormack et al., 2014), but higher than the 60% reported in a neurology unit in a 
general hospital in Sweden (Binzer et al., 1997). 
The gender difference may arise for a number of reasons. Women may be more likely to 
perceive and label a noxious sensation due to heightened body vigilance (Warner, 1995). 
Young women may be more likely to be socialised to communicate bodily distress (Mechanic, 
1972), and women may be more likely to seek help for somatic symptoms (Nathanson, 1977). 
Other factors linked to gender may include genetic or personality predispositions (McCrae et 





Our study found a higher rate of British patients compared to the control group. Hysteria, 
historically, was conceptualised as a disorder which arose when cultural or ethnic groups did 
not hold sophisticated psychological models with which to understand emotional distress or 
explain common somatic symptoms (Kleinman, 1982; Lambo, 1956). The argument follows 
that as Freudian theories became more common in western culture, the incidence of hysteria 
reduced. The argument’s subtext is that somatic complaints are an expression of emotional 
distress by less ‘psychologically sophisticated’ people who do not have the tools to express 
suffering or grief.  
This reasoning is almost entirely discredited. The incidence of functional neurological 
symptoms in western culture has not reduced since Freud’s exposition (Carson et al., 2000) 
and there is no evidence to suggest that certain ethnic groups or cultures have higher rates of 
FND or unexplained symptoms. A systematic review concluded that the lack of high-quality 
evidence from cross-cultural studies makes it difficult to draw firm conclusions on the cross-
cultural variations of FND but that when FND does occur, its features are similar across 
countries (Brown & Lewis-Fernández, 2011). This suggests some degree of universality of the 
disorder. In addition, the argument that ‘psychologically unsophisticated’ patients are more 
likely to present with somatic symptoms is spurious given the epidemiological evidence that 
patients with functional somatic symptoms also report high rates of psychological symptoms 
(Katon et al., 1991).  
The ethnic profile of our control group is very similar to the profile of all SLaM patients in the 
CRIS records. Perera et al., (2016) reported that 50% of active CRIS patients were British. The 
statistical difference in British ethnicity is likely partly explained by the ethnic profile of 
schizophrenia patients in our control group, supported by previous research which highlights 
the link between high rates of psychosis in the Black Caribbean population (Fearon et al., 
2006). Our sensitivity analysis shows that with the removal of schizophrenia patients, the 
statistical difference in British ethnicity rates disappears. From our study, the evidence 
suggests that within SLaM, a London-based Trust with a culturally diverse metropolitan 
population, FMD is no more common a mental health diagnosis amongst certain ethnicities 
than other disorders.  
Previous evidence suggests a link between lower socio-economic status (SES) and FND (Binzer 
et al., 1997; Stefansson et al., 1976). Commonly used indicators of SES in health research 
includes education, income, wealth (Galobardes et al., 2007) and parental education (Erola et 
al., 2016). None of these variables were routinely available in CRIS so a robust SES measure 
was not included. Potential proxies of SES in our results include marital status, housing and 





In our study, FMD patients are more likely to be married (both male and females), more likely 
to live in privately owned homes, more likely to be employed, and less likely to receive 
benefits than control patients. Of patients in the study who were actively employed or had a 
history of employment, significantly fewer FMD patients worked in elementary occupations 
which required fewer skills. While marital status, housing and occupation are likely collinear 
factors, together, they may indicate a higher SES status. Again, our results will be influenced by 
our comparator group whose SES status may artificially inflate the results observed in our FMD 
group.  
The rate of employment in care-giving positions within health and social care amongst FMD 
patients is worth highlighting. Previous evidence in this area is conflicting. Recent results from 
a movement disorders clinic found no difference in the proportion of healthcare workers 
between FMD and control patients (although the rate was elevated in the functional group at 
25% versus 20%) (Perry et al., 2017) and no difference in rates were observed between 
patients with essential and psychogenic tremor (Kenney et al., 2007). McCormack et al. (2014) 
observed that 45.5% of FMD patients had previously been employed as health or social care 
workers, significantly higher than the rate observed in their control group. 
Office for National Statistics data in 2001 reported that healthcare workers accounted for 6% 
of the UK’s economy; and four-fifths of these workers were women (Yar et al., 2006). 19% of 
FMD patients in our study had worked or currently worked in health or social care jobs 
compared to 8.2% in the control group. The difference between groups may partly be 
explained by underemployment in the control group or the higher prevalence of females in our 
FMD group. When health and social care work was stratified by gender, the difference was 
maintained only in women. In our logistic regression analysis, health and social care work was 
not associated with an FMD diagnosis, likely because gender was accounted for.  
Nonetheless, a reasonable proportion of FMD patients worked in care-giving employment, 
10% of FMD patients were carers to family members or friends, and 40% had a carer 
themselves. A common theoretical argument is that working in healthcare roles or observing a 
family member with a neurological disease allows a person to model neurological symptoms 
(Shill & Gerber, 2006). It is possible that there is something particular about the social act of 
giving care that precipitates or moderates the development of functional neurological 
symptoms, for example through burnout, low pay or insecure employment. Alternatively, a 
confounding factor like personality, not assessed in our regression analysis, might 





5.4.1.2 Health  
A range of functional motor symptoms were observed with weakness the most common type. 
Weakness was also the most common symptom reported in FND patients admitted to an acute 
stroke ward (Gargalas et al., 2015). In movement disorders clinics, tremor is more commonly 
found to be the most prevalent functional symptom (Factor et al., 1995; Hinson & Haren, 
2006), but service referral patterns likely explain this finding. Most FMD patients had more 
than one symptom. Caution is necessary when interpreting our results as symptoms were 
categorised after collection from the medical records and it is possible that some observer bias 
was involved in the construction of symptom categories. 
Over half of the FMD group (58.2%) had used, or currently used a wheelchair, Zimmer frame or 
a walking stick. This is lower than the rate of 84.8% in patients with FMD admitted to a 
neuropsychiatry unit (McCormack et al., 2014). Patients in McCormack et al.’s study were 
more likely to more severe or entrenched symptoms given their inpatient admission. This is 
supported in our study where of the FMD patients who had received an inpatient admission, 
76.3% used a walking aid while 23% did not. Our rate of 58.2% is likely to be an underestimate 
given that no information on mobility aid status was available in 35% of patients’ records.  
FMD patients were less likely to be current smokers compared to control cases. Unexpectedly, 
the significant smoking rate difference was not explained by the presence of schizophrenia 
patients in the control group. Patients with mental health disorders generally however have 
consistently high rates of smoking compared to the general population (Dierker & Donny, 
2008; Lê Cook et al., 2014) and smoking may, at least partially, account for their higher 
mortality compared to the general public. In this case, smoking may be a form of symptom 
control and reduce anxiety.  
Our finding suggests that FMD is a protective factor against smoking compared to the control 
group but FMD patients in our study were still more likely to smoke than the English general 
public. This was relatively surprising as it was hypothesised that patients with an FMD 
diagnosis might be more health-conscious or health-anxious and, as a result, be less likely to 
smoke than the general public. There is however little previous research on smoking in FMD or 
other somatoform disorders. A survey of general practice found no difference in current 
smoking rates between patients with persistent medically unexplained symptoms and patients 
with medical diagnoses (Dirkzwager & Verhaak, 2007). Our logistic regression analysis did not 
find any relationship between smoking and FMD membership. It is likely that pre-morbid 
employment, a history of health or social care work and a psychiatric admission history partly 





No differences were observed on BMI scores between our FMD and control groups, however 
FMD males had a significantly higher mean score than male controls. Firm conclusions cannot 
be drawn as BMI data was not consistently available. It is possible that BMI was recorded by a 
clinician when weight was treated or seen as specifically problematic. Our study collected the 
latest available data on BMI so it is also possible our results are an underestimate as patients’ 
scores may improve once in the healthcare system as a general response to healthcare, or to 
specific weight management treatment.  
74.5% of FMD patients had a comorbid physical health condition and they were nearly twice as 
likely to experience illness compared to the control group. The most common type of illness 
was neurological of which headache was the most common example. FMD patients were less 
likely to have infectious and parasitic diseases, a result which may be explained by the higher 
occurrence of HIV and hepatitis amongst substance abuse patients in our control group.  
That FMD patients experience more neurological comorbidities is not unexpected. NES 
patients report more migraine than patients with epilepsy (Shepard et al., 2016). Neurological 
disease comorbidity has been reported in 12-17% of FMD patients (Feinstein et al., 2001; Kim 
et al., 1999). In these studies, comorbid disease was most frequently organic tremor and 
Parkinson’s disease. The high rate of physical health co-morbidities found in our FMD group 
may be somewhat inflated however due to our classification of headache as a neurological 
disease rather than as a comorbid functional disorder. A further analysis which reclassified 
headache as a functional disorder would likely reduce the rate of comorbid illness in FMD 
patients. Future research might benefit in distinguishing headache from migraine and 
classifying them as two separate entities.  
These results might be influenced by a referral or surveillance bias. In order to qualify for 
inclusion in our study, FMD patients will have been referred to a physician prior to their FMD 
diagnosis. Attending a doctor’s appointment will mean you are more likely to detect an 
existing illness compared to control patients who may be less likely to have their physical 
health monitored. In addition, a clinician might be more likely to look for, and subsequently 
find, physical health issues as they may be concerned about potentially misdiagnosing a 
functional patient. There is some evidence of this in our study as the ‘unknown’ rate of 
physical diagnoses was higher in the control group than the FMD group indicating that the 






5.4.1.3 Life events 
No associations were found regarding rates of childhood sexual or physical abuse or adulthood 
sexual or physical abuse and FND diagnosis.  
The 20% rate of CSA in our study was slightly lower than previous reported rates in FND. Rates 
range from 24% (Roelofs et al., 2002), 25% in an all-female sample (Akyuz et al., 2017) to 
26.3% (Sar et al., 2004). These studies recruited from psychiatric settings and used a broad 
definition of functional disorder.  
Our 22.7% rate of CPA corresponds to the rate in Nicholson et al.’s (2016) study of 23.2%, and 
the 23.8% rate reported in patients with conversion disorder in public hospitals in Lahore 
(Farooq & Yousaf, 2016), but is lower than the 27.3% reported by McCormack et al. (2013) in 
an inpatient setting, and the 28% reported by Roelofs (2002) in psychiatric settings. In 
psychiatric outpatient settings in Turkey, physical abuse has been reported to be as high as 
44.7% (Sar et al., 2004) and 53% (Akyuz et al., 2017), both in psychiatric outpatient settings in 
Turkey. These higher rates may reflect cultural differences and the high proportion of women 
in study samples.  
The finding in our study that childhood abuse rates did not differ between the FMD and 
control group may be surprising given the theoretical antecedents of FND. Nonetheless, it is 
well established that there is a link between sexual abuse and many other later life mental 
health disorders, for example the association between the experience of CSA and psychosis is 
well-established (Bebbington et al., 2011) and a meta-analysis reported a history of sexual 
abuse was associated with an increased risk of anxiety, depression, eating disorders, 
posttraumatic stress disorder, sleep disorders, and suicide attempts (Chen et al., 2010). These 
associations persist, regardless of gender or the age at which abuse begins. It is therefore likely 
that abuse will feature to some degree in a proportion of all mental health diagnoses. We are 
likely to have observed a statistical difference had we compared FMD patients to health 
controls.  
It is important to note the assessments used to measure prevalence of abuse. Many previous 
studies used semi-structured clinician-led interviews such as the Structured Trauma Interview 
(Akyuz et al., 2017) and the Life Events and Difficulty Schedule (Nicholson et al., 2016). The 
result in our study may underestimate the true rate given our retrospective design and our 
necessary reliance on clinicians’ data. Memory of past experiences is dependent on cognitive 
ability and shaped by subsequent re-tellings. Patients with mood disorders may be 





Eliciting information on abusive or traumatic experiences requires skilled training and a 
considerable amount of clinical time, a factor we could not assess in our results.  
In addition, we were limited in the type of information we could collect. The type of abuse, the 
length of time it persisted, who the abuser was in relation to the victim, and the age of abuse 
onset may all contribute to the emergence of FMD. Due to the limitations of using a 
retrospective clinical database, we did not include a severity index in our study or assess the 
experience of specific types of abuse. A patient who experienced sexual abuse once will be 
categorised in the same way as a patient who was chronically abused throughout their 
childhood, likely obscuring some of the nuances in the link between exposure to abuse and 
FMD manifestation. In addition, the lack of specific information on abuse means we are unable 
investigate possible causal processes involved.  
The qualitative analysis in our study of life events showed an increase in negative events prior 
to symptom onset. FMD patients were more likely to have been bullied in primary or 
secondary school, to be involved in workplace, school or university disputes, legal disputes, 
and to experience problems in a sexual relationship like divorce or interpersonal violence. 
Taken together, these events could be defined as difficulties within interpersonal relationships; 
a finding somewhat echoed by Stone et al. (2004) who note that patients with pseudoseizures 
had a higher rate of life events linked to family life than patients with motor symptoms.  
Regarding personality, dependent personality disorder and histrionic personality disorder have 
been reported to feature in between 10-20% of FND cases (Toone, 1990). This finding is not 
borne out in our diagnostic results as only 7.8% of the FMD sample had a secondary comorbid 
personality disorder diagnosis. It is possible that clinicians are reluctant to give a definitive 
personality diagnosis. In addition, our study did not include any validated personality 
assessment. Firm conclusions on the role personality play in FMD cannot be made. 
5.4.1.4 Regression analysis 
Our logistic regression analysis found the independent variables associated with an FMD 
diagnosis were female gender, being married, having pre-morbid employment, having a 
comorbid physical health problem, and having a carer. Part of these associations may be 
explained by the make-up of the control group. When patients with a schizophrenia diagnosis 
were removed from both the control and FMD group, the only predicative independent 





5.4.1.5 Outcome measures 
The first and last available HoNOS, HoNOS-ABI and PHQ-9 scores were collected. Two HoNOS 
scores were available for 21.4% of the FMD group, but 49.7% of the control group. FMD 
patients’ HoNOS scores remained stable over time but were not significantly different to the 
control group, who did see improvements in scores over time. FMD patients’ HoNOS-ABI and 
PHQ-9 significantly improved with time.  
Previous research suggests prognosis of FND is poor. A systematic review by Gelauff and Stone 
(2016) reported that 40% of patients were the same or worse at follow-up while 20% of 
patients showed a complete remission. The primary purpose of our study was not to assess 
prognosis. It is also difficult to draw definitive conclusions on patient improvement given the 
low percentage of available clinical information on FMD patients and the fact that the clinical 
scores relate only to time and not to a specific psychosocial intervention or medication. Our 
sample was drawn from across the Trust and different patients may have been given different 
types of treatment or no intervention at all, information that was not available to assess. The 
reduction in scores might equally be explained by a regression to the mean phenomenon. The 
following chapter examines scores linked to a CBT intervention and allows for a more robust 
interpretation of clinical improvement.  
A future study might find it beneficial to examine the clinical sub-scales which could help draw 
out the associations between specific psychological factors and socio-demographic variables, 
symptoms and clinical correlates. 
5.4.2 Strengths and limitations 
This study is one of the largest on FMD in the field and benefits from access to a range of rich 
clinical data.  
The method we employed to identify cases relied on a keyword search. This allowed for the 
establishment of a large case series of patients with a confirmed diagnosis of FMD. Our search 
strategy however did not allow us to assess the false negative rate and it is likely that there 
were patients in the CRIS database who did not appear in our search, but who nonetheless had 
an FMD diagnosis. Given the multitude of synonyms associated with a functional disorder 
diagnosis, it is possible that our search terms were not exhaustive and more FMD patients 
were present in the database than were detected in our study. While the search strategy we 
employed allowed for the collection of a large amount of data, it does not allow us to calculate 





A second limitation relates to the specialised nature of SLaM services and possible limitations 
on generalisability. SLaM provides a tertiary neuropsychiatry service through the Lishman Unit 
and a neuropsychiatry outpatient service who receive referrals from across the UK. Our FMD 
patients may be more severe than patients observed in other Trusts. While this may affect the 
generalisability of our findings, it is unlikely to affect our comparative analyses as SLaM also 
provides many tertiary services which also offer national referrals. These services are 
represented in our control group, for example the Behavioural Genetics Service, the maternal 
and perinatal mental health services, and Attention Deficit and Hyperactivity disorder (ADHD) 
services. Our case-control design ensures that the selection factors and biases that lead to a 
patient receiving treatment from secondary and tertiary mental healthcare services are 
accounted for in our analyses and it is the factors that are most specific to FMD that we sought 
to highlight. 
Another potential difficulty linked to the referral issue is that this study will only represent 
patients who have receive a referral to clinical services at all. There may be FMD patients who 
are less likely to receive a referral to secondary or tertiary services and such patients may be 
systematically different to those we have observed in this study. For example they may have 
more severe symptoms or be demographically different in certain ways. Such a bias is inherent 
in much healthcare research where those patients who receive referrals and treatment are 
likely to be different to those who do not.      
The data in this study was obtained from clinicians’ notes. Any clerical errors will therefore be 
reproduced in our study. Clinicians’ own biases or fluctuating trends in clinical formulation or 
case note writing may affect results. An example of this would be a theoretical presumption on 
the link between bullying and FMD. A clinician who believes a link exists may be more likely to 
ask about bullying experiences or to record it compared to a clinician making other causal 
assumptions. These types of biases may be mitigated due to our study’s large sample size and 
the broad range of services included in the study.  
A ‘not known’ and ‘not applicable’ category was included when appropriate throughout our 
study to allow for the estimation of missing data. This allowed for the recording of instances 
where no information on a variable was available. In the case of childhood sexual and physical 
abuse, rates of ‘unknown’ information were higher in the control group, perhaps suggesting 
clinicians were not as likely to routinely address abuse experiences compared to FND 
consultations. A related issue concerns researcher bias. Data in this study could not be 





A further limitation relates to information regarding life events. Assessing potential life 
experience precipitants highlighted associations between FMD and certain life events like 
bullying or difficulties in the workplace. There is a potential difficulty however as the 
categorical nature of the data could not account for the severity or duration of these events. 
Two separate experiences of bullying or abuse may represent very different phenomenological 
experiences as patients will assign different meaning and narratives to experiences Our results 
regarding these precipitants should be viewed as preliminary and our life event results should 
not be viewed as having predictive power. Future research in this area may benefit from the 
employment of vignettes and standardised face-to-face interviewing to allow for subjective 
experience and personally ascribed meaning to be taken into account. 
5.4.3 Conclusions 
This study is one of the largest studies on FMD. It draws on a large medical database which 
allows for the exploration of a broad range of clinical, demographic and health factors. This is 
an exploratory study and its results suggest there are specific and distinctive features of 
functional motor disorder.  
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Chapter Six: A case-control study assessing outcomes of functional motor disorder patients 






Chapter Five described an exploratory study investigating the demographic, social, and health 
factors associated with the presentation of FMD in South London and the Maudsley (SLaM) 
NHS Trust. This chapter investigates the outcomes of patients with the same disorder who 
received outpatient CBT from a neuropsychiatric clinic in SLaM.  
The neuropsychiatry clinic treats patients with psychological complications resulting from 
neurological disorders such as epilepsy, Tourette’s syndrome, movement disorders, and 
dementia. The clinic also receives referrals for patients with depersonalisation, functional, 
somatoform, and other dissociative disorders.  
This introduction discusses the cognitive-behavioural model of therapy, evidence for CBT 
treatment of somatoform disorders generally and functional disorders specifically, the types of 
assessments used to assess clinical change, and outlines the aims of this study.  
6.1.1 The cognitive-behavioural model  
CBT is a talking therapy that emphasises the importance of cognitions and behaviours in the 
maintenance of mental disorder and distress.  
In early iterations of the CBT model, Beck (1970) and Ellis (1962) argued that maladaptive 
cognitions contribute to the maintenance of emotional distress and behavioural problems. 
These cognitions include general beliefs and schemas about the world, the self, and the future, 
which can give rise to specific and automatic thoughts about situations, and which may lead to 
maladaptive behaviour. The CBT model makes three assumptions: i) cognitive activity affects 
behaviour, ii) cognitive activity can be monitored and altered by the self, and iii) changing 
peoples’ cognitions can change behaviour (Dobson & Dozois, 2010).  
The goal of CBT is the reduction of symptoms and the improvement of functioning. Treatment 
is viewed as a collaborative exercise in problem-solving where maladaptive cognitions are 
challenged and changed in order to modify behaviours (Hofmann et al., 2012). CBT draws from 
the “three P” model which distinguishes causal factors as predisposing, precipitating and 
perpetuating in the development of distressing symptoms (Beck, 1976). 
Predisposing factors are those relatively early risk factors such as genetics, birth or 
developmental processes. As outlined in Chapter Five, there is some evidence on the 





include witnessing parental illness as a child (Walker et al. 1993), childhood adversity, parental 
neglect and childhood physical and sexual abuse (Alper, 1993; Fiszman et al., 2004; Kaplan et 
al., 2013; Karatzias et al., 2017; Leroi et al., 1995; Morrison, 1989; Roelofs & Spinhoven, 2007; 
Walker et al., 1997; Walker et al., 1993; Wing et al., 1998). The evidence suggests a dose-
response relationship between trauma and functional disorder symptoms (Karatzias et al., 
2017) where specific types of events may have stronger associations than others such as the 
death of a partner or parent, and life threatening illnesses or injury. 
Precipitating factors may occur close to the onset of symptoms for example the loss of a job, 
the onset of a physical disease, financial or social distress like the breakdown of a relationship. 
Known factors in the precipitation of unexplained symptoms include physical assault, domestic 
violence (Koss et al., 1991), trauma (Solomon, 1988), and natural disasters (Escobar et al., 
1992). These experiences may interact with predisposing factors and push the patient into a 
distressed state.  
The timing of the event may be important. Nicholson et al. (2016) found FMD patients were 
more likely to have experienced a severe life event in the month prior to symptom onset 
compared to patients with depression and healthy controls. These events were also more 
likely to be, ‘escape events’, defined as events that could be changed or affected by becoming 
unwell. Examples include unpleasant work environments or relationship difficulties, where 
becoming unwell could help a person escape an unpleasant experience (Aybek et al., 2014). 
Unlike the often inconspicuous onset of a disorder like depression or anxiety, Stone et al. 
(2012b) argue that functional symptoms often start acutely and may be an active responses to 
life events. 
Perpetuating factors are those that prolong the symptom experience. These factors range 
from social isolation (Lidbeck, 1997) to personal factors like attention (Barsky et al., 1988), 
bodily arousal (Heim et al., 1998), illness beliefs (Kolk et al., 2003; Sensky, 1997), and illness 
behaviour (Allen et al., 2006). Perpetuating factors are often the first to be addressed in CBT 
sessions.  
No unified causal model explains why some people develop functional motor symptoms and 
others do not. Each patient may have causes that are specific to them alone. CBT’s theoretical 
model identifies cognitive, behavioural, affective and physiological factors focusing on the 
issues linked to the perpetuation of symptoms. There is an underlying assumption that no 
single process or cause explains symptoms but rather a multi-factorial interaction these factors 





One approach that reflects the multi-factorial nature of CBT is the ‘five areas assessment’ 
(Williams, 2001) highlighted in Figure 33 below. The person’s social situation, symptoms, 
behaviour, thoughts, and emotions are appraised, and the causal explanations that a patient 
makes regarding their symptoms are viewed as highly relevant.  
 
Figure 33 The five areas assessment model (reproduced courtesy of Kent and McMillan (2009)) 
In treating FND, a CBT therapist adopts a number of techniques to address perpetuating and 
precipitating factors. Techniques include muscle relaxation, psychoeducation, grounding 
techniques to address anxiety, challenging misinterpretations of physical symptoms, teaching 
problem solving skills in daily life, facilitation of emotional awareness, cognitive restructuring 
of dysfunctional thoughts and illness beliefs, and helping to improve interpersonal 
communication. Thought diaries are often used where patients list symptoms along with 
accompanying feelings and thoughts (Sharpe et al., 1992). These techniques are often 
employed in order to identify and restructure maladaptive cognitions and to alter illness 
behaviour.   
Patient engagement is an important part of the CBT process, and may be particularly difficult 
for FMD patients as they may be invested in finding a medical explanation for symptoms. 
Clinicians will often begin by eliciting patients’ conceptualisations of their own symptoms. It is 
advised that all medical investigations are completed by the time the patient starts therapy to 
remove any doubt about symptom cause although the possibility of a physical diagnosis can 
never be definitively ruled out (Kent & McMillan, 2009). This is not necessarily an impediment 





integrated view of their symptoms, one that highlights the interaction between physical and 
psychological processes.  
In summary, CBT attempts to help patients become aware of, and to examine the way they 
think, respond emotionally, and behave in response to their unexplained symptoms. While the 
overall aim is often to increase functioning and reduce symptoms through the reinterpretation 
of bodily symptoms, changing illness cognitions, beliefs, and avoidant behaviour are an 
important part of the CBT process.  
6.1.2 Existing evidence for CBT 
This section outlines evidence on the effectiveness of CBT for somatoform disorders generally 
and functional disorders specifically. 
6.1.2.1 Somatoform disorders 
There is good evidence that CBT is effective in the treatment of most somatoform disorders.  
A meta-analysis included sixteen studies which trialled the effects of psychotherapy for severe 
somatoform disorder (Koelen et al., 2014). The effect of psychotherapy on physical symptoms 
(Cohen’s d = 0.80) and psychological symptoms (Cohen’s d = 0.75) was large and these 
improvements were maintained nearly a year after treatment. Younger people, women, and 
patients with somatization disorder showed greatest improvements.  
A systematic review comprising fifteen randomised controlled trials (RCTs) examined the 
effects of CBT on CFS (Price et al., 2008). Fatigue mean scores at post-treatment significantly 
reduced with 40% of participants showing a clinically significant response to treatment 
compared with 26% in usual care. 
Another review of CBT distinguished between trials targeting specific syndromes such as CFS, 
IBS and pain (25 studies) and those focussing on general somatisation (6 studies) (Kroenke & 
Swindle, 2000). The most frequent primary outcomes in these studies were reductions in 
physical symptoms, followed by reductions in psychological distress and improvements in 
functional status. Across all studies, physical symptoms were most responsive to treatment 
compared to control conditions.  
Nezu et al. (2001) completed a systematic review on the effects of treatments on medically 
unexplained symptoms. CBT resulted in improvements in physical and social functioning. 
Looper and Krimayer (2002) also found evidence on the efficacy of CBT in the treatment of 





treatment offered for these patients but that a minimum duration of treatment has yet to be 
established.  
A Cochrane review evaluated psychological therapy and its effects on somatoform disorders 
and patients with medically unexplained physical symptoms (van Dessel et al., 2015). Fourteen 
of the 21 studies were CBT studies. They found CBT was more effective than usual care in 
reducing the severity of symptoms and this remained at follow-up. Studies with the lowest 
effect sizes also offered the lowest intensity CBT. Overall, CBT had the same proportion of 
dropouts as usual care. The authors suggest that psychological therapies are better than 
standard care but, effect sizes are small. 
Regarding specific somatoform diagnoses, of six trials examining the effect of CBT on back 
pain, symptoms improved significantly in four (Turner, 1982; Nicholas et al., 1991; Turner & 
Jensen, 1993; Lamb et al., 2010). However, depressive symptoms improved in only one trial 
(Turner, 1982). The number of CBT sessions offered across these studies tended to be small 
ranging from five to eight.  
There is evidence that CBT is effective in the treatment of CFS. A systematic review (Whiting et 
al., 2001) reported an overall positive effect of CBT in three of four RCTs (Deale et al., 1997; 
Prins et al., 2001; Sharpe et al., 1996). One of the trials followed patients for five years post-
intervention and global improvement was sustained as well as the proportion of patients who 
had recovered completely (Deale et al., 2001).  
CBT is effective in the treatment of IBS. A meta-analysis assessed the results of eighteen RCTs 
(Li et al., 2014) and CBT was superior in reducing the number of symptoms compared to 
waiting lists, medical intervention controls, and basic support groups. A recent meta-analysis 
found psychological therapies, of which CBT treatment was the most frequent, produced a 
greater average improvement in mental health and daily functioning compared to control 
interventions, but no significant effects emerged for the number of sessions or the duration of 
therapy (Laird et al., 2017).  
A small trial examined the effect of CBT for patients with medically unexplained physical 
symptoms and compared it to optimised medical care (Speckens et al., 1995). This study 
acknowledged the heterogeneous nature of patients’ symptoms and adopted a broad CBT 
approach. While the authors didn’t specify a primary outcome measure, they did report a 
higher recovery in the intervention group along with a lower intensity of physical symptoms. 
Another study comparing eight sessions of CBT to a waiting list control found reductions in 





CBT sessions compared to usual care for patients with multiple unexplained somatic symptoms 
(Allen et al., 2006). Symptoms were significantly less severe in those after receipt of CBT and 
there was a greater decrease in health care costs. 
These findings suggest psychotherapy generally and CBT in particular are effective in the 
treatment of a range of unexplained symptoms although the evidence on the number of CBT 
sessions needed is not definitive. There is considerable heterogeneity in the follow-up lengths 
employed across studies and the outcome measures chosen. Most commonly, symptom 
reduction is the primary outcome in studies although this may not necessarily be the primary 
focus of CBT.  
The following section examines the evidence for FNDs specifically. 
6.1.2.2 Functional neurological disorders 
There is evidence on the efficacy of CBT for functional neurological symptoms. CBT has been 
trialled in the treatment of NESs but less evidence exists on its effectiveness for patients with 
motor symptoms (Halligan et al., 2001).  
La France et al. (2009) conducted a small non-controlled trial with 17 patients with NES. The 
CBT therapist in this study encouraged patients to make connections between their mood, 
cognition and environment as well as recognising automatic and catastrophic thinking, and 
misinterpretations of normal bodily sensations. Eleven of the 17 patients saw a 50% drop in 
their seizure attacks and anxiety, depression, quality of life, and psychosocial functioning 
improved.  
In an RCT assessing the efficacy of CBT for NES, participants received standard neuropsychiatric 
care or standard neuropsychiatric care and one-on-one CBT (Goldstein et al., 2010). Twelve 
CBT sessions were offered with the primary aim of interrupting behavioural, physiological and 
emotional patterns at the start of a seizure. Participants in the intervention group reported a 
greater reduction NES than the control group although the difference was only slightly 
significant at a six-month follow-up period.   
Sharpe et al. (2011) conducted a large RCT testing a CBT-based guided self-help workbook for 
patients with functional symptoms recruited from neurology services. This was compared to 
usual care. This sample included, but was not exclusive to, patients with functional motor 
symptoms. A number of limited face-to-face sessions were offered to explain the workbook 
and gave support where needed. At three months, 30% of intervention patients rated 





There is limited evidence for CBT for functional motor disorder specifically. LaFrance and 
Friedman (2009) reported a case of a 22-year-old patient with functional generalised dystonia 
and facial twitching. By session four she had a complete resolution of her abdominal and arm 
dystonia. Her facial twitching improved intermittently but by week twelve, the authors report 
a complete remission.   
Psychodynamic psychotherapy has been trialled for FMD patients with mixed results. Hinson et 
al. (2006) conducted a trial where ten patients received twelve weeks of psychodynamic 
psychotherapy, and antidepressants when necessary. Nine of ten patients showed an 
improvement in motor symptoms on a video rating scale. The same therapy was trialled by 
Kompoliti et al. (2014) over a six-month period. They found benefits for psychotherapy 
compared to observation and support. The small sample sizes of these studies make definitive 
conclusions are difficult to draw.  
Given the high prevalence of functional disorders generally and the ubiquity of CBT as a 
treatment option in most mental health trusts, there is a surprising lack of information on 
CBT’s effectiveness in treating FMD.  
Unlike anxiety disorders or depression, the treatment of FMD with psychological therapies 
presents unique challenges. The continual revision in its case definition, the tendency for 
patients to be relayed between physical and mental health clinicians and the high rate of 
comorbid physical disease in this patient group may have contributed to a dearth of evidence 
in this area. It is likely that most patients are treated in primary care settings alone and many 
may never be offered or even accept psychological therapy.  
Acceptability of CBT is a critical issue. Many of the studies outlined above do not report pre-
treatment up-take rates or dropout rates once therapy starts. It is likely that patients who do 
not accept a psychosocial account of their symptoms will not be willing to take part in therapy. 
Problematically, many of the primary outcomes in these trials are reduction in somatic 
symptoms, but they do not address the psychological effects of the treatment. Our study 
attempted to address these concerns and address the general paucity of existing evidence on 
the effect of CBT on FMD. 
6.1.3 Aim of study 
This study utilised the CRIS medical record database used in Chapter Five to evaluate the 
outcomes of patients with FMD receiving CBT in an outpatient neuropsychiatry clinic in SLaM 





The socio-demographic and health characteristics of FMD patients were compared to a group 
of patients with organic symptoms who also received CBT at the same clinic in order to 
examine the potential risk factors for poor outcomes. Organic disease patients were chosen as 
the comparison group as they were less likely to have functional comorbidities and were 
therefore more likely to allow the identification of risk factors in FMD patients. We also sought 
to compare CBT-uptake and dropout rates, the rate of physical symptom improvements in 
FMD patients and the change in acceptance of psychological explanations amongst FMD 
patients between the start and end of therapy, and patients’ clinical outcomes. 
6.2 Methods 
6.2.1 Study setting 
The study sample was derived from the SLaM Biomedical Research Centre’s (BRC) 
retrospective case register. A detailed description of CRIS and the SLaM trust is outlined in 
Chapter Five.  
The neuropsychiatry service in SLaM provides neuropsychiatry inpatient and outpatient 
services in the form of assessment and treatment, neuroimaging, telemetry services, speech 
and language therapy, support and education for families and carers, and cognitive 
rehabilitation. Neuropsychiatric CBT assessment and treatment is provided by the clinic in the 
form of both inpatient and outpatient services.  
If a patient is referred to the outpatient neuropsychiatry clinic, they are assessed by a 
neuropsychiatrist who takes a clinical history, completes a physical examination, and makes a 
formal assessment of the patient’s mental state. They may also conduct a neuropsychological 
exam and complete neuroimaging and neurophysiological assessments.  
If recommended by the consultant neuropsychiatrist, the patient may be referred for an 
outpatient CBT assessment.  
6.2.2 The CBT intervention 
The neuropsychiatric CBT team is made up of four CBT specialist practitioners. They offer two-
hour assessments for patients who may have psychological, emotional, behavioural or 
psychosocial problems. Following assessment, they may offer patients a course of CBT. 
Treatment sessions are one hour. The normal course of treatment is 15 sessions which usually 





CBT sessions can include psycho-education, cognitive and behavioural techniques, and relapse 
prevention strategies. The therapist may challenge cognitive distortions that affect motivation 
and a patient’s ability to engage on an interpersonal level. They will attempt to build a 
patient’s insight so they can learn to accept a psychological understanding of their symptoms 
and teach methods by which the patient’s locus of control shifts from an external to internal 
model. The patient may be encouraged to link their past and present experiences with their 
physical symptoms but this is not always the case. Other techniques include keeping mood and 
thought diaries where the patient links their mood and thoughts to their environment. These 
diaries may be used as homework material for the following week’s session. Other activities 
include using relaxation techniques when a patient has fears and expectations around 
improvement and graded exposure techniques where they attempt to reduce avoidance.  
6.2.3 Data collection 
The aim of this study was to obtain detailed demographic, clinical, and treatment-related data 
for all patients with functional motor disorder treated with CBT in the neuropsychiatry 
outpatient clinic. This is a retrospective treatment outcome study with FMD cases and a clinical 
comparison group. 
6.2.3.1 Ethics approval 
CRIS was approved as an anonymised data resource for secondary analysis by Oxfordshire 
Research Ethics Committee (08/H0606/71+5). All CRIS projects are reviewed and approved by 
a dedicated patient-led oversight committee (Fernandes et al., 2013). 
6.2.3.2 Inclusion and exclusion criteria 
The study’s inclusion criteria were as follows:  
I. Aged over-18;  
II. Patients received CBT treatment due to an ICD-10 diagnosis, ‘Conversion disorder with 
motor symptom or deficit’ (F44.4) or received treatment as a result of functional 
motor or movement symptoms (without a formal ICD-10 diagnosis stated in CRIS’s 
structured text).  
Inclusion criteria for control group participants were as follow:   





II. Had a physical diagnosis with no evidence of functional symptoms and had received 
CBT treatment from the same neuropsychiatry clinic.  
The study’s exclusion criteria were as follows:  
I. Any participants treated only for NESs;   
II. A patient who was referred for treatment but treatment had not started; 
III. Patients who had received only a CBT assessment and were awaiting treatment or 
referral to the clinic. Participants were however included if CBT treatment had begun 
but was not yet complete.  
Twenty participants were included in this study whose treatment was on-going (nine cases and 
eleven controls). Controls were unmatched for demographic or clinical variables to allow for 
the assessment of between-group differences according to these variables.  
6.2.3.3 Search strategy 
The names of the four CBT clinicians working within CBT neuropsychiatry clinic were used as 
search terms on the CRIS interface to identify participants. CRIS returns patient level data if the 
clinician’s name appears in the patient’s clinical records at any stage. Table 45 outlines the 
numbers of patients returned with each clinician search in CRIS.  
Table 45 Total service users returned in number of CRIS search linked to each clinical 
psychologist 
 n (%) 
Clinician one 29 (3.1) 
Clinician two 215 (22.8) 
Clinician three 291 (30.9) 
Clinician four 406 (43.1) 
Total  941 (100) 
Duplicate cases removed 590 
In total, 1531 patients were returned from the search. 590 (38.5%) were duplicates and were 
removed, leaving 941 unique service users.  
Of these 941 patients, 573 patients were removed from our analysis. These patients had 
functional symptoms which were not classified as functional motor symptoms. The majority of 
these symptoms comprised NESs. Twenty-one patients were removed because they did not 
fulfil study criteria, for instance they were aged under-18. This left 200 patients with functional 





Figure 34 outlines the flowchart showing the number of patients considered for inclusion in 
the study.  
 
Figure 34 Flowchart showing total number of patients considered for study inclusion 
throughout study 
One hundred and two FMD patients and 71 control patients were excluded from our analysis 
because they did not receive CBT treatment. These patients should be considered as ‘pre-
treatment dropout’. In these cases, CBT was suggested but they patient did not end up 
receiving it. This left a total of 98 FMD patients and 76 control patients in our study. Table 46 
outlines the stage of the care pathway at which patients when excluded from our study. 
Table 46 Stage of treatment pathway at which patients were excluded from treatment 
Stage of treatment pathway at 






n (%) χ2 95% CI 
p 
 value 
Referred for assessment, excluded 24 (23.3) 33 (46.5) 10.01 7.8 - 37.5 0.002 
Assessed, excluded 21 (20.6) 7 (9.9) 3.5 -1.2 – 21.5 0.06 
Referred for treatment, excluded 20 (19.6) 17 (23.9) 4.3 -8.7 – 18 0.5 
Inpatient at Lishman Unit, excluded 37 (36.3) 14 (19.7) 5.5 2.1 – 30 0.02 
Total 102 (100) 71 (100)    
 
36.3% of excluded FMD patients and 19.7% of excluded control patients were treated in the 





65 FMD and 57 control group patients were excluded at the point they were referred for 
assessment, at the stage they received an assessment, or after they received a referral for 
treatment. The reasons why they were excluded at these stages are outlined in Table 47. 
These reasons why FMD and control group patients were excluded at pre-CBT treatment were 
compared. Apart from admission to the Lishman Unit, the most common reason potential FMD 
patients were excluded was because they did not attend an assessment or treatment 
appointment (29.2% of excluded participants). The most common reason for exclusion 
amongst the control group was because there was no information on treatment sessions 
available in their notes (38.6% of excluded participants) and this reason was significantly more 
common in the control compared to the FMD group (χ2: 12.8, 95% CI: 11.6 – 43, p = 0.0003). A 
significantly higher proportion of FMD patients refused treatment compared to control group 
participants (χ2: 8.6, 95% CI: 5.4 – 30.3, p = 0.03). All exclusion causes are outlined in Table 47.  







n (%) χ2 95% CI 
p 
value 
Did not attend assessment or 
treatment appointment 
19 (29.2) 19 (33.3) 4.1 -13.2 - 21 0.6 
No information in notes 7 (10.8) 22 (38.6) 12.8 11.6 – 43 0.0003 
Local PCT declined funding 7 (10.8) 5 (8.8) 0.14 -10.3 – 13.7 0.7 
Received treatment elsewhere 6 (9.2) 3 (5.3) 0.7 -7 – 14.5 0.4 
Patient decided clinic too far or wanted 
treatment locally 
4 (6.2) 1 (1.8) 1.5 -4.4 – 13.4 0.2 
Patient refused treatment 14 (21.5) 2 (3.5) 8.6 5.4 – 30.3 0.003 
Harm to patient (e.g. hospitalisation, 
self-harm or suicide before treatment) 
1 (1.5) 2 (3.5) 0.5 -5.4 – 10.7 0.5 
Staff decided patient wouldn’t respond 
to or engage with treatment 
4 (6.2) 1 (1.8) 1.5 -4.5 – 13.4 0.2 
Staff decided patient wasn’t suitable 
for treatment 
3 (4.6) 1 (1.8) 0.7 -5.7 – 11.3 0.4 
Total 65 (100) 57 (100)    
PCT: Primary care trust 
 
6.2.4 Measures  
Data were taken from both unstructured and structured fields in CRIS. Unstructured fields 
include patients’ notes, correspondence and events. Structured fields included outcomes like 
date of birth, clinical outcome scores and diagnoses. 
Demographic and clinical variables were extracted for all participants including year of birth, 





patients’ first ICD-10 diagnosis received in SLaM and any subsequent diagnosis that was 
categorically different from the first.  
Health variables included the most recent available information on smoking status, the most 
recent available BMI score, and information on any psychiatric inpatient admissions and 
discharges.  
Life event information was collected which included any experience of childhood sexual or 
physical abuse (classified as experienced under the age of 18) or any experience of sexual or 
physical abuse over the age of 18. Additionally, any positive family history of a mental health 
problem was recorded including the relationship to the patient and what the condition was.  
Acceptance of psychological accounts of symptoms was assessed from unstructured text 
before the patient started treatment and at the end of treatment. This was assessed as a five-
point categorical variable as, ‘yes’, ‘no’, ‘patient unsure’, ‘information not known’ or ‘not 
applicable’. 
CBT attendance was recorded as the number of CBT sessions offered and the number of actual 
sessions attended. If there was a discrepancy between the two, the reason was recorded. The 
date in which patients attended their assessment session was collected along with the date of 
their first and last treatment session, and their last follow-up session.  
Information on dropout and its reasons was taken and, if available, we defined dropout as the 
early cessation of treatment. 
The following sections describe in more detail the measures used regarding ‘patient 
improvement’ and clinical outcome scores.  
6.2.4.1 Patient improvement 
Clinical outcome measures were recorded when available. A scoring system was agreed upon 
by the study team which was comprised of a three point scale, ‘patients’ symptoms improved’, 
‘symptoms remained the same’, or ‘symptoms got worse’.  
Control patients’ improvement was based on individual patients’ primary goal set in therapy. 
Often this goal was not symptom-specific, but instead related to day-to-day functioning or 
mood.  
Pre-CBT scores were those classified as occurring nearest to the patients’ CBT assessment date 





session. A cut-off of 180 days was used. If a score was measured 180 days before or after the 
date in question, it was excluded.  
Clinical outcome scores included Clinical Outcomes in Routine Evaluation – Outcome Measure 
(CORE-OM), HoNOS, HoNOS-ABI and PHQ-9 scores. Below is an account of the psychometric 
properties of the CORE-OM measure. For further detail on the properties of HoNOS, HoNOS-
ABI and PHQ-9 measures see Sections 5.2.3.2, 5.2.3.3, and 5.2.3.4 respectively. 
6.2.4.2 CORE-OM  
The CORE-OM is a self-report questionnaire measuring psychological distress and is used to 
assess the outcome of psychological therapies. The questionnaire covers four domains relating 
to specific problems such as depression, anxiety and trauma, functioning in everyday life and 
relationships, subjective well-being, and risks to self and others.  
The measure contains 34 items and all items are scored on a five point scale (0 – 4) relating to 
the previous week. The measure takes between 5-10 minutes to complete. It was specifically 
designed for assessment and treatment evaluation and contains both high and low intensity 
items which relate to a patient’s overall emotional wellbeing. An example of a low intensity 
item includes, “I have been able to do most things I needed to” while a high intensity item is, “I 
have felt panic or terror”. A recommended cut-off between clinical and normal populations is a 
score of 10, a score derived from large samples of the UK population (Connell et al., 2007). A 
reliable change is considered to be five or more. Clinically significant change is indicated when 
a client’s CORE score moves from within the clinical range to that of the non-clinical population 
(below ten after therapy). The score presented in our study is the mean item score multiplied 
by ten, giving the clinical score. 
The CORE-OM has good criterion validity. Its correlation with the Beck Depression Inventory is 
r = 0.85. It has high internal consistency for secondary care (α = 0.95) and primary care settings 
(α = 0.93) (Barkham et al. 2005), and similarly high internal consistency scores for non-clinical 
samples (α = 0.94) (Barkham et al., 2001). A one-week test-retest correlation in a student 
sample of 43 participants was reported with a Spearman’s rho = 0.90 (Evans et al., 2002).  
The measure has been used to assess emotional well-being in a wide range of conditions and 
settings such as the treatment of depression in primary care (Gilbody et al., 2007), the 
outcomes of patients receiving CBT in primary and secondary care (Stiles et al., 2006), online 
CBT (Richards et al., 2013), and for patients with functional symptoms referred from neurology 





6.2.5 Statistical analysis 
Data were analysed using SPSS (IBM SPSS Statistics for Windows, Version 22.0, Armonk, NY: 
IBM Corp). Graphs were made using GraphPad Prism (version 7.00 for Windows, La Jolla 
California, USA). 
Descriptive statistics using means, standard deviations, count, and frequency data were used 
to assess differences between FMD and control groups. Differences between groups were 
calculated using Chi-square analyses for frequency data, t-test comparisons for normally 
distributed mean scores, and Mann-Whitney U calculations for non-normal comparisons. An 
exact McNemar’s test was used to determine the change in proportion of patients accepting 
the role of a psychological explanation for symptoms. A repeated measures ANOVA was 
conducted to assess the change in CORE-OM, scores and their associations with socio-
demographic variables. A binary logistic regression analysis was used to assess the socio-
demographic variables associated with treatment dropout in FMD patients.  
6.3 Results 
6.3.1 Participants 
In total, there were 98 FMD patients and 76 control group patients.  
There were significantly more females in the FMD group (71, 72.4%) compared to females in 
the control group (34, 44.7%) (χ2: 13.6, 95% CI: 12.2 – 41.9, p = 0.001).  
No significant differences in ethnicity between the FMD and control group. Britishness was the 
most common ethnicity in both the FMD (67.3%) and control (71.1%) groups.  
42.9% of the FMD group was single and a slightly higher proportion of control group patients 
were single (57.9%). 41.8% of the FMD group was married compared to 32.9% of the control 
group however there were no statistical differences in any type of marital status between 
groups.  
The most frequent form of housing type for FMD patients was privately owned 
accommodation (42.3%). Just under half of the control group lived in privately owned 
accommodation at 47.6%. Rates of residency in council accommodation, privately rented, or 
supported and temporary accommodation were similar across groups. There was a slight 
difference between groups in the rates of participants living with family members, with 25.6% 





of accommodation between groups. See Table 48 for a full breakdown of frequencies of 
gender, ethnicity, marital status, and housing for FMD and control groups.  
Table 48 Gender, ethnicity and marital status of F44.4 and control group patients 







 95% CI 
p 
value 
Gender      
 Female 71 (72.4) 34 (44.7) 13.6 12.2 – 41.9 0.001 
 Male 27 (27.6) 42 (55.3)    
Ethnicity      
 British 66 (67.3) 54 (71.1)  0.3 -10.9 – 18 0.60 
 Any other ethnic group 10 (10.2) 4 (5.3)  1.4 - 4.4 – 13.6 0.24 
 Any other black 
background 
9 (9.2) 2 (2.6)  3.1 -1.6 – 14.5 0.08 
 Any other white 
background 
5 (5.1) 7 (9.2)  1.1 -4.3 – 13.6 0.30 
 Any other Asian 
background 
4 (4.1) 1 (1.3) 1.2 -3.7 – 9 0.27 
 African 2 (2) 3 (3.9) 0.6 -4.1 – 9.3 0.46 
 Caribbean  1 (1) 2 (2.6) 0.65 -3.5 – 8.2 0.42 
 Indian 0 (0) 2 (2.6) 2.6 -1.7 – 9.1 0.11 
 Not known 1 (1.3) 1 (1.3) 0 -4.9 – 5.9 1 
Marital status      
 Single 42 (42.9) 44 (57.9) 3.8 - 0.8 – 30 0.051 
 Married or civil partner 41 (41.8) 25 (32.9) 1.4 -6.4 – 23.6 0.23 
 Divorced/Separated 9 (9.2) 4 (5.3) 0.9 -5.2 – 12.4 0.33 
 Cohabiting 4 (4.1) 2 (2.6) 0.29 -5.7 – 8 0.60 
 Widowed 2 (2) 1 (1.3) 0.13 -5.4 – 6 0.72 
Housing Type      
 Council tenant 10 (12.8) 7 (11.1) 0.09 -10.6 – 13.2 0.76 
 Living with family 20 (25.6) 12 (19) 0.86 -8.4 – 20.8 0.35 
 Privately owned 33 (42.3) 30 (47.6) 0.39 -12 - 22.4 0.53 
 Privately rented 14 (17.9)  13 (20.6) 0.16 -11.1 – 17 0.69 
 Other* 1 (1.3) 1 (1.6) 0.02 -5.6 – 7.4 0.88 
Not known 20 (20.4) 13 (17.1)    
* 
Supported and temporary accommodation  
At the point of analysis, the average age of FMD patients was 44.5 years (SD: 12). The average 
age of participants in the control group was 45.4 years (SD: 13) and there were no significant 
differences in age between groups.  
The average age at which psychological symptoms began in the FMD group was 30 years (SD: 
14), compared to 27.8 years (SD: 15) in the control group. This difference was not statistically 
significant. 
On average, there was a ten-year gap between symptom onset amongst FMD patients and 
their CBT assessment at the neuropsychiatry clinic. The mean age at which they received this 
assessment was 40.3 years of age (SD: 13), the same in the control group at 40.7 years of age 





Participants were stratified by gender to assess whether there were any age differences 
between FMD and control groups. No differences in age emerged between groups for either 
males or females. See Table 49 for a full breakdown of patients’ age at analysis, symptom 
onset and CBT assessment. 




Group test 95% CI 
p  
value 
Mean age (SD)      
 Age at analysis
1
 44.5 (12) 45.4 (13) 1.3 -1.4 – 7.4 0.19 
 Age at psychological symptom onset
2
 30 (14) 27.8 (15) 3105.5  0.27 
 Age at CBT assessment
2
 40.3 (13) 40.7 (13) 3669  0.87 
Mean age v gender      
 Female age of symptom onset
 2
 28.9 (13) 27.4 (14) 1043  0.49 
 Male age of symptom onset
2
 33 (15) 28 (15) 404.5  0.15 
 Female age at CBT assessment
2
 39.9 (13) 41.2 (12) 1134.5  0.62 
 Male age at CBT assessment
2
 41.5 (13) 40.3 (13) 539  0.73 
1
Independent samples t-test comparing mean age 
2 
Mann-Whitney U test 
The most recent data on employment was collected for both groups. A smaller proportion of 
FMD patients was employed compared to the control group (34% v. 48.7%) but the difference 
was not statistically significant.  
52.6% of the FMD group was unemployed compared to 35.5% of the control group, a 
statistically significant difference (χ2: 5, 95% CI: 1.4 – 31.9, p = 0.03). There were no other 
significant differences in employment rates between groups. 5.2% of the FMD group were 
medically retired.  
Unemployment was stratified by gender. There was a significant difference in the gender 
ratios of patients who were unemployed. A higher proportion of females was unemployed 
compared to females in the control group (74.5% versus 40.7%, χ2: 8.5, 95% CI: 8.9 – 55.3, p = 
0.004).  
Information was collected on whether participants were employed pre-morbidly. The rates 
were high in both groups, with 94.6% of the FMD and 91.7% of the control group employed 
prior to the onset of their symptoms. There was no statistical difference.   
Over a third of the FMD group received benefits (39.6%) but this did not differ significantly 
from the control group (35.7%). The most common type of benefit received by participants 
was Personal Independence Allowance (previously known as DLA). There were no statistical 
differences in the type of benefits received by participants between groups. Table 50 gives a 





Table 50 Employment and benefit status of functional motor and control group patients.  
In Chapter Five, social and healthcare work emerged as a common occupation amongst FMD 
patients. This was assessed again in this study. The current or most recently held position was 
recorded.  
While patients in the FMD group were more likely to work in social and health care settings 
(21.3% versus 14.9%), the numbers were low and the difference was not statistically different. 
When broken down by gender, a difference emerged. All FMD patients who worked in social or 
health care settings were women compared to 63.6% in the control group (χ2: 8.1, 95% CI: 5.9 
– 69.2, p = 0.005). 





n (%) χ2 95% CI 
p  
value 
Employment      
 Employed 33 (34) 37 (48.7) 3.8 -0.8 – 29.7 0.051 
 Unemployed 51 (52.6) 27 (35.5) 5 1.4 – 31.9 0.03 
 Retired 4 (4.1) 3 (3.9) 0.004 -7.5 – 7.0 0.94 
 Sick leave 3 (3.1) 0 (0) 2.4 -2.2 – 8.8 0.12 
 Student 1 (1) 2 (2.6) 0.65 -3.5 – 8.2 0.42 
 Voluntary work 0 (0) 3 (3.9) 3.8 -1.0 – 11.0 0.0504 
 Medically retired 5 (5.2) 4 (5.3) 0.001 -7.4 – 8.5 0.97 
Not known 1 (1) 0 (0)    
Unemployed       
 Female
 
n (%) 38 (74.5) 11 (40.7) 8.5 8.9 – 55.3 0.004 
 Male n (%) 13 (25.5) 16 (59.3)    
Employed pre-morbidly?      
 Yes 88 (94.6) 66 (91.7) 1.06 -4.4 – 13.5 0.30 
 No 5 (5.4) 4 (5.6) 0.003 -7.7 – 9.20 0.96 
 Not applicable 0 (0) 2 (2.8)    
Not known 5 (5.1) 4 (5.3)    
Benefits*      
 Receives benefits 36 (39.6) 25 (35.7) 0.25 -12.1 – 19.4 0.61 
 Does not receive benefits 55 (60.4) 45 (64.3)    
Not known 7 (7.1) 6 (7.9)    
 Disability Living Allowance/Personal 
Independence Allowance 
14 (37.8) 11 (57.9) 2.1 -9.9 – 46.8 0.16 
 Employment Support Allowance 
(formerly Incapacity Benefit) 
7 (18.9) 1 (5.3) 1.9 -9.9 – 30.6 0.17 
 Housing Benefit 4 (10.8) 0 (0) 2.2 -8.5 – 25.4 0.14 
 Income Support Allowance 4 (10.8) 4 (21.1) 1.1 -10.7 – 36 0.31 
 Illness Benefit 3 (8.1) 0 (0) 1.6 -10.7 – 21.9 0.21 
 Child Benefit/Child Tax Credit 3 (8.1) 2 (10.5) 0.09 -14.2 – 25.9 0.77 
 Carer’s Allowance 1 (2.7) 0 (0) 0.5 -15.1 – 14.2 0.47 
 Job Seeker’s Allowance 0 (0) 1 (5.3) 2.0 -5.5 – 26.1 0.16 
 Freedom Pass 1 (2.7) 0 (0) 0.5 -15.1 – 14.2 0.5 
Total 37 (100) 19 (100)    





FMD patients were significantly more likely to be a carer than patients in the control group 
(11.8% v 2.7% χ2: 4.7, 95% CI: 0.2 -17.8, p = 0.03). There were no gender differences in rates of 
carers between groups.  
More FMD than control group patients had a carer (27.6% v 14.3%, χ2: 4.1, 95% CI: - 0.5 – 26.1, 
p = 0.005). When this was assessed by gender, there were no differences between groups.  
Table 51 outlines the rates of patients working in social and healthcare settings and carer 
status.  
Table 51 History of employment in social care and health settings and carer status for 
functional motor and control group patients 





n (%) χ2 95% CI 
p 
 value 
Social or health care worker      
 Yes 20 (21.3) 11 (14.9) 1.1 -6.4 – 18.5 0.29 
 No 74 (78.7)  63 (85.1)    
Not known 4 (4.1) 2 (2.6)    
 Female social/health worker  20 (100) 7 (63.6) 8.1 5.9 – 69.2 0.005 
 Male social/health worker 0 (0) 4 (36.4)    
Carer      
 Yes 11 (11.8) 2 (2.7) 4.7 0.2 – 17.8 0.03 
 No 82 (88.2) 72 (97.3)    
Not known 5 (5.1) 2 (2.6)    
 Female carer  7 (63.6) 1 (50) 0.1 -45.2 – 68.6 0.72 
 Male carer  4 (36.4) 1 (50)    
Has a carer?      
 Yes 24 (27.6) 10 (14.3) 4.1 - 0.5 – 26.1 0.005 
 No 63 (72.4) 60 (85.7)    
Not known 11 (11.2) 6 (7.9)    
 Females with a carer  17 (70.8) 5 (50) 1.3 -17.4 – 56.2 0.3 
 Males with a carer 7 (29.2) 5 (50)    
6.3.2 Diagnoses 
6.3.2.1 ICD-10 diagnoses 
The first diagnosis received by each participant from SLaM was recorded. In the FMD group 48 
(50.5%) participants received a neurotic, stress-related or somatoform disorder diagnosis (F40 
– F48) when first diagnosed in SLaM, and 20 (21.1%) were given an unspecified mental 
disorder (F99) diagnosis.  
For control group participants, the most common first diagnosis from SLaM was within the 
category of diseases of the nervous system (G00-G99) (28.4% of participants), followed by an 





A second diagnosis was recorded for participants if the first diagnosis changed. Forty-two 
(42.9%) FMD patients received a second diagnosis. Twenty-four (31.6%) control group 
participants received a second diagnosis. Again, the most frequent type of diagnosis from 
SLaM was a neurotic, stress-related and somatoform disorder (66.7%) followed by an F99 
diagnosis (14.3%). Control group patients’ most common second SLaM diagnosis was a 
neurotic, stress-related and somatoform disorder (20.8%), followed by behavioural and 
emotional disorders with onset in childhood and adolescence (16.7%).  
Fourteen (14.3%) FMD participants received a third SLaM diagnosis. The most common type of 
diagnosis was within the neurotic, stress-related and somatoform disorders category (78.6%). 
Four (5.3%) control group received a third ICD-10 diagnosis and half of these were mood 
disorders.  Table 52 outlines the first, second and third diagnoses received by participants.   
The control group consisted of participants who had an organic disorder and comorbid 
psychiatric complaints. Control group participants were chosen if they had an organic disease 
for which they were receiving CBT treatment. The data displayed in Table 53 outlines control 
patients’ ICD-10 diagnoses in more detail. These data are from the structured fields within 
CRIS. In some cases, an official ICD-10 diagnosis will not be recorded within these fields. If this 
was the case, information on diagnosis and symptoms was taken from unstructured text, such 
as notes or correspondence.  
The most frequent type of control group diagnosis was disease of the nervous system. Of 
these, unspecified epilepsy was the most common disorder (47.6% of nervous diseases), 
followed by epilepsy and recurrent seizures (28.6% of nervous diseases). The next most 
common type of physical disorder was Tourette’s syndrome (66.7% of behavioural and 












Table 52 First, second and third psychiatric diagnoses received by F44.4 and control groups in 
SLaM Trust 
  First SLaM 
Diagnosis 
 Second SLaM 
Diagnosis 
 Third SLaM 
Diagnosis 


















ICD-10 psychiatric diagnosis received from SLaM        
 (F00-F09) Organic, including 
symptomatic, mental disorders 
2 (2.1) 4 (5.4)  0 (0) 2 (8.3)  0 (0) 0 (0) 
 (F10-F19) Mental and behavioural 
disorders due to psychoactive 
substances 
0 (0) 1 (1.4)  1 (2.4) 1 (4.2)  0 (0) 0 (0) 
 (F20 – F29) Schizophrenia, 
schizotypal and delusional 
disorders 
0 (0) 0 (0)  0 (0) 0 (0)  0 (0) 0 (0) 
 (F30 – F39) Mood (affective) 
disorders 
1 (1.1) 10 (13.5)  6 (14.3) 6 (25)  0 (0) 2 (50) 
 (F40 – F48) Neurotic, stress-related 
and somatoform disorders 
48 (50.5) 8 (10.8)  28 (66.7) 5 (20.8)  11 (78.6) 1 (25) 
 (F50 – F59) Behavioural syndromes 
associated with physiological 
disturbances and physical factors 
0 (0) 2 (2.7)  0 (0) 0 (0)  1 (7.1) 0 (0) 
 (F60 – F69) Disorders of adult 
personality and behaviour 
0 (0) 0 (0)  1 (2.4) 1 (4.2)  1 (7.1) 0 (0) 
 (F70 – F79) Intellectual disabilities 0 (0) 0 (0)  0 (0) 0 (0)  0 (0) 0 (0) 
 (F80 – F89) Disorders of 
psychological development 
1 (1.1) 0 (0)  0 (0) 0 (0)  0 (0) 0 (0) 
 (F90 – F98) Behavioural and 
emotional disorders with onset in 
childhood and adolescence  
1 (1.1) 9 (12.2)  0 (0) 4 (16.7)  0 (0) 0 (0) 
 (F99) Unspecified mental disorder 20 (21.1) 13 (17.6)  6 (14.3) 1 (4.2)  1 (7.1) 1 (25) 
Other diagnoses  
 (FXX) 4 (4.2) 0 (0)  0 (0) 0 (0)  0 (0) 0 (0) 
 (Z00 – Z99) Factors influencing 
health status and contact in health 
services 
15 (15.8) 5 (6.8)  0 (0) 1 (4.2)  0 (0) 0 (0) 
 (F00-F99) Mental, behavioural and 
neurodevelopmental disorders 
0 (0) 1 (1.4)  0 (0) 0 (0)  0 (0) 0 (0) 
 (G00-G99) Diseases of the nervous 
system 
1 (1.1) 21 (28.4)  0 (0) 3 (12.5)  0 (0) 0 (0) 
 (M00-M99) Diseases of the 
musculoskeletal system and 
connective tissue 
2 (2.1) 0 (0)  0 (0) 0 (0)  0 (0) 0 (0) 
 Not known 3 (3.1) 2 (2.6)  0 (0) 0 (0)  0 (0) 0 (0) 




















ICD-10 psychiatric diagnosis received from SLaM   
(F00-F09) Organic, including symptomatic, mental 
disorders 
4 (5.4) 2 (8.3) 0 (0) 
(F10-F19) Mental and behavioural disorders due to 
psychoactive substances 
1 (1.4) 1 (4.2) 0 (0) 
(F20 – F29) Schizophrenia, schizotypal and 
delusional disorders 
0 (0) 0 (0) 0 (0) 
(F30 – F39) Mood (affective) disorders 10 (13.5) 6 (25) 2 (50) 
(F40 – F48) Neurotic, stress-related and 
somatoform disorders 
8 (10.8) 5 (20.8) 1 (25) 
(F50 – F59) Behavioural syndromes associated with 
physiological disturbances and physical factors 
2 (2.7) 0 (0) 0 (0) 
(F60 – F69) Disorders of adult personality and 
behaviour 
0 (0) 1 (4.2) 0 (0) 
(F70 – F79) Intellectual disabilities 0 (0) 0 (0) 0 (0) 
(F80 – F89) Disorders of psychological 
development 
0 (0) 0 (0) 0 (0) 
(F90 – F98) Behavioural and emotional disorders 
with onset in in childhood and adolescence  
9 (12.2) 4 (16.7) 0 (0) 
 F95 Tic disorder 3 (33.3) 0 (0) 0 (0) 
 F95.2 Tourette’s disorder 6 (66.7) 3 (75) 0 (0) 
 F95.9 Tic disorder, unspecified 0 (0) 1 (25) 0 (0) 
(F99) Unspecified mental disorder 13 (17.6) 1 (4.2) 1 (25) 
(FXX) 0 (0) 0 (0) 0 (0) 
(Z00 – Z99) Factors influencing health status and 
contact in health services 
5 (6.8) 1 (4.2) 0 (0) 
(F00-F99) Mental, behavioural and 
neurodevelopmental disorders 
1 (1.4) 0 (0) 0 (0) 
(G00-G99) Diseases of the nervous system 21 (28.4) 3 (12.5) 0 (0) 
 (G20.X) Parkinson’s disease 2 (9.5) 0 (0) 0 (0) 
 (G40) Epilepsy and recurrent seizures 6 (28.6) 0 (0) 0 (0) 
 
(G40.0) Localization-related (focal) (partial) 
idiopathic epilepsy and epileptic syndromes 
with seizures of localized onset 
1 (4.8) 0 (0) 0 (0) 
 
(G40.2) Localization-related (focal) (partial) 
symptomatic epilepsy and epileptic syndromes 
with complex partial seizure 
1 (4.8) 0 (0) 0 (0) 
 
(G40.4) Other generalized epilepsy and epileptic 
syndromes 
1 (4.8) 0 (0) 0 (0) 
 G40.9 Epilepsy, unspecified 10 (47.6) 1 (33.3) 0 (0) 
(M00-M99) Diseases of the musculoskeletal system 
and connective tissue 
0 (0) 0 (0) 0 (0) 
 Not known 2 (2.6) 0 (0) 0 (0) 
Total 76 (100) 24 (100) 4 (100) 
 
6.3.2.2 Functional motor symptomatology 
The kind of symptoms experienced by FMD patients was classified according to their type and 





categories of tremor, weakness, numbness, paralysis, and pain. Some symptoms did not 
naturally fit this classification, like slurred speech, visual disturbance, and gait disturbance.  
It was common for participants to have more than one symptom. All participants had at least 
one motor symptom for which they were receiving treatment. Eighty-two participants (83.7%) 
had two symptoms, 40 participants (40.8%) had three symptoms, and 12 (12.2%) participants 
had four symptoms.  
The most common symptom type was weakness affecting 47 patients (26.9%), most frequently 
occurring in the leg or the entire body. After weakness, pain was most frequently reported by 
participants, affecting 46 patients (26.3%), followed by tremor. The tremor category 
incorporated symptoms such as shaking, tremor, jerking, and dystonia. Pain in the back or 
chest was also common, affecting 17 participants. Twenty-two participants had gait 
disturbance. Of all body regions, the area most frequently affected was the leg, occurring in 27 
cases (15.4%). Table 54 displays a heat map outlining the most common combinations of 
symptoms and the region of the body in which they occurred.  
Table 54 Heat map displaying the frequency of functional motor symptom type and the body 
region affected  
 
Tremor Weakness Numbness Paralysis Pain 
Total 
 n (%) 
Hand 8 0 0 1 1 10 (5.7) 
Leg 1 14 7 2 3 27 (15.4) 
Not known 3 3 1 0 4 11 (6.3) 
Unilateral 
body 




12 1 1 6 5 
25 (14.3) 
All limbs 4 7 5 1 1 18 (10.3) 
Arm 6 5 2 0 7 20 (11.4) 
Face/Head 2 2 4 0 1 9 (5.1) 
Back/chest 2 1 0 0 17 20 (11.4) 
Mouth 0 1 1 0 1 3 (1.7) 
Feet/ankle 0 0 2 0 2 4 (2.3) 
Eyes 1 0 0 0 2 3 (1.7) 
Total 43 (24.6) 47 (26.9) 28 (16) 11 (6.3) 46 (26.3) 175 (100) 
Specific symptoms were not included in this table including: 22 patients with gait 
disturbance, 16 with slurred speech, stammering or swallowing difficulties, 9 with 
blindness or visual disturbance, 6 with incontinence and 2 with hearing loss  
In a separate analysis, the classification used by McCormack et al. (2014) was applied. This 
grouped symptoms as ‘abnormal’, ‘defined by loss’, or both. Thirty-nine FMD patients (39.8%) 
had abnormal symptoms such as gait disturbance, visual disturbance or tremor. Twenty-three 





paralysis and numbness. The remaining 36 (36.7%) had symptoms characterised by both loss 
and abnormality.  
6.3.3 Health 
The latest available information on patients’ smoking status was assessed. Data were available 
for 75.5% of FMD and 73.7% of control patients.  
40.5% of the FMD group and 35.7% of the control group smoked. There was no statistical 
difference in rates between groups. Data suggests that the rate of smoking in the English adult 
public is 19% (Health and Social Care Information Centre, 2015). The rate of smoking in the 
FMD and control groups is therefore considerably higher than the English public.  
When data were stratified by gender, age and employment status, no statistical differences 
between groups in rates of smoking emerged. Table 55 gives a full breakdown of the rates of 
smoking in both groups. 
Table 55 Table showing differences in smoking frequency and BMI mean scores between F44.4 













Smoking       
 Yes 30 (40.5) 20 (35.7) 1.23 0.60 – 2.5 0.58 19%* 
 No 44 (59.5) 36 (64.3)    81%* 
Not known 24 (24.5) 20 (26.3)     
Female smokers
1
  20 (38.5) 5 (20) 2.5 0.8 – 7.7 0.11 17%* 
Male smokers
2 





 45.6 (9.4) 43.9 (12) 0.58 -4.3 – 7.7 0.57  
Employed
4 
 10 (38.5) 10 (38.5) 1 0.3 – 3.1 1 19%* 
Unemployed
5
 20 (41.7) 10 (33.3) 1.4 0.6 – 3.7 0.46 35%* 
BMI normal range (18.5 – 24.9)      
 Mean (SD)
3
 27.4 (12) 17.9 (7) - - - 25.6** 
Not known 92 (93.9) 72 (94.7)     
Female mean (SD) 28.3 (13.2) - - - - 26.9** 
Male mean (SD)
6
               -          - - - - 27.4** 
Physical health condition       
 Yes 76 (79.2) 76 (100) 0.02 0.001 – 0.04 0.01  
 No 20 (20.8) 0 (0)     
Not known 2 (2) 0 (0)     
1
 Female smokers versus female non-smokers 
2
 Male smokers versus male non-smokers 
3 
Independent samples t-test (unequal variance assumed); BMI scores available for 6 
FMD patients & 4 or control patients so no statistical comparisons made 
4 
Employed smokers versus employed non-smokers 
5
 Unemployed smokers versus unemployed non-smokers; excludes ‘retired’, ‘medically 
retired’, ‘sick leave, ‘student’ & ‘voluntary work’ groups 
6 
One control group score available, no analysis conducted 
* Health and Social Care Information Centre (2015)  





BMI data were gathered when available, but was only available for six FMD participants and 
four control group patients. Like smoking, the most recent available data in all cases was 
collected for each participant. FMD patients had a mean BMI score of 27.4 (SD: 12), slightly 
higher than the average English BMI score of 25.6. A BMI score above 24.9 is considered 
overweight. Control group patients had a mean BMI of 17.9 (SD: 7). Due to the low sample, 
statistical comparisons were not made.  
Comorbid physical health conditions were assessed in all patients. In order to qualify for 
inclusion in the control group, all participants had to have an organic condition. The rate of 
physical health conditions in the control group is therefore 100%. The rate in the FMD group is 
79.2%, a significantly lower (OR: 0.02, 95% CI: 0.001 – 0.04, p < 0.05).  
6.3.4 Psychiatric inpatient stays 
Whether or not patients received an inpatient admission in SLaM was recorded from 
information provided in the structured fields in CRIS. Rates of hospital admissions were low in 
both groups. 9.2% of FMD patients had received an inpatient admission, higher than the 
control group admission rate of 3.9%. There was no statistical difference between the groups. 
Of all patients receiving an admission, no patient was admitted more than once. 
When stratified by gender, no differences in admission emerged between groups.  
Of FMD patients admitted, the mean number of days they spent in hospital was 88.2 days (SD: 
60) (range: 1 – 155 days) which was slightly lower in the control group at 75 days (SD: 69.3) 
(range: 26 – 124 days). There was no statistical difference between the groups.  
See Table 56 for a breakdown of the frequency of psychiatric admission for FMD and control 














Table 56 Inpatient rates and days for F44.4 and control groups  





n (%) OR  95% CI 
p 
value 
Inpatient stay?      
 Yes 9 (9.2) 3 (3.9) 2.46 0.64 – 9.4 0.19 
 No  89 (90.8) 73 (96.1)    
Inpatient stay x gender      
 Female
1
 7 (9.9)  1 (2.9) 3.6 0.43 – 30.6 0.24 
 Male
2
 2 (7.4) 2 (4.8) 1.6 0.21 – 12.1 0.65 
No. of inpatient days      
 Mean (SD)* 88.2 (60) 75 (69.3) 0.28 -94.2 - 121 0.79 
 Females mean (SD) 74.4 (61) 124 -   
 Males mean (SD) 136.5 (6.4) 26 -   
1
 Females with an inpatient stay versus females with no inpatient stay 
2 
Males with an inpatient stay versus males with no inpatient stay 
* t-test 
6.3.5 Life events 
Any record in patients’ notes of childhood physical or sexual abuse was recorded. CSA 
experience was not known in 18.4% of FMD patients and 19.7% of control group cases. 
There was a significant difference in the experience of CSA. 23.8% of FMD patients 
experienced CSA, higher than the rate reported in the control group, at 8.2% (OR: 3.5, 95% CI: 
1.2 – 10, p = 0.02). No differences emerged following the stratification of results by gender or 
family mental health history.  
No information on CPA was available in 17.3% of FMD patients’ notes and 18.4% of control 
group patients’ notes. Similar rates of CPA were reported in both groups (28.4% of FMD and 
21% of control group patients). There was no statistically significant difference between 
groups. No differences emerged after stratification by gender or family mental health history.  
Whether or not a participant had experienced physical or sexual abuse after the age of 18 was 
recorded. In both groups, the rate of unknown exposure was 18.4%. FMD patients experienced 
more physical or sexual abuse in adulthood than in the control group (23.8% versus 16.1%) but 
there was no statistically significant difference and no differences emerged when rates were 
stratified according to gender or family mental health history. 
Any evidence of family mental health problems was recorded and rates were compared 
between groups. The information was unknown in 18.4% of cases in both the FMD and control 
groups. Over half of FMD patients had a family member with a mental health disorder (65.4%), 
almost identical to the rate in the control group (66.7%). Females in both groups had higher 
rates of family members with a mental health problem compared to their male counterparts 





See Table 57 for a breakdown of the rates of childhood and adulthood exposure to sexual and 
physical abuse and the rate of family members with a mental health problem. 
Table 57 Child and adult physical and sexual abuse rates for F44.4 and control groups 





n (%) OR 95% CI 
p 
value 
History of child sexual abuse 19 (23.8)  5 (8.2) 3.5 1.2 – 10 0.02 
 Female
1
 18 (30) 3 (12.5) 3 0.8 – 11.3 0.11 
 Male
2
 1 (5) 2 (5.4) 0.9 0.08 – 10.8 0.94 
 Family mental health history
3
 11 (73.3) 2 (66.6) 1.4 0.1 – 20 0.81 
Not known 18 (18.4) 15 (19.7)    
History of child physical abuse 23 (28.4) 13 (21) 1.5 0.7 – 3.3 0.3 
 Female
1
 19 (31.1) 7 (29.2) 0.8 0.3 – 2.3 0.6 
 Male
2
 4 (20) 6 (15.8) 1.3 0.3 – 5.4 0.7 
 Family mental health history
3
 14 (87.5) 6 (75) 2.3 0.3 – 20.7 0.45 
Not known 17 (17.3) 14 (18.4)    
History of adult physical or sexual abuse 19 (23.8) 10 (16.1) 1.6 0.7 – 3.8 0.3 
 Female
1
 19 (31.6) 8 (30.8) 1.04 0.4 – 2.8 0.9 
 Male
2
 0 (0) 2 (5.5) 0.3 0.02 – 7.3 0.5 
 Family mental health history
3
 9 (75) 5 (71.4) 1.2 0.15 – 9.8 0.86 
Not known 18 (18.4) 14 (18.4)    
History of family mental health problems 51 (65.4) 40 (66.7) 0.94 0.5 – 1.9 0.87 
 Female 37 (68.5) 19 (70.4) 0.92 0.34 – 2.5 0.87 
 Male 14 (58.3) 21 (63.6) 0.8 0.27 – 2.4 0.68 
Not known 18 (18.4) 14 (18.4)    
1 
Females abused in F44.4 group versus females abused in control group  
2
 Males in abused in F44.4 group versus males abused in control group 
3 
Family mental health history in F44.4 group versus family mental health history in control    
group 
 
6.3.6 Psychological comorbidity and acceptance of psychological explanations 
Any mention of lifetime prevalence of anxiety, depression or fatigue within unstructured text 
was assessed. This does not reflect a formal diagnosis, simply a record of the patient 
experiencing these psychological factors at some stage in their life. Depression was a broad 
category including low mood, depression, suicidal thoughts or ideation. Anxiety was 
categorised as anxiety or stress that interfered with participants’ everyday life. Fatigue was any 
experience of tiredness that was mentioned as something that interfered or interrupted the 
participant’s normal everyday functioning, and that was considered by the clinician to be 
outside the bounds of normal, everyday fatigue.  
80.2% of the FMD group had a mention of anxiety within their medical records, significantly 
lower than the anxiety rate found in the control group of 91.8% (χ2: 4.4, 95% CI: 0.07 – 22.3, p 





Depression had a similar incidence in both groups with 85.7% of FMD patients and 88.2% of 
control group patients.  
Fatigue was more commonly reported in FMD patients’ notes affecting 72.2% of patients 
compared to just over half of the control group at 55.4% (χ2: 4.3, 95% CI: 0.12 – 32.8, p = 0.04).  
See Table 58 for a breakdown of rates across groups.  










 95% CI 
p 
value 
Anxiety 77 (80.2) 67 (91.8) 4.4 0.07 – 22.3 0.04 
 Not known 2 (2) 3 (3.9)    
Depression* 84 (85.7) 67 (88.2) 0.23 -8.8 – 13.1 0.63 
 Not known            -           -    
Fatigue 57 (72.2) 36 (55.4) 4.3 0.12 – 32.8 0.04 
 Not known 19 (19.4) 11 (14.5)    
Includes low mood, depression, suicidal thoughts, & suicidal 
ideation 
The researcher assessed whether FMD patients accepted a psychological account or 
explanation of symptoms before they started CBT treatment and whether this had changed 
after treatment. As this was not a relevant component of control patients’ treatment, this was 
not assessed.  
Just under half of the FMD patients (49%) accepted a psychological explanation for their 
symptoms at the start of CBT treatment, a third (27.6%) did not accept a psychological 
account, 13.3% were not sure what the cause of their symptoms were, and in ten cases 
(10.2%) no information was available or a psychological account was not applicable to the 
patient.  
After therapy, 71.6% accepted a psychological account of their symptoms and a lower 
proportion did not accept a psychological explanation (17.9%).  Fewer participants were now 
unsure at 5.3%.  
Table 59 outlines the rate of patients’ acceptance of psychological explanations for symptoms 







Table 59 Proportion of F44.4 patients who accept the role of psychological factors in their 














Accepted psychological factors before therapy? 48 (49) 27 (27.6) 13 (13.3) 9 (9.2) 1 (1) 
Accepted psychological factors after therapy? 68 (71.6) 17 (17.9) 5 (5.3) 5 (5.3) 0 (0) 
 
Acceptance of psychological symptom explanations was assessed in further detail to assess the 
proportion of patients who changed their acceptance of psychological factors before and after 
therapy.  
Forty-six patients accepted a psychological explanation both before and after treatment. Nine 
patients didn’t accept the role of psychological factors before treatment but by the end of 
treatment had changed their minds. Fourteen patients didn’t accept the role of psychology 
either before or after treatment and no patient accepted a psychological account before 
treatment but rejected its role after therapy.  
An exact McNemar’s test determined that there was a statistically significant increase in the 
proportion of people accepting a psychological explanation for symptoms as a result of CBT (p 
= 0.004).  
Table 60 outlines the proportion of FMD patients who accepted the role of psychology before 
and after therapy and the numbers who changed their acceptance over time.  
Table 60 Proportion of F44.4 patients who accepted the role of psychology in their symptoms 
before and after therapy 
Accepted a psychological explanation after 
therapy? 
  Yes No 
Patient accepted role of 
psychological factors before 
therapy? 
Yes 46 0 
No 9 14 
6.3.7 CBT dropout 
Four clinicians worked in the CBT clinic at the time of data collection. Some had worked there 
longer and had treated more patients. The number and proportion of patients treated by each 
clinician is outlined in Table 61. Clinician four treated the highest number of participants 
(44.3%) overall and the highest proportion of FMD patients (44.9%). Clinician one and two 















Clinician one 9 (9.2) 3 (3.9) 12 (6.9) 
Clinician two 12 (12.2) 6 (7.9) 18 (10.3) 
Clinician three 33 (33.7) 34 (44.7) 67 (38.5) 
Clinician four 44 (44.9) 33 (43.4) 77 (44.3) 
 
Participants were at different stages of treatment when data were collected. In total, nine 
FMD patients were receiving on-going treatment (9.2% of the sample) at the time data was 
collected. Eleven control group participants were in the middle of their treatment sessions 
(14.5% of the control group sample).  
The same rate of participants attended all sessions in both groups with 55 FMD patients 
(56.1%) and 43 control group patients (56.6%) attending all sessions offered. Twenty-eight 
FMD patients (28.6%) did not complete all sessions offered, compared to 20 control group 
participants (26.3%). In total, therapists decided to stop sessions early in six FMD cases and 
with two control patients. There were no statistically significant differences between 
attendance rates or reasons for dropout between the two groups.   
Table 62 gives an overview of the rates of attendance and dropout for FMD and control 
patients.  









 95% CI 
p 
value 
Attended all sessions 55 (56.1) 43 (56.6) 0.004 -15 – 15.9 0.95 
Dropped out of treatment early 28 (28.6)  20 (26.3) 0.11 -12 – 16.1 0.74 
Therapist stopped sessions 6 (6.1) 2 (2.6) 1.2 -4.1 – 10.6 0.27 
Sessions on-going at time of data collection 9 (9.2) 11 (14.5) 1.2 -5 – 16.4 0.28 
Total 98 (100) 76 (100)    
 
FMD patients who attended all CBT sessions were compared to FMD patients who dropped 
out early or whose therapist stopped sessions early. 
Data were stratified by gender, marital status, ethnicity, employment, history of childhood 
sexual abuse, acceptance of the role of psychological factors prior to CBT, wheelchair use, age, 
improvement category, and CORE-OM, PHQ-9, and HoNOS-ABI scores.  
There were no differences between therapy completers and participants who dropped out 





patients who were classified as improving as a result of CBT therapy. FMD patients who 
dropped out of therapy early were more frequently victims of CSA compared to therapy 
completers (36.7% versus 16.3%, χ2: 3.9, 95% CI: -1.7 – 42, p = 0.05) and patients who attended 
all CBT sessions were more likely to see their symptoms improve than patients who dropped 
out early (58.5% versus 29.2%, χ2: 5.6, 95% CI: 3.1 – 50.6, p = 0.02).  
Table 63 outlines the rates of FMD patients completing therapy compared to FMD patients 
who did not complete all sessions according to socio-demographic variables.   
Table 63 Socio-demographic differences between F44.4 patients who attended all CBT sessions 
offered versus those who dropped out early 
 
Attended all  
sessions 







 95% CI 
p 
value 
Total 55 (61.8) 34 (34.7) 13 11.7 – 41.2 0.003 
Gender Female 42 (76.4) 23 (67.6) 0.82 -11.3 – 29.7 0.37 
 Male 13 (23.6) 11 (32.4)    
Marital 
status 
Single, divorced, widowed or 
separated 
22 (48.9) 14 (48.3) 0.003 -23.9 – 24.9 0.96 
 Married, civil partner or cohabiting 23 (51.1) 15 (51.7)    
Ethnicity British 36 (65.5) 24 (70.6) 0.25 -16.8 – 25.1 0.62 
 Other ethnicity 19 (34.5) 10 (29.4)    
Work Employed 17 (30.9) 13 (39.4) 0.66 13.1 – 30.4 0.42 
 Unemployed/retired/sick leave 38 (69.1) 20 (60.6)    
Abuse History of CSA 7 (16.3)  11 (36.7) 3.9 -1.7 – 42 0.05 
 No history of CSA 36 (83.7) 19 (63.3)    
Psych  Accepted psych role before 28 (68.3) 13 (48.1) 2.7 -5.6 – 44 0.10 
 Didn’t accept psych role before 13 (31.7) 14 (51.9)    
Disability Uses wheelchair or walking aid 22 (43.1) 20 (60.6) 2.4 -6.1 – 39 0.12 
 Walks unaided 29 (56.9) 13 (39.4)    
Age Mean age at assessment
1 
(SD) 39.1 (13) 41.7 (13)   0.73 
Outcomes Patient improved 31 (58.5) 7 (29.2) 5.6 3.1 – 50.6 0.02 
 Patient got worse/stayed the same 22 (41.5) 17 (70.8)    
 Mean pre-CBT CORE-OM (SD)
2
 15.3 (6) 17.4 (7.8) 22.5  0.49 
 Mean post-CBT CORE-OM (SD)
2
 10.2 (7) 9.4 (2.7) 28  0.86 
 Mean pre-CBT PHQ-9 (SD)
3 
 14.8 (6.2) 5 (5.7) 2.5  0.08 
 Mean post-CBT PHQ-9 (SD)
3
 11.2 (5.1) 5 (7) 3.5  0.11 
 Mean pre-CBT HoNOS-ABI (SD)
4
 12.4 (6.5) 8.2 (4) 24.5  0.16 
 Mean post-CBT HoNOS-ABI (SD)
4
 6.9 (5.5) 8.6 (4) 5.5  0.73 
1 
Mann-Whitney U test 
2 
Mann-Whitney U test, data from 20 attenders and 3 drop out patients 
3 
Mann Whitney U test, data from 13 F44.4 attenders and 2 F44.4 drop out patients 
4 
Mann-Whitney U test, data from 17 F44.4 attenders and five F44.4 drop out patients 
A logistic regression was performed to ascertain the effects of gender, marital status, ethnicity, 
employment, CSA, symptom improvement, acceptance of psychological explanations before 
therapy, and wheelchair use on the likelihood that participants would drop out of CBT therapy. 





patient dropout. The logistic regression model was not statistically significant (χ2 (8) = 7.5, p = 
0.49) and the model explained 21.4% (Nagelkerke R2) of the attendance to CBT. 
Comparisons were made between FMD and control patients who completed all therapy 
sessions by socio-demographic variables. Of therapy completers, more female FMD patients 
completed therapy compared to female control group patients (76.4% versus 48.8%, χ2: 7.9, 
95% CI: 7 – 46.3, p = 0.005). No other socio-demographic differences emerged between the 
FMD and control group therapy completers.  
Participants who dropped out of therapy early where grouped with patients whose therapists 
had stopped sessions and the profile of FMD and control group patients was compared. Of 
patients who dropped out early, control patients were more frequently single than FMD 
patients (78.9% versus 48.3%, χ2: 4.4, 95% CI: -0.53 – 54.7, p = 0.04) while FMD patients who 
dropped out were more likely to have experienced CSA (χ2: 3.9, 95% CI: -3 – 51.1, p = 0.05).  
Table 64 outlines the socio-demographic differences between FMD and control groups 
























Table 64 Socio-demographic differences between F44.4 and control patients grouped by their 
attendance at CBT  
  F44.4  
Group  
n (%)  
Control 
Group  
       n (%) χ
2
 95% CI 
p 
value 
Attended all CBT sessions offered 55 (56.1) 43 (56.6) 0.004 -15 - 15.9 0.95 
 Female 42 (76.4) 21 (48.8) 7.9 7 – 46.3 0.005 
 Male 13 (23.6) 22 (51.2)    
 Single 22 (48.9) 21 (53.8) 0.20 -17.7 – 27 0.66 
 Married 23 (51.1) 18 (46.2)    
 British 36 (65.5) 32 (74.4) 0.89 -10.9 – 27.4 0.35 
 Other ethnicity 19 (34.5) 11 (25.6)    
 Employed 17 (30.9) 21 (48.8) 3.2 -2.9 – 37.5 0.07 
 Unemployed, retired, sick leave 38 (69.1) 22 (51.2)    
 History of CSA 7 (16.3)  3 (8.8)  1.19 -7.8 – 21.5 0.28 
 No history of CSA 36 (83.7) 31 (91.2)    
 Mean age at assessment (SD)
1
  39.1 (13) 40.4 (12)   0.61 
 Patient improved after CBT 31 (58.5) 30 (69.8) 1.3 -9.5 – 30.7 0.26 
 Patient worse/same after CBT 22 (41.5) 13 (30.2)    
 Pre-CBT CORE-OM score (SD)
2
 15.3 (6) 16.4 (7) -0.54 -5.3 – 3.1 0.59 
 Post-CBT CORE-OM score (SD)
2
 10.2 (7) 12.7 (7) -1.1 -6.9 – 1.9 0.26 
 Pre-CBT PHQ-9 score (SD)
2
 14.8 (6.2) 12.8 (10) 0.51 -6.8 – 10.8 0.62 
 Post-CBT PHQ-9 score (SD)
2
 11.2 (5.1) 6.4 (6) 1.9 -0.29 – 9.8 0.06 
 Pre-CBT HoNOS-ABI (SD)
1
 12.4 (6.5) 12.4 (7) 115  0.87 
 Post-CBT HoNOS-ABI (SD)
1
 6.9 (5.5) 6 (4) 115  0.87 
Dropped out or therapist stopped 
therapy* 
34 (34.7) 22 (28.9) 0.66 -9 – 20 0.42 
 Female 23 (67.6) 10 (45.5) 2.65 -6.7 – 48 0.10 
 Male 11 (32.4) 12 (54.5)    
 Single 14 (48.3) 15 (78.9) 4.4 -0.53 – 54.7 0.04 
 Married 15 (51.7) 4 (21.1)    
 British 24 (70.6) 13 (59) 0.79 -15.5 – 38.5 0.38 
 Other ethnicity 10 (29.4) 9 (40.9)    
 Employed 13 (39.4) 10 (45.5) 0.17 -24.6 – 35.7 0.68 
 Unemployed 20 (60.6) 12 (54.5)    
 History of CSA 11 (36.7) 1 (5.9) 3.9 -3 – 51.1 0.05 
 No history of CSA 19 (63.3) 16 (94.1)     
 Mean age at assessment (SD)
1
 41.7 (13) 40.3 (13)   0.74 
 Patient improved after CBT 8 (27.6) 7 (38.9) 0.64 -17.9 – 40.7 0.42 
 Patient worse/same after CBT 21 (72.4) 11 (61.1)    
 Pre-CBT CORE-OM score (SD)
1
 17.4 (8) 15 (40 2  0.56 
 Post-CBT CORE-OM score (SD)
1
 9.4 (3) 13.1 (1) 0.5  0.14 
 Pre-CBT PHQ-9 score (SD)** 5 (5.7) 10 - - - 
 Post-CBT PHQ-9 score (SD)** 5 (7) 8 - - - 
 Pre-CBT HoNOS-ABI (SD)** 8.2 (4) 12 - - - 
 Post-CBT HoNOS-ABI (SD)** 8.6 (4) 13 - - - 
Sessions ongoing 9 (9.2) 11 (14.5) 1.2 -5 – 16.4 0.28 
Total 98 (100) 76 (100)    
1 
Mann-Whitney U test for non-parametric test 
2 
Independent t-test 
*Therapist stopped therapy in 6 F44.4 cases and 2 control group cases 






Reasons for early therapy cessation were collected and compared between FMD and control 
groups. There was no available information in CRIS records on why patients had dropped out 
for 15 FMD patients (44.1%) and 14 control patients (63.6%).  
In five cases (14.7%), FMD patients dropped out because they believed a physical cause 
accounted for their symptoms. In three cases in both the FMD and control group, participants 
believed therapy was not helpful or was making them worse. Three FMD patients dropped out 
because they felt the clinic was too far away and two developed a physical health problem 
while receiving treatment. In one case an FMD patient became too busy, another disengaged 
from therapy, one was unhappy with the CBT service generally, and another participant found 
CBT distressing. No statistical differences in reasons for CBT dropout were observed between 
groups. See Table 103, (“Appendix 6.1: Reasons for early therapy cessation for F44.4 and 
control groups”) for dropout reasons.  
6.3.8 CBT treatment length 
The mean number of treatment sessions attended by FMD patients was 14.06 (SD: 8, range: 1 - 
46) and for control group patients was 13.4 (SD: 7.3, 1- 40).  
The mean number of treatment sessions missed by patients who dropped out was compared. 
The mean number of missed sessions was 2.44 (SD: 4.3) for FMD patients and 2.15 for the 
control group (SD: 3.8), with no statistical difference between the two groups. This suggests 
that patients had completed most of the treatment course before they dropped out.  
Patients are assessed by a CBT therapist before they start treatment. The mean number of 
days between the assessment and the start of CBT treatment was 62.6 days (SD: 74.6) for FMD 
patients and 53.2 days (SD: 46.9) for control patients. There was no statistical difference 
between days.  
The mean number of days between participants’ first and last treatment session was 266 days 
(SD: 362) for FMD patients and 268 days (SD: 408) for control group patients.  
The mean number of days between FMD patients’ first treatment session and their last follow-
up session was 390.2 days (SD: 277.7) and 414.1 days (SD: 297.7).  
Table 104 in ‘Appendix 6.2: Missed treatment sessions and mean days between appointments’ 
outlines the mean number of missed treatment sessions and the mean number of days 





6.3.9 Therapy outcomes 
This section outlines the response to treatment of FMD and control group patients.  
Although therapy was on-going for nine FMD and eleven control patients at the time of data 
collection, they were included in our analysis as these participants had high attendance rates 
and they did not seem to differ greatly from other patients in the study. None had missed any 
CBT session and most had completed a high number of sessions. The mean number of 
attended sessions for FMD patients whose therapy was ongoing was 15.4 sessions (SD: 8), and 
for the control group it was 15.7 sessions (SD: 11.7).  
For FMD patients with on-going sessions, two of the nine (22.2%) had symptoms that did not 
change, five had symptoms that improved (55.6%), and symptom improvement was unknown 
in two cases (22.2%).  
For the control group, three patients’ symptoms were worse (27.3%), two were the same 
(18.2%), three were better (27.3%), and in three cases, symptom improvement information 
was unknown (27.3%).  
As this group of patients did not seem to differ greatly from other patients in the study, it was 
decided to include them in our subsequent analyses.   
6.3.9.1 Target symptom  
Based on information from clinical notes, the researcher classified patients’ symptoms as 
either ‘improved’, the ‘same’ or ‘worse’.  
In total, 44 FMD patients (49.4%) and 40 control group patients (58%) improved, with no 
statistically significant difference between groups. Of FMD patients who improved, seven 
dropped out (15.9%), and in one case (2.3%) the therapist stopped the sessions early. In the 
control group, 6 patients (15%) whose symptoms had improved dropped out and in one case 
their therapist stopped the sessions (2.5%).  
Eight FMD patients’ (8.2%) and nine control group patients’ (11.8%) symptoms were worse 
after CBT treatment. Thirty-seven (37.8%) FMD patients and 20 (20.4%) control group patients’ 
symptoms remained the same after CBT.  
Of patients whose symptoms were worse or the same after CBT treatment, 17 (37.8%) FMD 
and 10 (34.5%) control patients dropped out early while there were four FMD cases (8.9%) and 





No information on patients’ improvement was available for nine FMD patients (9.2%) and 
seven control patients (9.2%). 
Patients whose symptoms were the same or worse were merged and data were stratified by 
socio-demographic variables. Comparisons were made between FMD and control groups 
according to gender, ethnicity, marital status, employment, receipt of welfare benefits, age, 
acceptance of psychological explanations prior to CBT, and health variables. 
For patients who improved, no differences in socio-demographics emerged between groups, 
apart from gender. A higher proportion of female FMD patients improved compared to female 
control group patients (χ2: 9, 95% CI: 9.9 – 52.2, p = 0.003).  
Patients whose symptoms stayed the same or got worse were compared but there were no 
differences between FMD and control groups on any of the measured socio-demographic 
variables.  
Table 105 (see Appendix 6.3: Socio-demographic differences between F44.4 and control group 
patients according to their improvement) outlines the socio-demographic differences between 
FMD and control group patients who improved as well as comparisons between FMD and 
control groups for those patients who got worse or stayed the same.  
A univariate analysis was conducted to examine FMD within-group differences. FMD patients 
who improved were compared to FMD patients who stayed the same or got worse according 
to socio-demographic variables. The variables assessed were gender, ethnicity, marital status, 
employment, carer status, benefits, wheelchair use, age, acceptance of a psychological 
explanation of symptoms prior to CBT, acceptance of a psychological explanation after CBT, 
experience of CSA or CPA as well as health variables.  
Amongst FMD patients who improved, a higher proportion were in employment (χ2: 4, 95% CI: 
-1 – 40.1, p = 0.05), worked as health or social care workers (χ2: 4.3, 95% CI: -0.3 – 37.7, p = 
0.04), accepted a psychological explanation for their symptoms both before (χ2: 7.7, 95% CI: 
7.9 – 53.4, p = 0.006) and after CBT (χ2: 7.5, 95% CI: 5.6 – 43.2, p = 0.006), and had 
experienced CPA (χ2: 14.3, 95% CI: 19.6 – 62.4, p = 0.002) compared to those who stayed the 
same or got worse. 
Amongst patients who got worse or stayed the same, a higher proportion received welfare 
benefits (χ2: 4.6, 95% CI: 0.43 – 41.8, p = 0.03) and they more frequently used a wheelchair or 





There were no differences in proportions between groups according to gender, ethnicity, 
marital status, employment rates pre-morbidity, patients with carers or patients who act as 
carers, age of psychiatric symptom onset, the age of CBT assessment, the experience of CSA, 
smoking status, family history of mental health disorders, or birth status.  
Table 65 outlines the results of these within-group comparisons. 
Table 65 Differences in socio-demographics between F44.4 patients who improved after CBT 












 95% CI 
p 
value 
Total 44 (49.4) 45 (50.6) 0.03 -14 – 16.4 0.87 
Gender Female 32 (72.7) 33 (73.3) 0.004 -19 – 20.3 0.95 
 Male 12 (27.3) 12 (26.7)    
Ethnicity British 32 (72.7) 28 (62.2) 1.1 -10.4 – 30.4 0.29 
 Other ethnicity 12 (27.3) 17 (37.8)    
Marital 
status 
Single, divorced, widowed or separated 24 (54.5) 24 (53.3) 0.013 -20.5 – 22.8 0.91 
Married, civil partner or cohabiting 20 (45.5) 21 (46.7)    
Work Employed 20 (45.5) 11 (25) 4 -1 – 40.1 0.05 
 Unemployed, retired or sick leave 24 (54.5) 33 (75)    
 Employed pre-morbidly 39 (92.9) 42 (100) 3.01 -3.01 – 19.4 0.08 
 Not employed pre-morbidly 3 (7.1) 0 (0)    
 Health/social care worker  14 (33.3) 6 (14) 4.3 -0.3 – 37.7 0.04 
 Not a health/social care worker 28 (66.7) 37 (86)    
Carer Patient is a family carer 5 (11.9) 5 (11.9) 0 -15.8 – 15.8 1 
 Patient is not a family carer 37 (88.1) 37 (88.1)    
 Patient has a carer 8 (20) 13 (33.3) 1.8 -7.9 – 33.4 0.18 
 Patient doesn’t have a carer 32 (80) 26 (66.7)    
Benefits Receives benefits 9 (22) 24 (44.2) 4.6 0.43- 41.8 0.03 
 Does not receive benefits 32 (78) 19 (55.8)    
Disability Uses wheelchair or walking aid 15 (36.6) 26 (63.4) 5.8 3.5 – 47.2 0.02 
 Doesn’t use wheelchair 26 (63.4) 15 (36.6)    
Age Mean age at psych symptom onset (SD)
1
 31.4 (16) 29 (11) - 0.8 -8.4 – 3.6 0.43 
 Mean age at assessment
1
 (SD) 40.6 (15) 39.5 (11) -0.38 -6.7 – 4.5 0.70 
Psych 
factors 
Accepted psych factors before 26 (81.3) 17 (48.6) 7.7 7.9 – 53.4 0.006 
Didn’t accept psych factors before 6 (18.8) 18 (51.4)    
Accepts psych role after 37 (92.5) 25 (67.6) 7.5 5.6 – 43.2 0.006 
Didn’t psych role after 3 (7.5) 12 (32.4)    
Abuse Experienced CSA 8 (23.5) 8 (20.5) 0.09 -17.4 – 23.9 0.76 
 Didn’t experience CSA 26 (76.5) 31 (79.5)    
 Experienced CPA 13 (63.9) 8 (20.5) 14.3 19.6 – 62.4 0.002 
 Didn’t experience CPA 23 (36.1) 31 (79.5)    
Health Smokes 11 (32.4) 14 (43.8) 0.89 -13.8 – 35.3 0.34 
 Does not smoke 23 (67.6) 18 (56.3)    
 Family mental health history 24 (66.7) 22 (64.7) 0.03 -21.5 – 24.5 0.86 
 Not family mental health history 12 (33.3)  12 (35.3)     
 Normal birth and delivery 19 (82.6) 18 (90) 0.48 -17.6 – 30.5 0.49 
 Problems during birth 4 (17.4) 2 (10)    
*Eight F44.4 patients got worse and nine control patients got worse 
1 





Based on the univariate analysis, variables that showed a significant association with symptom 
improvement were chosen for inclusion in a binary logistic regression analysis. These variables 
included acceptance of psychological explanations before and after CBT, experience of 
childhood physical abuse, receipt of benefits, working as a social or healthcare worker, 
employment status and use of a wheelchair or walking aid. The model explained 41.7% 
(Nagelkerke R Square) of the variance seen in symptom improvement but no variables 
significantly predicted symptom improvement. 
6.3.9.2 CORE-OM scores pre- and post-treatment 
Patients’ CORE-OM scores were taken prior to CBT and after its conclusion.  
Pre-CBT CORE-OM scores were those taken within 180 days of the CBT assessment date or first 
treatment session. Post-CBT CORE-OM scores were those taken within 180 days of the last day 
of treatment or the last follow-up appointment. Due to a general lack of available outcome 
measures, this relatively wide time range was used for inclusion of scores. 
Of the 24 FMD patients with CORE-OM scores at both the pre- and post-CBT stage, 20 FMD 
patients completed all their CBT sessions, three had dropped out early and one still had on-
going sessions. Of control group participants, 22 had completed all of their CBT sessions while 
two dropped out early.  
An analysis was conducted to assess whether there were any significant differences in socio-
demographics between FMD patients who had CORE-OM scores versus those who did not. No 
differences were found (see Table 106, ‘Appendix 6.4: Socio-demographic differences between 
patients with clinical outcome scores and those with one or none’).  
Of patients with two CORE-OM scores, a repeated measures t-test showed FMD patients’ 
scores dropped from a moderate mean of 15.5 (SD: 6.2) to a clinically low mean of 10 (SD: 6.6) 
(t = 3.9, df = 23, 95% CI: 2.6 – 8.3, two-tailed p = 0.001). Control group patients’ scores also 
dropped from a mean of 16.3 (SD: 6.8) (considered a moderate score) to a mean of 12.8 (SD: 
6.6) (considered clinically mild), denoting a statistically significant drop (t = 2.9, df = 23, 95% CI: 
1.06 – 5.9, two-tailed p =0.007).  
Table 66 shows the mean scores of both patient groups before and after CBT treatment and 
stratified by socio-demographic variables. Any variables with less than ten participants, after 






Table 66 Pre- and post-treatment clinical mean CORE-OM score for F44.4 and control group  
















F44.4 Group (Total participants = 24) 15.5 (6.2) 10 (6.6) 5.4 3.9 0.001 0.86 
Gender Female (Total = 18) 14.9 (6.7) 9.2 (5.7) 5.7 3.5 0.003 0.82 
Ethnicity British (Total = 16) 16.2 (6) 10 (7) 6.3 3.4 0.004 0.85 
Marital 
status 
Single (Total = 10) 14.6 (8) 10.3 (7) 4.2 1.9 0.10 0.71 
Married (Total = 11) 15.4 (5) 10.2 (8) 5.1 2.5 0.03 0.80 
Work Employed (Total = 11) 14.4 (7) 6 (5) 8.4 3.7 0.004 1.08 




Accepted psych factors pre-CBT  
(Total = 12) 
15.9 (7) 8.9 (7) 7 3.1 0.01 0.87 
Accepted psych factors post-CBT 
(Total = 15) 
15.7 (7) 9.6 (7) 6.1 3.2 0.007 0.78 
Carer Patient doesn’t have carer (Total = 18) 15.2 (6) 9.4 (7) 5.9 3.4 0.004 0.78 
Disability Uses wheelchair or other walking aid 
(Total = 8) 
17.2 (5) 9.7 (6) 7.5 2.8 0.03 0.98 
 No wheelchair/walking aid   
(Total = 15) 
14.5 (7) 10.8 (7) 3.6 2.5 0.03 0.64 
Abuse No history of CPA (Total = 15) 14.5 (6) 9.4 (6) 5.0 3.4 0.004 0.89 
Health History of familial mental health 
problems (Total = 15) 
15.5 (7) 10.5 (7) 5.0 3.0 0.01 0.76 
 Does not smoke (Total = 10) 13 (7) 8.9 (7) 4.0 2.1 0.08 0.66 
Control Group (Total participants = 24) 16.3 (6.8) 12.8 (6.6) 3.5 2.9 0.007 0.92 
Gender Male (Total = 15) 15.1 (7.6) 12.9 (7) 2.2 1.4 0.19 0.35 
Marital 
status 
Single (Total = 16) 15.9 (7) 13 (6) 2.9 1.8 0.10 0.48 
Ethnicity British (Total = 19) 15.5 (6) 11.6 (6) 3.9 2.8 0.01 0.67 
Work Employed (Total = 13) 13.9 (5) 10.5 (6) 3.4 2.4 0.04 0.64 
Carer Patient doesn’t have carer (Total = 17) 14.4 (6) 11.5 (7) 2.9 2.4 0.03 0.59 
Scores range from 0-40: Healthy (0-5); low level (5-10); mild (10-15); moderate (15-20); moderate-to-
severe (20-25); severe (25 -40) 
*Participants’ first CORE-OM score included if within 6 months of assessment or first treatment date 
& second CORE-OM score included if within 6 months of the final treatment or follow-up session. 
Data were stratified by socio-demographic variables. Within the FMD group, there were 
significant improvements for female (t = 3.5, df = 17, 95% CI: 2.2 – 9.2, p = 0.003), British (t = 
3.4, df = 15, 95% CI: 2.3 – 10.2, p = 0.004), married (t = 2.5, df = 10, 95% CI: 0.56 – 9.7, p = 
0.03), and employed patients (t = 3.7, df = 10, 95% CI: 3.3 – 13.5, p = 0.004), patients who 
accepted psychological explanations before (t = 3.1, df = 11, 95% CI: 2 – 11.9, p = 0.01) and 
after CBT treatment (t  = 3.2, df = 14, 95% CI: 1.9 – 10.2, p = 0.007), those who did not have a 
carer (t = 3.4, df = 17, 95% CI: 2.2 – 9.5, p = 0.004), patients who both used (t  = 2.8, df = 7, 95% 
CI: 1.2 – 13.8, p = 0.03) and did not use a wheelchair or walking aid (t = 2.5, df = 14, 95% CI: 0.5 
– 6.8, p = 0.03), those with no history of CPA (t = 3.4, df = 14, 95% CI: 1.8 – 8.2, p = 0.004) and 






Figure 35 displays a paired dotted line graph of individual patients’ scores before and after CBT 
treatment in the FMD and control groups. 
  
Figure 35 Paired dotted line graphs showing change in clinical mean CORE-OM 
scores for the functional and control groups at the start and end of treatment 
To assess treatment outcomes, we conducted a repeated-measures (pre-CBT versus post-CBT) 
ANOVA, with patient group (FMD versus control) as a fixed factor. The Bonferroni-corrected 
interaction between the FMD and control groups and the change over time (pre- versus post-
CBT) was not statistically significant (F1,46 = 1.13, p = 0.30, partial η
2 = 0.02). The pre-CBT scores 
between the FMD and control groups did not differ significantly, and there was no significant 
difference in post-CBT scores between groups. Figure 36 displays a line graph showing the 
change in overall mean CORE-OM scores between the FMD and control groups.  
 
Figure 36 Line graph demonstrating change in overall mean CORE-OM scores between F44.4 





Further sub-group analyses within FMD patients were conducted using a repeated measures 
ANOVA (see “Appendix 6.5: CORE-OM mean clinical score sub-analysis: repeated measures 
ANOVA”). The interaction between the change in FMD patients’ CORE-OM mean clinical scores 
over time and the socio-demographic variables listed in Table 66 (e.g. gender, ethnicity, etc.) 
was tested for statistical significance.  
The only interaction of statistical significance was that of FMD patients’ CORE-OM scores and 
employment status (F1, 22 = 4.6, p = 0.04, partial η
2 = 0.17). FMD participants who were 
employed saw a significant drop in their CORE-OM clinical mean scores (t = 3.7, df = 10, two-
tailed p = 0.004) while there was no significant difference for unemployed participants (t = 2.1, 
df = 12, two-tailed p = 0.056).  
6.3.9.3 HoNOS scores pre- and post-treatment  
Four FMD and five control patients had a HoNOS score within 180 days of their assessment or 
first day of treatment and within 180 days of their final treatment session or follow-up 
appointment. The small numbers limited the number of statistical tests used in this study. 
FMD patients’ HoNOS scores got slightly worse over time with a mean of 7.25 (SD: 2.4) at the 
start of treatment increasing to a mean of 8 (SD: 3.3) after treatment, though the change was 
not statistically significant (Z = -0.37, p= 0.72). Control group participants saw their scores 
improve over time from a mean of 9.6 (SD: 1.2) to 5.8 (SD: 1.9) and this change was also not 
statistically significant (Z = -1.5, p = 0.14).  
Given the small sample size, no further stratification or analyses were conducted. Table 67 
shows the breakdown of HoNOS scores before and after therapy. 


















F44.4 group (Total participants = 4) 7.25 (2.4) 8 (3.3) - 0.8 - 0.37 0.72 
Control group (Total participants = 5) 9.6 (1.2) 5.8 (1.9) 3.8 -1.5 0.14 
Range: 0 (best) - 48 (worst outcome) 
 
6.3.9.4 HoNOS-ABI scores pre and post-treatment 
In total, 22 FMD patients had HoNOS-ABI scores available before and after CBT treatment and 





Of the FMD patients, 17 had attended all the treatment sessions, four dropped out early, and 
in one case, the therapist stopped the session. Data were available for 15 control group 
participants of whom 14 had attended all their treatment sessions while one dropped out 
early. There were no significant socio-demographic or health differences between patients 
who had two available HoNOS-ABI scores and those with one or no available score (see Table 
107, ”Appendix 6.4: Socio-demographic differences between patients with clinical outcome 
scores and those with one or none”).  
The mean HoNOS-ABI score for FMD patients prior to the start of CBT was 11.5 (SD: 6) and 
after therapy it dropped to 7.3 (SD: 5) representing a significant change (Z = -3.1, p = 0.002). 
The mean pre-CBT score for control patients was 12.3 (SD: 7), and post-CBT it was 6.5 (SD: 4), a 
significant drop in mean scores (Z = -3, p = 0.003). Control group variables, when stratified by 
socio-demographics, contained less than five participants in each group so sub-group analyses 
were not conducted.  
Table 68 outlines HoNOS-ABI scores and scores after stratification by socio-demographic 
variables.  





















F44.4 group (Total participants = 22) 11.5 (6) 7.3 (5) 4.2 -3.1 0.002 0.76 
Gender Female (Total = 15) 11.3 (7) 6.2 (4) 5.1 -2.8 0.005 0.89 
Ethnicity British (Total = 12) 13.5 (6) 6.8 (4) 6.7 -2.6 0.009 1.31 
 Other ethnicity (Total = 10) 9 (5) 7.8 (7) 1.2 -1.6 0.10 0.19 
Marital 
status 
Single (Total = 10) 12.1 (7) 7.1 (5) 5 -2.2 0.03 0.82 
Work Unemployed (Total =13) 13.1 (7) 8.6 (6) 4.9 -2.1 0.03 0.69 
Psych 
factors 
Accepted psychological explanation 
pre-CBT (Total = 10) 
11.8 (7) 7.5 (7) 4.3 -2.2 0.003 0.61 
 Accepted psychological explanation 
post-CBT (Total = 12) 
12.8 (8) 6.8 (6) 6.0 -2.5 0.012 0.85 
Carer Patient does not have carer (Total = 13) 11.2 (6) 5.7 (3) 5.5 -2.8 0.005 1.16 
Abuse Did not experience CPA (Total = 12) 9.9 (6) 6.9 (6) 3 -2.1 0.04 0.5 
Disability Uses walking aid (Total = 11) 12.7 (7) 6.4 (4) 6.3 -2.6 0.01 1.1 
Health Family mental health history 
(Total = 10) 
11.6 (7) 7.1 (4) 4.5 -2.4 0.02 0.79 
 Does not smoke (Total = 8) 8.6 (6) 4.9 (3) 3.7 -2.0 0.04 0.78 
Control group (Total participants = 15) 12.3 (7) 6.5 (4) 5.8 -3.0 0.003 1.01 
Scores range from 0 to 48 (most severe) 
Like the CORE-OM scores, there were significant within-group differences in both the FMD 
(Wilcoxon signed ranks = -3.1, p = 0.002) and control groups (Wilcoxon signed ranks = -3.0, p = 





British, single, who accepted a psychological explanation before CBT, who accepted a 
psychological explanation after CBT, patients without a carer, those who did not experience 
childhood physical abuse, those who used a walking aid, those with a family history of mental 
health problems and those who did not smoke saw significant decreases in their HoNOS-ABI 
scores. In many variables are missing here as they contained less than five participants.   
Figure 37 displays a paired dotted line graph showing the change in scores over time for both 
the FMD and control group.  
  
Figure 37 Paired dotted graph showing each participants’ change in HoNOS-ABI scores pre- 
and post-CBT 
Similarly to the CORE-OM clinical score results, a two-way repeated measures ANOVA found 
no significant interaction between the FMD and control groups and changes in pre- and post-
CBT HoNOS-ABI scores (F1,35 = 0.58, p = 0.45, partial η
2 = 0.02).  








Figure 38 Figure showing change in mean HoNOS-ABI scores between F44.4 and control 
groups before and after CBT treatment 
Interaction effects were explored within FMD patients according to socio-demographic 
variables (see “Appendix 6.6: Mean adjusted HoNOS-ABI sub-analysis: repeated measures 
ANOVA”). There was a significant interaction between change in FMD patients’ HoNOS-ABI 
scores and ethnicity (F1,20 = 5.3, p = 0.03, partial η
2 = 0.21), but no other significant interaction 
was found.  
6.3.9.5 PHQ-9 scores pre and post CBT treatment  
Pre-CBT PHQ-9 scores were collected if they were within 180 days of the patient’s assessment 
date or their first day of CBT treatment. Post-CBT PHQ-9 scores were those within 180 days of 
the patient’s last date of treatment or last follow-up session.  
PHQ-9 data were available for 16 FMD patients and ten control patients. Of FMD patients with 
available PHQ-9 scores, 13 had attended all sessions, two dropped out early and one 
participant still had some sessions to complete.  
Table 108 (“Appendix 6.4: Socio-demographic differences between patients with clinical 
outcome scores and those with one or none”) outlines the characteristics of FMD patients with 
two available PHQ-9 scores versus patients with one or no available PHQ-9 scores. There were 
no differences in socio-demographics between these groups of FMD patients, although 
patients with two PHQ-9 scores were more likely to be single than patients with one or no 
available PHQ-9 score (χ2: 4.2, 95% CI: -1.9 – 52.9, p < 0.05).  
The mean PHQ-9 score for FMD patients prior to the start of CBT was 13.5 (SD: 7). Post CBT, 





tailed p = 0.02). Due to the small sample size, no stratified analyses w conducted for the 
control group.  
See Table 69 for a full breakdown of PHQ-9 scores before and after CBT according to socio-
demographic variables. 
Table 69 Mean total PHQ-9 scores before and after CBT treatment for F44.4 and control 
















test 95% CI 
p 
value 
F44.4 group (Total participants = 16) 13.5 (7) 9.9 (6) 3.6 2.6 0.6 – 6.5 0.02 
 Female (Total = 14) 13.1 (7) 9.3 (6) 3.8 2.4 0.4 – 7 0.03 
 Unemployed (Total = 11) 16.1 (6) 11.8 (5) 4.3 2.4 0.4 – 8.2 0.04 
 Doesn’t receive benefits (Total = 10) 13 (8) 9.1 (6) 3.9 2.2 -0.1 – 7.9 0.06 
 Patient does not have carer (Total = 11) 11.8 (6) 8.8 (5) 3 1.8 -0.6 – 6.6 0.10 
 Single (Total = 10) 11.2 (7) 8.9 (5) 2.3 1.3 -1.8 – 6.4 0.24 
 Didn’t experience CSA (Total = 10) 12.4 (6) 8.1 (6) 4.3 2.4 0.2 – 8.4 0.04 
Scoring guide: ‘0-4’ no depression; ‘5-9’ mild; ‘10-14’ moderate; ‘15-19’ moderately severe; ‘20-27’ 
severe 
Within-group FMD differences were explored by socio-demographic variables. FMD patients 
who were female (t = 2.4, df = 13, 95% CI: 0.4-7, two-tailed p = 0.03), unemployed (t = 2.4, df = 
10, 95% CI: 0.4 – 8.2, two-tailed p = 0.04), and those that did not experience CSA (t = 2.4, df = 
9, 95% CI: 0.2 – 8.4, two-tailed p = 0.04) saw a significant decrease in their mean score 
between the beginning and end of CBT.  
Figure 39 displays the paired dotted line graph showing change in PHQ-9 scores over time in 







Figure 39 Paired dotted graph showing each participants’ change in PHQ-9 scores pre- and 
post-CBT 
Using a repeated-measures two-way ANOVA, the interaction between the FMD and control 
groups and the change over time between the pre-and post-CBT assessment was examined. 
This was not statistically significant (F1,24 = 0.22, p = 0.64, partial η
2 = 0.01). Mean PHQ-9 scores 
between groups are displayed at pre- and post-treatment in Figure 40. 
 
Figure 40 Figure showing change in mean PHQ-9 scores between F44.4 and control groups 
before and after CBT treatment 
Repeated measure two-way ANOVAs were conducted to assess interactions within the FMD 
group according to socio-demographic variables. No significant interactions were found (see 






6.4.1 Main findings 
In our study, half of FMD patients (49.4%) saw improvements in symptoms from the beginning 
to the end of CBT therapy. 41.6% of FMD patients’ symptoms remained the same and 9% of 
cases got worse, comparable to the 10.1% of control group patients with neurological disease 
whose symptoms also worsened. FMD patients improved as a response to CBT treatment 
according to the clinical outcomes measures available. FMD patients’ mean CORE-OM, HoNOS-
ABI and PHQ-9 scores all saw clinically significant reductions indicating improvement in 
psychological distress, depression, and physical functioning. Control patients also had 
significant improvements in scores. There were no significant interactions between FMD and 
control groups and pre- and post-therapy clinical scores, indicating that CBT is effective for 
both groups.  
Regarding socio-demographic, and health outcomes, and experience of traumatic events, no 
differences emerged in ethnicity, marital status, housing, age or benefits between groups. 
FMD patients were however more likely to be female, unemployed, to be a carer and to have a 
carer, to have experienced CSA but were less likely to have a comorbid physical health 
condition. FMD patients had lower rates of anxiety but higher rates of fatigue compared to the 
control group.  
While only half the FMD group experienced improvements in symptoms may seem 
disappointing, these findings should be viewed within the context of previous literature on 
prognosis in FND. 
A  systematic review of 22 studies on prognosis in patients with functional motor symptoms by 
Gelauff et al. (2014) found 39% of patients had the same or worse symptoms at follow-up 
(11.6% less than in our study), but only 20% of patients had complete symptom remission. 
Their review included a number of studies which assessed treatment outcomes. The 
treatments included in the review were heterogeneous but, of these studies, the proportion of 
patients who were the same or worse was 49%, analogous to our result. The mean follow-up 
of 7.4 years in their review makes definitive comparisons difficult. 
Speckens et al. (1995) reported results from an RCT testing CBT on patients with medically 
unexplained physical symptoms. They reported a 6-month post-treatment improvement of 
64% in the intervention group, with 18% remaining the same. At 12-month follow-up however, 
improvement had dropped to 51%, and 27% were the same or worse, suggesting 





findings include the person conducting the therapy sessions. Previous research suggests GPs 
using CBT are no more effective than treatment as usual (Arnold et al., 2009; Sumathipala et 
al., 2008). Specken’s study took place in a general medical outpatient clinic and the attending 
physician was involved in the initial treatment session. The authors argue that the lack of a 
psychological referral was important to participants a factor which may have affected 
treatment dropout in our findings.  
Two caveats are worth noting when comparing our findings to previous CBT trials. Our study 
comprises results from a naturalistic study without the artificial selection criteria often applied 
in RCTs. Our results highlight the practicalities of delivering CBT in the community and our 
findings are closer in comparison to a pragmatic RCT measuring effectiveness than to one 
assessing pure efficacy. Our method may mean our results have increased generalisability. 
Secondly, most of the RCTs outlined above do not list the reasons why patients refused to 
participate. The method we adopted means we have a relatively good degree of information 
on the reasons patients did not take up CBT when offered and why they dropped out, results 
pertinent to future service planning. Our analytic approach is similar to an intention-to-treat 
analysis often used in RCT studies whereby patients are included in the analysis even if they 
had dropped out.  
LaFrance et al.’s (2009) study of CBT reported a reduction of NES frequency of 50% in 16 
patients (76.2%). They also reported improvements in depression, anxiety, family life, and 
psychosocial functioning. CBT’s effectiveness in improving psycho-social symptoms is well 
established, a fact again confirmed in a large RCT testing CBT on patients with health anxiety in 
medical clinics (Tyrer et al., 2014). CBT may therefore be particularly effective in reducing the 
underlying psychological factors that cause or worsen physical symptoms.  
CBT has been shown to be effective in reducing the psychological symptoms associated with 
FND or unexplained symptoms. However, Kroenke and Swindle (2000) concluded that 
reductions in physical complaints can occur independently of psychological distress reduction. 
Our study found reductions in both physical symptoms and psychological distress. While our 
clinical scores capture a proportion of participants’ fluctuations in psychological distress, our 
symptom improvement measures may be overly prescriptive. The goals of CBT are often not 
simply somatic symptom reduction, but initially are often aimed at improving the thinking and 
behaviour associated with symptoms. Commonly, patients themselves discuss their goals at 
the start of treatment. Had our symptom improvement score measured a more global 
measure of improvement or included patients’ achievement of individual personal goals set at 





classified as ‘improved’. The use of medical records, rather than face-to-face contact limited 
the type and range of measures that we could employ, an issue discussed in more detail in 
Section 6.4.2 of this discussion.  
The socio-demographic findings in our study are broadly similar to Chapter Five’s findings. The 
same rate of gender was found. Our rate of 72.4% females is similar but lower than the 78.8% 
rate reported by McCormack et al. (2014) in an inpatient specialist unit in SLaM, perhaps 
reflecting a higher rate of severity in the inpatient setting. Similar rates of ethnicity, marital 
status and housing status were found amongst FMD patients in this study and FMD patients in 
Chapter Five. In this study however, no FMD patient was homeless and fewer lived in sheltered 
or supported accommodation. A higher proportion of patients in this study were employed 
compared to FMD patients in Chapter Five. Sexual abuse rates in childhood were broadly 
similar (23.8% versus 20% in Chapter Five) but childhood physical abuse was somewhat higher 
in this study (28.4% versus 22.7%). Age rates in both studies were similar. Similar to findings in 
Chapter Five, the most frequent symptom amongst FMD patients was weakness. Equal 
proportions of FMD patients had symptoms defined as ‘abnormal’ and ‘loss’ but our finding 
differs from McCormack et al.’s inpatient results where the majority of their patients reported 
symptoms defined by loss of motor function.  
The similarities in socio-demographics can be partly explained as many of the patients who 
feature in this study are also included in Chapter Five. The differences between FMD groups in 
employment and accommodation rates are not surprising. Being homeless, unemployed or 
having precarious or unstable living conditions will likely make regular attendance in 
outpatient CBT more problematic and these patients may be less likely to be offered a 
treatment course in general. The higher rates of abuse observed in this study may be linked to 
a referral bias whereby patients who experienced abuse in childhood likely have higher 
symptom morbidity, and are more likely to receive a CBT referral.  
6.4.1.1 Prognostic factors 
A number of socio-demographic characteristics emerged in the comparison of FMD patients 
whose symptoms improved compared to those who stayed the same. 
Our univariate analyses found that a significantly higher proportion of FMD patients who got 
worse or stayed the same received welfare benefits compared to those patients who 
improved. FMD patients who received benefits at the time of admission to a tertiary referral 
hospital were more likely to have poorer outcomes (Crimlisk et al., 1998) and the same finding 





a proxy measure for socio-economic status. Patients in lower SES categories may have more 
difficulty in overcoming the social and psychological barriers linked to symptom remission but 
another explanation is that receiving benefits may reflect more ingrained illness beliefs, 
secondary gain or increased disability which in themselves may explain a poorer prognosis.  
Our findings show a higher percentage of patients whose symptoms improved were employed, 
and a positive interaction in CORE-OM scores was found in FMD patients who were employed 
versus FMD patients who were unemployed. This finding has also been reported in NES 
patients (McKenzie et al., 2010; Reuber et al., 2003). Moreover, our study found a higher 
proportion of patients who improved worked or had worked as health or social care workers. 
As discussed previously, working in health or social care has been highlighted as a feature 
amongst FND patients, but to our knowledge has not previously been considered a positive 
prognostic factor. Being a clinical worker may be an advantage to participants as they may be 
more likely to have previously been exposed to the language and themes of CBT and recovery 
prior to their referral, aiding recovery. Alternatively, the positive effect of health and social 
care work may be explained entirely by employment itself.  
Of patients whose symptoms stayed the same or got worse, a higher proportion used a 
walking aid than those FMD patients who improved. This finding likely reflects pre-treatment 
severity whereby these patients’ with mobility aids had more severe or chronic symptoms at 
the start of CBT compared to those patients who improved as a result of CBT. While we did not 
measure whether there was any change in use of walking aids as a result of CBT, McCormack 
et al. (2014) reported that following specialist neuropsychiatry inpatient treatment, wheelchair 
usage fell by 42.4%. Such a measure was not possible in our study as wheelchair usage was 
uncommon across the FMD group. 
Our findings suggest that accepting a psychological account of symptoms both before and after 
CBT predicts greater symptom improvement, a finding reported previously. Sharpe et al. 
(2010) found that a strong independent predictor of poorer outcomes after one year was the 
non-attribution of symptoms to psychological factors. Another study reported that belief in 
stress or an ‘emotional state’ as the cause of functional motor symptoms was associated with 
greater improvements after admission to an inpatient rehabilitation programme (Saifee et al., 
2012). These findings are mildly tautological as a cornerstone of CBT is often the re-attribution 
of symptoms and the restructuring of illness beliefs. What is particularly interesting however 
are the three FMD patients (7.5%) in our study who did not accept a psychological explanation 
but nonetheless saw improvements in physical symptoms. While Saifee et al. (2012) argue that 





acceptance to treatment programmes, our findings suggest, for a small proportion of patients, 
improvement may be possible without accepting a psychological account.  
Our study found no prognostic effect of marital status, a result also reported in Feinstein et 
al.’s (2001) study. Crimlisk et al. (1998) suggest however that a change in marital status and 
the leaving of an unhappy relationship is associated with better prognosis, a process we did 
not measure. 
In our study gender did not play a role in FMD patients’ improvement. Research on prognosis 
and gender has mixed results. Czarnecki et al. (2012) found females in their study had a higher 
rate of recovery compared to males, while other research found no influence of gender on 
outcomes (Binzer & Kullgren, 1998; Crimlisk et al., 1998; Ibrahim et al., 2009; Thomas et al., 
2006). The over-representativeness of females in our study, and in most FND research, make 
conclusions on the prognostic value of gender difficult to draw. 
Age of symptom onset is often reported in FND literature as a prognostic factor, with a higher 
age of onset linked to poorer prognosis (Moene et al., 2000; Stone et al., 2003). No difference 
in age of onset was found in our study between those who improved and those who stayed 
the same or got worse. Nevertheless, the long delay we observed between symptom onset 
and the offer of treatment is a general concern for NHS services.  
While the variables outlined above were statistically significant in our univariate analyses, our 
multivariate logistic regression analysis results did not find a positive association when these 
prognostic factors were considered at once. It is therefore likely that welfare benefits, 
employment, pre-morbid employment, wheelchair use, ethnicity, gender, and psychological 
acceptance are covariates. Studies with larger samples are needed to establish robust 
theoretical, causative and prognostic models.  
6.4.1.2 Patient dropout 
Engagement is an important part of the CBT process (Kent and McMillan, 2009). Therapists and 
commissioners invest time and resources in reducing dropout and missed appointments. In the 
neuropsychiatry CBT clinic, patients are selectively chosen based on presumptions about their 
ability to engage in therapy. Clinicians will discharge patients if a patient has missed an 
appointment more than once, without giving prior warning to their clinician. After the first 
missed appointment they will receive a reminder letter from the clinic warning of the 





Predictors of adherence to treatment are relatively under-studied in FND generally. Patients 
referred to an FND clinic from the emergency department are less likely to attend their initial 
outpatient consultation compared to patients from other settings (Perez et al., 2016). Glass et 
al. (2017) reported FND patients on antidepressant medication at baseline, or those with 
Generalised Anxiety Disorder, were less likely to miss an outpatient follow-up visit, arguing 
that these factors may signify an existing willingness to engage in interdisciplinary treatment. 
They also found that patients with functional weakness were more likely to be at risk of 
treatment nonadherence compared to other types of FND, suggesting that this may be 
explained by gender and psychopathology (Glass et al., 2017). A recent paper following 
patients with NES for over a year and a half reported 80% attended their first outpatient 
psychiatric appointment, but only 14% attended their fourth and final appointment (Tolchin et 
al., 2017). The authors found lower scores on the Brief-IPQ (indicating less concern about the 
illness) predicted greater nonadherence.  
Of the 200 FMD patients in our study who were offered a CBT assessment appointment, only 
49% went on to receive treatment. The relatively low rate of CBT uptake is partly explained by 
patients receiving a more appropriate inpatient referral to the Lishman Unit. The lower uptake 
may also be partly explained by the national referral status of the clinic as patients may have 
to travel longer distances to attend sessions which may be particularly problematic in the case 
of patients with motor deficits. The acceptability of CBT to the patient will play a role in 
treatment uptake. A higher proportion of FMD compared to control patients in our study 
refused treatment after their assessment. It is possible that the psychological-nature of the 
therapy did not align with their illness beliefs although once CBT began, no difference in 
dropout rates emerged between patient groups.  
Clinicians offer CBT to patients they believe will engage in and respond to treatment and 
patients who oppose a psychosocial explanation will likely self-select out of CBT. Despite the 
likely selection bias, the CBT treatment dropout rate of 34.7% for FMD patients is reasonably 
high. Wierzbicki and Pekarik (1993) assessed psychotherapy dropout in a meta-analysis and 
reported a rate of 46.9%. A recent meta-analysis reported the dropout of patients with a 
spectrum of psychological disorders from CBT was lower, at 26.2% (Fernandez et al., 2015). 
Depression, and outpatient rather than inpatient settings were associated with higher rates of 
CBT attrition. It is likely that patients with somatoform disorder have higher rates of dropout 
generally, with previous reports of dropout for these patients ranging from 21-50% (Crane et 





We investigated the socio-demographic variables linked to treatment dropout. Patients who 
stopped treatment early had a higher rate of CSA. Patients with experiences of CSA may have 
more severe symptoms prior to CBT. This is reflected in patients’ CORE-OM and HoNOS-ABI 
scores where FMD patients with a history of physical abuse had a higher pre-treatment mean 
than FMD patients with no history of abuse8. Similar to Glass et al. (2017), we found that 
patients who did not drop out were more likely to report improvements in their symptoms 
compared to those who did drop out. Those who do not see immediate improvements in 
symptoms may become disenchanted, and as a result disengage. Dropping out early also 
lessens the chance that a patient will have the opportunity to improve. Again, interpretation is 
limited as these socio-demographic differences were only found in our univariate analysis, but 
were not significantly different when combined in a logistic regression model. Future studies 
should assess the effect of severity of symptom and quality of life on adherence to CBT.  
While the treatment dropout is likely to be partially explained by patients unwilling to accept a 
psychological account of symptoms, in CFS, a diagnosis potentially as problematic to patients 
as an FMD diagnosis, dropout from the CBT arm of the ‘Pacing, graded Activity, and Cognitive 
behaviour therapy, a randomised Evaluation’ (PACE) trial was only 11% (White et al., 2011). 
This rate is significantly lower than that seen in our study but a patient deciding to drop out of 
an RCT is not entirely comparable to our observational results. Deciding to remain in treatment 
offered as part of an RCT is likely a qualitatively different decision. It might be fuelled by a wish 
to contribute to scientific knowledge rather than factors associated with the treatment itself. 
In addition, RCT studies may make an extra effort and have greater expertise in employing 
methods to reduce dropout and have more access to financial and administrative resources to 
avoid dropout compared to well-established NHS clinics. 
6.4.2 Strengths and limitations 
Our study is the first to assess the outcomes of FMD patients receiving CBT from an outpatient 
neuropsychiatry clinic. This is a relatively large retrospective study, which like Chapter Five, 
benefits from the richness of clinical information available in one large, anonymous medical 
database. The comprehensive search strategy we employed, whereby the records of every 
patient linked to the service’s CBT clinicians was screened for inclusion, means our FMD 
sample is a good representation of patients seen in the clinic. The relatively large sample size 
and the inclusion of a control group allow for the detailed exploration of associations in socio-
demographic variables, and relatively robust statistical comparisons.  
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We originally hoped to include a larger control group, matching at least two control patients to 
every FMD patient. The 76 control group patients we included were however the only 
available candidates who fitted our inclusion criteria. A possible third control group including 
patients with only NES might serve as a useful comparator in a future study.   
One limitation of this study relates to its observational design. While an RCT can make robust 
conclusions about the effectiveness and efficacy of a treatment, our control group differed 
only by diagnosis but all patients received the same treatment. We can conclude that CBT 
appears to have a beneficial effect for a proportion of both patient groups but we do not know 
whether this improvement is explained simply by a regression to the mean phenomenon or 
whether the effects observed would be lesser or greater had a waiting group or placebo 
treatment been used. Our results might serve as a useful pilot study for a larger RCT in this 
area.  
The retrospective nature of this study also has limitations. Like in Chapter Five, any clerical 
errors made in the CRIS database will be reproduced. Patients were not interviewed face-to-
face by the researcher. As such, the experience of receiving CBT cannot be gauged. The author 
of this study did spend time observing CBT staff meetings and assessment and treatment 
sessions with FMD patients and this provided valuable insight into the running of the CBT clinic 
and was a useful aid when reading clinicians’ medical notes in CRIS.  
The retrospective nature of the study and the use of a medical database meant that type of 
measures we could use was restricted. This meant potentially useful measures like the Social 
Functioning Questionnaire or the Illness Perception Questionnaire were not included. A 
second issue relates to our measures of psychological functioning which may have limited 
generalisability. We used lifetime prevalence measures to assess anxiety, low mood and 
fatigue. One might expect to find 100% prevalence for any individual on these measures, 
regardless of their mental or physical health status. That we did not may reflect the differences 
in the type and style of medical notes kept by different clinicians. Thirdly, the retrospective 
study design means we have had to rely heavily on categorical data which have less nuance 
than continuous outcomes and limits the number of tests we can utilise. The design also 
precludes us from concluding which elements of CBT sessions were most useful and which 
techniques brought the most improvement. Such research is difficult however and would likely 
require the recording of sessions through an observer or the use of video, methods which in 





A further issue relates to patients’ clinical outcome scores. The HoNOS-ABI and HoNOS are 
clinician-rated measures. There is the possibility that clinicians may, consciously or 
unconsciously, give more favourable scores at the end of treatment. While it can and should 
be assumed that most staff members are unbiased in their scoring, services often implement 
quality control measures such as independent assessments to help reduce any potential 
inflation of results. In our study, we also included CORE-OM and PHQ-9 measures which are 
self-report scales. We found similar scores across measures and no socio-demographic 
differences between patients with complete scores and those without. We also conducted an 
analysis, not reported here, assessing pre- and post-CBT scores according to the treating 
clinician, and found no differences.  
Perhaps a greater concern is the low number of participants who had complete scores at both 
pre- and post-treatment. It is possible that clinicians do not upload scores to the electronic 
records if scores are poor or show deterioration with time. We compared the socio-
demographic differences of patients with complete scores and those with only one or no 
available results and found no significant differences between patient groups. The low number 
of available scores may reflect different clinicians’ preferences in using different measures or 
differences in habits of uploading outcome measures to the patient record system. However, it 
is unlikely that any such preferences alone will systematically bias our findings.  
Our study did not include a follow-up period, so the longer-term prognosis of patients cannot 
be assessed. A future, prospective study would be helpful in ascertaining whether 
improvements were sustained over time, the nature of patients’ care pathway after their 
discharge from the CBT clinic, and their long-term clinical, occupational and psycho-social 
outcomes. In addition, we were unable to investigate prognosis regarding specific functional 
motor symptomatology due to the heterogeneity of symptom types and our sample size. 
Nonetheless, this would be a useful addition to a large study in the future.   
While our study shows preliminary evidence for the effectiveness of CBT in improving FMD 
patients’ functioning, this research area would benefit from a large RCT with blinded 
investigators and a wide range of assessment measures. The CODES trial, a large RCT assessing 
CBT versus standardised medical care will provide robust evidence on the effectiveness of CBT 
in patients with NES (Robinson et al., 2017), the area of FMD remains under-served in evidence 






A proportion of FMD patients respond positively to CBT and the treatment has a moderate 
dropout rate. While the patients who are offered and go on to accept treatment are a select 
sample, their clinical scores show good improvements in psychological and physical 
functioning. These patients present with a range of functional motor symptoms, and many 
experience pain and weakness.  
Many participants accepted a psychological account of symptoms before treatment, but a 
proportion did not but went on to change their mind and had accepted a psychological 
account by the end of treatment. Acceptance of the role of psychological factors is helpful in 
predicting improvement but for a small group of patients, symptoms improve regardless of 
their belief in the cause.  
While our study suggests CBT is effective, we cannot conclude that CBT is a superior treatment 
to any other intervention and we do not know which specific components of the therapy are 
most effective. These are topics which would be best addressed in a future large RCT, evidence 
that is distinctly lacking from existing literature.  
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In this thesis, I have investigated FNDs as they present to stroke and psychiatric services. The 
first half of the thesis investigated presentations of patients with unexplained symptoms to 
stroke settings focusing, in particular, on recently established HASUs. The last two chapters 
explored presentations of FMD in a large mental health setting, investigating socio-
demographic, health and clinical factors as well as the effectiveness of CBT. 
Five main findings emerged from these studies: 
Functional patients consistently present to stroke settings, constituting 1.7% (95% CI: 1.3% - 
2.2%) of all presentations, and 11.8% (95% CI: 9.3% - 14.9%) of stroke mimic presentations. In 
acute stroke units, patients with functional disorders account for 13.8% (95% CI: 7.9% - 23.2%) 
of stroke mimic presentations. 
Hyper acute stroke clinicians describe an array of potential causes of functional stroke 
presentations, with some arguing that patients are consciously performing symptoms. Many 
feel unsure how to discuss potential causes with these patients and 90% of survey respondents 
do not believe there are clear guidelines on how to manage them. 
Patients with unexplained stroke-like symptoms have strongly negative emotional responses 
to admission to hyper acute stroke wards and feel that they have little control over their 
symptoms. Two months later, patients are often uncertain about the cause of their admission. 
40% continued to experience residual physical symptoms; many experienced anxiety, and 
often expressed a desire for a more detailed explanation about the potential cause of their 
symptoms.  
Our case-control study examined presentations of FMD to SLaM, a large mental health trust. 
Our study supports previous epidemiological research showing FMD more commonly affects 
women, that patients frequently work in social or health care, and frequently have a comorbid 
physical and functional illness with headache and NES most frequently accounting for these 
respectively. We found no association between rates of childhood sexual or physical abuse in 
the FMD group compared to the psychiatric patients in our comparison group, but tentative 
evidence suggests FMD patients more commonly experience precipitant events that we 
defined as ‘disruptions to interpersonal relationships’. 
Finally, our case-control CBT study indicates that both FMD and patients with organic disease 
respond to outpatient CBT. Half of the FMD group saw improvements in their physical 
symptoms, and measures of psychological distress and depression, when available, showed 





who were offered CBT but who did not go on to receive therapy, 57% were patients who 
themselves had refused treatment, for a variety of reasons, higher than the 39% of patients in 
the control group who themselves refused treatment. This suggests that pre-treatment 
acceptability for CBT amongst FMD patients is relatively low. Dropout rates after treatment 
commencement showed no significant difference between FMD and control patients.  
The findings and limitations of individual studies have been explored previously. This chapter 
discusses general issues, including differences in patient groups between studies, differences 
within FMD symptoms themselves, the gender ratio of FND, the use of medical databases, and 
potential future service and treatment provisions. 
7.1 Between- and within-group difference  
A question arising in the introduction of this thesis is whether functional patients who appear 
in HASUs differ from the FMD patients seen in psychiatric settings. They appear to have certain 
similarities but differ with regards to symptom chronicity and severity. Functional stroke 
patients share a similar age and gender profile to the patients we observed in SLaM, and like 
SLaM patients and the functional patients observed in our meta-analysis, functional stroke 
patients most commonly experienced weakness. One would expect FMD patients in psychiatric 
services to have a higher number of comorbid psychiatric symptoms, but a proportion of 
functional stroke patients also had a history of depression and many described experiencing 
low mood and anxiety as a response to the admission.  
Perhaps the most obvious difference between functional patients in the HASU and FMD 
patients seen in SLaM was the temporality of their symptoms. 44% of functional stroke 
patients had transitory physical symptoms which resolved two months after their discharge. 
While functional stroke patients’ physical symptoms were acute, for a proportion of patients, 
their psychological symptoms of lower mood and anxiety continued two months after 
discharge. 
A proportion of our functional stroke patients likely represent the early stages of a chronic FND 
course, while patients in our SLaM studies will more often represent advanced stages. On 
average, SLaM patients experienced symptoms for ten years prior to receiving a functional 
diagnosis from the Trust. It is possible that if functional stroke patients’ psychological 
symptoms don’t resolve quickly, or if they do not receive an adequate referral or early 





Research suggests only a proportion of functional stroke mimic patients receive a 
psychological referral. 37.5% of functional patients admitted to a HASU were later referred by 
their GP to psychological treatments, counselling, pain clinics or mental health services 
(Gargalas et al., 2015). The remaining patients may not need such a referral, but without 
longer-term follow-ups this is difficult to conclude. It is well established that a confident 
diagnosis and early intervention in FND is important as patients have a better prognosis if they 
have had a shorter duration of symptoms prior to treatment (Aybek et al., 2013; Factor et al., 
1995; Jankovic et al., 2006; Lempert et al., 1990; Thomas et al., 2006).  
For some patients, a stroke admission will represent a small proportion of a larger, more 
extensive care pathway, particularly if they are dissatisfied with their original consultation 
(Crimlisk et al., 1998). Each admission or medical referral increases the risk of harm to the 
patient from unnecessary intervention. Admission to a stroke ward increases the probability of 
receipt of thrombolytic therapy. While thrombolysis in non-stroke patients has been found to 
be relatively safe (Chernyshev et al., 2010; Kostulas et al., 2017; Scott & Silbergleit, 2003; 
Winkler et al., 2009), it is unclear what the effect of repeated administrations in the same non-
stroke patient may be. A case study reported that a patient with a factitious disorder diagnosis 
received thrombolytic therapy twice and went on to develop a minor groin haematoma 
(Belagaje et al., 2012).  
Acute stroke services require systematic methods of training stroke clinicians in how to explain 
functional symptoms as well as guidelines and referral methods to prevent symptoms 
becoming intractable. The two-month follow-up and qualitative methodology in Chapter 
Four’s stroke study cannot fully account for the potential relapse and remission of functional 
symptoms but prospective, longitudinal research would help identify the long term pathway of 
functional stroke patients, whether this course differs substantially to patients in psychiatric, 
medical or neurology outpatients settings, and the protective factors that help some functional 
stroke symptoms resolve without the need for further referral. 
Linked to the issue of whether functional stroke patients differ to FMD patients in psychiatric 
services is the question of whether different functional disorders are themselves a unified, 
coherent disorder or whether they should be regarded separately. In the 19th century, French 
neurologist J-M Charcot attempted to develop a reliable classification of hysterical symptoms 
but recent debate contests whether functional symptoms represent distinct categorical 
entities or form one dimension. 
Kirmayer and Robbins (1991) proposed a dimensional model that conceived all somatoform 





awareness. Wessely et al. (1999) argue that drawing distinctions between somatoform 
syndromes is redundant given the many commonalities between disorders. They allude to the 
predominance of females, strong associations with psychological distress, high prevalence of 
childhood trauma and abuse, and difficult doctor-patient interactions as examples of the 
shared features of somatoform syndromes. They advocate a unidimensional approach arguing 
that current classifications of somatoform disorders are artefacts of professional medical 
specialisation and organisation, rather than distinct syndromes (Wessely & White, 2004).  
Evidence employing latent variable analysis suggests that there may be a uni-dimensional 
somatoform syndrome predisposing patients towards developing unexplained physical 
symptoms, but there is also consistent evidence for coherent and distinct syndromes. Robbins 
et al. (1997) found evidence to support the conceptualisation of CFS, IBS and fibromyalgia as 
distinct syndromes while noting a strong overlap between syndromes. Deary et al. (1999) 
identified five distinct symptom factors, CFS, IBS, fibromyalgia, somatic depression, and 
somatic anxiety. Fink et al. (2007) found evidence for three specific syndromes: 
cardiopulmonary, musculoskeletal and gastrointestinal symptoms, arguing that these 
symptoms represent an underlying phenomenon they term, ‘bodily distress’.  
With regards to differences within FND itself, previous research highlights differences between 
NES and FMD patients. NES patients are often younger, more likely to have experienced CSA or 
a precipitating stressor (Driver-Dunckley et al., 2011; Ekanayake et al., 2017; Stone et al., 
2004b). The evidence on psychiatric comorbidity is mixed. Ekanayake et al. (2017) reported 
that NES patients have higher rates of depression and anxiety than FMD patients. Hopp et al. 
(2012) however found similar rates in both groups, arguing that NES and FMD represent one 
coherent disorder, an argument echoed by Erro et al. (2016) who suggested that NES and FMD 
have a shared psychopathology with distinct phenotypic manifestations. Many of these 
studies’ are derived from data from patients recruited from different clinics however, so 
referral processes may plausibly account for these differences.  
The studies outlined in Chapters Five and Six of this thesis specifically exclude patients with 
only NES so we cannot draw conclusions on differences between FMD and NES patients. It is 
possible however to discuss the potential differences and similarities within FMD and to ask 
whether differing motor symptoms represent distinct entities or a coherent disorder. For 
example, there is some evidence that patients with weakness and paralysis, have a better 
prognosis compared to patients with movement disorders like tremor (Gelauff et al., 2014). 
In our case-control studies, we observed a wide variation in FMD patients’ motor symptoms. A 





representing a rich array of motor deficits and abnormalities. In our SLaM studies, most 
patients had more than one functional motor symptom with 83.7% of patients in Chapter Six 
with at least two functional motor symptoms, and over 30% in Chapter Five with a comorbid 
functional disorder. This may also underestimate functional disorder comorbidity as we 
classified headache as a physical illness.  
While reading the medical notes, it was frequently difficult to ascertain which functional 
symptom was the ‘primary symptom’. We abandoned an initial attempt to hierarchically 
categorise motor symptoms. In addition, our categories are, inevitably, relatively artificial as 
weakness in one patient may look and feel different in another and was often accompanied by 
a differing array of comorbid physical and mental health symptoms. It was rare to observe the 
same collection of symptoms in more than one patient. Finally, the motor symptoms we 
observed appeared to evolve over time, with some remitting entirely and new ones emerging.  
As with many other mental health disorders, FMD’s phenotype does not appear to follow a 
fixed course. Instead, these symptoms seem to represent complex and varied 
symptomatology, one that is difficult to predict. The complex evolution of symptoms is not 
peculiar to our study. In one study, patients with NES were followed up between 6 and 12 
months after a diagnosis and, in this period, new unexplained symptoms emerged in 23.5% 
(McKenzie et al., 2011). In a study of FMD patients, 35% went on to develop additional 
unexplained symptoms (Feinstein et al., 2001).  
Reliable classification of disease and disorders is important in the establishment of robust 
epidemiological data and subsequent effective treatment. While a unified, dimensional 
approach might help resolve some issues related to the reliability of motor symptoms and 
their comorbidity with other functional symptoms and disorders, an entirely unidimensional 
model would obscure the existing, hard-won nuance in this field. Such calls are premature 
based on current evidence. Many psychological disorders share similar or identical causal 
pathways and phenotypic commonalities, but nonetheless remain distinct conceptual entities. 
More importantly, abandoning the current symptom-driven classification system would affect 
the kind of treatment on offer. An example of this is physiotherapy, a recommended 
treatment for FMD, but where it would make little intuitive sense to offer this to NES patients.  
More generally, unifying symptoms and syndromes under one category does not help address 
why some patients present with certain functional syndromes or, more specifically why one 
FMD patient might have a gait disturbance and another experiences tremor or weakness, 
especially in cases where there is no precipitating physical factor or where disease modelling in 





have been made in understanding the causes of somatoform disorder generally, the field lacks 
coherent syndrome- and symptom-specific theoretical explanations. Some would argue that a 
relatively trivial ‘trigger’, such as a physical injury, often lies behind symptom manifestations 
(Pareés et al., 2014). 
The retrospective nature of our studies meant we could not conduct a longitudinal factor 
analysis which would have allowed us to identify symptom patterns and their long-term 
course. FMD would benefit from a large-scale prospective case-control or cohort study which 
could help assess the development and evolution of FMD symptoms, their course, and the 
factors predicting their severity and remission. 
This thesis was not designed to test a specific theoretical model or to identify specific 
psychological mechanisms in the development and maintenance of FMD. The aim of this 
research was to build an evidence base on  FND patients’ presentations to stroke settings and 
to utilise and explore existing evidence from a large retrospective database.  
Nonetheless, some current psychological accounts of FND may help shed some light on our 
results. Firstly, theories of attentional processes may be relevant. When distracted for 
instance, FND patients are frequently less symptomatic. This suggests that patients’ attention 
towards their own movement production and their higher likelihood of monitoring internal 
sensations may disrupt normal movement. This may be apposite for techniques stroke 
clinicians could utilise when diagnosing and treating functional patients on the ward.  
Research also suggests that FND patients may have an altered style of belief formation, for 
instance a study found patients demonstrated a ‘jumping to conclusions’ style of decision 
making (Parees et al., 2012). This may be relevant to our findings on patients’ illness beliefs on 
the stroke ward where we found functional patients believed their symptoms would have 
serious consequences on their lives.  
Theoretical accounts of FND suggest that patients’ beliefs and expectations about bodily 
functioning are integrated within existing bodily sensory information to produce distorted 
perceptual experiences (Brown, 2004; Edwards et al. 2012). Such distorted beliefs and 
expectations could arise through multiple mechanisms but our findings suggest such beliefs 
may be linked to existing comorbid physical health conditions or difficulties arising from 
interpersonal problems. The causal relationship between such experiential factors and 
resulting beliefs is not well understood.  
The psychological mechanisms involved in FMD share overlapping characteristics with other 





Five and Six for example, fatigue and pain were common comorbidities amongst FMD patients. 
Elements of the symptomatology of FMD are not unlike that seen in CFS where the inability to 
move certain limbs can resemble the extreme fatigue observed in CFS. In FMD, these 
symptoms are more commonly localised to specific regions of the body and may be less 
extreme than that seen in CFS, although in Chapter Five’s study, there were a small number of 
FMD patients with complete bodily paralysis.  
The psychological models underlying treatments for CFS and FMD share similarities but differ 
in important ways. CBT models for CFS specifically propose that the symptoms and resulting 
disability are perpetuated by a fear of symptoms which leads to activity avoidance which 
perpetuates symptoms. This fear avoidance model differs from the CBT model of FMD which 
tends to focus more heavily on maladaptive attentional processes and distorted illness beliefs. 
The specific distraction techniques developed by neurologists in the diagnosis and treatment 
of FMD for instance are unlikely to be relevant or useful for CFS or chronic pain patients.  
The treatment models for FND and unexplained syndromes like CFS do have much in common. 
Both models address illness beliefs, symptom focus or attention, psychological distress and the 
perpetuating factors relevant to the patient; however the emphasis on these factors will differ 
between patient groups and will be affected by the patient’s individual formulation. Evident 
throughout the field of unexplained symptoms more generally however is a dearth of large 
randomised controlled trials testing the individual components of these models and their 
longer-term benefits.  
7.2 Gender  
FND is consistently found to affect more women than men. Established theories exist to help 
explain the gender differences observed in diseases and disorders like multiple sclerosis 
(Harbo et al., 2013), autoimmune diseases (Ngo et al., 2014), depression (Ustün, 2000), and 
heart disease (Maas & Appelman, 2010), but despite its long history, FND lacks a coherent 
account of its gender disparity.   
Cultural theorists attempted to explain the prominence of hysteria amongst women in the 19th 
century as an exercise in the social control by doctors over an emerging class of working 
French women (Appignanesi, 2008). While elements of this theory may be true, it 
misrepresents current evidence by stating that the disorder has all but disappeared. We 
observed similar rates of females in our meta-analysis study, our HASU qualitative study and in 
our case-control studies in psychiatric settings. FND exists and continues to affect more 





Why are women more commonly affected than men? Biological processes may play a role. 
Women with higher anxiety report increased cognitive symptoms like misinterpretations and 
catastrophizing thoughts in the premenstrual phase compared to the follicular phase (Nillni et 
al., 2012). Laboratory studies found women were more sensitive to external environmental 
cues when noticing and defining physical symptoms (Kirmayer & Robbins, 1991). Genetic 
factors may contribute although there is little current evidence for FND specifically. Our crude 
assessment of a family mental health history in Chapter Five for example found half of FMD 
patients had a family member with a mental health problem and, most commonly, this relative 
was a mother. Environmental exposure could also explain this finding or interact with genetic 
processes.  
Psycho-social factors have been attributed to the development of FND in women. These 
include social factors such as greater social and cultural permission for women to express 
psychological and physical distress as well as the specific social roles and responsibilities that 
women assume in society (Kirmayer & Robbins, 1991). This was explored in Chapter Five’s 
case-control study. Female FMD patients were more likely to work in social or health care 
settings, suggesting they occupy a specific economic position - one characterised by low pay, 
high responsibility and dependent interpersonal relationships. Our logistic regression results in 
Section 5.3.6, suggest that when gender and marital status are accounted for however, neither 
health or social care work, nor being a carer in themselves are predictive of an FMD diagnosis. 
It is possible that the high proportion of female health and social care workers is an artefact of 
the fact that 95% of all social care workers are women and that carers are more likely to have a 
lower SES (Eborall, 2005). 
Ways in which the body is conceptualised and symptoms are experienced may differ between 
the genders, contributing to an increased risk of developing unexplained symptoms. Social 
psychological research suggests women and men hold different conceptualisations of the body 
with women often associating the word ‘body’ in its desiccated, anatomical parts and men 
conceptualising it as a functional whole (Jodelet, 1993). Embodied cognition research may 
shed light on this subject with findings suggesting that sensorimotor experience evoke 
psychological responses, for example nodding your head up and down can affect people’s level 
of agreement with an argument (Wells & Petty, 1980). This may operate differently in men and 
women, for example, making a fist can lead men to increase feelings of power, while for 
women, it can lead to a heightened sense of powerlessness (Schubert, 2004). While 
psychological interventions for FND are premised on the assumption that reducing 





research suggest that treatments that directly involve the body might directly affect those 
psychological processes through bottom-up processes. 
Women’s higher risk of exposure to childhood trauma such as physical and sexual abuse has 
been proposed as a potential explanation for FND’s gender ratio (Keynejad et al.). Chapter 
Five’s case-control study however, found that while rates of childhood sexual and physical 
abuse and abuse occurring in adulthood were higher in female FMD compared to male FMD 
patients, rates did not differ between female cases and controls. In our study, this specific type 
of trauma is therefore equally common in women in both groups and while exposure to CSA 
may play a role in the development of FMD, it does not appear to be a specific risk and may be 
a risk for all mental disorder in general. It is possible that experiences of abuse interact with 
negative illness beliefs, social deprivation, personality characteristics, depression and anxiety, 
and mediate or moderate the relationship between trauma and FMD, but it is likely that such a 
pathway exists in the development of many psychological disorders.  
Kuehner (2017) argues that structural gender inequality at the state level, as measured by 
political participation, economic autonomy, and access to reproductive rights affects 
depression rates in women and it is reasonable to assume similar processes may affect the 
occurrence of FMD in women. It is plausible that individual differences as well as meso-level 
processes such as group membership, neighbourhood effects, family dynamics, social 
networks, and larger macro-level social structures like legal frameworks, health care 
structures, and culturally sanctioned beliefs about neurological  all interact in the development 
of FMD in women. There has been little research which combines micro-, meso- and macro-
level processes, but longitudinal cross-cultural research that incorporates methods of 
psychological enquiry may help unravel some of these broader, structural processes and shed 
light on the processes that lead to the manifestation of FND.  
7.3 Data collection and the use of medical records  
“If one looks at the charts of patients institutionalised in asylums and state hospitals in 
the 1920s and 1930s, one finds extremely detailed clinical and phenomenological 
observations, often embedded in narratives of an almost novelistic richness and 
density…this richness and detail and phenomenological openness have disappeared, and 
one finds instead meagre notes that give no real picture of the patient or his world…and 
are of little use in helping us bring about the synthesis of neuroscience with psychiatric 
knowledge that we so need”   





Medical records account for clinicians’ observations, interactions with patients and the 
interventions they employ. Within institutions they can serve as a means of communication 
between staff members involved in an individual’s care. They are also a legal document that 
justifies adequate care. With the transformation of clinical notes into large electronic medical 
databases, these notes have begun to form part of case registers which are being harnessed to 
assess treatment interventions and outcomes.  
Our case-control studies were necessarily influenced and restricted by the format of our case 
register. The most significant advantage of using CRIS in our studies was its size, particularly for 
FMD, a disorder with a relatively low prevalence, where community studies are impractical. 
Using CRIS in our Chapter Six allowed us to observe CBT in its naturalistic setting, and its 
findings have the potential to be more generalisable than standard RCTs. 
The disadvantage is that inaccuracies in the case register will be reproduced in our research. 
Keeping records up to date can be problematic for clinicians and where contradictions appear 
in the notes, it can be difficult to assess what information is correct. There is no way for a 
researcher to know exactly how accurate the information provided is. The retrospective nature 
of this research limits our ability to draw causal inferences; a disadvantage inherent in most 
observational research.  
One of the potential problems in using an electronic database like CRIS, and the problem 
outlined by Oliver Sacks, is that the use of case registers can lead to an emphasis on 
standardised, categorical checklists and short templates rather than richer, ‘novelistic’ clinical 
notes that account for and describe patients’ phenomenological experiences.  
The data collection method used in Chapters Five and Six of this thesis departs from many 
previous CRIS studies. Our approach was an attempt to utilise the qualitative richness and 
detail of the clinical notes. A number of issues arose however as a result. Firstly, it was time 
consuming. Had we relied on structured output alone, data could have been exported without 
the need to read the notes. Instead, our method took the author over a year. Secondly, as the 
database is updated every night, there was an urge to want to continue collecting new cases to 
increase our sample size. A relatively arbitrary decision had to be made to stop data collection 
in order to progress the study. This decision was not based on a pre-defined power calculation 
but rather on the time available to the researcher. 
Relying on structured data alone however would limit the type and range of information we 
could collect. This tension between the need for larger sample sizes as well as rich detail is 





The second issue relates to styles in clinicians’ note writing. There was tendency for clinicians 
to rely on documentation shortcuts like abbreviations, deliberately vague language or generic 
terminology. In some cases clinicians spent a large portion of their notes describing attempts 
to contact patients or any risk management issues. This style often meant there was more 
information on secondary issues related to clinical care rather than the actual clinical 
interactions or the patients’ experiences.  
We were helped by the fact that many of the clinical notes are written in the traditional 
‘Maudsley’ assessment style which includes a family, developmental and social history, a 
Mental State examination, a physical examination, and the clinician’s formulation and 
diagnosis (Owen et al., 2014). The consistent structure of these notes and their depth of detail 
allowed for the collection of rich information on early life events and recent precipitants. Our 
post-hoc categorisation of such information meant the categorisations were informed by the 
data itself and not by any pre-conceived bias. The tradition of note-taking by SLaM 
psychiatrists suggests that Sack’s (1995) pessimism regarding the shortcomings of modern 
medical notes may not be universal. 
A more extreme extension of Sack’s argument is that with technological medical advances, like 
the development of large electronic databases and the standardisation of assessments, 
clinicians can neglect their role as listeners to the stories, thoughts, and feelings of their 
patients (Reiser, 1978). The studies in Chapter Four and Five help address some of this 
shortage in attempts to understand phenomenological and experiential accounts of functional 
symptoms, but the advances in stroke care coupled with the seeming lack of intervention or 
attention to functional stroke patients suggests that such a worry is not entirely unwarranted. 
As case registers become more technologically advanced with the inclusion of biological and 
imaging data, there is an even greater need to find ways and space to account for and include 
first person experiences. 
7.4 Future research 
The following sections discuss potential future improvements in services and treatments.  
7.4.1 Services 
The distinct dichotomy in neurological and psychiatric services perpetuates the dualism 
inherent within conceptualisations of functional neurological symptoms and it may hinder the 
treatment of functional symptoms, with patients moving between such services without 
coherent treatment or any continuity of care. This may be system may be maintained as clinics 





not to be rewarded for good communication or effective referral (Creed et al., 2011). In some 
ways, the structure of this thesis itself mirrors the institutional divide in neurology and 
psychiatry, serving to illustrate its pervasiveness.  
Our findings in Chapter Three and Four suggest that patients in stroke settings are often 
denied adequate explanations about their symptoms and possible treatments. This is likely 
fuelled by neurologists and physicians feeling ill-equipped to provide what they view as 
psychological or psychosocial explanations. Of those functional stroke patients that do receive 
a referral to psychological services, results from Chapter Six suggest, a proportion will refuse to 
accept a referral which they may view as stigmatising or unnecessary.  
To manage functional symptoms effectively, a combined psychological and neurological 
approach is needed (Mula, 2013). The integration of these services could help reduce stigma 
and self-stigma amongst patients concerned they will be labelled with a psychological disorder 
or who fear being accused that their symptoms are ‘made up’. It could also encourage 
neurology staff to deal with the psychological aspects of neurological disorders, which are 
currently described as under-recognised and under-treated (White et al., 2012). A number of 
structural service changes might help lessen the dichotomy between neurological and 
psychological treatments and move towards an integration of disciplines.  
Firstly, the assimilation of training of neurology and psychiatry trainees might help forge links 
between the disciplines. However, given the continued trend towards ever greater 
specialisation in medical training, and the length of neurology training programmes in 
particular, a merging of psychiatric and neurological training is unlikely.   
Consultation-liaison psychiatry services are one of the few psychiatric subspecialties which 
assess and treat FND patients in medical settings, often working at the intersection of 
medicine and psychiatry. Their presence in hospitals is important but FND patients may be 
relatively underserved by this speciality as pressures on services grow. To avoid encumbering 
services, hospital physicians may choose to refer FND patients to GPs or discharge them, 
rather than burdening overstretched services within the hospital.  
Neuropsychiatry services may help reduce the divide. The prefix ‘neuro’ may be advantageous 
as it likely to be more palatable to FND patients. Neuropsychiatry, in its current status 
however, needs to extend beyond tertiary provision. Current neuropsychiatric services serve 
only a small number of regional UK centres and its provision has been described as patchy and 
inadequate (Agrawal et al., 2008). Clinicians working further away from neuropsychiatry 
services have a lower awareness of them and do not know how to access them, increasing the 





Neurologists often manage FND patients within their outpatient clinics but restrictions on their 
time, may mean appointments are short and that they are unable to offer extensive follow-up 
appointments. Neurologists’ interventions may more commonly take the form of diagnostic 
explanation or referral to another service, rather than a specific treatment (Stone, 2009). It is 
possible that this approach is sufficient for a proportion of patients, but on the stroke ward, 
not all clinicians provide even this rudimentary intervention, and it is unlikely to be sufficient 
for patients with severe or chronic symptoms or for patients with significant psychopathology.  
An alternative approach is to adopt elements of the German system of psychosomatic 
medicine. This system has three levels. The first involves intensive GP training in 
psychosomatic medicine. GPs receive a curriculum of 80 hours training, with over 60,000 of 
the 360,000 German GPs completing additional courses on psychosomatic care. In addition, 
GPs are financially reimbursed for longer consultations with functional patients and if they feel 
limited in the kind of treatment they can offer, there are local collaborative groups with 
psychotherapists which they can join to help develop specific treatments (Creed et al., 2011). 
The second level involves outpatient psychotherapy from psychologists and doctors. CBT, 
albeit provided by private health insurance, can be offered to patients for more than 100 
sessions. As in the UK, only a proportion of patients are willing to receive psychological 
treatment and brief CBT interventions are offered through consultation-liaison psychiatry 
services in medical departments. It is hoped that engagement in such a service might prompt 
the psychologically-sceptical patient to engage at a later stage in more intensive therapy if 
necessary. 
The third level of care involves the provision of inpatient and outpatient treatment through 
psychosomatic hospitals which cover regions as well as departments of psychosomatic 
medicine within general hospitals (Zipfel et al., 2016). These hospitals are run by both clinical 
psychologists and internal medicine physicians with psychotherapeutic training (Buhring, 
2012). Treatments offered include nonverbal therapies like art, music and motor therapy, 
physiotherapy, biofeedback techniques and a range of psychotherapies, more diverse but not 
unlike the Lishman Unit in London (McCormack et al., 2013). 
Psychosomatic medicine in Germany has a distinct advantage in that it is not a subspecialty of 
psychiatry but represents its own discipline. Scheidt (2017) argue that the German system is 
particularly distinctive in that its cross-disciplinary approach can be integrated into any clinical 
medical speciality. Such an approach would potentially allow for patients with a range of 
functional syndromes to be cared for in one setting with interventions that focus on 





inpatient services in the UK which are symptom specific, for example the Lishman Unit, a 
neuropsychiatry service, or specialist inpatient chronic fatigue services (McDermott et al., 
2014).  
In the German system, patients admitted with functional stroke symptoms could be discharged 
to a psychosomatic ward where they receive integrated medical and psychological care with 
none of the potential stigma that might come with a psychological referral.  
This integration of both physical and psychological techniques and the ability of one service to 
offer a wide range of techniques in both inpatient and outpatient settings, is likely the true 
exemplar of the biopsychosocial model. 
7.4.2 Treatment 
Our study found evidence that CBT is clinically effective in the treatment of FMD, however we 
are unable to identify why the therapy might be effective or the most efficacious therapeutic 
components. Most current research on psychological treatments for FMD has tested forms of 
CBT, with few testing third-wave psychotherapies. While CBT employs methods like grounding 
and relaxation techniques to help patients engage with their bodily processes, the aim of such 
tools is the general reduction of panic and anxiety while the body itself tends not to be the 
primary focus of the therapy. 
A possible treatment for FMD that has not been widely considered is that of body 
psychotherapy. While physiotherapy is specifically recommended in the treatment for FMD, 
there are no trialled, specific manuals which incorporate psychological interventions with 
physiotherapeutic techniques. Instead, it is recommended that patients with a psychiatric 
comorbidity are referred to psychotherapy after they have seen motor symptom 
improvements in physiotherapy (Nielsen et al., 2014). Body psychotherapy might avoid the 
need for two separate referrals, as it employs physical and psychological approaches. 
Body psychotherapies “explicitly use body techniques to strengthen the dialogue between 
patient and psychotherapist about what is being experienced and perceived…the body is 
considered a means of communication and exploration” (Heller, 2012). Body psychotherapy 
directly addresses the inherent link between cognition and somatic experience without making 
any artificial distinctions between mind and body.  
One form is ‘body-oriented psychological therapy’ which is delivered in a group format. 
Techniques include ‘checking in’ where patients are asked how their body feels, ‘warming up’ 
using movements like stretching and breathing, ‘structured tasks’ such as demarcating the 





group mirroring or creating group sculptures. Throughout, there is a focus on individual 
difficulties and problem-solving strategies and discussing experiences with the group, 
identifying the impact of symptoms on their lives and attempting to identify solutions to 
individual difficulties (Rohricht & Priebe, 2006). 
Body psychotherapy has shown positive results in the treatment of patients with chronic 
depression (Röhricht et al., 2013) although it was found to have limited effectiveness in 
improving the negative symptoms of schizophrenia (Priebe et al., 2016). Nevertheless, this 
study did report significant improvements in movement disorder symptoms, although this was 
not a primary outcome. 
Body psychotherapy relies on ‘bottom-up’ conceptualisations of psychological symptoms, 
emphasising the significance of physical and sensory perceptions. This approach specifically 
relates to current psychological models of FND. Brown (2004) argued that unexplained physical 
symptoms are moderated by an over-reliance on top-down brain processes like belief rather 
than ‘bottom-up’ processes like somatic perception. The theory is supported by evidence that 
patients with FMD have poor sensitivity to internal body signals (Ricciardi et al., 2016), a 
weaker ability to identify and describe emotions (Demartini et al., 2014), and those with a high 
number of medically unexplained symptoms are less responsive to the rubber hand illusion, 
suggesting a decreased emphasis on bottom-up visual input compared to top-down processes 
(Miles et al., 2011). Body psychotherapy might be one way to help reduce the strength of 
these top-down processes, and help patients attenuate to bodily processes while the group 
dynamics might help improve personality issues (Blum et al., 2008).  
7.5 Concluding remarks 
FND is a disorder with a rich history. Functional neurological symptoms occur in many medical 
settings and every doctor will encounter these symptoms at some stage in their career. 
Stigmatising views about functional symptoms, a lack of understanding about the disorder 
coupled with increasing financial pressure on health services may serve to entrench these 
symptoms and worsen patients’ experiences in medical settings. Such processes may lead to 
increased self-stigma amongst patients and reluctance to receive psychological treatment 
when appropriate. As new diagnostic tools and treatments emerge, it is likely that new forms 
of functional symptoms will develop and present to new services. These services will need to 
develop ways to treat FND as current methods of discharging patients, often with vague or 





Progress in the understanding and treatment of FND has been hampered by the fragmentation 
and segmentation of medical and psychological services. The unification of services, or an 
alliance between disciplines would have distinct advantages for FND patients.   
FND is a disorder with a consistent incidence, and with distinct epidemiological characteristics. 
It is also a disorder with a relatively unstable symptomatology, one that often does not follow 
a predictable course and is different to that seen in organic neurological disease. Future 
research which applies a prospective methodology might help understand the reliability and 
course of the disorder and a greater number of RCTs are required in the area of motor 
symptoms specifically.  
As epidemiological understandings of FND develop rapidly, in part thanks to technological 
advances like large retrospective case registers and their linkages with other data sources, our 
theoretical accounts must also advance to help the interpretations of emerging findings.  
These theoretical approaches need to incorporate emerging phenomenological, biological, 
psychological and social accounts, to help advance our understanding and develop better 
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Appendix 2.1: Checklist for the assessment of quality of quantitative studies 
 









1 Question/ objective sufficiently described?     
2 Study design evident and appropriate?     
3 Method of subject/comparison group selection or source of 
information/input variables described and appropriate? 
    
4 Subject (and comparison group, if applicable) characteristics 
sufficiently described? 
    
5 If interventional and random allocation was possible, was it 
described? 
    
6 If interventional and blinding of investigators was possible, 
was it reported? 
    
7 If interventional and blinding of subjects was possible, was it 
reported? 
    
8 Outcome and (if applicable) exposure measure(s) well 
defined and robust to measurement/misclassification bias? 
Means of assessment reported? 
    
9 Sample size appropriate?     
10 Analytic methods described/justified and appropriate?     
11 Some estimate of variance is reported for the main results?     
12 Controlled for confounding?     
13 Results reported in sufficient detail?     







   
   
   





















No exclusion criterion 
applied in paper 
No exclusion criterion 
information given  
Incomplete Data 
Patient was unconscious, 
in a coma, stupor, 
experienced trauma 
Patients not given rt-PA  
Hypodensity of 1/3 or 
more of the MCA 
territory  
Treated after 4.5h of 
symptom onset 
Patients with diagnosis of 
subarachnoid 
haemorrhage 
Stroke suspected after 
24h of symptom onset 
Stroke symptoms of less 
than 24h duration 
Stroke symptoms of 
more than 5h duration 
Unable to give informed 
consent or declined 
consent 
Aged under-18 
Patients presenting via 
telemedicine or by 
telephone 
Patients who did not 
undergo MRI, CTA or CT 
Patients who died in the 
medical setting 
Table 71 List of exclusion criteria applied to study samples and their frequency across 
studies one to nineteen 
Appendix 2.2: Exclusion criteria applied across all studies 





















































































































































































































































































































































































































































No exclusion criterion 
applied in paper 
No exclusion criterion 
information given  
Incomplete Data 
Patient was 
unconscious, in a coma, 
stupor, experienced 
trauma 
Patients not given rt-PA  
Hypodensity of 1/3 or 
more of the MCA 
territory  
Treated after 4.5h of 
symptom onset 
Patients with diagnosis 
of subarachnoid 
haemorrhage 
Stroke suspected after 
24h of symptom onset 
Stroke symptoms of 
less than 24h duration 
Stroke symptoms of 
more than 5h duration 
Unable to give 
informed consent or 
declined consent 
Aged under-18 
Patients presenting via 
telemedicine or by 
telephone 
Patients who did not 
undergo MRI, CTA or CT 
Patients who died in 
the medical setting 
Table 72 List of exclusion criteria applied to study samples and their frequency 

















































































































































































































































































































































































































































































































No exclusion criterion 
applied in paper 
No exclusion criterion 
information given  
Incomplete Data 
Patient was 
unconscious, in a 
coma, stupor, 
experienced trauma 
Patients not given rt-
PA  
Hypodensity of 1/3 or 
more of the MCA 
territory  
Treated after 4.5h of 
symptom onset 
Patients with diagnosis 
of subarachnoid 
haemorrhage 
Stroke suspected after 
24h of symptom onset 
Stroke symptoms of 
less than 24h duration 
Stroke symptoms of 
more than 5h duration 
Unable to give 
informed consent or 
declined consent 
Aged under-18 
Patients presenting via 
telemedicine or by 
telephone 
Patients who did not 
undergo MRI, CTA or 
CT 
Patients who died in 
the medical setting 















































































































































































































































































































































































































































































































No exclusion criterion 
applied in paper 
No exclusion criterion 
information given  
Incomplete Data 
Patient was 
unconscious, in a coma, 
stupor, experienced 
trauma 
Patients not given rt-PA  
Hypodensity of 1/3 or 
more of the MCA 
territory  
Treated after 4.5h of 
symptom onset 
Patients with diagnosis 
of subarachnoid 
haemorrhage 
Stroke suspected after 
24h of symptom onset 
Stroke symptoms of 
less than 24h duration 
Stroke symptoms of 
more than 5h duration 
Unable to give 
informed consent or 
declined consent 
Aged under-18 
Patients presenting via 
telemedicine or by 
telephone 
Patients who did not 
undergo MRI, CTA or CT 
Patients who died in 
the medical setting 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































No exclusion criterion 
applied in paper 
No exclusion criterion 
information given  
Incomplete Data 
Patient was 
unconscious, in a coma, 
stupor, experienced 
trauma 
Patients not given rt-PA  
Hypodensity of 1/3 or 
more of the MCA 
territory  
Treated after 4.5h of 
symptom onset 
Patients with diagnosis 
of subarachnoid 
haemorrhage 
Stroke suspected after 
24h of symptom onset 
Stroke symptoms of 
less than 24h duration 
Stroke symptoms of 
more than 5h duration 
Unable to give 
informed consent or 
declined consent 
Aged under-18 
Patients presenting via 
telemedicine or by 
telephone 
Patients who did not 
undergo MRI, CTA or 
CT 
Patients who died in 
the medical setting 
Table 75 List of exclusion criteria applied to studies 































































































































































Appendix 2.3 Definitions of stroke across papers 
Table 76 Definitions of stroke used across papers 
Stroke definition n Studies 
Stroke and TIA 20 
Bray, Girlado, Nor 2004, Nor 2005, Scott & Silbergleit, Tobin, 
Jiang, Reid, Vanni, Smith, Ay, Ferro, Fothergill, McNeill, 
Berglund, Mouradian, Broadley & Thompson, Wolf, Weir & 
Buchan, Karliński 
Stroke 15 
Agarwal, Ali, Hand, Kose, Libman, Winkler, Yaghi, Zanaty, 
Ramanujam, McWhirter, Thomassen, Vatankhah, Wojner, 
Simonsen, Gargalas 
IS, includes AIS 12 
Brunser, Mehta, Tsivgoulis, Zinkstof , Dassan, Herzberg, Sarikaya, 
Guillan, Lewandowski, Glickman, Sivakumaran, Hemmen 
IS, TIA and intracranial haemorrhage 5 Puetz, Martínez Fernández, El Husseini, Sharma, Cumbler 
IS, TIA, haemorrhagic stroke  3 Chenkin, Cramer, Chen 
IS and haemorrhagic stroke  2 Montaner, Vroomen 




IS and intracerebral haemorrhage 2 Foerch, Zweifler 
IS, TIA and intracerebral haemorrhage 2 Gioia, Rizos 
Stroke, TIA & SAH 2 Moeller, Harbison* 
Hemispheric and posterior fossa stroke 1 Artto 
AIS and aborted IS 1 Chang  
Acute MCA territory ischaemia 1 Chen, Bogosavljevic 
Stroke/acute cerebrovascular event 1 Förster 
Definite, probable or possible AIS and 
intracranial haemorrhage  
1 Merino 
IS, CVT, TIA and intracerebral 
haemorrhage  
1 Romano 
AIS, TIA, cerebral sinovenous thrombosis 
and intracranial haemorrhage  
1 Shellhaas  
Cerebral infarction, cerebral 
haemorrhage and TIA  
1 Norris  
Brain infarct, SAH, TIA and intracerebral 
haemorrhage 
1 Kothari  
Cerebral infarction & intracranial 
haemorrhage 
1 Weir 
Stroke, TIA and carotid stenosis 1 Barker 
IS, SAH and intracerebral haemorrhage  1 Onwuekwe 
Acute cerebrovascular disease 1 Whiteley  
Stroke, TIA, old stroke 1 Damasceno** 
SAH, CVT, TIA, constituted vascular 
accident, cerebral haemorrhage, spinal 
ischemia, cervical artery dissection 
without CVA and arteriovenous 
malformation without CVA 
1 Cordonnier 
IS, TIA, SAH, CVT, spinal stroke and 
intracerebral haemorrhage 
1 Leys 
AIS, TIA, intracerebral haemorrhage 1 Chan 
AIS & acute intracranial haemorrhage 1 Chalela 
Infarctions, TIAs and haemorrhages 1 Sibon 
Stroke, TIA and intracranial haemorrhage  1 Sequeira  
IS, TIA, CVT, intracranial haemorrhage, 
medullar pathology, SAH 
1 Quenardelle*** 
AIS, aborted stroke and TIA 1 Rostanski 
*subarachnoid haemorrhage classified as stroke mimic in paper but reclassified as stroke for this review 
** Old stroke and TIA counted in stroke group by review author, patients classified as "outside Maputo" not counted 
in analyses 
*** Subarachnoid haemorrhage (n =8) is counted as an stroke mimic in this study and was not altered by author to 
allow the reporting of demographics  
Abbreviations: AIS = Acute Ischemic Stroke, CVT = Cerebral Venous Thrombosis, CVA = Cerebrovascular Accident,  IS 






Appendix 2.4: Most common stroke mimic diagnoses across studies 
 
Table 77 The most common stroke mimic diagnoses and the frequency with which they occur 
across studies 
Most frequent differential 
diagnoses 
Number of papers 
where SM 





Seizure 22 190 
Conversion Disorder 14 208 
Migraine 11 221 
Epilepsy  4 89 
Sepsis 2 31 
Other 2 103 
Neuropathy 2 41 
Metastatic cancer/tumour 2 44 
Encephalopathy 2 46 
Vertigo 1 39 
VBI attack 1 16 
Vasovagal episode 1 3 
Toxic metabolic disorder 1 34 
Syncope 1 23 
Old deficit 1 11 
Musculoskeletal abnormalities 1 3 
Metabolic infectious 1 58 
Infectious cause 1 8 
Hypotension 1 11 
HIV 1 27 
Delirium 1 23 
“Nothing negative found” 1 16 
“Internal medicine patients” 1 127 

















Appendix 2.5: Functional disorder synonyms across studies 
Table 78 Frequency of functional disorder synonyms across studies  
Functional term n Papers 
Conversion Disorder 19 
Ali, Artto, Brunser, Chang, Förster, 
Hemmen, Libman, Mehta, Scott & 
Silbergleit, Tsivgoulis, Vroomen, 
Winkler, Chernyshev, Sarikaya, 
Lewandowski, Ferro, Zweifler, 
Cumbler*, Broadley 
Functional 10 
Tobin, Reid, Ay, McWhirter, Whiteley, 
McNeill, Simonsen, Cumbler*, 
Gargalas, Sivakumaran 
Psychiatric 7 
Harbison, Kose, Rizos, Sharma, 
Cordonnier, Cumbler*, Wolf 
Somatisation 5 
Nor (2005), Spokoyny, Dassan, Jiang, 
Fothergill 
Psychogenic 4 Shellhaas, Zinkstof, Chenkin, Moeller* 
Somatoform Disorder 3 Chen(2011)*, Giraldo, Guillan 
Medically unexplained 2 Moeller*, Cumbler* 
Functional/psychological 2 Nor (2004), Weir 
Psychological 2 Sequeira, Quenardelle 
Left hemiparesis due to anxiety 1 Chen (2011)* 
Right hemiparesis due to anxiety 1 Chen (2011)* 
Functional/medically unexplained 1 Hand 
Conversion reaction 1 Yaghi 
Functional brachiofacial hemiparesis 1 Herzberg 
Psychoneurosis 1 Norris 
Anxiety attack 1 Ferro* 
Depression 1 Ferro* 
Non-organic hemiparesis 1 Leys 



















Appendix 2.6: Studies reporting no FND patients in their stroke mimic breakdown 
 
Table 79 Studies reporting zero functional disorder patients as stroke mimics 
 
Bray  
et al. 2005 
Kothari  
et al. 1995 
Foerch  
et al. 2012 
Sample n (%) 100 86 205 
Stroke patient n (%) 73 (73) 62 (72) 202 (98.5) 
Stroke mimic n (%) 27 (27) 24 (27.9) 3 (1.4) 
Study setting  Emergency medical service Ambulance Stroke unit 
Study design and aim Prospective validation of 
prehospital  screening tools 
Retrospective record 
review 
Prospective study of  
suspected acute  stroke  
Assessment type Paramedics were instructed 
to complete a MASS 
assessment on all 
designated EMS dispatches 
for ‘stroke’ that were 
symptomatic and conscious  
Final discharge diagnosis 
and ultimate disposition 
were abstracted from the 
inpatient chart. 
Final diagnosis 
established at hospital 
discharge on the basis of 
all clinical data, brain 










7 cardiac, 5 seizure, 3 
hypoglycaemia, 3 subdural 
hematoma, 3 fracture, 2 
tumour, 1 sepsis, 1 
migraine, 1 vertigo, 1 
Parkinson’s disease) 
8 Infection/sepsis, 5 
syncope, 2 cardiac 
disease, 2 seizure, 1 brain 
metastasis, 2, drug 
overdose, 1, 
hyponatremia, 1 arthritis, 
1 global amnestic 
syndrome, 1 radial nerve 
palsy 
 1 migraine with aura, 1 
endocarditis with septic 























Appendix 2.7: Age and gender of medical mimic and functional mimic patients from studies 
reporting demographic details 
 
Table 80 Age and gender profile of medical mimic and functional disorder patients from 























 mean age  
(SD) 
FD 








Artto  Stroke 
centre 
14 10 (71.4) 4 (28.6) 53.1 (12.6) 56.5 (2.3) 7 (70) 4 (100) 
Ay  Stroke  
centre 





7 2 (28.6) 5 (71.4) 80.5 (7.8) 42.6 (9.4) 1 (50) 2 (40) 
Ferro Primary  
care & ED 
21 15 (71.4) 6 (28.6) 68 (17.4) 60.3 (12.1) 4 (26.7) 6 (100) 
Gargalas  Acute  
stroke  
261 163 (62.5) 98 (37.5) 63.5 (16.7) 49.1 (18.8) 81 (49.7) 62 (63.3) 
Guillan  Stroke  
centre 
15 10 (66.7) 5 (33.3) 53.1 (15.1) 47.6 (7.7) 6 (60) 4 (80) 
Sarikaya  University 
hospital 
23 20 (87) 3 (13) 62.8 (20.3) 59 (15.4) 8 (40) 2 (66.7) 
Scott  Teaching 
hospital ED 
6 2 (33.3) 4 (66.7) 63.5 (33.2) 38.5 (11.1) - - 
Vroomen  Stroke  
centre 
32 19 (59.4) 13 (40.6) 46.3 43 12 (92.3) 10 (76.9) 




7 6 (85.7) 1 (14.3) 70.6 (14) 53 3 (50) 0 (0) 
Wolf  ED 263 226 (86) 37 (14) 65.6 62 (19) 117 (51.8) 23 (62.2) 









FD = Functional disorder; MM = Medical mimic; SM = Stroke mimic 
a 
Statistically significantly difference in age (t = 22.8, df = 246, p = 0.001) 
b 





Appendix 2.8: Stroke mimic forest plot  
 
 
Figure 41 Forest plot displaying the proportion of patients with an eventual stroke mimic 
diagnosis from medical services. The size of each square is proportional to the weight given to 
the study in the summary statistics. 
Group by
Study Setting
Study name Statistics for each study Event rate and 95% CI
Event Lower Upper Relative Relative 
rate limit limit Z-Value p-Value weight weight
Acute stroke unit Cordonnier 0.166 0.148 0.187 -22.481 0.000 9.30
Acute stroke unit Dassan 0.341 0.217 0.491 -2.073 0.038 8.20
Acute stroke unit Forster 0.065 0.048 0.087 -16.728 0.000 9.04
Acute stroke unit Gargalas 0.224 0.201 0.249 -17.680 0.000 9.30
Acute stroke unit Leys 0.143 0.125 0.164 -22.155 0.000 9.28
Acute stroke unit Norris 0.138 0.115 0.164 -17.699 0.000 9.23
Acute stroke unit Reid 0.309 0.265 0.358 -7.190 0.000 9.20
Acute stroke unit Sivakumaran 0.102 0.078 0.132 -14.555 0.000 9.08
Acute stroke unit Thomassen 0.498 0.432 0.564 -0.068 0.946 9.13
Acute stroke unit Weir, Buchan et al., 0.293 0.252 0.338 -8.294 0.000 9.22
Acute stroke unit Weir, Murrary et al., 0.036 0.026 0.049 -19.642 0.000 9.01
Acute stroke unit 0.176 0.114 0.261 -5.989 0.000
Ambulance Harbison ( i) 0.225 0.169 0.292 -6.896 0.000 9.81
Ambulance Karlinski ( i) 0.325 0.280 0.373 -6.776 0.000 10.09
Ambulance Berglund ( ii) 0.421 0.359 0.485 -2.414 0.016 10.01
Ambulance Ramanujam ( ii) 0.595 0.551 0.639 4.141 0.000 10.13
Ambulance Chen, Sun et al., 0.118 0.100 0.138 -21.821 0.000 10.14
Ambulance Fothergill 0.362 0.307 0.421 -4.460 0.000 10.03
Ambulance Kothari 0.279 0.195 0.383 -3.948 0.000 9.49
Ambulance Nor, McAllister et al., 0.219 0.175 0.272 -8.757 0.000 9.96
Ambulance Sequeira 0.196 0.183 0.209 -32.451 0.000 10.23
Ambulance Wojner 0.280 0.241 0.324 -8.946 0.000 10.10
Ambulance 0.288 0.192 0.407 -3.353 0.001
ED El Husseini ( ii) 0.348 0.286 0.416 -4.270 0.000 3.59
ED Ferro ( ii) 0.086 0.054 0.137 -9.012 0.000 3.38
ED Harbison ( ii) 0.290 0.207 0.390 -3.913 0.000 3.45
ED Brunser 0.134 0.113 0.159 -18.440 0.000 3.65
ED Chalela 0.390 0.341 0.442 -4.100 0.000 3.64
ED Chan 0.493 0.414 0.573 -0.163 0.870 3.57
ED Chernyshev 0.135 0.108 0.167 -14.367 0.000 3.62
ED Glickman 0.460 0.342 0.583 -0.629 0.529 3.40
ED Hand 0.309 0.262 0.360 -6.886 0.000 3.63
ED Hemmen 0.192 0.157 0.233 -11.469 0.000 3.62
ED Jiang 0.481 0.445 0.518 -1.010 0.313 3.67
ED Kose 0.127 0.104 0.154 -16.634 0.000 3.63
ED Lewandowski 0.118 0.087 0.158 -11.667 0.000 3.55
ED Libman 0.190 0.155 0.231 -11.538 0.000 3.62
ED Martínez Fernández 0.244 0.208 0.284 -10.735 0.000 3.65
ED McWhirter 0.291 0.245 0.342 -7.432 0.000 3.63
ED Moeller 0.267 0.217 0.324 -7.227 0.000 3.60
ED Montaner 0.090 0.073 0.109 -20.993 0.000 3.64
ED Nor, Davis et al., 0.487 0.434 0.540 -0.486 0.627 3.64
ED Rizos 0.474 0.441 0.508 -1.487 0.137 3.68
ED Rostanski 0.122 0.088 0.166 -10.791 0.000 3.54
ED Scott 0.040 0.018 0.086 -7.645 0.000 2.98
ED Sibon 0.332 0.269 0.400 -4.619 0.000 3.59
ED Tobin 0.223 0.172 0.285 -7.451 0.000 3.56
ED Tsivgoulis 0.104 0.081 0.133 -15.263 0.000 3.60
ED Vanni 0.290 0.224 0.367 -5.051 0.000 3.55
ED Whiteley 0.296 0.254 0.343 -7.949 0.000 3.64
ED Wolf 0.641 0.594 0.686 5.649 0.000 3.65
ED 0.245 0.191 0.309 -6.921 0.000
EMS Berglund ( i) 0.495 0.457 0.533 -0.271 0.786 16.91
EMS Ramanujam ( i) 0.584 0.551 0.616 4.960 0.000 16.94
EMS Bray 0.270 0.192 0.365 -4.416 0.000 15.92
EMS Chenkin 0.105 0.076 0.143 -11.846 0.000 16.30
EMS Cramer 0.335 0.310 0.360 -11.965 0.000 16.97
EMS Gioia 0.437 0.406 0.469 -3.849 0.000 16.95
EMS 0.351 0.215 0.517 -1.762 0.078
Hospital Barker 0.208 0.188 0.228 -21.757 0.000 9.57
Hospital Chang 0.155 0.111 0.214 -8.520 0.000 9.11
Hospital Cumbler 0.461 0.412 0.510 -1.562 0.118 9.48
Hospital Onwuekwe 0.345 0.272 0.427 -3.630 0.000 9.21
Hospital Romano 0.034 0.024 0.048 -18.522 0.000 9.20
Hospital Sarikaya 0.071 0.047 0.104 -11.921 0.000 9.02
Hospital Sharma 0.223 0.166 0.292 -6.697 0.000 9.17
Hospital Shellhaas 0.210 0.151 0.284 -6.457 0.000 9.08
Hospital Smith 0.082 0.064 0.104 -17.967 0.000 9.38
Hospital Spokoyny 0.085 0.045 0.155 -6.823 0.000 8.22
Hospital Zweif ler 0.130 0.077 0.211 -6.393 0.000 8.55
Hospital 0.152 0.097 0.231 -6.559 0.000
Mixed Damasceno 0.100 0.081 0.122 -18.773 0.000 35.95
Mixed Giraldo 0.101 0.053 0.183 -6.214 0.000 31.22
Mixed Yaghi 0.070 0.041 0.116 -9.022 0.000 32.83
Mixed 0.089 0.035 0.210 -4.552 0.000
Primary care or outpatients Ferro ( i) 0.096 0.041 0.211 -4.763 0.000 16.57
Primary care or outpatients Karlinski ( ii) 0.516 0.429 0.601 0.353 0.724 20.81
Primary care or outpatients Harbison ( iii) 0.287 0.231 0.351 -6.049 0.000 21.06
Primary care or outpatients McNeill 0.694 0.579 0.790 3.209 0.001 19.90
Primary care or outpatients Mouradian 0.313 0.293 0.334 -16.325 0.000 21.66
Primary care or outpatients 0.364 0.210 0.553 -1.416 0.157
Stroke unit El Husseini ( i) 0.677 0.576 0.764 3.345 0.001 6.95
Stroke unit Artto 0.014 0.008 0.024 -15.749 0.000 6.75
Stroke unit Ay 0.013 0.007 0.024 -13.656 0.000 6.51
Stroke unit Broadley 0.109 0.078 0.151 -11.033 0.000 7.07
Stroke unit Chen, Bogosavljevic et al., 0.014 0.007 0.030 -11.111 0.000 6.17
Stroke unit Foerch 0.015 0.005 0.044 -7.238 0.000 5.04
Stroke unit Guillan 0.024 0.015 0.040 -14.151 0.000 6.78
Stroke unit Herzberg 0.284 0.205 0.379 -4.206 0.000 6.96
Stroke unit Mehta 0.167 0.110 0.244 -6.571 0.000 6.85
Stroke unit Merino 0.300 0.290 0.310 -35.174 0.000 7.43
Stroke unit Quenardelle 0.383 0.357 0.409 -8.565 0.000 7.40
Stroke unit Simonsen 0.007 0.003 0.019 -9.866 0.000 5.49
Stroke unit Vroomen 0.048 0.034 0.067 -16.510 0.000 7.11
Stroke unit Winkler 0.028 0.013 0.058 -9.253 0.000 6.16
Stroke unit Zinkstof 0.018 0.015 0.022 -39.560 0.000 7.33
Stroke unit 0.065 0.043 0.099 -11.560 0.000
Telestroke Agarwal 0.127 0.081 0.192 -7.651 0.000 18.81
Telestroke Ali 0.229 0.202 0.259 -14.678 0.000 20.29
Telestroke Puetz 0.149 0.122 0.182 -14.359 0.000 20.07
Telestroke Vatankhah 0.200 0.192 0.209 -49.632 0.000 20.47
Telestroke Zanaty 0.108 0.096 0.121 -31.591 0.000 20.36
Telestroke 0.158 0.082 0.284 -4.379 0.000
Overall 0.190 0.125 0.278 -5.731 0.000





Appendix 2.9: Functional stroke mimic forest plot 
 
 
Figure 42 Forest plot displaying the proportion of stroke mimic patients with functional 
disorder diagnosis by service setting. The size of each square is proportion to the weight given 







Study name Statistics for each study Event rate  and 95% CI
Event Lower Upper W eight Re lative  Re lative  
rate limit limit Z- Value p-Value (Pooled tau) weight weight
Acute stroke unit Cordonnier 0 .103 0.070 0.149 -10.042 0.000 1.17 12.15
Acute stroke unit Dassan 0 .133 0.034 0.405 -2 .464 0.014 0.72 7.50
Acute stroke unit Forster 0 .167 0.082 0.310 -3 .887 0.000 1.02 10.60
Acute stroke unit Gargalas 0 .375 0.319 0.436 -3 .980 0.000 1.21 12.60
Acute stroke unit Leys 0.056 0.030 0.101 -8 .687 0.000 1.09 11.36
Acute stroke unit Norris 0 .074 0.037 0.141 -6 .874 0.000 1.06 11.01
Acute stroke unit Reid 0 .129 0.079 0.203 -6 .892 0.000 1.13 11.74
Acute stroke unit Sivakumaran 0 .200 0.111 0.333 -3 .921 0.000 1.07 11.13
Acute stroke unit Weir_Buchan 0.144 0.093 0.217 -6 .997 0.000 1.15 11.90
Acute stroke unit 0 .138 0.079 0.232 -5 .672 0.000
Ambulance Harbison ( i) 0 .075 0.024 0.208 -4 .185 0.000 0.86 18.06
Ambulance Karlinski ( i) 0 .004 0.000 0.059 -3 .911 0.000 0.36 7.49
Ambulance Fothergill 0 .134 0.079 0.217 -6 .260 0.000 1.11 23.52
Ambulance Kothari 0 .020 0.001 0.251 -2 .724 0.006 0.35 7.41
Ambulance Nor_McAllister 0 .049 0.016 0.142 -5 .002 0.000 0.86 18.21
Ambulance Sequeira 0.064 0.048 0.086 -16.807 0.000 1.20 25.31
Ambulance 0.057 0.024 0.129 -6 .126 0.000
ED El Husseini ( ii) 0 .007 0.000 0.101 -3 .497 0.000 0.35 1.79
ED Ferro ( ii) 0 .313 0.136 0.567 -1 .462 0.144 0.91 4.59
ED Harbison ( ii) 0 .148 0.057 0.335 -3 .229 0.001 0.91 4.58
ED Brunser 0 .044 0.019 0.102 -6 .717 0.000 0.98 4.96
ED Chernyshev 0.217 0.136 0.330 -4 .389 0.000 1.12 5.65
ED Glickman 0 .017 0.001 0.217 -2 .859 0.004 0.35 1.78
ED Hand 0 .057 0.026 0.120 -6 .694 0.000 1.02 5.13
ED Hemmen 0 .038 0.012 0.111 -5 .491 0.000 0.87 4.37
ED Jiang 0 .058 0.038 0.088 -12.087 0.000 1.16 5.86
ED Kose 0 .024 0.006 0.089 -5 .207 0.000 0.76 3.82
ED Lewandowski 0 .447 0.299 0.605 -0 .648 0.517 1.09 5.52
ED Libman 0 .013 0.002 0.085 -4 .316 0.000 0.55 2.77
ED McWhirter 0 .112 0.063 0.191 -6 .462 0.000 1.10 5.54
ED Moeller 0 .243 0.157 0.356 -4 .079 0.000 1.13 5.70
ED Montaner 0 .005 0.000 0.082 -3 .666 0.000 0.35 1.79
ED Nor_Davis 0 .054 0.028 0.100 -8 .361 0.000 1.08 5.45
ED Rizos 0.053 0.035 0.080 -12.854 0.000 1.17 5.88
ED Scott 0 .667 0.268 0.916 0.800 0.423 0.64 3.24
ED Tobin 0 .065 0.021 0.184 -4 .459 0.000 0.86 4.33
ED Tsivgoulis 0 .268 0.168 0.398 -3 .332 0.001 1.11 5.61
ED Whiteley 0.100 0.058 0.168 -7 .221 0.000 1.11 5.60
ED Wolf  0 .141 0.104 0.188 -10.204 0.000 1.19 6.01
ED 0.099 0.066 0.146 -9 .816 0.000
EMS Bray 0 .018 0.001 0.230 -2 .808 0.005 0.35 39.26
EMS Chenkin 0 .029 0.004 0.181 -3 .445 0.001 0.54 60.74
EMS 0.024 0.003 0.164 -3 .499 0.000
Hospital Barker 0 .001 0.000 0.023 -4 .595 0.000 0.36 5.57
Hospital Chang 0 .033 0.005 0.202 -3 .311 0.001 0.54 8.50
Hospital Cumbler 0 .039 0.019 0.079 -8 .335 0.000 1.05 16.38
Hospital Onwuekwe 0 .010 0.001 0.141 -3 .233 0.001 0.35 5.54
Hospital Sarikaya 0 .130 0.043 0.335 -3 .064 0.002 0.84 13.15
Hospital Sharma 0 .108 0.041 0.255 -3 .986 0.000 0.92 14.39
Hospital Shellhaas 0 .100 0.033 0.268 -3 .610 0.000 0.85 13.29
Hospital Spokoyny 0 .667 0.333 0.889 0.980 0.327 0.76 11.98
Hospital Zweif ler 0 .154 0.039 0.451 -2 .218 0.027 0.71 11.20
Hospital 0 .085 0.041 0.167 -6 .020 0.000
Mixed Damasceno 0 .006 0.000 0.090 -3 .591 0.000 0.35 25.32
Mixed Giraldo 0.111 0.015 0.500 -1 .961 0.050 0.52 36.94
Mixed Yaghi 0 .923 0.609 0.989 2.387 0.017 0.53 37.75
Mixed 0.246 0.059 0.631 -1 .325 0.185
Primary care and outpatients Ferro ( i) 0 .200 0.027 0.691 -1 .240 0.215 0.49 17.51
Primary care and outpatients Karlinski ( ii) 0 .007 0.000 0.108 -3 .445 0.001 0.35 12.76
Primary care and outpatients Harbison ( iii) 0 .048 0.016 0.140 -5 .033 0.000 0.86 31.11
Primary care and outpatients McNeill 0 .200 0.111 0.333 -3 .921 0.000 1.07 38.62
Primary care and outpatients 0 .089 0.029 0.240 -3 .880 0.000
Stroke unit El Husseini ( i) 0 .008 0.000 0.113 -3 .412 0.001 0.35 3.36
Stroke unit Artto 0 .286 0.111 0.561 -1 .549 0.121 0.86 8.19
Stroke unit Ay 0 .100 0.014 0.467 -2 .084 0.037 0.52 4.94
Stroke unit Broadley 0 .129 0.049 0.297 -3 .564 0.000 0.91 8.66
Stroke unit Chen_Bogosavljevic 0 .714 0.327 0.928 1.095 0.273 0.66 6.29
Stroke unit Foerch 0 .125 0.007 0.734 -1 .287 0.198 0.32 3.06
Stroke unit Guillan 0 .333 0.146 0.594 -1 .266 0.206 0.90 8.56
Stroke unit Herzberg 0 .034 0.005 0.208 -3 .274 0.001 0.54 5.14
Stroke unit Mehta 0.700 0.473 0.859 1.736 0.082 0.96 9.06
Stroke unit Quenardelle 0 .167 0.137 0.202 -13.682 0.000 1.22 11.54
Stroke unit Simonsen 0 .500 0.123 0.877 0.000 1.000 0.55 5.24
Stroke unit Vroomen 0 .406 0.253 0.581 -1 .054 0.292 1.07 10.11
Stroke unit Winkler 0 .143 0.020 0.581 -1 .659 0.097 0.51 4.80
Stroke unit Zinkstof  0 .280 0.201 0.376 -4 .241 0.000 1.17 11.05
Stroke unit 0 .253 0.156 0.383 -3 .513 0.000
Telestroke Ali 0 .063 0.036 0.108 -9 .042 0.000 1.11 75.87
Telestroke Puetz 0 .006 0.000 0.091 -3 .582 0.000 0.35 24.13
Telestroke 0 .037 0.007 0.160 -3 .967 0.000
Overall 0 .103 0.062 0.165 -7 .816 0.000





Appendix 3.1: Qualitative survey responses  
 
Table 81 Written survey responses to the question, “Patients with functional stroke symptoms 
should be managed” 
Patients with functional stroke symptoms should be managed:  Participant 
"In community where possible" Female, 39, 
physiotherapist 
"I don't think it is possible to manage them in one (setting). 
Multiple teams need to work together." 
Female, 28, 
physiotherapist 
"Neurology/stroke wards where staff have relevant experience 
or in specialist rehab units for functional disorders in some 
particularly challenging cases 
Male, 34, physiotherapist 
“A setting with access to the correct services - usually PT, 
psychology, OT etc. - this could be in inpatient setting or at 
home if possible” 
Anonymous 
“In mental health with a combination of PT and OT” Female, 32, clinical 
psychologist 
“Inpatient hospital or GP” Anonymous 
"Variety of settings with physical and psychological 
management" 
Anonymous 
"MDT setting with psychiatry and psychology" Female, 31 
physiotherapist  
"Dependent on severity. Some can be managed at home and 
with psychological support and rehab. Others need inpatient" 
Female, 33 




"A combination of primary care and mental health" Female, 37, speech and 
language therapist 
"In primary care if symptoms are mild. In mental health if this is 
the main background issue. In other settings which require a 
combination of physical and mental health - a holistic approach 
is essential!" 
Female, 52, occupational 
therapist 
"In primary care with mental health support" Female, 31, 
physiotherapist 
"Joint care from secondary to primary" Female, stroke/TIA nurse 
"Community psychiatry" Female, 28, SHO 
"Functional clinics" Male, 30, physiotherapist,  
“Neurologists with a special interest in functional disease and 
multidisciplinary team support” 
Female, 37, acute 
medicine consultant 
“Need auxiliary in secondary care then direct to appropriate 
community based management” 
Female, 58, allied health 
professional 
 
Table 82 Written responses to the statement, “There are effective treatments for functional 
stroke patients” 
“There are effective treatments for functional stroke patients” Participant 
“Just not utilised in all cases” Male, 32, physiotherapist 
"Success rates are not 100%!!" Female, 30, 
physiotherapist 
“Most research is case study based: uncertain effects" Male, 39, physiotherapist 





Table 83 Written response to the statement, “Patients with functional stroke symptoms are 
difficult to manage 
“Patients with functional stroke symptoms are difficult to 
manage” Participant 
“Only because we don’t have special psychiatry/psychology 
coverage attached to stroke 
Female, 40, speech and 
language therapist 
 
Table 84 Responses to, “Which setting currently provides the most effective treatment?” 
 
Table 85 Written responses to the statement, “Patients with functional symptoms have an 
undiagnosed physical illness” 
“Patients with functional symptoms have an undiagnosed physical 
illness” Participant 
"Sometimes - can't answer this, easily they can” Female, 30, 
neuropsychiatrist 
"Disagree but there are exceptions” Female, registrar 
 
  
Table 86 Written responses to the statement, “Patients with functional stroke symptoms have 
a psychiatric disorder” 
“Patients with functional stroke symptoms have a psychiatric 
disorder” 
Participant 
“Some will, some won't” Female, 52, 
occupational therapist 
"Psychological rather than psychiatric" Female, 43, consultant 
“I understand that functional stroke symptoms are present in 
many ‘non-functional’ strokes, in addition to patients presenting 
with purely ‘functional’ symptoms” 
Female, 40, speech 




Which setting currently provides the most effective treatment 
for patients with functional stroke symptoms? Participant 
"Complex needs with expertise in functional difficulties with 
PT and OT" 
Female, 32, clinical 
psychologist 
" Depends/variety of settings required” Anonymous 
"Allocated units for FND. Community with specialist therapists 
and physiotherapy if appropriate” 
Female, 30, 
physiotherapist 
“I don't think any setting is particularly effective” Male, 39, physiotherapy 
“Specialist neuro/liaison psychiatry” Neuropsychiatry 
consultant, 55 
“Functional clinics” Male, 30, physiotherapist 






Table 87 Written responses to the statement, “What is the role of the doctor or health care 
team in managing functional stroke symptoms?” 
What is the role of the doctor or health care team in 
managing functional stroke symptoms? 
Participant 
“To signpost” Female, 43, consultant 




Table 88 Written responses to the statement, "Physiotherapy could prove an effective 
treatment for some functional stroke patients" 
"Physiotherapy could prove an effective treatment for 
some functional stroke patients"  
Participant 
"In combination with mental health/psychology/OT Anonymous 
"In combination with psychology" Female, 29, neurologist 
 
Table 89 Written responses to the statement, “Patients with functional stroke symptoms have 
personality disorders” 
“Patients with functional stroke symptoms have 
personality disorders” 
Participant 
“I think it's 25% of patients not all of them” Female, 30, occupational 
therapist 
"Some will, some won't. Often see high levels of stress" Female, 52, occupational 
therapist 
“Sometimes, certainly can be elements” Female, 30, neuropsychiatrist 
“Depends on the patient” Female, 32, physiotherapist 
 
Table 90 Written response to the statement, "There are clear guidelines on how to manage 
patients with functional stroke symptoms” 
 "There are clear guidelines on how to manage patients with functional 
stroke symptoms” Participant 







Appendix 3.2: Stroke staff questionnaire 
 
 
This survey assesses your attitudes and opinions regarding patients with functional or 
medically unexplained symptoms. It forms part of a study on the feasibility of a physiotherapy 
trial for functional stroke patients. Participation is voluntary and all information will be treated 
as private and confidential. Thank you for your participation.  
 
1. Have you ever worked with a patient with functional stroke symptoms?  
Yes   No 
 
If yes, please complete the rest of the survey. If no, thank you for your participation. 
 
Please select one answer for each of the following statements: 
 
2. “Patients with functional stroke symptoms are difficult to manage” 
Strongly Agree Agree Disagree Strongly Disagree 
 
3. “Patients with functional stroke symptoms have an undiagnosed physical illness” 
Strongly Agree Agree Disagree Strongly Disagree 
 
4. “Patients with functional stroke symptoms have personality disorders” 
Strongly Agree Agree Disagree Strongly Disagree 
 
5. “Patients with functional stroke symptoms have a psychiatric illness” 
Strongly Agree Agree Disagree Strongly Disagree 
 
 
6. Patients with functional stroke symptoms should be managed:  
Please choose one  
- In primary care 
- In medical/surgical outpatients 
- In mental health 
- Outside the NHS 










7. Which setting currently provides the most effective treatment for patients with 
functional stroke symptoms:  
Please choose one 
- Primary care 
- Medical/surgical outpatients 
- Mental health 
- Outside the NHS 
- Other settings 
 
 
8. What is the role of the doctor or health care team in managing functional stroke 
symptoms?  
Please select up to three: 
(a) To provide reassurance and support 
(b) Not to get too involved in their management 
(c) To have no involvement with them at all 
(d) To refer for further investigations to identify a cause 
(e) To prescribe psychotropic medication 
(f) To act as a gatekeeper preventing inappropriate investigation 
(g) To provide counselling and appropriate psychological management 
 
9. “Further research is needed into the area of functional stroke symptoms” 
Strongly Agree Agree Disagree Strongly Disagree 
 
10. “There are effective treatments for functional stroke patients” 
Strongly Agree Agree Disagree Strongly Disagree 
 
11. “Physiotherapy could prove an effective treatment for some functional stroke patients” 
Strongly Agree Agree Disagree Strongly Disagree 
 
12. “There are clear guidelines on how to manage patients with functional stroke 
symptoms” 















Appendix 3.3: Information sheet for NHS staff 
INFORMATION SHEET FOR NHS STAFF 
 
REC Reference Number: 15/LO/1914 
 
 
Study Title: The feasibility of a randomised controlled trial study for 




You are invited to take part in a study being carried out at Friend’s Stroke Unit, 
King’s College Hospital in conjunction with King’s College London.  
 
Purpose of the study 
 
The purpose of this study is to investigate whether it is possible and useful to 
conduct a future study which would trial and test a physiotherapy intervention 
for patients with functional or unexplained stroke symptoms.   
 
What the study involves 
 
Taking part in this study involves an interview with a researcher. You will be 
asked some questions about your views on a possible future study. This future 
study would examine whether physiotherapy is effective in treating patients with 
functional stroke symptoms.  
 
The interview will be recorded with an encrypted audio device.  
 
Do I have to take part? 
 
Taking part in this study is entirely voluntary. You do not have to take part and 
you can withdraw your consent from the study at any time, without giving a 
reason.  
 
What are the possible risks of taking part? 
 
If you find the interview distressing or uncomfortable at any time, please inform 
the researcher and the interview can be stopped immediately or completed at a 
later date.  
 
What are the possible benefits of taking part?   
 
This research will be used to inform the design of a possible treatment for 
functional stroke patients on stroke wards. If future research is successful, this 






Will my taking part be kept confidential? 
 
Your involvement in this study will be strictly confidential. Only the research 
team will have access to the information you provide. All information will be held 
in safe, secure filing cabinets and on secure computer servers operated and 
managed by King’s College London. The information that you provide will not be 
shared with any person or organisation outside the study team, however the 
local NHS Research and Development office may request access to monitor the 
quality of the study.  
 
All data will be stored in line with the Data Protection Act of 1998.  
 
How is the project being funded? 
 
This project is funded by the National Institute of Health Research through the 
Biomedical Research Centre at King’s College London as part of a PhD project.  
 
What will happen to the results of the study? 
 
The results of the study will be analysed and may be published in a peer-
reviewed journal. All information will be anonymous and no identifiable 
information will be published. This study will also form part of a PhD project at 
King’s College London.  
 
Who should I contact for further information? 
 
If you have any questions or require more information about this study, please 
contact me using the following contact details:  
 
Name: Nicola O’Connell      
Email: Nicola.o’connell@kcl.ac.uk      
Telephone: 020 7848 0138 
 
What if I have further questions, or if something goes wrong? 
 
If this study has harmed you in any way, if you wish to make a complaint about 
the conduct of the study or you wish to find out more details about the study, 
you can contact King's College London using the details below for further 
advice and information:  
 
Professor Anthony David, 16 De Crespigny Park, London, SE5 8AF 
 
Thank you for reading this information sheet and for considering taking part 





Appendix 3.4: Consent form for NHS staff 
CONSENT FORM FOR NHS STAFF 
 
Please complete this form after you have read the Information Sheet 
and/or listened to an explanation about the research. 
 
Title of Study: The feasibility of a randomised controlled trial 




Thank you for considering taking part in this research. The person organising 
the research must explain the project to you before you agree to take part. If 
you have any questions arising from the Information Sheet or explanation 
already given to you, please ask the researcher before you decide whether to 
join in. You will be given a copy of this Consent Form to keep and refer to at any 
time. 
 
I confirm that I understand that by signing my initials in each box I am 
consenting to this element of the study. I understand that it will be 
assumed that uninitialled boxes mean that I DO NOT consent to that part 





1. *I confirm that I have read and understood the information sheet dated 
02/12/2015 Version Two for the above study. I have had the opportunity to 
consider the information and asked questions which have been answered 
satisfactorily. 
 
2. *I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason. Furthermore, I understand 
that I will be able to withdraw my data up to 2 weeks after my interview.  
 
3. *I consent to the processing of my personal information for the purposes 
explained to me. I understand that such information will be handled in 
accordance with the terms of the UK Data Protection Act 1998. 
 
4. *I understand that my information may be subject to review by responsible 
individuals from a research and development office for monitoring and audit 
purposes. 
 
5. *I understand that confidentiality and anonymity will be maintained and it will 














6. *I agree to be contacted for future studies of a similar nature            
                             
 
7. *I consent to my interview being audio recorded. 
 
 








__________________               __________________              _____________ 
Name of Participant                 Date        Signature 
 
 
__________________               __________________              _____________ 



























Appendix 3.5: Interview schedule for NHS stroke staff 




- Researcher introduces herself and outlines the aims of the project – this study aims to 
explore the views of patients on a possible trial which would take place on the stroke 
ward. The study is also interested in exploring the experiences of patients on the 
stroke ward who may have an alternative diagnosis to stroke.  
 
- The study aims to gain an understanding of different views and there are no ‘wrong 
answers’ 
 
- The interview should take about 20 minutes and will be recorded to ensure accuracy in 
the study. All of your answers will be treated with upmost confidentiality and all 
information that might be published at a later date will be anonymous.  
 
- Consent form.  
 
- Allows the participant to introduce themselves.  
 
- Allows the participant to introduce themselves.  
 
Part One: Experiences with and attitudes towards stroke mimic patients and functional stroke 
mimic patients 
 
- Can you describe a typical functional stroke mimic presentation is?  
- Could you think of an example from the last few weeks?  
- How were the symptoms managed?  
- Did you order any investigations or referrals?  
- What factors did you consider when making this choice?  
- What was the outcome?  
- Was this example typical of other patients you have seen without a diagnosis of 
stroke?  
- If yes, why? If no, why not? 
- What do you believe is the cause of the presentation?  
- Do you have any opinion of what the prognosis of these patients is?  
- How many functional stroke mimic patients do you treat in a week or a month?  
 
- Can you give an overview of some of your experiences working with stroke mimic 
patients?  
- Can you describe how you diagnose a stroke mimic patient? How do you diagnose a 
functional stroke mimic patient?  
- How does the treatment of a suspected functional stroke mimic patient differ from a 
stroke patient on the ward, if at all? 
 
- Are there any differences in how you diagnose stroke mimic patients depending on 
who the consultant or staff on duty are or any occupational issues on the ward, like 
access to MRI?  
 
- How much are you influenced by the policies or practices of the consultant or team 
you are working with when you manage these patients? Do any of these issues affect 






- Do you feel that this varies between different teams that you have worked with? 
 
- How long is a stroke mimic patient likely to stay on the stroke ward? Generally, where 
are they discharged or referred to? Do you organise follow-up appointments with 
stroke mimic patients? If not, what are the reasons? 
 
- How easy or difficult do you think it is to treat stroke mimic patients generally and 
functional stroke mimic patients particularly? 
 
- Have you had any memorable functional stroke mimic cases? 
 
- In an ideal world, how would you treat functional stroke mimic patients on your ward? 
 
- Do you notice any differences in the rate at which stroke mimic patients and functional 
stroke mimic patients present to the ward? For example, are there certain times of the 
week or the year where there are higher rates of admissions? Are admission rates 
affected by events like Christmas or sporting events or do you feel admission rates stay 
the same throughout the year? 
 
Part Two: Attitudes towards a possible physiotherapy trial at the Friend’s Stroke Ward 
 
- My research team is discussing the possibility of providing some kind of physiotherapy 
trial for patients with functional stroke mimic symptoms. I am interested in how you 
might feel about such an intervention.  
 
- What do you think might be the advantages and challenges in conducting a trial like 
this generally and specifically on this ward?  
 
- Do you feel there is a need for research like this, or do you feel there is enough current 
evidence? If such a trial were to take place, do you think you would be interested in 
being involved?  
 
Part Three: Rounding Up 
 
- Are there any questions you would like to ask me? 
 
- Is there anything you have said that you would like to retract or anything that you 
have not said that you would like to add further? 
 































Appendix 4.2 Information sheet for patients 
 
INFORMATION SHEET FOR PARTICIPANTS 
 
REC Reference Number: 15/LO/1914 
 
 
Study Title: The feasibility of a randomised controlled trial study for 




You are invited to take part in a study being carried out at Friend’s Stroke Unit, 
King’s College Hospital in conjunction with King’s College London.  
 
Purpose of the study 
 
The purpose of this study is to investigate whether it is possible and useful to 
conduct a future study using physiotherapy for patients with functional or 
unexplained stroke symptoms.   
 
What the study involves 
 
Taking part in this study involves a short interview with a researcher. The 
interview should take no longer than 20 minutes. You will be asked some 
questions about your experiences at Friend’s Stroke Unit and about your views 
and opinions on a possible future study. This future study would examine 
whether physiotherapy is effective in treating patients with functional stroke 
symptoms.  
 
You are also invited to take part in a follow-up interview two months after the 
first interview.  The purpose of this is to examine whether your views or opinions 
have changed. Deciding to take part in a second interview is entirely optional 
and you can change your mind at any time.  
 
Both interviews will be recorded with an encrypted audio device.  
 
Do I have to take part? 
 
Taking part in this study is entirely voluntary. You do not have to take part and 
you can withdraw your consent from the study at any time, without giving a 
reason.  
 
What are the possible risks of taking part? 
 
Some participants might find it distressing to discuss their symptoms. If you find 





researcher and the interview can be stopped immediately or completed at a 
later date.  
What are the possible benefits of taking part?   
 
Participants in research often find it beneficial to talk to people outside their care 
team about their experiences. By taking part in this study, you are contributing 
to important research. This research will be used to inform the design of a 
possible treatment for patients on stroke wards. If future research is successful, 
this may mean new treatments are offered to patients, which may, in the long 
term, directly benefit patients.  
 
Will my taking part be kept confidential? 
 
Your involvement in this study will be strictly confidential. Only the research 
team will have access to the information you provide. All information will be held 
in safe, secure filing cabinets and on secure computer servers operated and 
managed by King’s College London. The information that you provide will not be 
shared with any person or organisation outside the study team however the 
local NHS Research and Development office may request access to monitor the 
quality of the study.  
 
All data will be stored in line with the Data Protection Act of 1998.  
 
How is the project being funded? 
 
This project is funded by the National Institute of Health Research through the 
Biomedical Research Centre at King’s College London as part of a PhD project.  
 
What will happen to the results of the study? 
 
The results of the study will be analysed and may be published in a peer-
reviewed journal. All information will be anonymous and no possible identifiable 
information will be published. This study will also form part of a PhD project at 
King’s College London.  
 
Who should I contact for further information? 
 
If you have any questions or require more information about this study, please 
contact me at: email: Nicola.o’connell@kcl.ac.uk      telephone: 020 7848 0138 
 
If you would like any more information about functional symptoms, 









What if I have further questions, or if something goes wrong? 
 
If this study has harmed you in any way, if you wish to make a complaint about 
the conduct of the study, or you wish to find out more information about the 
study, you can contact King's College London using the details below for further 
advice and information:  
Professor Anthony David, 16 De Crespigny Park, London, SE5 8AF 
 
The Patient Advice and Liaison Service (PALS) at King’s College Hospital offers 
support, information and assistance to patients. Their contact details are:  
 
Telephone: 020 3299 3601        Email: kch-tr.PALS@nhs.net 
 
Thank you for reading this information sheet and for considering taking part 




























Appendix 4.3: Consent sheet for patients 
 
CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDIES 
 
Please complete this form after you have read the Information Sheet 
and/or listened to an explanation about the research. 
 
Title of Study: The feasibility of a randomised controlled trial 
study for functional stroke patients in a stroke setting  
 
Rec Reference: 15/LO/1914 
 
Thank you for considering taking part in this research. The person organising 
the research must explain the project to you before you agree to take part. If 
you have any questions arising from the Information Sheet or explanation 
already given to you, please ask the researcher before you decide whether to 
join in. You will be given a copy of this Consent Form to keep and refer to at any 
time. 
 
I confirm that I understand that by signing my initials in each box I am 
consenting to this element of the study. I understand that it will be 
assumed that uninitialled boxes mean that I DO NOT consent to that part 





9. *I confirm that I have read and understood the information sheet dated 
2nd December 2015, Version Two for the above study. I have had the 
opportunity to consider the information and asked questions which have 
been answered satisfactorily. 
 
10. *I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason. Furthermore, I 
understand that I will be able to withdraw my data up to 2 weeks after my 
interview.  
 
11. *I consent to the processing of my personal information for the purposes 
explained to me. I understand that such information will be handled in 
accordance with the terms of the UK Data Protection Act 1998. 
 
12. *I consent to the interview taking place at my bedside.  
 
                                                                                                                
13. *I consent to the interview taking place in a private room on the ward.            
 
14. *I understand that my information may be subject to review by 
responsible individuals from a research and development office for 










15. *I understand that confidentiality and anonymity will be maintained and it 
will not be possible to identify me in any publications   
 
 
16. *I agree to be contacted in two months’ time by a King’s College London  
researcher who would like to invite me to participate in a follow-up 
interview    
 
17. *I agree to be contacted for future studies of a similar nature                                  
 
 
18. *I consent to my interview being audio recorded 
 
 







__________________               __________________              ___________ 






__________________               __________________              _____________ 




















Appendix 4.4: Interview schedule for patients 
 
Interview Schedule for patients 
Introduction 
 
- Researcher introduces herself and outlines the aims of the project.  
- Allows the participant to introduce themselves.  
 
Part One: Background to admission  
 
- Can you tell me about the lead up to your admission at the Friend’s Stroke Unit? 
-  What type of symptoms did you experience?  
- How were you admitted to the hospital? Were you referred from another hospital, for 
example, or did you arrive by ambulance? 
- How did you feel at the time of your admission?  
 
Part Two: History and experience of symptoms 
 
- Can you tell me about your symptoms? How long have you experienced these 
symptoms? Is this the first time you have experienced such symptoms or has this 
happened before? 
- Have you had previous treatment or is this the first time? 
- Do these symptoms affect your day-to-day living, and if so, how? 
- Did you (or do you) take any measures to prevent these symptoms – for example 
through treatment or in your day-to-day life? 
 
Part Three: Illness beliefs and attitudes   
 
- Are these symptoms something you feel you can or might be able to control or do you 
feel they beyond your control?  
- How did you feel when you first experienced these symptoms? How do you feel now? 
If there is a difference, what do you think contributed to that difference?  
- What did the doctors on the ward tell you about your symptoms? How do you feel 
about what they have told you?  
- Can you think of anything that might help you with these symptoms in the future? Any 
service or type of care that you feel is not currently offered? 
 
 
Part Four: Attitudes to a physical therapy trial  
 
- My research team is discussing the possibility of providing some kind of physiotherapy 
trial for patients with the same symptoms as you. I am interested in how you might 
feel about such an intervention.  
- Would you be interested in taking part in a research study that meant you received 
physiotherapy?  
- Would you be willing to participate in randomised trial where there is a chance you 
might be randomised to a control group? 
- Would you be willing to travel to take part? If so, how far would you be willing to 
travel? 
- Would you prefer that such an intervention was provided locally to you or would this 
hospital be a convenient setting for you? 
- On a scale of one to ten, with one meaning not at all interested and ten meaning 






- If you had to wait for this physiotherapy (on a study waiting list), perhaps for two or 
three months, would you still be willing to take part? 
- What are the main reasons you would decide to join (or not interested: not to join? 
- Sometimes in these studies, there is a control group. If you were allocated to this 
group it might mean you received no treatment but we might still visit you and ask you 
questions. Would you still be interested in taking part if this happened? 
- If there was a choice in the type of intervention that you received, would you have a 
preference? (Different examples include learning relaxation techniques, breathing 
exercises) What are the reasons you might prefer one such intervention over another? 
 
Part Five: Rounding Up 
 
- Finally, how do you view the future? 
- Are there any questions you would like to ask me? 
- Is there anything you have said that you would like to retract or anything that you 
have not said that you would like to add further? 
 





























Appendix 5.1: CRIS search criteria 
 
First search: F44.4 in primary diagnosis yielding 176 results.  
CRIS code: (Assmnts.Diagnosis.Primary_Diag="F44.4 - Dissociative motor disorders") 
Second search: “Functional Motor”, “Dissociative Motor”, “Psychogenic Motor”: free text 
search in ‘Events and Correspondence’ yielding 167 results. 
CRIS code: (Events.Event.Comments="&quot;Dissociative motor&quot;") OR 
(Events.Event.Comments="&quot;Functional motor&quot;") OR 
(Events.Event.Comments="&quot;Psychogenic motor&quot;") OR 
(Correspondence.Attachment.Attachment_Text="&quot;Psychogenic motor&quot;") OR 
(Correspondence.Attachment.Attachment_Text="&quot;Functional motor&quot;") OR 
(Correspondence.Attachment.Attachment_Text="&quot;Dissociative motor&quot;") 
Third search: F44.7 AND ((“motor” in events) OR (“motor” in correspondence)) yielding 60 
results 
CRIS code: (Assmnts.Diagnosis.Primary_Diag="F44.7 -  Mixed dissociative [conversion] 
disorders") AND ((Events.Event.Comments="Motor") OR 
(Correspondence.Attachment.Attachment_Text="Motor")) 
Fourth search: F44.4 in secondary diagnosis, yielding 12 results.  
CRIS code: (Assmnts.Diagnosis.Secondary_Diag_1="F44.4") 
Fifth search: F44.7 in secondary diagnosis AND ((“motor” in events) OR (“motor” in 
correspondence)), yielding 9 results 
CRIS code: (Assmnts.Diagnosis.Secondary_Diag_1="F44.7") AND 
((Events.Event.Comments="Motor") OR 
(Correspondence.Attachment.Attachment_Text="Motor")) 
Sixth search:  Free-text search of “motor conversion disorder” yielding 10 results 
Seventh search: Free-text search of “motor conversion” yielding 13 results 
Eight search: Search of “F44” in primary diagnosis and free-text search of “motor” in events, 
yielding 77 results 
CRIS code: Assmnts.Diagnosis.Primary_Diag="F44 - Dissociative [conversion] disorders") AND 
(Events.Event.Comments="Motor") 
Ninth search:  Search of “F44” in primary diagnosis field and free-text search of “weak” in 
events”, yielding 155 results 








Appendix 5.2: Main diagnoses given in CRIS for FMD and control group patients 
 






 SLaM diagnosis 
 Tertiary 




group       




group       






ICD-10 Diagnosis         
(F00-F09) Organic mental 
disorders 
7 (2.2)  5 (0.8)   5 (2.7) 15 (2.9)  1 (1.4) 12 (4.1) 
(F10-F19) Mental & behavioural 
disorders due to psychoactive 
substances 
3 (0.9)  112 (17.4)  2 (1.1) 92 (17.8)  1 (1.4) 52 (17.7) 
(F20 – F29) Schizophrenia, 
schizotypal and delusional 
disorders 
4 (1.2)  90 (14)  3 (1.6) 95 (18.3)  6 (8.1) 47 (16) 
(F30 – F39) Mood disorders 22 (6.8)  146 (22.7)  10 (5.4) 130 (25.1)  5 (6.8) 65 (22.2) 
(F40 – F48) Neurotic, stress & 
somatoform disorders 
185 (57.5)  70 (10.9)  139 (75.5) 62 (12)  49 (66.2) 33 (11.3) 
(F50 – F59) Behavioural 
syndromes associated with 
physiological disturbances 
2 (0.6)  17 (2.6)  1 (0.5) 9 (1.7)  1 (1.4) 2 (0.7) 
(F60 – F69) Disorders of adult 
personality and behaviour 
4 (1.2)  12 (1.9)  4 (2.2) 25  (4.8)  2 (2.7) 25 (8.5) 
(F70 – F79) Intellectual 
disabilities 
0 (0)  1 (0.2)   1 (0.5) 0 (0)  0 (0) 0 (0) 
(F80 – F89) Disorders of 
psychological development 
0 (0)  2 (0.3)  0 (0) 3 (0.6)  0 (0) 2 (0.7) 
(F90 – F98) Behavioural and 
emotional disorders with onset 
in in childhood and adolescence  
0 (0) 14 (2.2)  1 (0.5) 11 (2.1)  0 (0) 3 (1) 
(F99) Unspecified mental 
disorder 
41 (12.7)  73 (11.3)  7 (3.8) 37 (7.1)  2 (2.7) 31 (10.6) 
Other Diagnoses  
(FXX) 9 (2.8)  4 (0.6)  4 (2.2) 1 (0.2)  0 (0) 0 (0) 
No axis one disorder 0 (0) 3 (0.5)  0 (0) 2 (0.4)  0 (0) 0 (0) 
(Z00 – Z99) Factors influencing 
health status and contact in 
health services 
38 (11.8) 89 (13.8)  3 (1.6) 31 (6)  5 (6.8) 21 (7.2) 
(F00-F99) Mental, behavioural 
& neurodevelopmental 
disorders 
2 (0.6) 2 (0.3)  3 (1.6) 5 (1)  1 (1.4) 0 (0) 
(G00-G99) Diseases of the 
nervous system 
2 (0.6) 0 (0)  1 (0.5) 0 (0)  1 (1.4) 0 (0) 
(M00-M99) Diseases of the 
musculoskeletal system  
2 (0.6) 0 (0)  0 (0) 0 (0)  0 (0) 0 (0) 
(B20 – B24) HIV 0 (0) 1 (0.2)   0 (0) 0 (0)  0 (0) 0 (0) 
(X60 – X84) Intentional self-
harm 
0 (0) 1 (0.2)  0 (0) 0 (0)  0 (0) 0 (0) 
(R00-R09) Symptoms, signs and 
abnormal clinical and lab 
findings 
1 (0.3) 2 (0.3)  0 (0) 0 (0)  0 (0) 0 (0) 





Appendix 5.3: List of teams giving first SLaM diagnoses 











 95% CI p value 
Neuropsychiatry (psychiatric and 
general) hospital outpatients 
79 (39.9) 1 (0.4) 108 32.4 – 46.7 0.001 
Neuropsychiatry liaison service - 
general hospital inpatients 
35 (17.7) 0 (0) 43.9 12.4 – 23.7 0.001 
Liaison psychiatry – inpatients 25 (12.6) 46 (20.2) 4.4 0.2 – 14.8 0.04 
Lishman inpatient ward 23 (11.6) 1 (0.4) 25 6.7 – 16.5 0.001 
Liaison psychiatry – outpatients 7 (3.5)  3 (1.3) 2.3 -1 – 5.9 0.13 
Department of Psychological Medicine 5 (2.5) 0 (0) 5.8 0.17 – 5.8 0.02 
Brain Injury outpatients 4 (2) 0 (0) 4.6 -0.2 – 5.1 0.03 
General hospital outpatients 4 (2) 2 (0.9) 0.92 -1.6 – 4.2 0.34 
Liaison psychiatry -unspecified 2 (1) 0 (0) 2.3 -0.8 – 3.6 0.13 
Chronic Fatigue service 2 (1) 2 (0.9) 0.01 -2.3 – 2.8 0.92 
Mood, anxiety and personality services 
(MAP) and anxiety disorders outpatient 
service 
2 (1) 16 (7) 9.4 2.1 – 10.2 0.002 
Child and adolescent services 2 (1) 1 (0.4) 0.6 -1.5 – 3.2 0.45 
A&E 2 (1) 34 (14.9) 26.4 8.8 – 19.3 0.001 
Psychiatric hospital - inpatients 2 (1) 0 (0) 2.3 -0.8 – 3.6 0.13 
ADHD services 1 (0.5) 9 (3.9) 5.4 0.3 – 6.8 0.02 
Community mental health teams 1 (0.5) 6 (2.6) 2.9 -0.7 – 5.1 0.09 
OCD services 1 (0.5) 1 (0.4) 0.02 -1.9 – 2.4 0.87 
Drug and alcohol intervention services 1 (0.5) 25 (11) 20.3 6.1 – 15.3 0.001 
General hospital – inpatients 0 (0) 5 (2.2) 4.4 -0.16 – 5.1 0.04 
Eating disorder services 0 (0) 6 (2.6) 5.2 0.12 – 5.6 0.02 
Older adults services 0 (0) 9 (3.9) 7.9 1.1 – 7.3 0.005 
Crisis resolution and home treatment 
teams and home treatment teams 
0 (0) 5 (2.2) 4.4 -0.16 – 5.1 0.04 
Assessment and liaison neighbourhood 
teams and assessment and brief 
treatment teams 
0 (0) 25 (11) 23.1 6.8 – 15.8 0.001 
Homeless outreach 0 (0) 2 (0.9) 0.18 -1.8 – 1.8 0.67 
Integrated memory services 0 (0) 3 (1.3) 2.6 -0.8 – 3.8 0.11 
Psychotherapy outpatients/integrated 
psychological therapy service 
0 (0) 6 (2.6) 5.2 0.13 – 5.6 0.02 
Maternal and perinatal mental health 
services 
0 (0) 9 (3.9) 7.9 1.1 – 7.3 0.005 
Early intervention 0 (0) 3 (1.3) 2.6 -0.8 – 3.8 0.11 
Couple and sexual services 0 (0) 3 (1.3) 2.6 -0.8 – 3.8 0.11 
Criminal justice services 0 (0) 1 (0.4) 0.80 -1.5 – 2.4 0.40 
Behavioural genetics 0 (0) 3 (1.3) 2.6 -0.8 – 3.8 0.11 
HIV mental health services  0 (0) 1 (0.4) 0.80 -1.5 – 2.4 0.40 
Total 198 (100) 228 (100)    
 






Appendix 5.4: Employment rates categorised according to ISCO-08 criteria 
 
Table 93 Employment rates in functional motor and control groups according to the 








n (%) χ2 95% CIs 
p 
value 
Armed forces (skill level 1, 2, 4) 2 (0.8) 3 (0.08) 2 -0.6 – 2.9 > 0.05 
 Female  0 (0) 1 (33.3)    
 Male  2 (100) 2 (66.6)    
Managers (skill level 3, 4) 7 (2.95) 13 (3.6) 0.18 -2.8 – 3.7 > 0.05 
 Female 6 (85.7) 3 (23.1)    
 Male 1 (14.3) 10 (76.9)    
Professionals (skill level 4) 50 (21.1) 71 (19.8) 0.15 -5.4 – 8.3 > 0.05 
 Female 42 (84) 47 (66.2)    
 Male 8 (16) 24 (33.8)    
Technicians and associate professionals (skill 
level 3) 
47 (19.8) 41 (11.5) 7.8 2.1 – 14.8 0.005 
 Female 31 (66.6) 24 (58.5)    
 Male 16 (33.3) 17 (41.5)    
Clerical support workers (skill level 2) 24 (10.1) 31 (8.7) 0.3 -3.5 – 6.7 > 0.05 
 Female 22 (91.6) 25 (80.6)    
 Male 2 (9.1) 6 (19.4)    
Service and sales workers (skill level 2) 76 (32.1) 111 (31) 0.1 -6.7 – 9 > 0.05 
 Female 61 (25.7) 73 (65.8)    
 Male 15 (19.7) 38 (34.2)    
Skilled agricultural, forestry and fishing workers 
(skill level 2) 
1 (0.4) 1 (0.3) 0.04 -1.2 – 2 > 0.05 
 Female 0 (0) 0 (0)    
 Male 1 (100) 1 (100)    
Craft related trades workers (skill level 2) 10 (4.2) 22 (6.1) 1 -2.2 – 5.6 > 0.05 
 Female 0 (0) 3 (13.6)    
 Male 10 (100) 19 (86.4)    
Plant and machine operators (skill level 2) 6 (2.5) 27 (7.5) 6.8 1.2 – 8.6 0.01 
 Female 0 (0) 4 (14.8)    
 Male  6 (100)  23 (85.2)    
Elementary occupations (skill level 1) 14 (5.9) 38 (10.6) 3.9 -0.1 – 9.2 0.05 
 Female 11 (78.6) 15 (39.5)    
 Male 3 (21.4) 23 (60.5)    
Total 237 (100) 358 (100)    
Skill level 1: performance of simple and routine tasks 
Skill level 2: performance of tasks which involve the operating of machinery and equipment and require 
the ability to read information & make written records of work and simple arithmetical calculations 
Skill level 3: performance of complex technical and practical tasks that require an extensive body of 
factual, technical and procedural knowledge in a specialised field, requires high literacy and numeracy 
and well-developed inter-personal skills 
Skill level 4: requires complex problem solving, decision making and creativity based on an extensive 
body of theoretical and factual knowledge in a specialised field including analysis and research to 
extend the body of human knowledge in a field, diagnosis and treatment of disease, imparting 






Appendix 5.5: Rate of diseases in functional motor and control groups 
 









A00-B99 Certain infectious and parasitic diseases 10 (2.3) 47 (6.7) 
(A00-A79, B15-B19) Bacterial infections, and other intestinal infectious diseases, 
STDs and viral hepatitis 
 5 (50)   30 (66.7)  
(B20) HIV Disease  2 (20)    14 (31.1)  
(B35-B64) Infections caused by fungi, protozoans, worms and infestations  3 (30) 3 (2.2) 
C00-D49 Neoplasms 15 (3.4) 32 (4.6) 
(C00-C96) Malignant Cancer (new or old)  9 (60) 23 (74.2) 
(D00-D49) Benign neoplasms  6 (40) 9 (25.8) 
D50-D89 Diseases of the blood and blood-forming organs; and certain behaviours 
involving the immune mechanism 
 15 (3.4)  16 (2.1) 
E00-E89 Endocrine, nutritional and metabolic diseases  74 (16.7)  104 (15.6) 
(E00-E07) Disorders of the thyroid gland 12 (16.2) 18 (17.3) 
(E08-E16) Diabetes mellitus and other disorders of glucose regulation and pancreatic 
internal secretion 
21 (28.4) 38 (36.5) 
(E20-E35) Disorders of endocrine gland (excluding PCOS)  2 (2.7)  1 (1) 
(E28.2) Polycystic ovarian syndrome 9 (12.2) 2 (1.9) 
(E50-E64) Nutritional deficiencies 6 (8.1) 3 (2.9) 
(E65-E68) Obesity 1 (1.4) 10 (9.6) 
(E70 –E88) Metabolic disorders (excluding high cholesterol) 3 (4.1) 9 (8.7) 
(E78) High cholesterol 20 (27) 23 (22.1) 
G00-G99 Diseases of the nervous system 107 (15) 48 (7) 
(G20-G26, G30-G32) Extrapyramidal and movement disorders and other 
degenerative diseases  
1 (1.5) 7 (15.2) 
(G35-G37) Demyelinating diseases of the central nervous system 3 (4.4) 4 (8.7) 
(G40) Epilepsy 15 (22) 11 (23.9) 
(G40-G47) “Non-specific seizures” 3 (7.4) 5 (6.5) 
(G43) Headache 66 (36.8) 7 (15.2) 
(G45) Transient cerebral ischaemic attacks 2 (2.9) 3 (6.5) 
(G47) Sleep disorder 2 (2.9) 1 (2.2) 
(G50-G59) Nerve, nerve root and plexus disorders 3 (4.4) 3 (6.5) 
(G60-G65) Polyneuropathies and other disorders of the peripheral nervous system 1 (1.4) 6 (13) 
(G70-G73) Diseases of myoneural junction and muscles 2 (2.9) 0 (0) 
(G80-G83) Cerebral palsy and other paralytic syndromes 4 (5.9) 0 (0) 
(G89-G99) Other disorders of the nervous system 5 (7.4) 1 (2.2) 
H00-H59 Diseases of the eye and adnexa  5 (1.1) 6 (0.9) 
H60-H95 Diseases of the ear and mastoid process 4 (0.9) 6 (0.9) 
I00-I99 Disease of the circulatory system 60 (13.6) 105 (15.7) 
(I05-I09) Chronic rheumatic heart diseases 0 (0) 2 (1.9) 
(I10-I16) Hypertensive diseases 22 (36.7) 48 (45.7) 
(I20-I25) Ischemic heart diseases 13 (21.7) 15 (14.3) 
(I26-I28) & (I30-I52) Pulmonary heart disease, diseases of pulmonary circulation and 
other forms of heart disease 
9 (15) 13 (12.4) 
(I60-I69) Cerebrovascular diseases 13 (21.7) 15 (14.3) 
(I70-I99) Diseases of arteries, arterioles, capillaries, veins, lymphatic vessels and 
lymph nodes and unspecified disorders of circulatory system 















J00-J99 Diseases of the respiratory system 41 (9) 70 (10.5) 
(J00-J22) Acute upper respiratory infections, influenza and pneumonia and 
other acute lower respiratory infections 
0 (0) 4 (5.7) 
(J40-J47) Chronic lower respiratory diseases (excluding asthma) 8 (17.5) 20 (28.6) 
(J45) Asthma 33 (82.5) 44 (62.9) 
(J80-J94) Other diseases of pleura and respiratory system 0 (0) 2 (2.9) 
K00-K95 Diseases of the digestive system 37 (8.1) 69 (10.5) 
(K00-K14) Disease of oral cavity, salivary glands and jaws 0 (0) 2 (2.9) 
(K20-K38) Diseases of oesophagus, stomach, duodenum and appendix 13 (36.1) 14 (20) 
(K40-K46) Hernia 3 (5.6) 10 (14.3) 
(K50-K68) Non-infective enteritis, colitis, other diseases of intestines and 
peritoneum 
16 (44.4) 15 (22.9) 
(K70-K77) Diseases of liver 2 (5.6) 15 (21.4) 
(K80-K95) Disease of gallbladder, biliary tract, pancreas and other diseases of 
the digestive system 
3 (8.3) 13 (18.6) 
L00-L99 Diseases of the skin and subcutaneous tissue 19 (4.3) 31 (4.6) 
M00-M99 Diseases of the musculoskeletal system and connective tissue 36 (8.1) 75 (11.2) 
(M05-M19) Inflammatory polyarthropathies and osteoarthritis 13 (36.1) 31 (41.3) 
(M20-M27) Other joint disorders and dentofacial anomalies 2 (5.6) 3 (4) 
(M30-M49) Systemic connective tissue disorders, deforming dorsopathies, 
spondylopathies 
10 (27.8) 5 (6.7) 
(M50-M79) Other dorsopathies and other soft tissue disorders 9 (25) 31 (41.3) 
(M80-M94) Disorders of bone density and structure, other osteopathies, 
chondropathies 
2 (5.6) 5 (6.7) 
N00-N99 Diseases of the genitourinary system 31 (7) 31 (4.2) 
(N10-N39) Glomerular diseases, renal tublo-interstital diseases, acute kidney 
failure, chronic kidney disease, urolithiasis, other diseases of kidney and ureter 
and of the urinary system 
13 (41.9) 18 (53.6) 
(N40-N53) Diseases of male genital organs 1 (3.2) 6 (21.4) 
(N60-N98) Disorders of breast, inflammatory diseases of female pelvic organs 
and non-inflammatory disorders of female genital tract 
17 (54.8) 7 (25) 
Q00-Q99 Congenital malformations, deformations and chromosomal 
abnormalities 
12 (2.7) 1 (0.15) 
R00-R99 Symptoms, signs and abnormal clinical and lab findings, not 
otherwise classified 
 16 (3.6) 31 (4.2) 
(R03) Abnormal blood pressure reading 5 (31) 8 (28.6) 
(R00-R94) Symptoms, signs and abnormal clinical findings (excluding blood 
pressure), abnormal findings on examination of blood and diagnostic imaging 
11 (69) 23 (71.4) 
S00-S99 Injuries as a consequence of external cause 1 (0.2) 7 (1) 













Table 96 Breakdown of types of congenital malformations, deformations and chromosomal 





 n (%) 
Control 
group       
 n (%) 
Congenital malformations, deformations and 
chromosomal abnormalities 
12 (2.7) 1 (0.15) 
 Female 12 (100)  1 (100) 
 Mean age 44.3 (14)  43 
(Q20-Q28) Congenital malformations of the 
circulatory system 
3 0 
 Female 3 (0) 0 (0) 
 Mean age 50.6 (17) - 
(Q65-Q64) Congenital malformations of the urinary 
system 
7 0 
 Female 7 (100) 0 (0) 
 Mean age 41.3 (14) - 
(Q80-Q89) Other congenital malformations 2 1 
 Female 2 (100) 1 (100) 
 Mean age 45 (4) 43 
 
Table 97 Rate of tuberculosis, hepatitis, HIV and mycoses and protozoal disease in the 




 n (%) 
Control 
group       
 n (%) 
A15 – A69 (Tuberculosis, other bacterial 
disease, infections with a predominantly 
sexual mode of transmission and other 
spirochetal diseases) 
2 (20) 4 (8.9) 
 Female 1 (50) 1 (25) 
 Mean age 48 (8.5) 73.8 (14) 
B15 – B19 (Viral hepatitis)  3 (30) 26 (55.3) 
 Female 1 (33.3) 7 (26.9) 
 Mean age      56.7 (21.4) 47.6 (NK) 
B20 – B20 (Human immunodeficiency virus 
disease) 
2 (20) 14 (29.8) 
 Female 0 (0) 5 (35.7) 
 Mean age 45.5 (14.8) 46.3 (NK) 
B35 – B64 (Mycoses and protozoal diseases) 3 (30) 2 (4.3) 
 Female 3 (100) 1 (50) 









Appendix 5.6: History of familial mental health issues 
 
Table 98 Table showing breakdown of familial mental health issues according to group and 
relative type 







n (%) OR 95% CI p value 
History of familial mental health issues
 1
  125 (52.1) 197 (60) 0.73 0.5 - 1 > 0.05 
 Not known 82 (25.5) 315 (49)    




1.59 (0.9) 1.71 (1)  - 0.3 – 0.8 > 0.05 
Relative type      
 Mother
3 
 55 (30.4) 83 (29.1) 1.1 0.7 – 1.7 > 0.05 
 Father
4
 33 (18.2) 57 (20) 0.9 0.5 – 1.5 > 0.05 
 Son, one or more
4
 11 (6.1) 13 (4.6) 1.3 0.5 – 3 > 0.05 
 Daughter, one or more
4
 7 (3.9) 11 (3.9) 0.96 0.4 – 2.6 > 0.05 
 Sister, one or more
4
 27 (14.9)  40 (14.1) 1.01 0.6 -1.8 > 0.05 
 Brother, one or more
4
 21 (11.6) 38 (13.3)  0.8 0.4 – 1.6 > 0.05 
 Second degree relative, one or more
4
 27 (14.9)  43 (15.1) 0.9 0.5 – 1.7 > 0.05 
 Total 181 (100) 285 (100)    
1 
History of familial mental health versus no history of familial mental health issues 
2 
Independent sample t-test 
3 
Reference group: all other relatives with mental health issues 
4 






















Appendix 5.7: Socio-demographic differences between groups with and without complete 
HoNOS scores 
 
Table 99 Socio-demographic differences in functional motor and control group patients with 













   
      95% CI 
           
p value 
Functional motor group  69 (21.4) 253 (78.6) 79.2 44.4 – 67.4 0.001 
Gender Female  52 (75.4)  186 (73.5) 0.10 -11.1 – 13.1 > 0.05 
 Male  17 (24.6) 67 (26.5)    
Ethnicity British  29 (42) 166 (65.6) 12.6 9.6 – 36.8 0.0004 
 Other ethnicity  40 (58) 87 (34.4)    
CSA Experienced CSA  10 (19.6) 40 (20.1) 0.008 -11.8 – 10.7 > 0.05 
 Didn’t experience CSA  41 (80.4) 159 (79.9)    
Work Employed 12 (17.6) 61 (26.5) 2.3 -3.4 – 18.9 > 0.05 
 Unemployed 49 (72.1) 130 (56.5)    
Health Physical health condition 46 (67.6) 173 (76.5) 0.72 -14 – 27.7 > 0.05 
 No physical health condition 22 (32.4) 53 (23.5)    
Control group  320 (49.6) 324 (50.3) 0.03 -7.2 – 8.6 > 0.05 
Gender Female 174 (54.4) 167 (51.5) 0.54 -5 – 10.8 > 0.05 
 Male 146 (45.6) 157 (48.5)    
Ethnicity British 158 (49.4) 170 (52.5) 0.62 -4.8 – 11 > 0.05 
 Other ethnicity 162 (50.6) 154 (47.5)    
CSA Experienced CSA 54 (23.9) 31 (19.3) 2 -2 – 11.1 > 0.05 
 Didn’t experience CSA 172 (76.1) 130 (80.7)    
Work Employed 48 (15.2) 56 (19.9) 2.45 -1.4 – 10.8 > 0.05 
 Unemployed 236 (74.9) 153 (54.4)    
Health Physical health condition 167 (58) 159 (61.4) 0.65 -5.1 – 11.8 > 0.05 
 No physical health condition 121 (42) 100 (38.6)    


















Appendix 5.8: Logistic regression results  
 
Table 100 Binary logistic regression model showing the relationship between independent 
variables and the likelihood of a functional motor patient having a comorbid functional 
disorder 
Variable B SE Wald OR 
p 
value 
Female 0.23 0.45 0.25 1.3 0.62 
Ethnicity 0.13 0.41 0.10 1.1 0.75 
Marital status 0.10 0.40 0.06 1.1 0.80 
Previous psychiatric inpatient stay 0.70 0.40 3.3 2 0.07 
Patient has carer 0.25 0.40 0.42 0.52 1.3 
Employed  -0.19 0.51 0.15 0.82 0.70 
Health or social care worker 0.25 0.50 0.25 1.3 0.61 
Smoker 0.16 0.38 0.17 1.2 0.68 
Experienced CSA -0.02 0.46 0.002 0.98 0.96 
Physical health problem -0.84 0.44 3.7 0.43 0.054 




Table 101 Binary logistic regression model showing relationship between independent 
variables and the likelihood of a psychiatric inpatient admission 
Variable B SE Wald OR 
p 
value 
Female -0.15 0.69 0.05 0.86 0.83 
British 0.21 0.55 0.15 1.23 0.70 
Married -0.1 0.55 0.04 0.90 0.85 
Employed pre-morbidly -2.42 0.99 6.03 0.09 0.01 
Welfare recipient 0.72 0.58 1.57 2.05 0.21 
Experienced CSA 0.54 0.64 0.71 1.7 0.40 
Experienced CPA -1.71 0.75 5.19 0.18 0.02 
Experienced ASPA 1.9 0.71 7.46 6.85 0.007 
Carer to family 1.7 0.99 2.9 5.37 0.09 
Patient has a carer -0.72 0.53 1.8 0.49 0.18 
Physical health diagnosis -0.33 0.59 0.31 0.72 0.58 
Health or social care worker 0.68 0.72 0.90 1.97 0.35 
Uses a walking aid  1.7 0.54 9.63 5.3 0.002 
Smoker 1.12 0.49 5.07 3.1 0.02 
CSA: childhood sexual abuse; CPA: childhood physical abuse; ASPA: 












Table 102 Binary logistic regression showing associations between independent variables and 












Female  0.53  0.62  0.73  0.39  1.7 
British  0.004  0.50  0.001  0.99  1 
Married  1.5  0.62  5.9  0.02  4.6 
Employed pre-morbidly  0.89  0.74  1.43  0.23  2.4 
Health or social worker  0.24  0.73  0.11  0.74  1.3 
Smoker  -0.81  0.51  2.5  0.11  0.45 
Psychiatric inpatient stay  -0.3  0.48  0.37  0.54  0.75 
Physical health problem  2.47  0.72  11.85  0.001  11.8 
Carer to family or friend  1.9  1.06  3.13  0.08  6.6 
Has a carer   0.98  0.58  2.9  0.09  2.7 
Abuse experience*  0.01  0.42  0.001  0.97  1.01 
           
Model χ2 = 46.9, p < 0.001          
Pseudo R
2 
= 0.34           





































Appendix 6.1: Reasons for early therapy cessation for F44.4 and control groups 
 









 95% CI 
p 
value 
No reason available in notes 15 (44.1) 14 (63.6) 2 -9.7 – 45 0.16 
Belief in a physical cause 5 (14.7) 0 (0) 3.5 -3.6 - 31 0.06 
Belief therapy wasn’t helping or 
was making patient worse 3 (8.8) 3 (3.9) 0.5 -14.4 – 20.2 0.48 
Clinic too far to travel 3 (8.8) 0 (0) 0.5 -14.4 – 20.2 0.48 
Symptoms improved 2 (5.9) 1 (4.5) 0.05 -17.6 – 15.9 0.82 
Physical health problem (e.g. 
problem drinking or broken bone) 2 (5.9) 0 (0) 1.3 -10.4 – 19.7 0.25 
Patient became too busy 1 (2.9) 1 (4.5) 0.1 -11.5 – 20.1 0.75 
Disengaged from therapy 1 (2.9) 1 (4.5) 0.1 -11.5 – 20.1 0.75 
Unhappy with service 1 (2.9) 0 (0) 0.64 -12.8 – 15.3 0.42 
Found CBT distressing 1 (2.9) 1 (4.5) 0.1 -11.5 – 20.1 0.75 
Police conviction 0 (0) 1 (4.5) 1.5 -6.7 – 22.8 0.22 



























Appendix 6.2: Missed treatment sessions and mean days between appointments 
 
Table 104 Missed treatment sessions and mean number of days between appointments 
 F44.4  
Group 









Treatment sessions attended 14.06 (8) 13.4 (7.3) 3563.5 0.62 
Treatment sessions missed 2.44 (4.2) 2.15 (3.8) 2449.5 0.66 
Day between assessment and first 
treatment session 
62.6 (74.6) 53.2 (46.9) 3090 0.69 
Days between first and last 
treatment session 
266 (362) 268 (408) 3341.5 0.51 
Days between first treatment and 
last follow-up session 






























Appendix 6.3: Socio-demographic differences between F44.4 and control group patients 
according to their improvement 
 
Table 105 Socio-demographic differences between patient groups who improved, got worse or 
remained the same after CBT treatment 







 95% CI 
p 
value 
Patient improved 44 (49.4) 40 (58) 1.15 -7.9 – 24.6 0.28 
Gender Female 32 (72.7) 16 (40) 9 9.9 – 52.2 0.003 
 Male 12 (27.3) 24 (60)     
Ethnicity British 32 (72.7) 30 (75) 0.06 -18.1 – 22.1 0.81 
 Other ethnicity 12 (27.3) 10 (25)    
Marital 
status 
Single/divorced/widowed/ separated 24 (54.5) 23 (57.5) 0.08 -19.4 – 25 0.78 
Married/civil partner/cohabiting 20 (45.5) 17 (42.5)    
Work Employed 20 (45.5) 21 (52.5) 0.41 -15.7 – 29 0.52 
 Unemployed/retired/sick leave 24 (54.5) 19 (47.5)    
Benefits Receives benefits 9 (22) 11 (31.4) 0.85 -12 – 30.6 0.36 
 Does not receive benefits 32 (78) 24 (68.6)    
Age Mean age at psychiatric symptom onset 
(SD)
1
 31.4 (16) 25.2 (13) 1.9 -0.38 – 12.8 0.07 
 Mean age at assessment (SD) 40.6 (15) 39.8 (12) 0.28 -5.14 – 6.8 0.78 
Role of 
psych 
Accepted psych role before 26 (81.3)          -    
Didn’t accept psych role before 6 (18.8)            -    
Health Experienced depression 38 (86.4) 33 (82.5) 0.24 -13.2 – 21.4 0.62 
 Didn’t experience depression 6 (13.6) 7 (17.5)    
 Smokes 11 (32.4) 13 (41.9) 0.62 -15.6 – 33.7 0.43 
 Does not smoke 23 (67.6) 18 (58.1)    
 Family mental health problem 24 (66.7) 20 (64.5) 0.04 -21.8 – 26.4 0.85 
 No family mental health issue 12 (33.3) 11 (35.5)    
Patient remained the same or got worse* 45 (50.6) 29 (42) 1.15 -7.9 – 24.6 0.28 
Gender Female 33 (73.3) 15 (51.7) 3.6 -2.7 – 44.3 0.06 
 Male 12 (26.7) 14 (48.3)    
Ethnicity British 28 (62.2) 21 (72.4) 0.81 -13.9 – 31.8 0.37 
 Other ethnicity 17 (37.8) 8 (27.6)     
Marital 
status 
Single/divorced/widowed/ separated 24 (53.3) 21 (72) 2.55 -6 – 40.2 0.11 
Married/civil partner/cohabiting 21 (46.7) 8 (27.6)    
Work Employed 11 (25) 13 (44.8) 3.1 -4.14 – 42.6 0.08 
 Unemployed/retired/sick leave 33 (75) 16 (55.2)    
Benefits Receives benefits 24 (44.2) 11 (37.9) 0.28 -18.6 – 29.8 0.60 
 Does not receive benefits 19 (55.8) 18 (62.1)    
Age Mean age at psychiatric symptom onset 
(SD)
1
 29 (11) 32.9 (16) -1.15 -10.7 – 2.9 0.26 
Mean age at assessment (SD) 39.5 (11) 42.8 (14) -1.13 -9.1 – 2.5 0.26 
Role of 
psych 
Accepted psych role before 17 (48.6) -    
Didn’t accept psych role before 18 (51.4) -    
Health Experienced depression 39 (86.7) 27 (93.1) 0.74 -11.5 – 21.2 0.39 
 Didn’t experience depression 6 (13.3) 2 (6.9)    
 Smokes 14 (43.8) 5 (26.3) 1.5 -12.9 – 42.8 0.21 
 Does not smoke 18 (56.3) 14 (73.7)    
 Family mental health issue 22 (64.7) 16 (72.7) 0.39 -19.7 – 32.6 0.54 
 No family mental health issue 12 (35.3) 6 (27.3)    
Not known 9 (9.2) 7 (9.2)    
*Eight F44.4 patients got worse and nine control patients got worse 
1 





Appendix 6.4: Socio-demographic differences between patients with clinical outcome scores 
and those with one or none 
 
Table 106 Characteristics of FMD patients with two available CORE-OM scores versus those 












 95% CI 
p 
value 
Gender Female  18 (75) 53 (71.6) 0.10 -20.5 – 22.6 0.74 
 Male  6 (25) 21 (28.4)    
Ethnicity British  16 (66.7) 50 (67.6) 0.007 -20.4 – 25.2 0.94 
 Not British  8 (33.3) 24 (32.4)    
Marital status Single  10 (47.6) 32 (61.5) 1.2 -12.9 – 39.4 0.28 
Married  11 (52.4) 20 (38.5)     
Work Employed  11 (45.8) 22 (29.7) 2.1 -7.4 – 39.7 0.15 
 Unemployed 13 (54.2) 51 (68.9)    
Carer Patient has carer  6 (25) 18 (28.6) 0.11 -20.6 – 23.5 0.74 
 Patient doesn’t have carer  18 (75) 45 (71.4)    
Disability Uses walking aid  8 (34.7) 36 (52.9) 2.3 -7.5 – 40.3 0.13 
 No wheelchair/walking aid  15 (65.2) 32 (47.1)    
Abuse History of CSA 2 (10)  17 (28.3) 2.7 -6 – 34.1 0.10 
No history of CSA 18 (90) 43 (71.7)    
History of CPA  5 (25) 18 (24.3) 0.004 -20 – 26.8 0.95 
No history of CPA  15 (75) 43 (58.1)    
Health History of familial mental 
health problems  
15 (68.2) 36 (64.3) 0.11 -22.3 – 26.6 0.75 
No history of familial 
mental health problems  
7 (31.8) 20 (35.7)    
Smokes  7 (41.2) 23 (40.4) 0.003 -25.8 – 29.7 0.95 























Table 107 Characteristics of FMD patients with two available HoNOS-ABI scores versus those 












 95% CI 
p 
value 
Gender Female  15 (68.2) 56 (73.7) 0.26 -15.7 – 30.4 0.61 
 Male  7 (31.8) 20 (26.3)    
Ethnicity British  12 (54.5) 54 (71.1) 2.1 -7.4 – 41 0.15 
 Not British  10 (45.5) 22 (28.9)    
Marital 
status 
Single  10 (52.6) 32 (50) 0.04 -24.4 – 28.8 0.84 
Married  9 (47.4) 32 (50)    
Work Employed  9 (40.9) 24 (32) 0.59 -14.5 – 33.8 0.44 
 Unemployed 13 (59.1) 51 (68)    
Carer Patient has carer  8 (38.1) 16 (24.2) 1.5 -9.5 – 39.3 0.22 
 Patient doesn’t have carer  13 (61.9) 50 (75.8)    
Disability Uses wheelchair or other walking aid  11 (55) 33 (46.5) 0.45 -8 – 33.5 0.50 
 No wheelchair/walking aid  9 (45)  38 (53.5)    
Abuse History of child sexual abuse 4 (23.5) 15 (23.8) 0.001 -27.8 – 21.1 0.98 
No history of child sexual abuse 13 (76.5) 48 (76.2)    
History of child physical abuse  5 (29.4) 18 (28.1) 0.01 -21.6 – 29.9 0.91 
No history of child physical abuse  12 (70.6) 46 (71.9)    
Health History of familial mental health 
problems  10 (55.6) 41 (68.3) 1.3 -10.2 – 35.6 0.25 
 No history of familial mental health 
problems  8 (44.4) 19 (31.7)    
 Smokes  8 (50) 22 (37.9) 0.75 -16.7 – 40.3 0.34 



























Table 108 Characteristics of FMD patients with two available PHQ-9 scores versus those with 
one or no available scores 









 95% CI 
p 
value 
Gender Female  14 (87.5) 57 (69.5) 2.2 -9.6 – 33.6 0.14 
 Male  2 (12.5) 25 (30.5)    
Ethnicity British  9 (56.3) 57 (69.5) 1.05 -13 – 41.3 0.31 
 Not British  7 (43.8) 25 (30.5)    
Marital 
status 
Single  10 (76.9) 32 (45.7) 4.2 -1.9 – 52.9 0.04 
Married  3 (23.1) 38 (54.3)    
Work Employed  5 (31.3) 28 (34.6) 0.06 -26 – 26.5 0.80 
 Unemployed 11 (68.8) 53 (65.4)    
Carer Patient has carer  3 (21.4) 21 (28.8) 0.32 -23.6 – 27.9 0.57 
 Patient doesn’t have carer  11 (78.6) 52 (71.2)    
Disability Uses wheelchair or other walking aid  8 (53.3) 36 (47.4) 0.17 -23.3 – 33.8 0.68 
 No wheelchair/walking aid  7 (46.7) 40 (52.6)    
Abuse History of child sexual abuse 1 (9.1) 18 (26.1) 2.1 -9.6 – 30.8 0.14 
No history of child sexual abuse 10 (90.1) 51 (73.9)    
History of child physical abuse  3 (25) 20 (29) 0.1 -25 – 25 0.75 
No history of child physical abuse  9 (75) 49 (71)    
Health History of familial mental health 
problems  8 (66.7) 43 (65.2) 0.01 -32.2 – 28.1 0.93 
 No history of familial mental health 
problems  4 (33.3) 23 (34.8)    
 Smokes  4 (33.3) 26 (41.9) 0.39 -21.4 – 33.4 0.53 





























Appendix 6.5: CORE-OM mean clinical score sub-analysis: repeated measures  ANOVA 
 
1. Gender 
Female functional participants saw a significant decrease in mean CORE-OM scores before and 
after CBT (t = 3.5, df = 17, two-tailed p = 0.003) but there was no significant change in male 
participants’ scores before and after treatment (t = 1.7, df = 5, two-tailed p = 0.14). The 
interaction between gender and the change over time within the F44.4 group was not 
statistically significant (F1, 22 = 0.14, p = 72, partial η
2 = 0.006). 
 
2. Ethnicity 
British participants in the F44.4 group also saw a significant decrease in mean CORE-OM scores 
before and after CBT (t = 3.4, df = 15, two-tailed p = 0.004) while non-British participants did 
not see a significant drop in score results (t = 2, df = 7, two-tailed p = 0.08). The interaction 
between gender and the change over time within the F44.4 group was not statistically 
significant (F1, 22 = 0.21, p = 66, partial η
2 = 0.009). 
 
3. Marital Status 
There was significant interaction in mean scores’ change over time and marital status (F1, 19 = 
0.08, p = 0.77, partial η2 = 0.004). Married participants saw a significant drop in CORE-OM 
scores post-CBT (t = 2.5, df = 10, two-tailed p = 0.03) compared to single participants, where 
there was no significant drop (t = 1.9, df = 9, two-tailed p = 0.10).  
 
4. Employment 
There was a significant interaction between CORE-OM clinical mean scores’ change over time 
and employment status (F1, 22 = 4.6, p = 0.04, partial η
2 = 0.17). Employed F44.4 participants 
saw a significant drop in their CORE-OM clinical mean scores (t = 3.7, df = 10, two-tailed p = 
0.004) while there was no significant difference for unemployed participants (t = 2.1, df = 12, 
two-tailed p = 0.056).  
 
5. Wheelchair usage 
There were significant improvements in CORE-OM clinical mean scores for both wheelchair 
users/walking aid users (t = 2.8, df = 7, two-tailed p = 0.03) and non-wheelchair users (t = 2.5, 
df = 14, two-tailed p = 0.03) before and after CBT treatment but there was no significant 
interaction between the group and the two groups and the change in scores over time (F1, 21 = 






6. Acceptance of psychological factors before and after treatment 
There was no significant interaction between those who accepted psychological factors before 
treatment and those who didn’t and the change in their treatment scores over time (F1, 15 = 
0.004, p = 0.95, partial η2 = 0.001). Those who accepted psychological factors displayed a 
significantly higher decrease in CORE-OM clinical mean scores (t = 3.1, df = 11, two-tailed p = 
0.01) while those who did not accept psychological factors saw a drop in scores, but this 
wasn’t statistically significant (t = 2.3, df = 4, two-tailed p = 0.09).  
 
There was no significant interaction between those who accepted psychological factors after 
treatment and those who didn’t accept such factors after treatment and time (F1, 18 = 0.22, p = 
0.64, partial η2 = 0.01). There was a significant change in scores for those who accepted the 
role of psychology after CBT treatment (t = 3.2, df = 14, two-tailed p = 0.01) while there was no 




Participants who had experienced childhood physical abuse had no significant change in CORE-
OM scores over time (t = 1.8, df = 4, p = 0.15) while those who did not experience childhood 
physical abuse saw a significant change over time (t = 3.4, df = 14, p = 0.004). The interaction 
between the childhood abuse variable and the change over time was not statistically 
significant (F1, 18 = 0.46, p = 0.51, partial η
2 = 0.03). 
 
There were less than five F44.4 participants who had experienced childhood sexual abuse or 
childhood physical abuse. Due to the small size of the groups, statistically tests were not 
completed for these groups.  
 
8. Smoking  
There was no significant change in scores over time within-groups for participants who smoked 
nor for those who did not smoke and the interaction between the two conditions (smokers 
and non-smokers) and the change over time was not significant (F1, 15 = 2.5, p = 0.14, partial η
2 
= 0.14).  
 
9. Family mental health history 
There was a significant decrease in CORE-OM scores for participants with family members with 
mental health problems before and after CBT (t =3, df = 14, p = 0.01), but not significant 





6, p = 0.06). There was no interaction between the groups and change in scores before and 
after CBT (F1, 20 = 0.02, p = 0.89, partial η
2 = 0.001).  
 
10. Carers 
Participants without carers saw a significant drop in CORE-OM scores over time (t = 3.4, df = 
17, p = 0.004) while there was no significant drop for those who did have a carer (t = 2.1, df = 
5, p = 0.09). There was no significant interaction between groups and pre- and post-CBT CORE-
OM scores (F1, 22 = 0.28, p = 0.60, partial η
































Appendix 6.6: Mean adjusted HoNOS-ABI sub-analysis: repeated measures ANOVA 
 
1. Gender 
There was no significant interaction between gender and the change in HoNOS-ABI scores over 
time (F1, 20 = 0.97, p = 0.34, partial η
2 = 0.05) although females saw their HoNOS-ABI scores 
drop more than male participants.  
 
2. Ethnicity 
There was a significant interaction between ethnicity groups and the change in HoNOS-ABI 
scores over time (F1,20 = 5.3, p = 0.03, partial η
2 = 0.21).  
 
3. Marital Status 
There was no significant interaction between marital status and the change over time in 
HoNOS-ABI scores (F1, 17 = 1.02, p = 0.22, partial η
2 = 0.06).  
 
4. Employment status 
There was no significant interaction between employment status and change over time in 
HoNOS-ABI scores (F1, 20 = 0.05, p = 0.83, partial η
2 = 0.002).  
 
5. Psychological acceptance before and after CBT 
There was no interaction effect between those accepting psychological factors before CBT and 
those not accepting psychological factors before CBT and change in HoNOS-ABI scores over 
time (F1, 13 = 0.53, p = 0.48, partial η
2 = 0.04).  
 
There was no interaction effect between those accepting psychological factors after CBT and 
those not accepting psychological factors after CBT and change in HoNOS-ABI scores over time 
(F1, 16 = 2.5, p = 0.13, partial η
2 = 0.14).  
 
6. Carers 
There was no significant interaction by carer group (has a carer versus has no carer) and the 
change in HoNOS-ABI scores over time (F1,19 = 0.92, p = 0.35, partial η
2 = 0.05).  
 
7. Abuse 
There was no significant interaction between experiencing childhood physical abuse or not and 
the change in HoNOS-ABI scores over time (F1,15 = 1.4, p = 0.25, partial η






Repeated measures ANOVA was not completed for those experiencing childhood sexual abuse 
and those not as the number of those experiencing childhood sexual abuse was below the pre-
agreed cut-off of five participants per group (n = 4). The same principle applied to comparisons 
of those experiencing adult sexual or physical abuse (n = 1).  
 
8. Wheelchair usage  
There was no interaction effect for wheelchair usage and change over time in HoNOS-ABI 
scores (F1,18 = 2.3, p = 0.15, partial η
2 = 0.11).  
 
9. Family mental health 
There was no interaction effect for those with family members with mental health problems or 
without and change in HoNOS-ABI scores over time (F1,16 = 0.05, p = 0.82, partial η
2 = 0.003).  
 
10. Smoking 
There was no significant interaction for smoking group and change in HoNOS-ABI scores pre- 
and post-CBT (F1,14 = 0.38, p = 0.55, partial η






















Appendix 6.7: Mean PHQ-9 scores sub-analyses: repeated measures ANOVA 
 
1. Gender 
There was no interaction between gender and the change over time in PHQ-9 mean scores (F1, 
14 = 0.17, p = 0.68, partial η
2 = 0.01). The total number of men with available scores at both 
time points was however only two.  
 
2. Ethnicity 
There was no significant interaction for ethnicity and change in PHQ-9 scores over time (F1,14 = 
2.3, p = 0.15, partial η2 = 0.14). 
 
3. Marital status  
There was no significant interaction between marital status and PHQ-9 scores over time (F1, 11 
= 0.41, p = 0.53, partial η2 = 0.04). There were only three married F44.4 participants with PHQ-
9 scores at both time points.  
 
4. Employment  
There was no interaction between employment status (unemployed n = 11, employed n = 5) 
and change in PHQ-9 scores over time (F1,14 = 0.57, p = 0.46, partial η
2 = 0.04). 
 
5. Psychological acceptance before and after CBT 
There were only two F44.4 participants who did not accept psychological factors as part of 
their symptomatology. Nine participants did accept these factors. There was no interaction 
between this variable and change in scores over time (F1, 9 = 1.08, p = 0.33, partial η
2 = 0.11).  
 
In relation to patients who did and did not accept the role of psychology in their symptoms 
after CBT, only one participant did not accept the role it plays. The interaction between the 
group accepting or not accepting psychological factors after CBT and the change in PHQ-9 
scores over time was not significant (F1,13 = 0.99, p = 0.34, partial η
2 = 0.07).  
 
6. Carer 
Only three patients with before and after CBT PHQ-9 scores reported having a carer. There was 
no significant interaction between having a carer or not and change over time in PHQ-9 scores 
(F1,12 = 0.12, p = 0.74, partial η








Three participants with before and after CBT PHQ-9 scores reported experiencing childhood 
physical abuse. There was no interaction effect for these groups over time (F1,10 = 0.02, p = 
0.89, partial η2 = 0.002).  
 
In total, four participants reported experiencing sexual or physical abuse as an adult. No 
interaction effect was reported (F1,12 = 1.71, p = 0.22, partial η
2 = 0.13).  
 
Regarding childhood sexual abuse, only one participant experienced childhood sexual abuse 
with two PHQ-9 scores and no analysis was completed.  
 
8. Wheelchair use 
There was no interaction for those F44.4 patients using wheelchairs or walking aids and those 
not and the change in their PHQ-9 scores over time (F1,13 = 0.15, p = 0.71, partial η
2 = 0.01).  
 
9. Family mental health  
Only four participants had no family members with mental health problems and two PHQ-0 
scores while eight did. Those with family members with mental health problems saw a greater 
decrease in PHQ-9 scores than those participants without a family member with a mental 





Four participants had two complete PHQ-9 scores and smoked. There was no significant 
interaction between smoking status and change in PHQ-9 scores over time (F1,10 = 1.9, p = 0.20, 
partial η2 = 0.16).  
 
 
 
 
 
 
 
 
 
 
 
